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Abstract 
Pneumonia is the leading cause of death in children worldwide and is estimated to kill 1.6 
million children every year. Pneumonia affects children and families everywhere, but is most 
prevalent in sub–Saharan Africa and South–east Asia. Serotype 1 is responsible for up to    
20 % of invasive pneumococcal diseases (IPD) in developing countries and has been the 
cause of several outbreaks in the African meningitis belt. Conjugate vaccines are effective in 
young children, induce immunological memory and reduce carriage. A conjugate vaccine 
against 7 serotypes (PCV7) was licensed in 2000 which resulted in a dramatic reduction of 
IPD. An increase in the number of cases due to non–vaccine serotypes (serotype 
replacement) led to the recent development and licensure of 10– and 13– valent conjugate 
vaccines that provide broader coverage. 
This thesis describes the development of purification and conjugation processes and 
associated analytical methods for the preparation of a Streptococcus pneumoniae serotype 
1 polysaccharide (Pn1) conjugate vaccine. 
The Pn1 polysaccharide was purified following a two–step process utilising a differential 
filtration with ethanol. Analytical tests including size analysis, uronic acid composition, O–
acetylation and purity (nucleic acids and protein) were optimized and performed on Pn 1 lots. 
The purified polysaccharide was found to meet World Health Organisation (WHO) 
specifications.  
The purified polysaccharide is viscous with a rigid structure that hampers full conjugation 
reactions and detailed characterisation. Size–reduction was performed and shown to have 
no impact on the structural integrity of the generated saccharide. The O–acetylated size–
reduced polysaccharide was amenable to full nuclear magnetic resonance (NMR) 
characterisation to confirm the structural identity of Pn1 and determine the percentage of cell 
wall polysaccharide (CWPS) and the degree and position of O–acetylation present. 
Composition analysis was performed using published hydrolysis methods, however, they 
resulted in low recoveries and therefore alternative microwave assisted conditions were 
investigated followed by chromatographic separation and analysis. 
The size–reduced polysaccharide was conjugated to hydrazide–derivatized protein carriers 
via the polysaccharide carboxyl groups. The conjugates prepared using different activators 
were evaluated in mice and the immunogenicity data showed that they were non–inferior to 
two commercially available conjugate vaccines.  
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CHAPTER 1. INTRODUCTION 
Streptococcus pneumoniae (also known as pneumococcus) is a major cause of serious 
diseases such as pneumonia, meningitis, bacteraemia and sepsis as well as more common 
illnesses including otitis media and sinusitis [1]. The majority of these disease outbreaks, in 
developed and developing countries, occur in children under the age of two as well as in the 
elderly. In 2002, the World Health Organization (WHO) estimated that 1.6 million childhood 
deaths were attributed to pneumococcal disease (Figure 1.1) [2]. 
 
Figure 1.1. Comparison of estimated deaths in 2005 from various bacterial diseases [2]. 
In 2008, the WHO estimated 476 000 of the 8.8 million deaths of children under 5 years of 
age were caused by pneumococcal infections [2], 99 % of these deaths occurred in Africa 
and Asia as shown in Figure 1.2 [3], and in 2010 pneumonia accounted for 18 % of 
childhood mortality (Figure 1.3) [4]. 
 
Figure 1.2. Estimated incidence of childhood pneumonia worldwide (2004) [5]. 
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Pneumonia is the most common form of invasive pneumococcal disease (IPD) and it 
accounts for one in every four deaths amongst young children. It is also the leading cause of 
non–invasive diseases such as otitis media [6]. Pneumonia has a bi–modal incidence rate 
that peaks twice; the first occurs in children under 2 years of age and the second peak arises 
in adults over 65 years of age (Figure 1.4) [7]. 
 
Figure 1.3. Global causes of childhood mortality in 2010 [4]. 
 
Figure 1.4. Incidence rate of pneumococcal infection by age group in 1998 [7]. 
1.1 Early history of Streptococcus pneumoniae 
The discovery of pneumonia is largely associated with two men, Sternberg and Pasteur, who 
both, independently, isolated the bacteria in 1880 [8]. While Pasteur named the isolate 
“microbe septicemique du saliva”, Sternberg called his Micrococcus pasteri in honour of 
Pasteur who had published his results a mere three months earlier [8]. The term 
“pneumoniekokke” was first used in 1883 by Matray, followed in 1886 by the more well–
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known name “pneumokokkus” by Fraenkel. The bacteria was renamed Diplococcus 
pneumoniae in 1920 as the morphology was more associated with the diplococcal group, but 
in 1974 it was reclassified as Streptococcus pneumoniae (S. pneumoniae) due to its growth 
in chains in liquid media and other similarities to the streptococci bacterial group [8-10]. 
Neufeld is credited with the identification of characteristics that separate S. pneumoniae from 
other bacteria, namely the bile solubility test and the Quellung reaction that results in the 
swelling of the capsule of the pneumococcus [11].  
1.2 Surface components of Streptococcus pneumoniae 
S. pneumoniae are Gram positive, lancet–shaped, encapsulated organisms that commonly 
exist in pairs (diplococci) but can present in short chains or as single cells (Figure 1.5a) [12].                   
S. pneumoniae is an aerotolerant anaerobe and is fastidious in that it has complex nutritional 
requirements [9, 13, 14]. The bacteria grow readily on blood agar plates and display alpha 
haemolysis unless grown anaerobically, where they show beta haemolysis. The bacteria are 
sensitive to bile salts which break down the cell wall with the presence of the cell’s own 
enzyme, autolysin. Three major surface layers are recognisable; the plasma membrane, the 
cell wall and the capsule (Figure 1.5b) [15]. 
  
Figure 1.5. a) Pneumococcal cell showing diplococcal formation as well as the outer capsular 
polysaccharide b) Idealised schematic of the surface components of a pneumococcal cell, modified 
from AlonsoDeVelasco et al. [15]. 
A common characteristic of Gram positive bacteria is the presence of a thick cell wall. This 
wall consists mainly of peptidoglycans which are repeating units of N–acetylglucosamine 
and N–acetylmuramic acid. Attached to the N–acetylmuramic is a five amino acid peptide 
chain which is cross–linked over the bacterial cell [16]. The peptidoglycan serves as an 
anchor for the capsular polysaccharides (PS) as well as a number of surface proteins, and is 
responsible for stimulating the inflammatory response in pneumococcal infections [9]. Cell 
wall polysaccharide (CWPS) is a uniquely identifying feature of all S. pneumoniae isolates. It 
was first described by Tillett and Francis in 1930 [17], but it took a further 50 years before 
the chemical structure of CWPS was fully elucidated. CWPS is comprised of glucose, 
a) b) 
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galactosamine, ribitol phosphate, phosphocholine and 2–acetamido–4–amino–2,4,6–
trideoxy–galactose (AAT) [18]. The cell wall polysaccharide is responsible for the serological 
cross–reactivity between S. pneumoniae and other streptococci as it activates the alternative 
complement pathway in the early stages of inflammatory response [9, 19].  
Pneumococci are divided into 93 different serotypes based on the expression of their 
capsular polysaccharide (PS) [20]. The Danish naming system has been used since the 
1980s to classify the different pneumococcal serotypes [9, 10, 21, 22]. The capsular PS is 
the thickest layer that protects the inner components of the pneumococcus. While the CWPS 
is common to all serotypes, the structure of the capsular PS is unique to each serotype. In 
Pasteur’s early observations of the pneumococcal cell, he recognised the capsule 
surrounding the cell when he wrote: "Each of these little particles is surrounded at a certain 
focus with a sort of aureole which corresponds perhaps to a material substance" [8]. The 
capsular PS was first isolated in 1917 by Dochez and Avery, in the urine of patients with 
pneumococcal pneumonia [23], but it was thought to be either a protein or of a protein nature 
due to the total nitrogen and nitrogen partition on the “active substance” [23]. It was isolated 
and identified as a carbohydrate in 1923 by Heidelberger and Avery [24]. 
Unlike peptidoglycan, the capsular PS does not produce an inflammatory response, instead 
it protects the bacteria from phagocytosis by acting as a shield from antibodies and by 
separating bound opsonins from their receptors on the phagocytes [9]. The capsular PS is 
the main virulence factor that protects the bacteria against the host’s immune system [15, 
25]. Encapsulated bacteria were found to be 100 000 times more virulent than non–
encapsulated strains [15, 26]. Other factors contribute to the bacteria’s virulence include the 
CWPS, enzymes such as autolysin, neuraminidase as well as the pneumolysin and 
pneumococcal surface proteins [15, 27]. 
1.3 Pneumococcal disease 
The only natural reservoir of S. pneumoniae is the human nasopharynx and the bacteria is 
transmitted through respiratory droplets [28]. Both pathogen and host gain an advantage 
from nasopharyngeal colonisation. S. pneumoniae is able to exchange genetic material, with 
the host, and may gain properties enabling it to potentially become antibiotic resistant [29]. 
For the human host this colonisation promotes the release of the B–cells against the PS 
capsule. 
In most cases the carrier is asymptomatic with disease being shown in only a small portion 
of the population [9]. The greatest of pneumococcal infections carriage rates are found in 
young children [30]. Studies have shown that in developed countries 40 – 60 % of young 
children are carriers compared to 12 % of older children, 6 – 10 % adolescents and only       
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
5 
 
3 – 4 % of adults are thought to be carriers [31, 32]. According to Gray et al., by the age of 
two, infants are colonised at least once by Streptococcus pneumoniae. Only one serotype is 
carried at a time and the first strain is always carried for the longest period of time [33]. 
Transmission is usually within high population areas, within families [30, 33, 34], in 
orphanages and day care centres [34-36] and closed communities [37]. 
From the nasopharynx, the bacteria may cause non–invasive and invasive pneumococcal 
infections; it may spread to the sinuses causing sinusitis, to the middle ear cavity causing 
otitis media or into the lungs causing pneumonia. In the worst cases, S. pneumoniae is 
known to cause systemic infections, with the detection of the bacteria in the bloodstream, 
including bacteraemia, endocarditis or meningitis all of which have considerable mortality 
rates [9, 38].  
1.3.1 Non–invasive pneumococcal disease 
Non–invasive pneumococcal infections occur outside the major organs and blood and are 
less serious than invasive diseases. Two of the main forms of non–invasive pneumococcal 
infections are middle ear infections and non–bacteremic pneumonia. 
Non–bacteremic pneumonia is a less serious form of pneumonia, which, while displaying all 
of the characteristics of pneumonia including detection on the lungs by X–ray, is not found in 
the blood. Middle ear infections (otitis media – OM) are one of the most common infections 
in children and are typically caused by viral, bacterial or fungal pathogens with the most 
widely occurring bacterial pathogen being S. pneumoniae [39, 40]. Otitis media is an 
inflammation of the middle ear with an accumulation of fluid in the middle ear and swelling of 
the eardrum. The disease usually occurs in the first five years of life [41]. It has been 
reported that 60 % of children have experienced at least one episode of OM by the time they 
turn one year old [7]. 
1.3.2 Invasive pneumococcal disease  
Invasive pneumococcal diseases (IPD) are of a more serious nature and include diseases in 
the blood or a major organ. In the US, in 1997, approximately 500 000 cases of pneumonia 
were reported with a fatality rate of 5 – 7 %, 50 000 episodes of bacteraemia (fatality rate = 
20 %) and 3000 cases of bacterial meningitis with 30 % of the cases resulting in death were 
attributed to S. pneumoniae [42].  
Bacterial meningitis is an infection of the membranes (meninges) covering the brain and 
spinal cord. S. pneumoniae is the leading cause of bacterial meningitis in adults and, since 
the introduction of the Haemophilus influenzae type b (Hib) conjugate vaccines, the main 
pathogen in infants [43]. The incidence of bacterial meningitis caused by S. pneumoniae in 
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the United States is between 13 – 19 % where it is estimated that 3000 to 6000 cases occur 
every year [7]. Pneumococcal meningitis has been found to be associated with higher rates 
of death and neurological conditions than meningitis caused by Neisseria meningitidis and 
Hib [44].  
Bacteraemia is a bacterial infection of the blood and accounts for 70 % of IPD in children 
younger than 2 years of age [7]; in adults most cases of bacteraemia are cause by S. 
pneumoniae [45]. Bacteremic pneumonia is the inflammation of one or both lungs where S. 
pneumoniae is also found in the blood and accounts for 12 – 16 % of IPDs among children 2 
years of age and younger [7]. It is estimated to be responsible for more than 50 % of all 
pediatric pneumonia [5]. 
Specific serotypes are responsible for certain types of disease; for instance, an Israeli study 
in 2011 found that the highest incidence of pneumonia was contracted from serotype 1, 
followed, in descending order, by 5, 22F, 7F, 14, 9V and 19A. Much lower incidence rates 
were found for serotypes 6A, 6B, 23A and 35B suggesting that the first seven serotypes 
have a higher disease potential in children less than five years of age [46]. 
Serogroups 3, 6, 19 and 23 are found to be the main serotypes isolated from middle ear fluid 
[1, 39, 47], serotypes 1 and 14 are mostly isolated in the blood and contribute mainly to 
bacteraemia, and serogroups 6, 10 and 23 were mostly found in the cerebrospinal fluid 
indicating that these serotypes are mainly responsible for bacterial meningitis [48-50]. 
1.4 Serogroup distribution of Streptococcus pneumoniae in Africa  
In 2000, approximately 156 million new episodes of childhood clinical pneumonia occurred 
with 90 % of all cases occurring in sub–Saharan Africa and South Asia. The mortality rate of 
pneumonia is also largely concentrated in Africa and South Asia as illustrated in Figure 1.6 
[3]. Of all these cases, 11 to 20 million of them (7 – 13 %) were severe enough to require 
hospitalisation [2]. About half the world’s pneumonia and diarrhoea related deaths occur in 
just five mostly poor and populous countries: India, Nigeria, Democratic Republic of the 
Congo, Pakistan and Ethiopia (Table 1.1). 
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Table 1.1. Number of deaths in children under 5 years due to pneumonia in 2010 by country [3]. 
Rank Country Deaths among children under age 5 due to pneumonia and diarrhoea 
1 India 609 000 
2 Nigeria 241 000 
3 Democratic Republic of the Congo 147 000 
4 Pakistan 126 000 
5 Ethiopia 96 000 
 Total Worldwide 2 197 000 
  
Figure 1.6. Mortality rate of children (deaths per 100 000) under 5 years of age due to S. pneumoniae 
[51].  
Streptococcus pneumoniae causes approximately 75 % of all serious IPD infections in South 
African HIV positive children [52]. In 2000, approximately 10.8 % of the 870 000 deaths 
attributed to Streptococcus pneumoniae were from HIV positive children with 19.8 % of 
those deaths occurring in African children [51]. S. pneumoniae is the leading bacterial 
opportunistic infection in children who do not receive antiretroviral treatment (ART), and is up 
to 40 – fold greater in HIV positive children; this rises to 65 % in HIV infected children in 
Southern Africa where the prevalence of HIV in young children is less than 5 %. Children 
who receive ARTs have a 21–fold increase in IPD infection risks than those without HIV [53]. 
Figure 1.7 illustrates the serotype distribution of Streptococcus pneumoniae globally and in 
Africa. The main difference in the serotype distribution between developed and developing 
countries is the contribution of serotypes 1 and 5. In Africa, Asia and Latin America these 
two serotypes are responsible for the high incidents of invasive pneumococcal disease [54]. 
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Figure 1.7. Serotype distribution a) globally and b) Africa [55]. 
Figure 1.8 illustrates the five most prevalent serogroups responsible for IPD in six African 
countries in young children. Serogroup Pn6 has the highest incidence rate in South Africa 
but is replaced by serogroup Pn1 in Egypt, Rwanda and Kenya, and P 14 in Ethiopia and 
Gambia. In adults, this order changes and Pn1 is the dominant serotype in Rwanda, Kenya, 
and Egypt as well as in South Africa. In South Africa, in 2008, pneumonia caused 12.4 % of 
deaths in children under 15 years of age; this was the second most common cause of 
natural deaths in the country [56]. 
  
Figure 1.8. Five most prevalent serogroups responsible for invasive pneumococcal disease in a) 
young children, and b) adults in Africa [57]. 
Pn1 has been the dominant serotype in the meningitis belt over a number of years [58]. In 
one study, the serotype distribution of pneumococcal infections was examined in three 
countries situated in the African meningitis belt. The seasonal pattern of pneumococcal 
meningitis share some of the same conditions as those of the epidemic meningitis season 
and it was found that the highest incidence of cases were found during the dry season, 
during which respiratory infections and decreased host immunity occurs [58].  
a) b) 
a) b) 
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Table 1.2. Serogroup distribution by country in the African meningitis belt. Modified from Gessner et 
al. [58]. 
Serogroup Burkina Faso Senegal Ghana 
 Age 5+ yr. Age 2+ yr. Age 5+ yr. 
1 18 90 51 
3 – 8 2 
5 – 8 – 
6 – 13 1 
12 2 6 – 
14 2 2 1 
19 2 4 – 
Others 4 12 7 
Total 28 143 62 
The results (Table 1.2) showed that at least 60 % of all isolated cases in Burkina Faso, 
Senegal and Ghana were due to pneumococcal serotype 1. It was also noted that these 
incidents fell out of the usual age range for pneumococcal infections as they were recorded 
in children over the age of 2 in Senegal and over 5 years of age in both Burkina Faso and 
Ghana. These results suggest uniqueness in the epidemiology of Pn1 and are an indication 
that a Pn1 vaccine should be developed as a potenti l booster dose or monovalent vaccine 
to be administered in the later years of childhood.  
1.5 Immune response to polysaccharide and conjugate vaccines 
The ability to distinguish the body’s own cells from foreign cells is the most important 
characteristic of the immune system. The immune system will launch an attack (immune 
response) when it encounters foreign cells or organisms (antigens).  
There are many different types of cells that make up the immune system and which are 
responsible for the immune responses, three of which are described below.  
 Phagocytes: These are large white cells that specialise in engulfing bacteria, viruses 
or any other foreign cells. There are three main types of phagocytes: granulocytes 
which are the first responders to the infection and specialise in large parasites. 
Macrophages are larger, longer lasting and can consume and destroy more foreign 
cells than granulocytes. Finally dendritic cells, while also responsible for destroying 
foreign cells, also activate the rest of the immune system. Both macrophages and 
dendritic cells reveal the antigens to T cells and stimulate the T cells during an 
immune response [6, 59, 60]. 
 T cells: The surface of T cells contain specialised antibody–like receptors that detect 
fragments of antigens on the surface of infected cells, instead of free–floating 
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antigens [60]. The molecules responsible for bringing these fragments to the surface 
are proteins called the major histocompatibility complex (MHC) molecules [61]. There 
are two main types of T cells: helper T (Th) cells and cytotoxic T lymphocytes (CTLs). 
The Th cells manage the body’s immune response by interacting with other cells; 
some will coordinate phagocytes, some will stimulate B cells to produce antibodies 
and memory cells and others will activate the CTLs which directly attack the infected 
cells and are most useful in combating viruses.  
 B cells: When a B cell is exposed to bacteria it becomes activated and will travel to 
either the lymph nodes or the spleen where it changes into either a memory or 
plasma cell [60, 62, 63]. Memory cells “remember” which antigens they were 
exposed to which will speed up the immune response when a secondary exposure 
occurs. When this second exposure occurs the memory cells will transform into 
plasma cells. Plasma cells express and release the antibodies of which there are five 
main types: 
 Immunoglobulin A (IgA) is concentrated in bodily fluids and guards the entrance 
to the body. 
 Immunoglobulin D (IgD) attaches to B cells and is important in instigating early B 
cell responses. 
 Immunoglobulin E (IgE) is responsible for the protection against parasitic 
infections and is responsible for allergy symptoms. 
 Immunoglobulin G (IgG) antibodies coat microbes which speeds up their uptake 
by other cells in the immune system. IgG also plays an important role in 
opsonophagocytosis and complement induced cytotoxicity by phagocytes [38]. 
 Immunoglobulin M (IgM) are very effective at killing bacteria [59, 60, 64]. 
Vaccines rely on the memory B cell function as they expose the body to small amounts of 
antigen that will lead to the development of memory B cells that will survive until the next, 
potentially harmful exposure. 
Antigens can elicit either thymus dependent (TD) or thymus independent (TI) responses. TD 
antigens interact with the MHC molecules on the surface on the antigen which will allow it to 
interact with T cells. The immune system’s ability to react to a TD antigen is present from 
birth where the interaction with the T cells leads to an expression of a membrane protein 
(CD40) which activates the B cells into producing IgG and IgM antibodies and aid in the 
maturation of B cells into memory cells [65-67]. Molecules that generate TD responses are 
proteins or peptides [65].  
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TI responses do not stimulate the B cells into creating memory cells, however they do 
stimulate the production of large quantities of IgM and much less quantities of IgG [67]. TI 
antigens can react in two different ways with B cells; TI–1 antigens encourage the expansion 
and differentiation of B cells which induce an immune response in both adults and neonates 
[66] whilst TI–2 antigens do not possess this ability to induce a strong IgG response and 
therefore can only work in older children and adults [67, 68]. The different responses of the 
immune system to an antigen are important to know when developing an effective vaccine.  
Polysaccharides are known as TI–2 antigens as they are hydrophilic molecules and they 
therefore cannot associate with the MHC proteins [69]. Figure 1.9 displays how PSs directly 
activate the B cells without the help of T cells, through an alternative pathway in the spleen 
[63]. The spleen however is not fully developed until the age of 1 – 2 years [62, 63] and so 
the production of capsular specific antibodies (IgG2 antibodies) is limited or even absent in 
young children [70, 71]. Memory cells are also absent with TI antigens and infections which 
reoccur cannot be dealt with in a timely manner [72].  
As proteins are TD antigens, conjugating a PS to a protein carrier will transform the 
polysaccharide into a TD antigen as the protein will induce a T cell response which will lead 
to IgM–IgG antibody switching and initiate the matur tion of B cells into memory cells [69, 
73-75]. Table 1.3 compares polysaccharide and conjugate vaccines in terms of immune 
responses. 
Table 1.3. Comparison of polysaccharide and conjugate vaccines [76]. 
Property Polysaccharide vaccines Conjugate vaccines 
Immunogenicity (5 year old – adult) High High 
Immunogenicity in young children Poor High 
Response to booster Poor High 
Avidity Low High 
Bacterial activity Low High 
Induction of memory Some Yes 
Effect on colonisation Some Yes 
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Figure 1.9. Immune responses induced by Streptococcus pneumoniae; A) polysaccharide vaccine 
and B) conjugate vaccine [38]. 
It was long thought that only peptide and protein antigens would elicit a T cell response. 
Recently it has shown that zwitterionic polysaccharides (ZPS) also have the ability to 
activate T cells in the absence of a protein carrier [74, 77, 78]. ZPS are polysaccharides that 
possess both positive (free amino groups) and negative (carboxylate or phosphate groups) 
charges. Some bacterial polysaccharide that are classified as zwitterionic polysaccharides 
include Staphylococcus aureus type 5 and type 8 polysaccharides, polysaccharide A (PSA) 
from Bacteroides fragilis and serotype 1 from S. pneumoniae. It was hypothesised that these 
polysaccharides interact with the MHC molecules. Studies of PSA showed that removing 
either the positive or negative charge eliminates the MHC binding and thus becomes a TI 
antigen [79-81]. 
Mertens et al. investigated the immune response of CD8+ T cells in mice when exposed to 
Pn1 PS. Pn1 PS does induce the production of T cells in the spleen and peritoneal cavity of 
mice and, as seen with PSA, removing one of the charged groups on the PS renders the 
production of T cells obsolete [82]. Trück et al. examined the memory B cell (MBC) 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
13 
 
responses in adults following immunisation with the 23 valent pneumococcal polysaccharide 
vaccine as well as the 7–valent conjugate vaccine [83]. Figure 1.10 graphically displays the 
change in MBC after vaccination with the two vaccines specifically for Pn1 and Pn3 
serotypes. Pn1 did not induce MBC, rather it lead to depletion of the pre–existing peripheral 
memory B cells. This lack of response has been shown to occur with other non–zwitterionic 
polysaccharides in the 23 valent polysaccharide vaccine [83]. It was also shown that the 
memory B cell responses were significantly different between the two different vaccine types 
for serotype 1 but not for serotype 3; this investigation determined that the Pn1 PS is not 
processed by the MHC pathway in humans as it was shown to do in mice and therefore 
cannot be considered a TD antigen. 
 
Figure 1.10. Change in memory B cell numbers pre– and post–vaccination. Participants received 
either one dose of PCV7 (black; n = 28) or a single dose of PPV23 (red; n = 28). Modified from Trück 
et al. [83]. 
1.6  Pneumococcal vaccines 
1.6.1 Whole cell vaccines 
The first recorded instance of a vaccine against Streptococcus pneumoniae was 
documented in 1911 in South Africa where workers in the diamond and gold mines 
experienced a very high incidence of pneumonia [84]. According to data released in 1907 at 
the Premier Diamond Mine, the rate of pneumonia occurrence was eight out of every 
thousand workers per month with two of the eight infected ending in death [85]. Sir Almoth 
Wright, known as the father of the typhoid vaccine, was brought in to investigate the best 
methods of protection against pneumonia. Sir Wright and his associates went on to inoculate 
550 000 mine workers with a vaccine that consisted of dried, heat inactivated sputum from 
pneumonia patients and it was claimed that the incidence of pneumonia in mine workers was 
decreased by more than 50 % [10, 19, 86, 87]. 
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Sir Wright’s protégé, F. Spencer Lister, went on to show that pneumococcal pneumonia was 
not caused by a single serotype; a multitude of serotypes were capable of eliciting type–
specific immunity in both animals and humans but it was necessary to inject a billion or more 
of the bacteria to elicit an immune response in man and up to 40 billion to produce an 
adverse effect [1, 88]. This was somewhat confirmed when Heidelberger et al. showed that 
10 billion pneumococcal bacteria from serotypes 1 and 2 were needed to produce between 
30 and 40 mg of capsular PS (amounts that are now used in the PS vaccine) [89]. 
Whole cell pneumococcal vaccines were again trialled during the First World War when the 
US military inoculated over 400 000 people. While some of the results suggested that these 
vaccinations were successful, many subjects showed negative reactions towards the 
vaccination and the trials were determined to be inconclusive [10, 19]. 
1.6.2 Pneumococcal polysaccharide vaccines 
After the First World War, many investigations into the pneumococcus revealed the 
importance of the capsular PS and the resulting antibody response to it [10, 17, 19]. Tillet 
and Francis injected the polysaccharides of serotypes 1, 2 and 3 into humans and saw an 
immune response to one or more of the serotypes [90]. This was confirmed by Finland et al. 
a year later [91]. During the Second World War, clinical trials in the military demonstrated 
that pneumococcal pneumonia could be prevented by immunisation with specific capsular 
PSs. A tetravalent PS vaccine consisting of serotypes 1, 2, 5 and 7 was shown to be 86 % 
effective in preventing pneumonia from those four serotypes but it had no effect in 
prevention against other pneumococcal serotypes [10, 92]. Heidelberger et al. showed that 
six PSs in a single formulation was able to induce the same amount of antibodies as six 
polysaccharides injected separately [93]. The results of this trial prompted the release, in 
1946, by Squibb and Sons, of two hexavalent vaccines, one specifically for adults and the 
other for children. However, these vaccines were released during the introduction of 
penicillin and other antibiotics that were shown to successfully treat pneumococcal and other 
bacterial infections and, due to bad sales, the vaccines were taken off the market in 1954 [9, 
10, 19]. 
It took 10 years until Austrian and Gold showed that pneumonia still caused serious 
infections with a high mortality rate in spite of antimicrobial treatments [94]. Led by Austrian, 
multivalent PS vaccine formulations containing up to fourteen capsular PSs were developed, 
tested and found to be safe and immunogenic. Trials were again performed with mine 
workers in South Africa where a 13–valent PS formulation was found to be between 78.5 % 
and 82.3 % efficacious [9, 95, 96]. 
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As a result of these trials, a 14–valent capsular PS vaccine was licensed in 1977 in the 
United States [9, 19, 97]. The capsular PSs included in this vaccine are shown in Table 1.4. 
The 14–valent vaccine included the 12 most common serotypes causing 70 – 80 % of 
disease in the United States, parts of Europe and South Africa. Serotype 2 was not among 
the common serotypes, especially in America, but was included due its prevalence in men 
predominantly from Malawi and Mozambique. Serotype 2 was also known to cause serious 
illness and was prevalent in Africa and parts of Europe [19, 98]. 
Table 1.4. Serotypes included in the licensed capsular polysaccharide vaccines. 
Vaccine Serotypes included Date licensed 
14 valent 1, 2, 3, 4, 6A, 7F, 8, 9N, 12F, 14, 18C, 19F and 25 1977 
23 valent 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F 1983 
With evidence increasing in support of microbial resistance and the discoveries of additional 
serotypes, the 14 valent vaccine was expanded to a 23–valent PS vaccine in 1983 [9, 98]. 
The 23 different serotypes provided coverage for 85 – 95 % of the serotypes found in 
Europe and the United States [37, 97-100] but less than 80 % in Asia [29, 101, 102]. The 
pneumococcal PS vaccine, much like other PS vaccines, has some major limitations in that it 
is weakly immunogenic; a decrease in the level of clinical protection was also noticed after a 
few years. A second dose, given after this decrease occurred, did not show a rise in 
antibody response [1]. As previously stated, the PS is a T–cell independent antigen and the 
immune system therefore needs mature B lymphocytes in order to elicit an immune 
response. As infants do not possess mature B lymphocytes, the PS vaccine is poorly 
immunogenic. The pneumococcal PS vaccine was also not as effective in the elderly, and in 
immunocompromised patients [9, 10, 29, 70, 102-106]. Whilst not proving to be very 
effective in the aforementioned groups, the vaccine was recommended for young children 
(under 2 years of age) who have an increased risk of pneumococcal disease, healthy adults 
over 65 years of age and for both young children and the elderly who live in homes, 
institutions or any other crowded living conditions. The vaccine is also not effective for those 
suffering from reoccurring middle ear infections, and certain types of cancer (blood, lymph 
and bone) [1, 9, 66, 87, 106, 107]. 
This poor immune response in infants to the pneumococcal PS vaccine led to the 
investigation of a second generation type of vaccine in which the PSs were covalently 
attached to different proteins. 
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1.6.3 Conjugate vaccines 
Avery and Goebel were the first to show that attaching a polysaccharide to a protein 
increased the immunogenicity of the PS; they covalently attached the PS from serotype 3 to 
globulin from horse serum [108-112]. These conjugates were tested in rabbits and resulted 
in a type–specific immune response to the conjugate and not to either the polysaccharide or 
protein injected separately [1, 113]. Conjugation of a polysaccharide to a protein solved the 
major problem with PS vaccines in that they could induce an immunological memory and an 
immunological response in infants [107]. 
It took 50 years before the work performed by Avery and Goebel was used to create the first 
conjugate vaccine against Hib. The Hib conjugate vaccine was first developed by 
Schneerson et al. [114, 115] and led to a large reduction of the disease, where, of the 169 
countries that introduced the conjugate vaccine into the infant immunisation schedule, 69 % 
of them describe coverage of above 80 % (Figure 1.11) [116]. 
 
Figure 1.11. Coverage of Hib conjugate vaccine [116]. 
This success led to the investigation into other conjugate vaccines, most notably for the 
prevention of pneumococcal diseases. There is an added challenge to pneumococcal 
vaccines as there are a variety of different serotypes that cause illness amongst infants, so 
multivalent vaccines had to be developed where each serotype was separately conjugated 
to a protein and formulated together into a conjugate vaccine that could induce antibodies 
against each serotype [1, 10]. There are currently three licensed multivalent pneumococcal 
conjugate vaccines available. These are listed in Table 1.5 and are described in further 
detail below. 
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Table 1.5. Licensed pneumococcal conjugate vaccines [117]. 
Vaccine Company Serotypes included Protein Licensed date 
Prevnar 
(PCV7) Pfizer 4, 6B, 9V, 14, 18C, 19F, 23F CRM197 2000 
Synflorix 
(PCV10) GSK 
1, 4, 5, 6B, 7F, 9V, 14, 18C, 
19F, 23F 
Protein D + DT + 
TT 2009 
Prevnar 13 
(PCV13) Pfizer 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, 23F CRM197 2010 
1.6.3.1 Prevnar7 
The first commercially available pneumococcal conjugate vaccine (PCV) was Prevnar 
(PCV7). PCV7 was licensed by Pfizer (formally Wyeth) in 2000 in the United States, 2001 in 
the United Kingdom, as a three dose regimen given at 2, 4, and 6 months, followed by a 
booster dose at 12 to 15 months (a 3 + 1 schedule). The vaccine consisted of seven 
different serotypes conjugated to the cross–reactive material 197 (CRM197) carrier protein, a 
non–toxic form of diphtheria toxoid (DT) that had already been successfully used in Hib as 
well as meningococcal group C (MenC) vaccines. The seven serotypes used in this vaccine 
were 4, 6B, 9V, 14, 18C, 19F and 23F which accounted for approximately 86 % of 
bacteraemia, 83 % of meningitis and 65 % of middle ear infections in children under 6 years 
of age in the United States [10, 118, 119]. An eighth serotype, Pn6A, was not included as it 
was thought that the cross reactivity within serogroup 6 meant that the capsular PS of one of 
them might protect against both serotypes and Pn6B was included instead of Pn6A due to 
the PS stability [1]. 
The conjugation chemistry involved in the production of this vaccine included periodate 
oxidation of the PS to form aldehydes, followed by reductive amination of the activated PS to 
the amines on the proteins with sodium cyanoborohydride, forming an imine which was 
reduced to form a stable amide linkage [120]. 
Figure 1.12 depicts how the incidence rates of IPDs dropped dramatically in the 5 years and 
under target group after the introduction of the vaccine in America and Australia. The 
efficacy of the vaccine in preventing vaccine–serotype–specific IPD in the United States as 
well as Europe was 97 %. The number of IPD cases in children below 5 years of age had 
fallen from an average of 17 240 cases per year before the introduction of conjugate 
vaccines to 4 454 cases in 2003 [2]. 
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Figure 1.12. a) Rate of vaccine–type IPD in United States before and after introduction of PCV7, by 
age group and year [2]. *Difference between each age group in 2003 is statistically different to the 
age groups from 1998 – 1999. b) Incidence of IPD in Australian children (by age group) from 2002 – 
2010; PCV7 was made available to all Australian children in 2005 [29]. 
An article by Whitney et al. in 2003 detailed the drop in invasive pneumococcal disease after 
the introduction of the 7–valent conjugate vaccine in 2000. The rate of disease dropped from 
an average of 24.3 cases per 100 000 people in 1998 – 1999 to 17.3 cases per 100 000 in 
2001. The largest rate of decline of 69 % occurred in infants under two years of age [2, 121]. 
Further studies on the prevention of IPD [122, 123], OM [1, 122, 124] and pneumonia [125, 
126] have also been reported. The reduction of IPD was documented in children with 
compromised immune systems such as sickle cell disease [127] and HIV [128] and the 
theory of herd immunity was described when a decrease in IPDs were shown in non–
vaccinated populations (adults over 50 and infants that were too young to be immunised) 
after the roll out of the PCV7 vaccine in the United States. At the time the Centre for Disease 
Control (CDC) estimated over two – thirds of the reduction of IPD in the US was attributed to 
herd immunity [129]. 
Antibiotic resistance decreased with the introduction of the PCV7 vaccine. Antimicrobial 
resistance only became a problem in the targeted area in the 1990s when resistance to 
penicillin rose steadily (except for the slight drop in 1999) until the introduction of PCV7 at 
the end of 2000 (Figure 1.13) [130]. The data illustrated that the vaccine targeted the most 
common serotypes responsible for antibiotic resistance. Resistance to three different 
antibiotics were also determined before and after the introduction of PCV7 into the target 
population. Penicillin, erythromycin and tetracycline all showed decreases in antibiotic 
resistance after 2000 (Table 1.6) [130]. 
a) b) 
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Figure 1.13. Reduction in penicillin resistance after the introduction of PCV7 in 2000 [130]. 
Table 1.6. Decrease in antibiotic resistance before and after the introduction of PCV7 [130]. 
Antibiotic 1998 – 1999 2001 – 2002 
Penicillin 28.9 % 19.5 % 
Erythromycin 29.5 % 15.0 % 
Tetracycline 39.3 % 13.9 % 
Whilst the incidence of carriage and IPDs decreased with the introduction of PCV7, 
serotypes that were not present in the vaccine became more prominent in contributing 
significantly to the incidence and carriage rates [38, 131-134]. The increase in these 
serotypes meant that the overall rate of IPD in young children in some countries had 
stabilised [131]. Singleton et al. found that the rate of IPD increased in Alaskan children after 
vaccination with PCV7 [132]. 
A study in the US looked at the change in serotype prevalence after the introduction of PCV7 
[135]. While the annual umber of cases decreased from 218 in 2000 to between 86 – 130 
during 2002 – 2007 and the incidence of serotypes found in the vaccine decreased by 92 %, 
serotypes not included in the PCV7 vaccine increased by 18.4 % and serotypes related to 
those found in the vaccine (for example, serotypes from the same serogroup) increased by 
207 %. 
Serotype Pn19A was shown to be the cause of the largest increase in IPDs after 
vaccination. It was thought, that with Pn19F included in the conjugate vaccine, cross–
protection for Pn19A would occur [136] but instead Pn19A went from being the ninth leading 
cause of IPD in the US, before the introduction of the vaccine, to the most prominent 
serotype in 2011, responsible for more than 40 % of IPD in children in the US, Europe and 
Asia [20, 137-142]. 
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It was not just serotype replacement that was cause for the development of new conjugate 
vaccines; it was also the geographic spread of serotypes. While the serotypes found in 
PCV7 were estimated to cover over 80 % of IPDs in North America and Australia, it 
decreased to approximately 70 % in Western Europe and Africa and 50 % in South America 
and Asia (Figure 1.14). 
 
Figure 1.14. Serotype coverage of seven valent pneumococcal conjugate vaccine [48, 57]. Modified 
from PneumoAction [143]. 
This was due to the difference in serotype distribution in different countries. Most of the 
serotypes included in PCV7 were commonly found throughout the world but additional 
serotypes were found to be important in other regions. 
1.6.3.2 Vaccine trials incorporating more serotypes 
Due to the increase in non–vaccine serotype replacement, conjugate vaccines with 
additional serotypes underwent clinical trials; a 9–valent vaccine (Pfizer) and two 11–valent 
vaccines (GlaxoSmithKline (GSK) and Sanofi Pasteur). A summary of the serotypes and 
carrier proteins contained in these vaccines can be found in Table 1.7. 
Table 1.7. Additional serotypes used in clinical trials for pneumococcal conjugate vaccines. 
Vaccine Additional serotypes* Protein carriers 
Clinical trial 
countries 
PCV9 1, 5 CRM197 
South Africa and 
Gambia 
PCV11PD 1, 3, 5, 7F Protein D Czech and Slovak Republics 
PCV11DT 1, 3, 5, 7F 
TT (1,4,5,7F,9V,19F,23F) 
DT (3,6B,14,18C) 
Philippines 
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Serotype 1 is the second most common serotype in Africa and the fourth most common in 
South America and Asia [55]. It is known to cause the majority of complicated pneumonia 
and pleural empyema [144] and is responsible for up to 20 % of IPDs in developing 
countries, particularly among the African meningitis belt [54, 58, 145, 146] and Asia [147]. 
Serotype 1 is most widely found in children over 2 years of age and serotype 5 is most 
widespread in infants under 6 months [54, 148, 149]. Serotype 5 is the third most prevalent 
serotype in Africa and South America that causes IPD. Serotype 3 is commonly found in 
adults but after the introduction of PCV7, this serotype became more prominent in children 
[150]. Serotype 3 is associated with otitis media as well as IPDs especially in Latin America 
[20, 47, 151]. Serotype 7F was found to be the dominant serotype responsible for IPD with 
fatal outcomes in Germany [151]. 
The 9–valent vaccine demonstrated high efficacy levels in all of the clinical trials; in a trial of 
40 000 infants in South Africa during 1998 to 2001, PCV9 was found to be 83 % effective in 
reducing IPD from the serotypes contained in the vaccine [152]. The study also took into 
account HIV–positive infants, whose risk of vaccine–preventable IPD is approximately 60 
times higher than HIV–negative children. This 9–valent vaccine was found to be 65 % 
effective in combating IPD in these subjects. Whilst these values are lower than for HIV–
negative subjects, the actual reduction in pneumonia would be 15 times greater than the 
HIV–negative children due to the higher risk of HIV–positive children [52, 121]. An added 
advantage of this vaccine was that it prevented 31 % of pneumonia associated with 
respiratory infections most common in South African hospitals [152]. The vaccine was also 
found to be 67 % effective against penicillin resistant IPD–causing pneumococcal strains 
and 56 % effective against trimethoprim–sulfamethoxazole resistant strains [153]. 
The Gambian trial of PCV9 was conducted from 2000 to 2004 and was used to investigate 
the efficacy against invasive pneumococcal disease. Children aged 6 – 51 weeks were given 
three doses of either PCV9 or a placebo. The vaccine was found to be 77 % effective 
against IPD caused by the nine serotypes included in the vaccine as well as 50 % effective 
against disease caused by all serotypes (measured by ELISA) [154, 155]. The 9–valent 
pneumococcal conjugate was shown not only to be effective against bacterial pneumonia 
but, in some instances, it provided protection against viral pneumonia [121]. Serotype 1, 
presented a problem in this study where cases of invasive diseases caused by Pn1 showed 
no reduction in vaccinated children compared to the placebo subjects [154, 155]. A trial in 
South Africa which looked at the 9–valent conjugate vaccine in HIV and non–HIV infected 
children also resulted in no levels of protection against serotype Pn1 [153]. Both of these 
outcomes were based on a small number of subjects and full conclusions about the efficacy 
of the Pn1 serotype could not be drawn. 
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The PCV11PD vaccine underwent clinical trials in the Czech and Slovak Republics to 
determine the vaccine’s efficacy against OM in children between 2000 and 2002 [156, 157]. 
The vaccine was found to reduce middle ear infections caused by S. pneumoniae by 52.6 % 
and 35.3 % of infections caused by non–typeable Haemophilus influenzae (due to the 
protein carrier). Cross protection for non–vaccine serotypes was not identified. This vaccine 
did not go into production and instead a 10–valent vaccine conjugated to three different 
protein carriers was developed [20]. 
PCV11DT, from Sanofi Pasteur, underwent clinical trials in the Philippines during a time 
span of four years (2000 – 2004) [158, 159]. Young children were vaccinated with three 
doses of either the 11–valent vaccine or a saline placebo. The vaccine efficacy was 
investigated as well as safety and immunogenicity data. The vaccine provided a 22.9 % 
reduction of community acquired pneumonia in children less than two years of age. However 
there was no data to support the notion that the vaccine protected against clinical 
pneumonia [158]. The immunogenicity of this 11–valent vaccine co–administered with other 
vaccines was also determined. When PCV11DT was co–administered with a diphtheria–
tetanus–pertussis, polio and Hib (polyribosyl–ribitol–phosphate conjugated to TT (PRP–TT)) 
vaccine, the response of the serotypes conjugated to tetanus toxoid (TT) was significantly 
reduced after both primary and booster vaccinations. This reduction did not occur in the four 
serotypes conjugated to DT and it was hypothesised that the tetanus protein had a 
suppressive effect on the pneumococcal conjugates [160]. 
Based on the immunogenicity and efficacy data of two PCV7 trials [123, 126] and the PCV9 
South African trial [153], it was determined that licensure of any new pneumococcal vaccines 
should be based on immunologic non–inferiority, safety and use with co–administered 
vaccines in comparison to PCV7 [161, 162]. From these trials it was determined that the 
threshold antibody concentration to be used as a reference would be 0.35 µg/ml for ELISA 
assays and for ≥8 OPA results which correlates to the efficacy against IPD [163], thus a 
vaccine is proven to be effective and can be licensed if subjects reach an antibody titre of 
0.35 µg/ml [20]. 
Following these trials, both GlaxoSmithKline and Pfizer released multivalent pneumococcal 
conjugate vaccines; Synflorix and Prevnar–13. 
1.6.3.3 Synflorix  
GlaxoSmithKline (GSK) marketed the 10–valent conjugate vaccine Synflorix (PHiD–
CV/PCV10), in 2009, as a second generation conjugate vaccine that included the three 
serotypes 1, 5 and 7F in addition to the seven found in Prevnar. Synflorix also used three 
protein carriers, DT, TT and Protein D. Protein D was a new carrier protein, derived from 
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non–typeable Haemophilus influenzae and is produced from a recombinant E. coli strain 
[164]. 
Serotype 18C was conjugated to TT and serotype 19F to DT [165]. Protein D was used as 
the carrier protein for eight (serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F) out of the ten 
serotypes, due to its potential to provide protection against acute otitis media caused by 
non–typeable Haemophilus influenzae. Due to the novelty of Protein D as a carrier protein it 
was thought to minimise the risk of interference (immune suppression due to epitope 
suppression and bystander interference) shown with proteins that were similar to an antigen 
included in some co–administered vaccines [156]. 
GSK produced a pneumococcal conjugate vaccine based on the conjugation method 
developed during their Hib studies. The conjugation procedure included a polysaccharide 
size reduction step by microfluidization followed by the activation of the PS with 1–cyano–4–
dimethylamino–pyridium tetrafluoroborate (CDAP) before coupling the PSs to the three 
proteins [166]. 
Synflorix was originally formulated as an 11–valent vaccine as it included serotype 3 but this 
serotype was removed from the final licensed product as it was shown not to be effective 
against acute otitis media caused primarily by this serotype. An atypical immune response 
was shown for serotype 3 as antibody concentrations after a booster dose were below those 
generated after the first vaccine dose [157, 167]. 
A total of 14 clinical studies were used to provide support for the vaccine’s 10 valent 
licensure with two studies from the 11–valent vaccine also made available to support the 
licensure [164]. A non–inferiority study was performed to compare PCV7 with Synflorix [168]. 
The test subjects were vaccinated with three doses of either Prevnar or Synflorix followed by 
a fourth booster dose 8 – 14 months following the last vaccination. OPA as well as serotype 
specific responses were monitored. It was found that PCV10 induced ELISA and OPA 
antibodies for all of the serotypes in the vaccine. The vaccine was also shown to be non–
inferior to the seven serotypes in Prevnar in terms of the threshold responses for ELISA and 
OPA. However serotypes 6B and 23F in Synflorix showed lower ELISA levels than those of 
Prevnar (difference greater than 10 %) yet the OPA results backed up the non–inferiority 
claim for those two serotypes. The three additional serotypes, Pn1, Pn5 and Pn7F were also 
tested for antibody production. Subjects were first primed with the PCV7 vaccine and then 
given PCV10 as a booster dose. Approximately 85 % of subjects reached the ELISA 
threshold response for serotypes 1 and 5 and 95 % of subjects for Pn7F. The OPA results 
however were very low (Table 1.8) and it was not known whether these responses were of a 
sufficient value for PCV10 to provide protection against the serotypes 1 and 5 with just one 
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dose. With respect to Pn1, it has not been proven whether the conjugation strategy gives 
rise to a poor immune response or whether the protein carrier itself (Protein D) is not 
compatible with this specific serotype [10]. 
Table 1.8. Percentage of subjects reaching the threshold value for OPA for all serotypes in PCV10 
after first priming with PCV7 followed by a booster dose of PCV10 [164]. 
Serotype PCV7 primed + PCV10 booster  
1 31.4 
4 100 
5 36.9 
6B 94.9 
7F 98.3 
9V 100 
14 100 
18C 98.3 
19F 98.3 
23F 98.4 
In accordance with the WHO requirements, a range of clinical studies of Synflorix were 
performed with co–administered vaccines. PCV10 was co–administered with N. meningitidis 
[169, 170], polio [171], whole–cell pertussis vaccines [117, 172], and measles, mumps, 
rubella and chickenpox vaccine [173] where both the safety and immunogenicity of the two 
vaccinations were maintained. PCV10 was also co–administered with the Hib vaccine in 
Korean infants and was found to be non–inferior to PCV7 [174]. Bermal et al. looked at the 
comparison of the co–administration of either PCV7 or PCV10 with the diphtheria–tetanus–
whole cell pertussis based vaccines in Filipino and Polish children [171] and the ELISA 
results suggested that five of the seven serotypes reached the threshold percentages for 
non–inferiority (the exceptions being serotypes 6B and 23F in the Polish group) and that in 
both countries, PCV10 showed higher antibody titres against Pn18C and 19F than those in 
the PCV7 group. The majority (98.2 %) of infants vaccinated with PCV10 reached threshold 
titres against serotypes 1, 5 and 7F. The PCV10 vaccine increased the serotype coverage 
against IPD to 80 % or more in most regions (Figure 1.15) [48, 57]. 
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Figure 1.15. Predicted coverage of PCV10 [48, 57]. Modified from PneumoAction [143]. 
1.6.3.4 Prevnar13 
By 2010, Pfizer had licensed their 13–valent vaccine that included serotypes 1, 3, 5, 6A, 7F 
and 19A in addition to those covered in PCV7 [175]. Initially it was thought that serotypes 6B 
and 19F would cross protect for serotypes of the same group but incidences of 6A and 19A 
were found to increase after PCV7 was licensed. These two serotypes are associated with 
high rates of antibiotic resistance and accounted for more cases in Europe and America of 
invasive disease than serotypes 1, 3, 5, and 7F combined (8.2 vs. 3.3 cases/100,000 
children 2 years and under). Given the relative burden and importance of invasive 
pneumococcal disease due to serotypes 1, 3, 5, 6A, 7F, and 19A, adding these serotypes to 
the Prevnar formulation would increase coverage for invasive disease to >90 % in the US 
and Europe, and as high as 70  – 80 % in Asia and Latin America (Figure 1.16) [57]. 
 
Figure 1.16. Predicted coverage of PCV13 [48, 57]. Modified from PneumoAction [143]. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
26 
 
The method for conjugation used in PCV13 was based on the procedure followed for PCV7 
and fourteen different clinical studies were used to support the licensure of this vaccine. 
Studies were performed to prove non–inferiority to PCV7 as well as the safety and 
immunogenicity and co–administration of the 13–valent conjugate vaccine. 
The vaccine underwent adult clinical trials in the US, where a comparison was made 
between a single dose of either PCV13 or the 23–valent PS vaccine and antibody responses 
were measured before as well as one month after vaccination. The results showed that 
PCV13 was more immunogenic than the PS vaccine for most of the serotypes found in both 
vaccines [176]. A study of Japanese adults was undertaken and the same results were 
described with PCV13 being more immunogenic than the PS vaccine [177]. 
The German trial compared PCV13 vaccine to PCV7 in infants over four doses (Table 1.9). 
Whilst the antibody titres for all seven serotypes, found in both vaccines, were comparable, 
Pn6B results were lower in PCV13 with 77.5 % of infants reaching the threshold compared 
to 87.1 % of infants vaccinated with PCV7. The OPA results were slightly lower in all 
serotypes for PCV13 but all comparable to the 7–valent vaccine. The additional six 
serotypes elicited antibody and OPA responses considerably higher than the PCV7 vaccine 
[178].  
Table 1.9. Comparison of the percentage of subjects reaching the threshold value for immunogenicity 
between PCV7 and PCV13 for serotypes not included in PCV7. 
 German study [178] USA study [179] 
Serotype PCV7 (%) PCV13(%) PCV7 (%) PCV13 (%) 
1 1.4 96.1 12.0 98.9 
3 6.3 98.2 43.8 97.8 
5 31.6 93.0 5.2 98.9 
6A 31.6 91.9 94.8 98.9 
7F 4.0 98.6 80.4 100 
19A 79.2 99.3 53.2 97.8 
Non–inferiority was investigated in an additional US study where a three–dose schedule of 
PCV7 and PCV13 were compared one month after the last dose. Non–inferiority was 
confirmed for PCV13, although the threshold titres were slightly less than PCV7 for the 
seven common serotypes. The six additional serotypes, as expected, produced higher 
antibody titres in PCV13 when compared to the 7–valent vaccine. It was also shown that 
toddlers experienced higher immune responses than infants [179]. 
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A Canadian study by Kellner et al. investigated the immunogenicity and tolerance of PCV13 
co–administered with MMR, diphtheria–tetanus–acellular––pertussis–polio–Hib, hepatitis B, 
meningococcal C and varicella vaccines and compared to PCV7 in both infants and toddlers. 
Immune responses of the co–administered vaccines did not change when co–administered 
with the pneumococcal conjugate vaccines. One month after a three dose regime, more than 
95 % of subjects had reached the threshold antibody level except for serotypes 23F (90 %), 
5 (85 %) and 3 (80 %) and all but serotype 3 had reached 98 – 100 % efficacy levels [180, 
181]. 
When PCV7 was introduced, there was some cross protection for serotype 6A (70 %) from 
serotype 6B (which was included in PCV7). PCV13 included both serotypes 6A and 6B and 
Cooper et al. investigated whether cross protection would transpire for serotype 6C [182]. 
The results suggested that 100 % of subjects reached the threshold of OPA responses for 
serotype 6A and 6B and 96 % of the subjects reached the OPA threshold for serotype 6C 
suggesting that PCV13 could provide cross protection serotype 6C. 
Due to their recent market release, efficacy data on both the 10 and 13 valent vaccines is 
limited, and there are only a few investigations comparing the two vaccines. One 
investigation compared the coverage that the three PCVs had against IPDs in children less 
than 5 years of age as shown in Figure 1.17 [183]. A predicted increase from 48 % to 76 % 
and 79 % of coverage against IPDs in Africa had been achieved with PCV7, PCV10 and 
PCV13 respectively. This value is globally predicted to rise from 50 % with PCV7 to 75 % 
with the introduction of PCV10 and 77 % with PCV13. PCV13 would significantly expand 
coverage beyond that of Prevnar7, and provide coverage for 6A and 19A that is not 
dependent on the limitations of serotype cross–protection. 
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Figure 1.17. Proportion of IPDs in children under 5 years of age predicted to be due to serotypes 
included in the 7– 10– and 13 valent formulations [183]. 
1.6.4 Pneumococcal vaccines in development 
Merck is currently developing a 15–valent pneumococcal conjugate vaccine containing the 
same serotypes covered in PCV13 with the addition of serotypes 22F and 33F. At the time of 
writing, the 15–valent conjugate vaccine had undergone preclinical evaluations in infant 
rhesus monkeys. These animals were chosen as they respond poorly to unconjugated 
pneumococcal PS [117, 184]. Infant rhesus monkeys were vaccinated three times with either 
PCV15 or PCV7 at 2 month intervals, and serotype–specific IgG antibodies were measured. 
The results indicate that antibody responses to PCV15 and PCV7 are comparable for the 7 
common serotypes and that post–vaccination responses to PCV15 were >10–fold higher 
than baseline for the 8 additional serotypes [184]. 
The vaccine has also been tested in healthy human adults where IgG levels were again 
comparable to PCV7 with an increase in antibody levels amongst the eight additional 
serotypes of between 3– and 13– fold [185]. Limited information is available on the trials in 
toddlers, that had been previously immunised with PCV7 and received a dose of PCV15, 
although a conference abstract suggests that IgG concentrations and OPA levels increased 
after vaccination for all serotypes [186]. 
The increase in the number of serotypes in a conjugate vaccine increases the protection 
against pneumococcal diseases, but as with Prevnar, serotypes not included in the vaccine 
become more prevalent. In addition to this, the cost of producing a conjugate vaccine with 
more and more serotypes becomes very high, as does the complexity with conjugation 
chemistries, formulations and clinical trials [134, 187]. Therefore vaccines being investigated 
are composed of proteins and other components that are common across all pneumococcal 
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serotypes [10, 20]. A protein antigen that is expressed in all stages of pathogenesis of the 
disease, is found in all serotypes and is present on the cell surface would be the ideal 
protein for further investigation. Unfortunately, a single protein is not able to fulfil all the 
criteria and a protein vaccine would most likely contain a number of different pneumococcal 
proteins; Moffit and Malley found over 20 different pneumococcal proteins that would fulfil 
these criteria [129]. Moffit et al. investigated immunisation with killed cells of a non–
encapsulated strain which would contain all the pneumococcal surface proteins without their 
protective capsular PS. One investigation determined that the non–encapsulated strain 
reduced nasopharyngeal colonisation by serotypes 6B and prevented cases of fatal 
aspiration pneumonia by serotypes 3 or 5 [188]. 
1.6.5 Pneumococcal serotype 1 
Serotype 1 is responsible for up to 20 % of IPD in some developing countries and was the 
cause for several outbreaks in the African meningitis belt. It is ranked among the top three 
ranked serotypes in GAVI–eligible countries and is among the top six ranked serotypes 
among children under 5 years of age in regions with the highest pneumococcal disease 
burden (e.g. Africa, Asia and Latin America) [55]. Serotype 1 has the potential to cause 
epidemics and it was the cause of meningitis outbreaks in Burkina Faso and Northern 
Ghana [149, 189, 190]. 
The epidemiology of Pn1 disease shows that the infections occur in two different age 
ranges. The first age range occurs in children over two years of age which is in contrast to 
the age of 6 – 18 months, typical of IPD from most other serotype infections. Serotype 1 is 
rarely found in carriage studies as it is not found in the nasopharynx but is most commonly 
isolated in the blood, which shows an indication of its invasiveness. 
The failures of Pn1 in the 9–valent trials may not be associated with the failure of the primary 
vaccine but could be due to a reoccurrence of the infection in the absence of a booster dose. 
This phenomenon has been documented in meningococcal serotype C conjugate 
vaccination without a booster dose [191]. 
Although there is limited data available regarding the immunogenicity of Pn1 conjugate 
vaccines, during the clinical trials for the two licenced pneumococcal conjugate vaccines the 
OPA results against serotype 1 were lower than most other serotypes and no data is 
available regarding a booster dose of Pn1 vaccine. 
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1.7 Aim and objectives 
Serotype 1 is a pneumococcal serotype that is often found in young children and adults and 
is responsible for invasive outbreaks in rural, indigenous areas and is one of the most 
prevalent serotypes in Africa and other developing regions. With the introduction of 
multivalent conjugate vaccines, the frequency of Pn1 infections was expected to decrease; 
however, literature to date suggests that the conjugate vaccine against Pn1 is not as 
effective as against other serotypes. Due to the unique epidemiology of pneumococcal 
serotype 1, a different strategy to aid in epidemic control would be required.  
The aim of this research project was to develop a process for the efficient purification of Pn1 
polysaccharide and the preparation of an immunogenic conjugate with the overall goal of 
producing a monovalent serotype 1 vaccine that could either be used alone, as a booster 
dose or in combination with a meningococcal vaccine that would have great value in the 
African meningitis belt and among indigenous communities.  
In order to achieve this aim, the specific objectives of this study were:  
i. To develop an efficient process for the isolation and purification of Pn1 
polysaccharide using a modified method of differential filtration with ethanol. 
ii. To establish characterisation assays of the polysaccharide with respect to the WHO 
specifications including identity, composition, size analysis and purity (nucleic acids, 
proteins and CWPS). 
iii. To perform detailed structural characterisation of the purified polysaccharide using a 
range of chromatographic and spectroscopic methods.  
iv. To investigate size reduction by mechanical and chemical means to prepare Pn1 
saccharide that would be amenable to conjugation chemistry and NMR 
characterisation. 
v. To establish methods for the hydrazide–derivatization of carrier proteins BSA, TT, 
CRM197 and PLD. 
vi. To investigate an alternate conjugation chemistry to that used commercially by 
utilising the Pn1 polysaccharide carboxyl groups and carbodiimide–based coupling to 
the derivatized protein carriers. 
vii. To evaluate the immunogenicity of the prepared conjugates in mice using 
commercially available conjugate vaccines as comparators in order to identify the 
best conjugation methodology and carrier protein for further vaccine development. 
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CHAPTER 2. GENERAL METHODS 
2.1 Fermentation of Pn1 
Clinical isolates of Streptococcus pneumoniae serotype 1 were obtained from the National 
Institute of Communicable Diseases (NICD). A selection of these clinical isolates underwent 
clonal selection and the clonal isolate producing high levels of capsular polysaccharide and 
low levels of CWPS was chosen for PS production. A laboratory working seed was prepared 
from the chosen clonal isolate which was used to inoculate a volume of sterile growth 
medium which was incubated under the appropriate, pre–determined conditions. This starter 
culture (20 ml) was used, in turn, to inoculate a starter culture (200 ml) that was inoculated 
into a larger culture before a final inoculation into the fermentor [192]. This fermentation 
process is shown in the process flow in Figure 2.1. Small scale cultivations (2 – 5 L) were 
used to develop the media composition as well as certain process parameter optimisations. 
Process and feeding strategies were developed in a Wave Bioreactor, making use of a 
disposable cell culture system [193]. At the end of the fermentation process, the broth was 
inactivated with phenol, harvested and clarified by centrifugation before downstream 
processing (purification) was carried out. 
 
Figure 2.1. Outline of the process stages for the fermentation of a single fermentor batch of Pn1. 
Initially 1 ml of the laboratory working seed was used to inoculate a small amount of media (20 ml). 
This process was repeated in order to scale up the starter culture (800 ml). This was finally inoculated 
into several litres of medium (7 L in Wave bioreactor and between 15 – 30 L in fermentor). After 
fermentation, the broth was inactivated and clarified before purification can continue. 
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2.2 Purification of Pn1 
Purification of Pn1 was based on the procedure described by Robert Liveyns et al. in 1989 
where increasing ethanol concentrations was employed [194]. The general method of 
purification is described and deviations from this method will be further detailed in Chapter 4, 
Section 4.1. 
A schematic representation of the purification process can be found in Figure 2.2. The 
inactivated fermentation broth was first clarified via centrifugation to a predetermined level. 
Following clarification, the supernatant was diafiltered (100 kDa membranes) against 25 mM 
sodium acetate (NaOAc), to remove all media components and other impurities, and 
concentrated down to approximately 6 L. The pH of this solution was adjusted to 7.8 with 
sodium hydroxide (3.5 M NaOH) and 18 g/L cetyltrimethylammonium bromide (CTAB) was 
added in sufficient quantities to precipitate out the polysaccharide. 93 g/L Celite was added 
to trap the newly formed PS–CTA+ salt and this slurry was stirred for 5 minutes before being 
allowed to settle. Rate nephelometry was used to determine the amount of PS left in the 
supernatant after CTAB precipitation. The Celite slurry was loaded onto a Millipore 
VANTAGE™ Chromatography column (internal diameter: 127 mm, cross sectional area of 
125 cm2, with an adjustable bed height) and washed with an acetate buffer containing a 
small amount of CTAB (0.05 %) to trap any PS that may still remain in solution as well as to 
remove any excess cell debris and media that may remain. Increasing concentrations of 
ethanol (EtOH) were applied to the column, starting at 5 % and increasing up to 60 %, to 
elute off the PS. A flow rate of 60 – 80 ml/min was maintained throughout the elution 
process. Fractions of each ethanol wash were collected and monitored for aggregates at 550 
nm and nucleic acids and proteins at 260 and 280 nm respectively. Polysaccharide elution 
was monitored using the uronic acid assay where the formation of a purple coloured 
complex was indicative of Pn1 elution. The fractions that tested positive for Pn1 were pooled 
together and solid sodium chloride (NaCl) added to produce a final concentration of 2 M 
NaCl. The PS was precipitated after a 1:1 volume of 96 % EtOH and the purified Pn1 was 
left at 0 – 4 °C overnight to allow for complete precipitation. The precipitated slurry was 
centrifuged for 10 min at 3500 rpm and the supernatant decanted. The wet pellet was 
dissolved in 125 ml water, diafiltered against seven volumes of 0.5 M NaCl buffer followed 
by seven volumes of water using a Labscale™ TFF system fitted with 2 x 100 kDa molecular 
weight cut off (MWCO) 50 cm2 membranes fitted in parallel. The final purified PS was 
concentrated down and stored at – 20 °C. 
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Figure 2.2. Process flow of the purification of Pn1 from the inactivated fermentation broth to final 
storage. 
2.3 Colorimetric assays 
Most carbohydrate and protein solutions in water are colourless. To determine their 
concentration in a solution, colorimetric assays have been developed. These colorimetric 
assays rely on a reaction between a reagent and the analyte in question. This reaction will 
produce a chromophore that can be measured at a specific wavelength. The concentration 
of the analyte in solution can be measured from the intensity of the colour using the Beer–
Lambert law which relates the absorbance of the analyte to its concentration using Equation 
2.1. 
 A   cl  Equation 2.1 
Where A is a dimensionless number (often called absorption units),   is the molar extinction 
coefficient which is structure, temperature and wavelength dependent, c is the concentration 
of the analyte in solution and l is the path length that the light must travel [195].  
The ideal colorimetric reaction should be sensitive, selective and non–reversible. The 
resulting coloured product should be stable and should also be very different to the 
compound being examined. The main difficulty with colorimetric assays is their specificity. 
No single colorimetric assay is absolutely specific and many other compounds/molecules 
may interfere with the assay. These interfering compounds may react with the chromophore 
producing a coloured complex that will interfere with the absorbance of the compound 
tested. A control blank, whose absorbance is subtracted from the analyte absorbance, is 
used to compensate for this interference. A control blank contains all compounds found in 
tested solution except for the analyte being tested.  
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All incubations, other than those performed at room temperature, made use of a Stuart 
heating block that was able to reach temperatures of 200 °C. All absorbances measured in 
the colorimetric assays were determined using a Shimadzu UV–Vis 1700 Spectrophotometer 
with UV Probe 2.2.1 software. 
2.3.1 Uronic acid assay 
Saccharide concentrations for Pn1 were determined with the uronic acid colorimetric assay. 
The Dische carbazole protocol [196, 197] is a widely used method for the conversion of 
uronic acids into 5–formylfuronic acid by heating under strongly acidic conditions. The 
reaction of 5–formylfuronic acid with carbazole yields a pink coloured complex with an 
absorption maximum at 530 nm as shown in Figure 2.3. 
 
Figure 2.3. Schematic of the hydrolysed saccharide reaction with carbazole. 
A modification of the Dische carbazole reaction for uronic acid in the presence of borate was 
developed and published in 1962 by Bitter and Muir [198]. The advantages of this modified 
procedure are: 
 An approximate two fold increase in sensitivity.  
 Maximum colour develops immediately. 
 The colour is stable for at least 16 hrs. 
 Improved reproducibility and reduction in interferences by chlorides and oxidants. 
As Pn1 contains a galacturonic acid moiety in its repeating unit, the method was modified 
from the published method to use galacturonic acid as a standard instead of glucuronic acid. 
This standard was used to create a reference curve in the range of 0 – 50 µg/ml and water 
was used as a blank sample. The final volume of all of the solutions was 150 µl. All solutions 
were placed on ice and 900 µl of a 0.025 M solution of sodium tetraborate in concentrated 
sulfuric acid was added. Samples were incubated at 100 °C for 5 min to allow for hydrolysis 
to occur. After the samples were removed from the heat and cooled to room temperature,  
30 µl of a 0.125 % solution of carbazole in ethanol was added and the samples were 
incubated for a further 15 min at 100 °C. The solutions were cooled to room temperature 
where the absorbances at 530 nm were recorded. A calculated correction factor of 1.5 was 
applied to all samples containing Pn1 to convert the amount of uronic acid in the 
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polysaccharide to the total amount of polysaccharide; this calculation is explained in Chapter 
3, Section 3.3.1.2. 
2.3.2 O–Acetyl Assay 
The O–acetyl content of Pn1 was determined using the Hestrin method [199]. This is the 
preferred method for determining the concentration of O–acetyl groups present on a long–
chain polysaccharide repeating unit. O–acetyl groups are released from the PS under 
alkaline conditions by hydroxylamine and converted to hydroxamic derivatives (Figure 2.4). 
These derivatives are complexed with ferric chloride to give a yellow complex that is 
detected using a spectrophotometer at 540 nm [200]. In order to account for interferences, a 
correction blank is also employed. In this case, the PS is reacted with hydroxylamine under 
acidic conditions. As hydroxamic derivatives are only formed under alkaline conditions, the 
generation of colour from the addition of ferric chloride will be indicative of interfering 
substances which will be corrected for. 
 
Figure 2.4. Schematic representation of the reaction of O–acetyl functional groups with 
hydroxylamine and the resultant reaction with ferric chloride. 
Pn1 has both O–acetyl and N–acetyl groups on its repeating unit. O–acetyl groups are the 
more labile and are liberated in cold, dilute base, whereas N–acetyl groups require much 
stronger alkaline conditions for release. In order to calculate the mass percentage of O–
acetylation on the PS, the concentration of the PS is determined and the percentage O–
acetylation is calculated using Equation 2.2.  
 
    Acetylation  
concentration from   acetyl assay
concentration from uronic acid assay
   100 Equation 2.2 
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Acetylcholine chloride was used as the standard. One mole of acetylcholine chloride is 
equivalent to one mole of O–acetyl. A standard curve was created in the concentration range 
of 0 – 600 µg/ml and water was used as the blank sample. The final volumes of all samples 
were 500 µl. All samples and standards were tested in quadruplicate; two of each solution 
were labelled as reaction samples and the remaining two were used to correct for the 
interference (known as correction samples). The reaction standards and samples were 
treated as follows: 1.0 ml of 1 M hydroxylamine in 1.75 M NaOH was added to all solutions 
and left to react for 2 minutes where after 500 µl of a 4 M HCl solution was added and the 
solutions were shaken to ensure mixing. The correction solutions were treated slightly 
differently as first 500 µl of a 4 M HCl solution was added to all the solutions to make them 
acidic and hence block the formation of the hydroxamic derivatives. 1.0 ml of the 1 M 
hydroxylamine in 1.75 M NaOH solution was added to each correction solution. To both the 
reaction and correction solutions 500 µl of a 0.37 M ferric chloride (FeCl3) in 0.1 M HCl 
solution was added with vigorous shaking. These solutions were left to react at room 
temperature for 20 minutes and vortexed to allow for the release of any bubbles that may 
have formed. The absorbance was read at 540 nm. The absorbance values for the 
correction tubes were subtracted from the reaction tubes to provide a final absorbance value 
corresponding to the amount of O–acetyl groups. 
2.3.3 UV protein assay 
This assay was specifically applied to the determination of protein concentration of TT and 
was performed by monitoring the UV absorbance at its maxima wavelength of 279 nm. 
Absorption by proteins in the UV spectrum, specifically at 260 – 280 nm, depends on the 
amount of tyrosine and tryptophan residues contained in the protein itself. Phenylalanine as 
well as disulfide bonds also absorb at 280 nm but to a small extent [201, 202]. The 
advantages of the UV absorption method are that it is both simple to perform and non–
destructive to the sample. The protein concentration (in mg/ml) is calculated using Equation 
2.3. 
 
Protein concentration   
A2  
 l
    w  
Equation 2.3 
Where Mw is the molecular weight of the protein, A279 is the absorbance value at 279 nm, Ɛ 
is the extinction coefficient (in M-1cm-1) and l is the path length (1 cm). The extinction 
coefficient of TT is 185 210  M-1cm-1 [203] and its molecular weight is 150 kDa. 
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2.3.4 Bradford (Coomassie) protein assay 
All protein concentrations, except for TT, were determined with the commercially available 
Bradford (Coomassie) assay kit [204]. This colorimetric method does not require the molar 
extinction coefficient of the protein to be known as it depends on the Coomassie Blue G250 
dye binding to the protein. This binding, which can only occur in an acidic environment, 
results in a spectral shift from the red/brown colour of the dye absorbing at 465 nm to       
610 nm producing a blue coloured complex. The difference between the two coloured 
solutions is greatest at 595 nm at which the absorbance is read. The binding of the protein to 
the dye is a result of hydrophobic interactions as well as van der Waals forces between the 
dye and certain basic amino acids (arginine, histidine and lysine). The number of these dye–
amino acid linkages is approximately proportional to the total number of positive charges on 
the protein [205]. Low molecular weight proteins (under 3 kDa), free amino acids and 
peptides do not produce a colour with the Coomassie dye and hence are not interfering 
substances in this assay. 
The reference curve was constructed with bovine serum albumin (BSA) in the concentration 
range of 25 – 2000 µg/ml. 30 µl of standard and prediluted sample were used, water was 
used as a blank sample. 1.5 ml of Coomassie reagent was added to each tube and mixed 
together. The solutions were left to react at room temperature for 10 minutes followed by the 
absorbance determination at 595 nm. 
2.3.5 Trinitrobenzenesulfonic acid assay 
In order to measure the amount of hydrazides coupled onto the carboxyls of the protein after 
protein derivatization, the trinitrobenzenesulfonic acid colorimetric assay was performed. 
This assay makes use of the 2,4,6–trinitrobenzene sulfonate (TNBS) reagent that was 
introduced as a colour reagent for amino acid analysis in 1960 by Satake [206]. TNBS is 
water soluble and does not react with ammonia or urea. TNBS reacts, under mild alkaline 
conditions, with amino groups via a Meisenheimer complex intermediate (Figure 2.5), to 
produce a coloured complex. The absorbance is measured at 550 nm as other amino groups 
will absorb at 340 and 420 nm [206]. 
This reaction distinguishes between hydrazine and hydrazides by the specific absorbance 
maxima of each complex. The TNBS–hydrazine complex has its absorbance maxima at    
570 nm whereas hydrazides absorb most strongly at 550 nm. Amino acids do not interfere 
with this assay as the absorbance maxima for these complexes are approximately 420 nm 
[207].  
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The absorbance of the coloured complex is measured at 550 and 750 nm. During the 
calculations, the absorbance at 750 nm is subtracted from the 550 nm reading. This is to 
correct for the interference that light scattering has on the absorbance values [208].  
 
Figure 2.5. Schematic of reaction of hydrazide derivatized protein with TNBS, formation of a 
Meisenheimer complex intermediate and final complex formation. 
Adipic acid dihydrazide (ADH) was used to construct the standard curve. As ADH contains a 
hydrazide grouping at each end of the molecule the molar concentration of hydrazides is 
double the molar concentration of ADH. The assay was performed in a 96 well microtitre 
plate. In the first two wells 100 µl of 2.5 mM ADH in water was added. The next two wells 
contained 100 µl of the sample to be tested and the last two wells used contained 50 µl of 
water. 50 µl of water was added to the remaining rows. 50 µl of each mixture from row 1 was 
transferred to the row 2 and mixed. This process was repeated for all rows in the well plate 
to create a dilution series. 100 µl of 0.1 N borate buffer (pH 9.0) was added to all the wells 
followed by 50 µl of a 0.1 % TNBS solution. The 96 well plate was covered and incubated at 
room temperature for 2 hours. The absorbance was read at 550 and 750 nm [209]. 
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2.4 Immunological Assays 
Biomolecular recognition is the ability of one biomolecule to interact with another specific 
type of biomolecule similar to a key fitting into a lock. The principle of biomolecular 
recognition is the basis for most immunological assays. In immunoassays the molecular 
recognition is between an antibody and an antigen which are the two fundamental molecules 
in the immune system. Both antibody (Ab) and antigen (Ag) cells contain recognition sites; if 
the recognition site of the antibody matches the recognition site of the antigen a Ab–Ag 
complex is formed. As the antibody will only react with a specific antigen, other antigens in 
the reaction mixture will remain unbound which creates high specificity in this form of 
analysis. In this way, no sample pre–treatment is needed [210]. Two different types of 
immunoassays were applied in this investigation, namely enzyme–linked immunosorbent 
assays (ELISA) and nephelometry. 
2.4.1 ELISA 
Enzymes are the most widely used labels in immunoassays. The enzyme label will act as a 
catalyst for the conversion of a colourless substance to a coloured product that can be 
detected at a particular wavelength. As the enzyme acts as a catalyst, only a small quantity 
is needed to convert a large number of substrate molecules, which would generate a large 
signal. ELISA can be classified into four main groups: direct, indirect, sandwich and 
competitive [211]. The competitive ELISA was used in these investigations. 
 
Figure 2.6. Pictorial representation of a competitive ELISA [212]. 
In competitive ELISA, as shown in Figure 2.6, the microplate is first coated with an antibody 
that is specific for the analyte being measured. The quantifiable analyte (antigen) is added to 
the plate along with an enzyme coated antigen which competes for the binding site of the 
antibody. After washing, to remove any unbound antigen, a colour reagent, that is specific to 
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the enzyme, is added and the absorbance measured. The intensity of the colour is 
proportional to the amount of enzyme added and is therefore inversely proportional to the 
amount of analyte present [212, 213]. 
100 µl of Pn1 PS immobilised antigen (1.5 µg/ml in PBS) was added to all wells of a 96 well 
plate (ELISA Plates F96 Maxisorp 96 well plates). The plate was covered and incubated 
overnight at 4 °C. Thereafter the plate was washed in a Biotek Platewasher with 0.03 % 
Tween 20 in PBS. 200 µl blocking solution (3 % BSA in PBS) was subsequently added and 
left to react for 1 hour at room temperature. The plate was washed with 0.03 % Tween 20 in 
PBS. One row acted as a negative control (water) and two rows acted as positive controls 
containing 50 µl of a 1.5 µg/ml Pn1 reference standard. 50 µl Ab/Ag diluent (0.3 % BSA in 
PBS) was added to the rows followed by 50 µl of sample that was diluted down throughout 
the sample rows. 50 µl of Type 1 antiserum working reagent (Statens Serum Institute (SSI), 
Cat No. SSI–AGGL–16744) was added to all wells and the plate was covered and incubated 
for one hour at room temperature. The plate was washed with 0.03 % Tween 20 in PBS and 
100 µl goat antirabbit horse radish peroxidase (HRP) (Whitehead Scientific, Cat No. 474 
1506) conjugate working reagent was added to all wells. The plate was again covered and 
incubated at room temperature for 45 min and washed a final time with 0.03 % Tween 20 in 
PBS. 100 µl of TMB Sureblue substrate (Whitehead Scientific, Cat No. 52–00.01) was added 
and left to react for 15 minutes followed by 50 µl of 0.5 M H2SO4 to stop the reaction. The 
absorbance of the plate was read at 450 nm on a Biotek plate reader. 
2.4.2 Nephelometry 
The principles of nephelometry rely on interactions between antibodies and antigens. A 
single antibody is specific for one particular antigen and when these two come into contact 
they bind to each other strongly and form a cluster (immune complex) that aggregates 
thereby increasing the turbidity of the sample [214]. 
When light is passed through the reaction solution, light is either scattered, absorbed or 
passes through the sample. Figure 2.7 shows schematically how a nephelometer works. The 
light source is set at a wavelength of 635 nm and is fixed at an angle of up to 90 degrees 
[215]. The laser beam passes through the sample into a light detector known as an Ulbricht 
sphere. If the sample contains particles the light is scattered and reflected inside the sphere 
and detected through a photodiode. In order to prevent the occurrence of stray light, the light 
source is accumulated into a narrow beam of high power density that results in a higher 
scattered intensity from the smaller particles. There is also a light trap situated at the bottom 
of the instrument that absorbs the portion of unscattered light (light not deflected by the 
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particles in the sample) [216]. The amount of light scattered is proportional to the 
concentration of antigen or antibody in the solution [215]. 
Nephelometry is used in numerous applications, automated drug solubility screening, 
quantification of proteins such as immunoglobulins in serum, monitoring polymerization 
reactions, monitoring effluent as well as monitoring changes in turbidity to test antimicrobial 
drugs [214-216]. 
 
Figure 2.7. Schematic of the inner workings of a nephelometer [216]. 
Nephelometry can also be used to measure the change in intensity of the scattered light 
during the formation of the antibody–antigen complexes by measuring the kinetics of the 
binding reaction between the antigen and antibody [217]. Lee used nephelometry to 
determine both the PS and protein content in pneumococcal conjugate vaccines [218]. 
In this investigation, nephelometry was used during purification to determine the amount of 
PS left in the supernatant after CTAB precipitation. The procedure followed by the 
Immunochemistry group at The Biovac Institute is as follows: In a microplate, 10 µl of Pn1 
working serum reagent (SSI, Cat No. 16744) was dispensed into all wells followed by 178 µl 
of 4 % polyethylene glycol (PEG) solution and mixed thoroughly. Pn1 standards and 
unknown samples are added and diluted down the rows. The plate was immediately 
analysed on the Nephelostar Galaxy nephelometer using software provided with the 
instrument. 
2.5 Electrophoresis 
Electrophoresis is the separation of macromolecules in an electric field. The capacity of an 
electric field to separate molecules carrying a charge is the foundation of electrophoresis. 
When an electrical field is applied between two electrodes, a charged molecule will be 
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attracted to the oppositely charged electrodes; i.e. a negatively charged compound will 
migrate towards the positive anode and the negative cathode will attract the positively 
charged molecules as shown in Figure 2.8 [210]. 
In biomolecule analysis the Lorentz force causes different molecules to move through the 
matrix under an electric field at different rates due to their net charges, masses and shapes 
[212]. The velocity of the molecule’s movement increases with an increase in net charge and 
the electrical field strength, although friction acts as a counter measure and decreases a 
molecule’s velocity. The frictional strength is primarily dependent on a molecule’s mass and 
shape as well as the viscosity and porosity of the supporting matrix over which the electric 
field is applied [212, 219]. 
 
Figure 2.8. Schematic of electrophoresis [210]. 
2.5.1 SDS Page 
One of the most common methods of separating proteins using electrophoresis is called 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE). SDS–PAGE uses 
sodium dodecyl sulfate (SDS) to denature proteins and an electric field is applied across a 
polyacrylamide gel. The negative charges on the SDS destroy the complex structure of the 
proteins (denaturing them) and are attracted to the anode in the electric field. The protein will 
bind different amounts of the anionic detergent SDS depending on its relative molecular 
mass with SDS having a constant binding ratio of 1.4 g SDS to every gram of protein. Thus 
SDS–PAGE, with the inclusion of molecular markers can determine the relative size or 
difference in size of the proteins. The gels used for all SDS–PAGE experiments were 
Criterion XT 3 – 8 % Tris–acetate pre–cast gels based on a Tris–acetate buffer system (pH 
7.0). These gels use discontinuous Tricine and acetate ion fronts that form moving 
boundaries that stack and separate the denatured proteins according to their relative 
molecular masses [212, 220].  
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This system used a pH neutral and stabilised solution of tris(2–carboxyethyl)phosphine as a 
reducing agent and a mixture of heat and SDS are used to denature the proteins. After the 
addition of the reducing agent and the SDS to the sample, it was heated at 95 °C for 5 min 
before being loaded onto the gel (Bio–Rad Criterion XT Tris–acetate 3–8 % resolving gel, 
Cat No. 345–9898). A XT Tricine Buffer kit (Bio–Rad, Cat No. 161–0797) was used for 
running buffer as well as the reducing agent. The gel was subjected to a constant electrical 
field of 150 V for 65 min with a starting current between 170 – 180 mA and a final current in 
the range of 85 – 95 mA [221]. Either of two different gel stains were used for detection: 
protein was detected using a Coomassie Blue R–250 stain and PS was detected using 
Schiff’s stain (periodic acid) [221]. 
2.5.2 Western blot 
The detection and identification of proteins is performed via a Western blot. Protein blotting 
is the transfer of proteins to a solid–phase membrane support. Once bound to membranes, 
these proteins can be used for biochemical or immunological analyses. The most commonly 
used protein blotting technique is known as Western blotting or immunoblotting. The two 
steps involved in Western blotting are the transferral of the proteins that have been 
separated via gel electrophoresis onto a membrane, followed by detection of the proteins by 
immunological methods. The membrane is composed of the hydrophobic polyvinylidene 
difluoride (PVDF) [221] that has a high protein binding capacity, target retention as well as a 
high resistance to cracking which makes it the preferred membrane for binding proteins. 
During the transfer the gel and membrane are sandwiched between filter paper and the two 
electrodes as shown in Figure 2.9 (all contained in a non–conductive cassette holder) and 
submerged under the conducting transfer buffer with an applied electric field [211, 222]. 
 
Figure 2.9. Schematic of the gel and membrane set–up for transferring proteins during Western blots 
[222]. 
The Western blot procedure was used, firstly, to separate protein components in samples 
obtained from downstream fermentation and secondly, to identify the proteins by use of an 
immunological detection system. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
44 
 
The membrane used was the Immun–Blot® PVDF membrane that was cut to approximately 
13.5 x 9 cm. Due to the hydrophobic nature of PVDF, it was immersed in 100 % methanol for 
2 minutes to pre–wet the membrane. The membrane was placed in cold transfer buffer 
(same buffer used to run the gels in SDS–PAGE (Section 2.5.1) for 10 minutes before the 
blotting sandwich was assembled as displayed in Figure 2.9. The sandwich was placed into 
the electrophoresis tank and run overnight at a maximum of 10 volts and 50 mA. The 
sandwich was disassembled and the membrane removed for detection. Detection was 
preceded by a blocking step in which the unoccupied binding site on the membrane were 
blocked to prevent any non–specific interactions. To do this the membrane was placed in 
Tris–buffered saline (TBS) for 10 min followed by 3 % bovine serum albumin (BSA) in TBS 
for 2 hours at 4 °C. The membrane was washed with Tween–20–TBS (TTBS) to remove any 
unreacted BSA. The membrane was incubated with a primary antibody (rabbit anti HIB (KPL, 
Cat. No. 4741506)) at room temperature for 2 hours and washed with TTBS to remove any 
unbound antibody. The membrane was incubated for a further hour at room temperature 
with a secondary antibody that was linked to horse radish peroxidase (HRP) (donkey anti 
rabbit HRP) (Jackson ImmunoReseach Laboratories, Cat. No. 711035152). Washing with 
TTBS followed by a wash with TBS (to remove traces of Tween) was performed and the 
membrane was incubated with Opti–4CN (Biorad, Cat. No. 170–8235) for 30 minutes at 
room temperature. Opti–4CN is an improved form of the colorimetric HRP substrate: 4–
chloro–1–naphthol. A final wash was performed with deionised water before the membrane 
was dried between filter paper [223]. In the presence of HRP and peroxide, a water soluble 
blue product was generated that was precipitated onto the membrane where the enzyme 
was located, allowing visual detection of the target antigen sample [224, 225]. 
A molecular weight marker (PageRuler plus pre–stained protein ladder (10 – 250 kDa)) was 
employed for all western blot experiments. Western blots were also performed to ensure that 
the structural integrity of the protein after conjugation. In this case the procedure followed is 
as detailed above except that the antibody employed was rabbit anti–TT/DT or 
pneumolysoid (PLD) depending on the carrier protein and the secondary antibody used was 
Goat anti–rabbit IgG peroxidase (KPL, Cat no: 4741506) and the colorimetric substrate was 
3,3’,5,5’–tetramethylbenzidine (TMB) 1 component membrane peroxidase substrate (Sigma 
Aldrich, Cat. No. T8665). 
2.6 Chromatographic methods 
Chromatography is the most widely used method of separation in bioanalytical chemistry. 
There are numerous chromatographic methods available that make use of the different 
chemical and physical characteristics of molecules, namely their molecular size, ionic charge 
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and adsorption qualities. Whilst chromatographic methods can vary enormously, they all 
separate components through the use of a stationary phase and a mobile phase. The two 
principle forms of chromatography used in this investigation were liquid and gas 
chromatography. In both cases the liquid and gas in the different forms refer to the mobile 
phases.  
The stationary phases in both methods are usually solid based in the form of a column. In 
general the sample containing the mixture of compounds to be separated is placed onto the 
stationary phase. The mobile phase is placed over the stationary phase and the compounds 
are separated based on their interactions with the stationary phase as shown in Figure 2.10. 
 
Figure 2.10. Principle of separation using chromatographic techniques [210]. 
In liquid chromatography these separated components are routinely detected by 
ultraviolet/visible (UV/Vis), refractive index (RI), fluorescence, conductivity and mass 
spectrometry (MS). In gas chromatography the compounds can be detected by numerous 
detectors including flame ionisation (FID), electron capture (ECD) or MS detectors [210]. 
2.6.1 Liquid Chromatography 
Liquid chromatography began in the early 1900s, in what is now known as “classical column 
chromatography”, where a glass cylinder is packed with a fine powder and the sample is 
applied to the top of the column and a solvent is poured onto the column. As the solvent 
moves down the column, using gravity, the components of the sample move through the 
column at different speeds and become separated. Advances to this technique have resulted 
in a more sophisticated, automated technique known as high performance liquid 
chromatography (HPLC). In this technique, samples are placed in an autosampler for 
automatic injection onto the column. The solvent is continuously pumped through the column 
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at a high pressure and the separated compounds are analysed by a detector as they elute 
from the column. The retention, elution and hence the separation of compounds is achieved 
by changing the composition of the mobile phase or introducing strong solvents or additives 
[226]. There are four main properties by which the samples are separated and five main 
techniques of separation. These can be found in Table 2.1. 
Table 2.1. Techniques used to separate compounds with liquid chromatography [227]. 
Property Technique 
Size Gel filtration (SEC) 
Charge Ion exchange (IEX) 
Hydrophobicity Hydrophobic interaction (HIC) 
Hydrophobicity Reverse phase (RP) 
Biorecognition (ligand specificity) Affinity (AC) 
The advantages of liquid chromatography over GC are numerous. Samples do not have to 
be volatile or heat stable so no derivatization is required. Sample preparation is therefore 
much less laborious and complex. The key prerequisite is that the sample must be able to 
dissolve in the mobile phase.  
Two liquid chromatographic techniques were used in this study, namely: gel filtration 
chromatography and ion exchange chromatography. 
2.6.1.1 Size exclusion chromatography 
The simplest form of chromatographic techniques in bioanalytical analysis is size exclusion 
chromatography (also known as gel filtration or gel permeation chromatography). Size 
exclusion chromatography (SEC) is a very robust technique that separates molecules based 
on the differences in their relative size. 
The compound solution is injected into a liquid solvent stream flowing through one or more 
columns packed with highly porous microparticles and the compound components are 
separated based on their size as shown in Figure 2.11 [227]. Each column has a 
characteristic exclusion limit which makes the column act as a molecular sieve. The 
molecules smaller or equal to the exclusion limit are retained as they are able to enter the 
pores and their progress is retarded compared to that of larger molecules. The molecules 
that do not enter the pores are eluted in the void volume as they pass through the column at 
the same speed as the mobile phase. Therefore, in size exclusion chromatography, 
molecules are eluted in order of decreasing size. Factors affecting the separation of 
molecules include: flow rate, stationary phase particle size, packing density of the stationary 
phase and the viscosity of the mobile phase.  
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Figure 2.11. Schematic of compounds separated by size [227]. 
Detection of the compounds in the eluent is achieved using either an ultraviolet absorption 
(UV) or refractive index (RI) detector. The RI detector detects compounds based on the 
difference between the refractive index of the compound and the solvent whereas the UV 
detector identifies compounds based on their absorption of light at a specific wavelength. 
Although this method is ideal for separating proteins, polysaccharides do not conform to 
standard elution principles as PSs are separated according to their apparent or 
hydrodynamic volume, which is not only dependent on the molecular weight but also by the 
molecular conformation in solution. Thus polysaccharides with an extended structure in 
solution may elute earlier than globular proteins of a higher molecular mass. 
Chromatography of the samples was performed using an Agilent 1200 HPLC system, 
equipped with micro–vacuum degasser, quaternary gradient pump with degasser, auto–
sampler, thermostatted column compartment, diode array detector (DAD), refractive index 
detector (set at 35 °C), fraction collector and Chemstation software. Separations were 
performed on one of two different column sets: either a Waters Ultrahydrogel guard column 
(code: WAT011565), Waters Ultrahydrogel 1000 column (code: WAT011530) and Waters 
Ultrahydrogel 500 column (code: WAT011535) columns mounted in series, in the order 
stated or Shodex guard column OHpak SB–G (code: F6709430), Shodex OHpak SB–805 
HQ (code: F6429104) and SB–804 HQ (code: F6429103) columns mounted in series in the 
order stated. 
The eluent for both sets of columns was 10 mM PBS buffer (pH 7.0) with an injection volume 
of 50 µl and a flow rate of 1 ml/min. The molecular weight was determined using a range of 
Pullulan standards shown in Figure 2.12. Molecular weights for the Pullulan standards were 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
48 
 
given in the certificate of analysis received from the supplier. Table 2.2 details the elution 
time and corresponding molecular weights of the standards.  
 
Figure 2.12. SEC–HPLC RID chromatograms of Pullulan standards on Shodex columns. 
Table 2.2. Molecular weights and elution times of Pullulan standards for both sonication and 
microfluidization. 
Standard Mw (kDa) Log (Mw) 
Waters columns Shodex columns 
Elution time (min) Elution time (min) 
P-800 788 2.897 15.126 13.168 
P-400 404 2.606 16.040 13.924 
P-200 212 2.326 17.077 15.113 
P-100 112 2.049 18.068 16.121 
P-50 47.3 1.675 19.172 17.239 
P-20 22.8 1.358 20.169 18.202 
P-10 11.8 1.072 20.806 18.871 
P-11 5.9 0.771 21.433 19.476 
2.6.1.2 Anion exchange chromatography 
High Performance Anion Exchange Chromatography with Pulsed Amperometric Detection 
(HPAEC–PAD) is frequently used to separate and identify carbohydrates without 
derivatization. The technique is highly selective and sensitive. HPAEC–PAD relies on the 
notion that carbohydrates are weakly acidic and are partially ionised at high pH values (˃12) 
and can thus be separated using anion exchange (neutral and cationic components will elute 
in the void volume) [228-230]. The column packing used in HPAEC is non–porous which 
minimises band broadening and is stable at high pH values and high pressures. There are 
various, specific column packings used for mono–, di– and poly– saccharides. The columns 
used in these investigations were the CarboPac PA1 and PA10, both of which are packed 
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with a polystyrene/divinylbenzene substrate onto which small  icroBead™ quaternary 
amine functionalized latex is electrostatically attached as shown in Figure 2.13 [231].  
 
Figure 2.13. An anion exchange resin bead [231]. 
Along with the column, the mobile phase (eluent) composition is very important. The 
composition of the eluent affects the speed of separation as well as the selectivity and 
sensitivity of the detection. Sodium hydroxide is the eluent of choice but its concentration 
depends on the substances under investigation. For neutral polysaccharides (glucose, 
galactose) a low concentration (± 20 mM) of NaOH allows for a more likely interaction with 
the stationary phase and hence separation. However for sugar acids (Pn1) and 
oligosaccharides a higher concentration of NaOH is needed as these compounds interact 
strongly with the column. Acetate (or nitrate) is added to shorten run times. Acetate acts as a 
”pusher” as it interacts with the anion exchange sites more strongly than hydroxide ions and 
will push out the charged compounds quicker [228, 231]. Acetate is also used in a gradient 
elution when there are mixtures of different size and different charged saccharides. As the 
eluent is a very important factor in the separation of saccharides, care must be taken to 
remove any contaminants such as carbonate. Carbonate contamination is very common as it 
is formed during the preparation of any alkaline solution through atmospheric carbon dioxide. 
Carbonate is a divalent ion at high pH values and can bind strongly to the anion exchange 
sites on the column which will not only interfere with the analysis of the saccharides but will 
drastically shorten the column lifespan [231-233].  
The detection method used is pulsed amperometry (the detection of ions in a solution based 
on electric current or changes in electric current). The hydroxyl groups on the carbohydrates 
are oxidized on the surface of a gold electrode at a specific potential resulting in the loss of a 
proton. This proton loss creates a current flow that can be measured. This oxidation at the 
surface of the electrode blocks the electrode which must then undergo a rise in potential to 
remove the contaminants. The potential is lowered to renew the surface of the electrode. 
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This all takes place as a pulse sequence over less than a second which allows for data to be 
recorded at every second. This detection allows for high specificity as only functional groups 
at the specific potential can be oxidized [231, 234]. 
Chromatography of the samples was performed using a Dionex BioLC chromatography 
system with an thermostatted auto–sampler (set at 20 °C), thermostatted oven (set at        
30 °C), gradient pump with degasser, electrochemical cell and borate trap (code: 047078) 
with Chromeleon software. Separations were performed on Dionex Carbopac PA1 analytical 
(code:  035391) and guard (code: 043096) columns.  The separation method was previously 
described by Talaga et al. [235]. Solvent A was water, solvent B was a 100 mM NaOH 
solution and solvent C was a 100 mM NaOH containing 1 M sodium acetate solution. 
Gradients of the three solvents were used simultaneously to elute the carbohydrates by 
mixing the three eluents. This resulted in the following gradient of NaOH: 0 – 15 min, 18 mM; 
15 – 18 min, 18 – 100 mM; 18 – 35 min, 100 mM; 35 – 55 min, 100 – 18 mM. The 
simultaneous gradient of sodium acetate was 0 – 18 min, 0 mM; 18 – 35 min, 0 – 300 mM; 
35 – 55 min, 300 – 0 mM. An injection volume of 20 µl of the hydrolysed Pn1 polysaccharide 
was used and the flow rate was 0.4 ml/min. The following pulse potentials and durations 
were used: E1 = 0.1 V, t1 = 400 ms; E2   −2 V, t2 = 20 ms; E3 = 0.6 V, t3 = 10 ms; E4 = 
−0.1 V, t4 = 70 ms.   
Pn1 PS was hydrolysed and derivatized for structural analysis on the HPAEC–PAD. The 
optimization of this method is detailed in Chapter 3, Section 3.4.3. Pn1 was first dried under 
vacuum at 45 °C (Thermo Speedvac Savant SPD131DDA Concentrator, 1.3 mbar, 3 hours). 
To this solid sample (between 0.1 – 0.5 mg) 1 ml 2 M trifluoroacetic acid (TFA) and 50 µg 
fucose were added. The solution was vortexed and irradiated by microwave (CEM Discover 
SP–D microwave) at 150 W and 121 °C for 60 seconds. Thereafter the samples were dried 
under vacuum at 45 °C and reconstituted in 500 µl water, filtered through 0.45 µm filters and 
into autosampler vials for HPAEC–PAD analysis. 
This microwave procedure was compared to the conventional heating procedure where 1 ml 
2 M TFA was added to a sample of Pn1 PS. Sample tubes were closed and placed in a 
preheated block for 2 hours at 121 °C. Samples were cooled to room temperature and 
transferred to Eppendorf™ tubes and dried under vacuum at 45 °C followed by 
reconstitution in 500 µl water, filtration through 0.45 µm filters before being placed into 
autosampler vials for HPAEC–PAD analysis. 
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2.6.2 Gas chromatography 
The idea of gas chromatography (GC) was first suggested by Martin and Synge in 1941 
[236] but it was only experimentally applied for analytical purposes in 1952 by James and 
Martin when modifications of the gas separation theory were applied to the separation of 
volatile fatty acids [237]. A simple GC consists of a carrier gas, an injector, a column and a 
detector. The mobile phase (carrier gas) in GC performs a different task to that used in LC. 
In GC the carrier gas is used only to transport the compounds through to the column. The 
retention time and separation of the compounds is based on their vapour pressure which is a 
temperature–dependant variable as well as the interaction between the compounds and the 
column (stationary phase). Hence the main adjustable variable is temperature so each 
component in the instrumentation is temperature controlled [226]. 
A schematic representation of the general layout of the gas chromatographic instrument is 
shown in Figure 2.14. When a sample is injected it is immediately vaporised in the injection 
port and taken up with the carrier gas through to the column where separation occurs. The 
column is situated in a temperature controlled oven and the temperature program starts at a 
relatively low temperature that normally separates the solvent from the sample. The 
compounds are separated through a heating program that is dependent on the nature of the 
compounds and the complexity of the samples. After separation the compounds leave the 
column and are recorded as a function of time. The most common detector used in GC 
analysis is a flame ionisation detector (FID). It is a simple yet highly sensitive detector where 
the carrier gas is mixed with hydrogen and combusted in air. Ions from the compounds are 
formed in this flame and collected in the form of a current that is proportional to the amount 
of sample injected [226]. The major development in GC was the introduction of open tubular 
capillary columns in 1957 by Golay [238-240], however this was improved upon in 1979 with 
the development of flexible silica material used in the tubing [240]. This tubing had major 
advantages over the traditional glass capillary columns in terms of flexibility and strength as 
well as inertness. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
52 
 
 
Figure 2.14. Schematic representation of an instrument used in gas chromatography. 
Sugar monomers, released from the polysaccharides by hydrolysis must first be derivatized 
before analysis on the GC. There are two main hydrolysis/derivatization techniques used in 
polysaccharide analysis. The first produces alditol acetate derivatives. This method is 
preferred as it produces a single peak which corresponds to each monosaccharide 
derivative. This makes identification and quantification simple. The alditol acetate method is 
widely used for mixtures of neutral and amino– sugars, however carboxyl groups cannot be 
derivatized with this method and the alternate procedure is favoured [241]. The alternate 
hydrolysis procedure, methanolysis, followed by derivatization, produces a fingerprint of 
methyl glycoside derivatives for every monosaccharide component of the polysaccharide, as 
both furanose and pyranose ring forms of both α– and β– anomeric configurations are 
derivatized and detected. Due to the carboxyl groups on Pn1, this method was preferred, 
however due to the resistance of the GalA glycosidic linkages to hydrolysis; this method had 
to be optimised.  
Pn1 PS was hydrolysed and derivatized for analysis on the GC. The optimisation of this 
method is detailed in Chapter 3, Section 3.4.4. Pn1 was first dried under vacuum at 45 °C 
(Thermo Speedvac Savant SPD131DDA Concentrator, 1.3 mbar, 3 hours). To this solid 
sample (between 0.1 – 0.5 mg) 20 µg myo–inositol (1 mg/ml solution in water) was added 
followed by 0.5 ml 3 N methanolic HCl (HCl/MeOH). Samples were irradiated with 
microwaves at 100 W and 121 °C for 60 seconds. Thereafter the samples were dried under 
nitrogen at 45 °C. 1 ml MeOH was added to each sample and dried an additional two times 
to remove any residual HCl. Finally 100 µl of silylating reagent (Hexamethyldisilazane/TMCS 
2/1 (v/v), silylating mixture Fluka I according to Sweeley) was added to each sample and 
incubated at 80 °C for 20 min. Samples were evaporated under nitrogen at 45 °C and 
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reconstituted in 500 µl hexane. Samples were filtered through 0.45 µm filters and into 
autosampler vials for GC analysis. 
The GC system used for separation of the hydrolysed polysaccharide was an Agilent 6820 
gas chromatograph with a flame ionisation detector with a DB–5 column (30 m x 0.32 mm, 
0.25 µm ID). Nitrogen was used as the carrier gas at a flow rate of 1 ml/min. The oven 
conditions followed the method by Kim et al. [242] which included an initial temperature of  
50 °C for two minutes. The temperature was then raised at 30 °C/min to 150 °C followed by 
an increase of 3 °C/min to 220 °C and finally a raise in temperature of 30 °C/min to      300 
°C where it was kept for 30 min. The inlet temperature was kept at 250 °C and the detector 
at 300 °C. An injection volume of 10 µl was used.  
As a confirmatory method, GC–MS was used. The GC system used for the separation was 
an Agilent 7890A gas chromatograph with an electron–ionisation mass spectrometer. The 
column used was a DB–5MS column. The method used for the GC–MS was the same as for 
the GC–FID however the mass spectra were recorded on a JEOL GCmate II mass 
spectrometer and analysed using AMDIS_32 software. 
This microwave procedure was compared to the conventional heating procedure where 1 ml 
3 N HCl/MeOH and incubated at 121 °C for two hours. Samples were dried under nitrogen at 
45 °C and washed twice with 1 ml MeOH to remove residual HCl. Samples were derivatized 
with the silylating agent as previously described.  
2.7 Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) is a spectroscopic method that is used to detect the 
reorientation of nuclear spin in an applied magnetic field [243]. The first nuclear magnetic 
resonance (NMR) signal was observed independently in 1945 by two physicists, Bloch and 
Purcell [244-246]. The physicists however were interested in the resonance aspect and did 
not investigate the structural analysis aspect; however chemists recognised this aspect and 
started to use NMR to investigate molecules. The most important advancement in NMR 
spectroscopy was the introduction of the superconducting magnet in the 1970s. This magnet 
provided a higher resolution to the analysis [247].  
The technique involves monitoring the absorption of energy associated with the transition of 
nuclei between two magnetic energy levels. The nucleus behaves like a spinning magnet, 
this spinning nucleus generates a magnetic field and an associated magnetic moment which 
interacts with the applied magnetic field [243]. In order to record the NMR spectrum of a 
sample it must be placed in a homogenous magnetic field. The sample is spun to improve 
the magnetic field homogeneity and small magnetic fields are applied to the main field, in a 
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process known as shimming, in order to cancel out any errors in the static field. In order to 
keep the ratio of magnetic field strength to the transmitter frequency constant, thereby 
preventing the drifting of the signal, the instrument is “locked” onto a strong narrow signal, 
usually deuterium [247]. 
Analysis by NMR yields spectra of magnetic sensitive nuclei (e. g. 1H, 13C and 31P) which 
depend on the structural environment of the nuclei and therefore provides a sensitive and 
non–destructive way of “looking” at the molecular structure of organic materials. The 1H 
NMR spectrum requires the least amount of sample and forms the starting point for the 
analysis. The saccharides and derived products are investigated as deuterium–exchanged 
samples, hence each signal arises from a C–linked proton and the chemical shift value 
depends on its electronic environment. It can be regarded as a distribution of protons 
according to their electron density. 2D homonuclear correlation (COSY and TOCSY) 
experiments are used to trace the spin systems corresponding to each monosaccharide 
constituent. The most common solvent used in NMR experiments is deuterium oxide (2H2O 
or D2O) as deuterium has a different resonance frequency than that of a proton (1H). D2O is 
used as carbohydrates are highly hydrophilic compounds.  
Samples analysed by NMR were lyophilized and exchanged twice with 99.9 % deuterium 
oxide and dissolved in 600 µl of the same D2O, and introduced into a 5 mm NMR tube. NMR 
spectra were recorded on a Bruker UltraShield™ 400 MHz NMR machine at 303 K unless 
otherwise stated. All chemical shifts are reported in ppm. The 1H NMR of Pn1 pneumococcal 
samples was referenced to the H3 of Cho–P–(O→ at 3.23 ppm and the 13C referenced to 
54.5 ppm of the C3 of CWPS; Cho–P–(O→ [248]. 
2.8 Conjugation of Pn1 to protein carrier 
There are many steps involved in successfully conjugating a PS to a protein. Functional 
groups on the protein amenable for conjugation consist of amine and carboxyls groups. 
These groups can be directly linked to the PS or, in this case, the carboxyl groups on the 
protein are converted into hydrazides with the addition of the spacer linker, adipic acid 
dihydrazide (ADH). This renders the protein more reactive as well as providing better 
accessibility of the functional group to the PS. The PS is prepared for conjugation by first 
size reducing the polymer (by chemical or mechanical means) to reduce the viscosity of the 
PS as well as creating more terminal residues that may be used in certain conjugations. The 
Pn1 PS is “activated” by creating an active ester intermediate which converts the carboxyl 
groups in the polysaccharide into more reactive groups to allow for successful conjugation to 
the derivatized protein. Conjugation of the reactive polysaccharide and derivatized protein is 
then achieved with the addition of the two components into the same vessel. Factors such 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
55 
 
as pH, temperature, reaction time, concentration and ratio of the reactants must be carefully 
monitored [10]. 
2.8.1 Protein derivatization 
The general derivatization method used in this study is described below. Modifications to this 
method for the different proteins employed can be found in Chapter 5: Protein Derivatization. 
The protein was either dissolved in or dialysed against a 60 mM 2–(N–
morpholino)ethanesulfonic acid (MES) buffer at pH 6.0 – 6.2. Solid ADH was added to the 
protein at room temperature in a ratio of 3.5 mg ADH / mg protein and the reaction mixture 
was stirred until all ADH dissolved. EDC, due to its very hydroscopic nature, was first 
dissolved in water to make up a 20 mM solution and this was added to the protein mixture at 
room temperature. A ratio of 0.15 mg EDC / mg protein was used. After mixing, the reaction 
was left unstirred at room temp for between 60 minutes and 16 hours depending on the 
protein and the desired level of derivatization required. 
The reaction mixture was quenched by raising the pH to 10 with 1 M NaOH. The reaction 
mixture was diafiltered against a 30 mM NaCl/ 3 mM sodium carbonate (Na2CO3) buffer at 
pH 10.5 using a Labscale™ TFF system fitted with 3 x 50 K  WCO 50 cm2 membranes 
fitted in parallel. Diafiltration continued until the permeate was clear of hydrazide (excess 
ADH). To test the permeate for ADH, 2 drops of permeate was added to a mixture of 100 µl 
0.1 % TNBS solution and 100 µl 0.1 M sodium borate, pH 9.0 followed by room temperature 
incubation for 5 min. An orange colour indicates the presence of ADH. SEC–HPLC was used 
to track the derivatization of the proteins. 
2.8.2 Polysaccharide size reduction 
2.8.2.1 Sonication 
For the sonication investigations the polysaccharide was first solubilised in water, placed in a 
50 ml beaker and cooled in an ice bath. The sample was exposed to a pre–set energy power 
output for a pre–determined time. The sonication cycle consisted of a 59s pulse with 15s 
break intervals. The total energy input was read from the sonicator display. Samples were 
passed through 0.45 um filters to remove any trace metal shed by the sonicator probe before 
analysis on SEC–HPLC. Sonication was performed on a VibraCell model VCX 750 
ultrasonic processor at the University of Stellenbosch.  
2.8.2.2 Microfluidization 
For microfluidization; polysaccharide samples of Pn6B and 14 were first dissolved in water at 
concentrations of 20 mg/ml. Samples were diluted to either 10 mg/ml (Pn6B and 14) or 5 
mg/ml (Pn1) due to the viscous nature of the polysaccharides. The samples were passed 
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through a Microfluidics M–110PS microfluidizer processor at a variable pressure for a 
predetermined amount of passes. 
In preparation for the conjugations used in the animal studies: 0.583 g of Pn1 was subjected 
to size reduction via microfluidization. 3.5 L of Pn1 Batch 019 (concentration: 166.7 µg/ml) 
was concentrated down to 125 ml using 2 x 30 kDa MWCO membranes on the Labscale 
TFF system. The concentrated sample was passed through a Microfluidics M–110PS 
microfluidizer processor four times at a pressure of 22 000 psi. 
2.8.3 HOBt mediated EDC conjugation 
The final HOBt mediated conjugation method applied to Pn1 and derivatized protein is 
detailed below. The optimisation of this method and its application to other protein carriers 
can be found in Chapter 6, Section 6.3. The conjugation reaction was performed on a       
100 mg Pn1 scale with an initial polysaccharide–protein mass ratio of 2:1. 
To the microfluidized Pn1, sufficient NaCl was added to give a Pn1 solution in 0.2 M NaCl. 
The derivatized protein was added to the polysaccharide solution at a ratio of 1 mg protein 
for every 2 mg polysaccharide. The pH of the mixture was monitored and adjusted to 
approximately 7.0 if needed. In a separate bottle EDC (2:1 w/w Pn1) and HOBt (1:1 molar 
ratio with EDC) were dissolved in a 1:1 solution of 10 mM MES/0.2 M NaCl, (pH 7.2) and 
dimethylsulfoxide (DMSO). The pH was checked and raised to approximately 6.50 with 1 M 
NaOH if necessary. The EDC/HOBt solution was added slowly to the PS–protein solution 
and checked for signs of precipitation. The pH of the solution was adjusted to 6.80 with 0.1 
M NaOH and left overnight at room temperature. The reaction mixture was dialysed 
extensively (3 x 2 L exchanges over a period of 2 days) in Slide–A–Lyzer cassettes of 10 
kDa MWCO against 10 mM PBS (pH 7.2). 
2.8.4 Triazine mediated conjugation 
This optimised triazine conjugation method resulted in a conjugate that was used in the 
animal studies. It was performed on a 100 mg polysaccharide scale and three different 
derivatized protein carriers (CRM197, TT and PLD) were used.  
To the microfluidized Pn1, sufficient NaCl was added to give a Pn1 solution in 0.2 M NaCl. 
The polysaccharide solution was cooled on ice to between 0 – 4 °C with stirring. The 
activating species of 2–chloro–4,6–dimethoxy–1,3,5–triazine (CDMT) and N–methyl–
morpholine (NMM) was first formed in DMSO and added with continuous stirring to the 
cooled Pn1 PS. After a further 5 min at 0 – 4 °C the PS solution was placed at room 
temperature and allowed to react for one hour where after the pH was measured to be 
between the range of 7.50 – 8.00. The derivatized protein was added to the polysaccharide 
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solution at a ratio of    1 mg protein for every 2 mg polysaccharide and the mixture was left to 
react at room temperature for 20 hours. The conjugate solution underwent extensive dialysis 
(3 x 2 L exchanges over a period of 2 days) in Slide–A–Lyzer cassettes; 10 kDa MWCO 
against 10 mM MES/0.2 M NaCl (pH 7.2). 
2.8.5 Conjugate purification 
In order to produce a conjugate vaccine for use in animal or human models – unreacted 
reagents and reactants, unwanted by–products as well as any other impurities must be 
removed. Whilst dialysis and diafiltration can remove a large amount of the smaller 
molecules, the unconjugated polysaccharide and protein often remain. Chromatographic 
methods such as size exclusion and hydrophobic interaction chromatography are widely 
used to remove protein and polysaccharide. 
2.8.5.1 Gel filtration liquid chromatography 
For purification of the conjugates, Sephacryl S500 HR packing was briefly investigated as a 
comparison to other purification technologies. 
Sephacryl media consists of cross–linked allyl dextran with N,N’–methylene bisacrylamide to 
form a hydrophilic matrix that provides high chemic l stability and tolerance for high flow 
rates. The porosity of the packing is determined by the dextran component and the S500 HR 
media was chosen as the packing material for these investigations as it has a fractionation 
range (Mr) of 1x104 – 1x108. The S500 column was attached to an ÄKTA–FPLC system 
equipped with a pump as well as a UV and conductivity detector. The running conditions, 
unless otherwise stated, can be found in Table 2.3. 
Table 2.3. Running conditions of the S500 HR packing material. 
 S500 HR column (XK16/40) 
Packing volume 125 cm2 
Bed height 40 cm 
Load volume 4 ml 
Protein sample concentration 2.1 mg/ml 
Mobile phase 0.2 M NaCl 
Flow rate 0.9 ml/min 
Volume of fractions collected 100 ml 
Detector used UV 
2.8.5.2 Hydrophobic interaction chromatography 
Most proteins have hydrophobic areas or patches on their surface, depending on the number 
of amino acids with hydrophobic functional groups (such as alanine, isoleucine, leucine, 
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methionine, phenylalanine, tryptophan, tyrosine and valine). To avoid contact with water, 
many of these residues are folded inside the protein’s structure but a few of them remain on 
the surface. As with ammonium sulfate precipitation, when the protein is released from the 
salt, it will interact with another hydrophobic medium. If this hydrophobic medium is found on 
a chromatographic resin the protein (and conjugate) is able to be separated from the 
unconjugated saccharide or any other components as the protein will interact with the 
column. The mechanism for this interaction could be due to surface tension, van der Waals 
forces, entropic considerations as well as the charge masking effect of small ions [249, 250]. 
When the salt concentration is decreased, the protein will be released from the column and 
elute. 
0.5 mg of sample was loaded onto a GE Healthcare HiTrap Phenyl HP (5ml) column and 25 
ml 1 M ammonium sulfate solution was used to bind the conjugate to the column and elute 
off the free saccharide. This mobile phase was changed to 0.05 M sodium phosphate (pH 
7.0) for 25 ml to elute off the conjugate. The flow rate was kept constant at 0.4 ml/min 
throughout the elution. The column was washed with 25 ml 1 M ammonium sulfate before 
the next sample was loaded. The elution of the compounds was monitored at 280 nm. 
2.8.5.3 Ammonium sulfate precipitation 
Most proteins are water soluble and their solubility is a function of the ionic strength and pH 
of the solution. At low concentrations, the presence of salt stabilises the various charged 
groups on the protein molecule, thus attracting the protein into the solution and enhancing its 
solubility. At high salt concentrations the maximum solubility of the protein can be reached 
and beyond this specific concentration, the water molecules become more and more 
attracted to the salt than to the protein due to the higher charge of the salt. This competition 
for hydration leads the proteins to start interacting with each other thus resulting in 
aggregation and eventually precipitation of the protein. The precipitation can be collected by 
centrifugation and the protein pellet is re–dissolved in a low salt buffer. The commonly used 
salt for this purpose is ammonium sulfate, due to its relative cost effectiveness and high 
solubility even at lower temperatures.  
Ammonium sulfate ((NH4)2SO4) is a salt that is widely used to precipitate proteins. It has 
been determined that polyvalent anions are more effective at salting out than monovalent 
anions and that the best combination for salting out a protein would be to use a polyvalent 
anion with a monovalent cation [251]. Both anions and cations have been arranged in the 
“Hofmeister series” which defines their ability to salt out proteins and other macromolecules. 
In terms of sulfate and ammonium ions, they are on the kosmotrope ends of the anion and 
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cation series; kosmotropes are known as “water structure makers” which have stabilising, 
salting out effects on proteins [251-254]. 
A saturated ammonium sulfate solution was prepared by dissolving 550 g ammonium sulfate 
((NH4)2SO4) in 1000 ml water and cool at 2 – 8 °C. Two volumes of saturated ammonium 
sulfate was added to the conjugate sample, mixed and left overnight at 2 – 8 °C. The 
solution was centrifuged to pellet out the conjugate and the supernatant was removed. The 
procedure was repeated and the final pellet was re–dissolved in 10 mM phosphate buffered 
saline (PBS) (pH 7.2). 
2.8.5.4 Deoxycholate precipitation 
The deoxycholate precipitation method for separating conjugated and unconjugated 
saccharide was first developed as a means of quantifying the amount of unconjugated 
saccharide in Hib conjugates, as the PRP–TT conjugate did not bind to hydrophobic 
interaction (HIC) columns. The method takes advantage of the PRP–TT conjugates ability to 
bind to deoxycholic acid (DOC) and precipitate out in acidic conditions leaving the 
unconjugated saccharide in the supernatant. The unconjugated saccharide is quantified 
using the appropriate assay and express as a percentage of the total PS in the conjugate 
[255, 256].  
1 ml of appropriately diluted sample was used; a PS concentration of 50 – 100 µg/ml was 
preferred, the pH of the diluent must not fall out of the range of 6.7 – 7.2. 100 µl freshly 
prepared 1 % w/v DOC (pH 6.8) was added, with mixing to each tube. The samples were 
incubated at 2 – 8 °C for 30 min. 1 M HCl (50 µl) was added and precipitation was 
immediately visible. The samples were centrifuged for 30 min to pellet out the DOC–
conjugate. The supernatant was assayed for PS using the colorimetric test for uronic acid. 
Care must be taken to remove any remaining traces of ammonium sulfate when used in 
conjugate purification as the ammonium sulfate will interfere in the colorimetric assays. 
2.8.6 Formulation 
In order to produce the conjugate in a form suitable for animal studies, the conjugates had to 
be formulated onto an aluminium–based adjuvant. The general formulation protocol is 
described below and further explanation of this in relation to specific conjugates can be 
found in Chapter 6, Section 6.4. 
In order to minimise bio burden in the conjugates, all formulations were performed under a 
laminar flow hood that was tested before and during use for any bacterial contamination. In 
all but one formulation, the final volume used was 1000 ml. Over a period of 90 minutes, 
0.067 M AlCl3 was slowly added to 0.25 M Na3PO4 solution.  
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flow rate (
ml
min
)  
addition volume 
time added
 
Equation 2.4 
The pH was left to stabilise over a period of 160 min after which 0.2 M succinic acid was 
slowly added (flow rate calculated as per Equation 2.4). A further volume of 0.25 M Na3PO4 
was added using the same flow rate as before to raise the pH. After the pH had stabilised, 2 
% Tween–80 and 2 M NaCl were added. The appropriate amount of antigen (conjugate) was 
added to give a final PS concentration of 2 µg/ml and the formulation was made up to the 
final volume with WFI grade water. Finally, the formulation was left to stir for a further 120 
min at room temperature to allow the pH to fully stabilise and allow for maximum antigen 
absorption before storage at 4 °C. 
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CHAPTER 3. STRUCTURAL CHARACTERISATION OF Pn1 PS 
3.1 Introduction 
In order to analyse the composition and determine the repeating unit of the polysaccharide 
specific information is needed: 
 The identity, relative amounts and sequence of the monosaccharides in the repeating 
unit. 
 The anomeric configuration of the glycosidic linkages, as well as the position on each 
residue of the linkage. 
 Whether the sugar is a furanose or pyranose ring form. 
 Any functional group modifications, positions of groups such as acetylation, 
phosphate groups, sulfate groups and any other modifications [257]. 
The molecular weight distribution of the PS should also be established. The purity and hence 
the chemical composition of a PS must first be determined in order to be used for further 
production or manufacturing purposes. As saccharides cannot be detected by absorption 
due to the absence of a chromophore, colorimetric assays in which a chromophore is 
generated are used to estimate the presence of certain specific sugars such as uronic acid, 
hexosamines and methylpentoses as well as certain functional groups. For the manufacture 
of vaccines, the WHO have established recommended values for specific sugars, functional 
groups and contaminants of each bacterial serotype [162, 258, 259]. 
To determine the identity and relative proportions of monosaccharides in the PS, a more 
comprehensive analysis is needed. This can be achieved by hydrolysing the PS into its 
monosaccharide components which can then be analysed using chromatographic methods 
such as HPLC [260, 261], GC [242, 262-266] and HPAEC [228, 229, 231, 234, 267, 268] . 
The glycosidic linkage position and size of the ring structures can be identified by cleavage 
reduction or methylation analysis [269-273]. The anomeric configuration used to be 
confirmed by the oxidation with chromium trioxide [274-277] but has been replaced by 
modern techniques such as NMR [278-285].  
3.2 The structure of Pn1 polysaccharide 
While Neufeld and Handel, in 1910, were the first to identify the first two (serotypes 1 and 2) 
of the 90–odd serotypes of S. pneumoniae, it was Heidelberger, Avery and Goebel who 
investigated the composition of the capsular PS of serotype 1 [286-288]. In the early studies 
of Pn1 PS in 1925, Heidelberger et al. found that the polysaccharide was not very soluble in 
its isoelectric form and could only be fully dissolved in an acidic or alkaline solution. They 
also discovered that it contained 5 % nitrogen, had an optical rotation of + 300° and an 
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isoelectric point of approximately 4; however, in 1948, Alberty and Heidelberger, confirmed 
the isoelectric point of Pn1 to be 2.8 [289]. The polysaccharide was hydrolysed into reducing 
sugars with a mineral acid but at the time, the identity of the sugars could not be determined. 
The formation of reducing sugars was detected when the PS was treated with nitrous acid 
and half of the 5 % nitrogen was released. This suggested that the nitrogen must be an 
integral part of the polysaccharide. No sulfur or phosphorus was detected. The 
polysaccharide tested positive for glucuronic acid but yielded mucic acid on oxidation which 
suggested that it contained galacturonic and not glucuronic acid. Both acidic and basic 
properties were shown for this PS, which was, at the time, different to the other two PSs 
studied (serotype 2 and 3) [286]. 
Avery and Goebel reported the first evidence of the presence and immunogenicity of the O–
acetyl functional group on Pn1 PS [287]. The authors were able to detect antibodies for the 
acetylated polysaccharide in type 1 antipneumococcal horse serum; the de–O–acetylated 
PS did not elicit antibodies. 
Further investigations into the composition of Pn1 were performed by Smith et al. who 
hydrolysed the polysaccharide with H2SO4 [290]. Galacturonic acid (GalA) and glucosamine 
(GlcN) were detected as well as the presence of a methylpentose and a hexose that 
behaves in a similar fashion to galactose. The PS contained 60 % uronic acid, 8 % amino 
sugar and 4 % total nitrogen was also reported. This hexosamine could not account for the 
entirety of the nitrogen and it was suggested that other nitrogenous material may be part of 
the polysaccharide structure. Guy et al. purified and modified the Pn1 PS in order to 
determine the repeating unit [291]. Through nitrous acid deamination, it was determined that 
the polysaccharide contains disaccharides of galacturonosyl–galactosamine and 
galacturonosyl–glucosamine. Residues of 2–amino–2–deoxyhexosylglucose were also 
identified. The partial structure of the polysaccharide was determined to be galacturonosyl– 
(1→3)–glucosaminyl–(1→3)–galacturonic acid.  
At the time the polysaccharide structure was known to consist of galacturonic acid (major 
constituent) and a hexosamine. The polysaccharide contained O–acetyl groups that were 
important in terms of its immunology and was amphoteric and contained nitrogen as a 
constituent in addition to that of the hexosamine. 
It was only in 1980, that Lindberg et al. provided the structure of the hexosamine [292]. The 
sugar was not isolated and identified but was rather determined as products of deamination 
(similar to those performed by Guy et al.). The optical rotation of the purified polysaccharide 
was found to be in agreement with previous studies and was indicative of a D–configuration 
for all three sugars in the repeating unit. NMR studies showed the presence of an N–acetyl 
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peak (at 2.06 ppm), the presence of methyl protons at 1.29 ppm which was thought to 
belong to a 6–deoxyhexosyl residue. The presence of an O–acetyl group was confirmed with 
a peak at 2.20 ppm and the three signals in the anomeric region were suggestive of three 
saccharides in the repeating unit. As galacturonic acid accounted for 60 % of the makeup of 
the polysaccharide, two of the sugars in the repeating unit were thought to be galacturonic 
acid. When the polysaccharide was N–acetylated the N–acetyl peak doubled in size which 
suggested that the third sugar could have been a diaminotrideoxy–sugar where only one of 
the amino groups was acetylated. In order to confirm the structure of the amino sugar, the 
polysaccharide was deaminated with nitrous acid followed by acid hydrolysis and detected 
as 2–amino–2,6–dideoxyglucose in its alditol acetate form by GLC–MS. When borohydride 
reduction preceded the acid hydrolysis, peaks indicative of 2–amino–2,4,6–trideoxyhexoses 
were detected by the mass fragmentation pattern. The authors concluded that in order for 
the results in the deamination reaction to have occurred, the starting sugar must have been 
2–acetamido–4–amino–2,4,6–trideoxygalactopyranose (AAT) [292]. The linkage sites of the 
two galacturonic acid residues were determined to be through O4 and O3 and the AAT 
sugar was determined to be linked through O3. The repeating unit is shown in Figure 3.1 
with a non–stoichiometric amount of O–acetyl groups whose location was not determined. 
It took another 20 years before the position of O–acetyl group was determined by Stroop et 
al. through the use of NMR spectroscopy [293]. The authors determined that the group is 
situated on the GalA residue (residue B in Figure 3.1) as the PS was able to survive through 
periodate treatment, and therefore must be on either the C2 or C3 position of the 4–
substituted GalA residue. 
 
 
Figure 3.1. Structure of Pn1 polysaccharide consisting of A – 2–acetamido–4–amino–2,4,6–trideoxy– 
galactose, B – galacturonic acid with O–acetylation and C – galacturonic acid. 
 
                                      A                           B                            C 
[3)-α-D-AATp-(1→4)-α-D-GalpA-(1→3)-α-D-GalpA-(1→]
n
 + (OAc) 
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3.3 Colorimetric assays 
Of the colorimetric, analytical tests required by the European Pharmacopoeia [294], only two 
were used to identify Pn1 namely: uronic acid and O–acetylation. 
Colorimetric assays were assessed in terms of their linearity and working range, the 
precision of the assay, the assay’s accuracy and its specificity.  
 Linearity: An assay’s linearity evaluates the procedure’s ability to obtain a response 
that is directly proportional to the concentration or amount of analyte in the given 
sample, and within a given range. In determining linearity, a minimum of five 
concentrations was recommended [295, 296]. Samples were prepared in triplicate 
and the mean absorbance was plotted against the concentration of the analyte in 
question. This plot was used to determine linearity and subsequently a regression 
line was calculated. Also determined were the y–intercept, the correlation coefficient 
and slope of the regression line. The linear range of the assay was determined from 
the 2nd order polynomial plot [295, 296]. 
 Assay precision: The precision of an assay is determined by how close the 
agreement (degree of scatter) is of a number of samples. The precision of an assay 
depends on firstly, the repeatability of the assay and the intermediate precision. The 
repeatability (intra–assay precision) is the variation experienced by a single analyst 
on a particular instrument. The repeatability is measure by analysing multiple (in this 
case 10) replicates of the same sample. The relative standard deviation is calculated 
for all samples and reported. Intermediate precision is reported as the analysis of the 
same assay by either a different analyst or instrument or on a different day. The 
reproducibility of an assay is calculated with the results of the assay performed by 
different laboratories. This was not performed for the colorimetric assays in question 
[295-297].  
 Assay accuracy: Accuracy is regarded as the closeness of a measured value to the 
true or accepted value. It provides an indication of any systematic error or bias in the 
method. Accuracy is determined by the measurement of the recovery of the sample 
in question by direct comparison with the true value. In this case a sample of known 
concentration at the lower, middle and upper level of the linearity curve was 
assessed. The percentage recovery of the sample must conform to the acceptable 
limits of 90 – 110 % [296, 297]. 
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 Limit of Detection (LOD): The limit of detection is considered to be the lowest 
amount of sample that can be detected (not quantified). The detection limit was 
calculated by determining the minimum level at which the sample can be detected. It 
is usually calculated by comparing the absorbances of the lower concentration of 
samples to that of the blank (signal to noise ratio). A ratio of 2:1 is considered an 
acceptable value for the detection limit [295, 297]. 
 Limit of Quantitation (LOQ): The quantitation limit is the lowest amount of sample 
that can be determined with suitable precision and accuracy. The LOQ was 
calculated in a similar fashion to the detection limit, by comparing the signal to noise 
ratio. However in this case, an acceptable value for the limit of quantification was 
taken as ratio of 10:1 [295, 297]. 
 Specificity: Assay specificity is the ability to assess whether the other substances in 
the sample may interfere with the assay detection. In determining specificity, a 
number of different substances normally found with the analyte in question, such as 
buffers, reagents, proteins etc., are analysed to determine if interferences do occur. 
Assay specificity was evaluated by investigating for matrix interferences caused by 
buffers, reagents etc. [295-297].  
3.3.1 Uronic acid assay 
The first instance of the use of carbazole to quantify uronic acid saccharides was reported by 
Dische in 1946 when uronic acid was quantified by its hydrolysis with concentrated H2SO4 
for 20 minutes in a boiling water bath, followed by the addition of a 0.1 % alcoholic solution 
of carbazole. This colour reaction reached its maximum intensity after 2 hours [196]. In 1949 
Dische modified this procedure by decreasing the concentration of sulfuric acid used as well 
as the temperature and length of incubation [197]. In this way a difference between uronic 
acids (i.e. glucuronic vs. galacturonic acid) could be determined. In 1958, Bowness 
determined that 5–formylfuroic acid was responsible for the colour formation with carbazole. 
Another compound formed during hydrolysis: 2,5–diformylfuran also reacts with carbazole 
although this reaction gives rise to different absorption spectra (550 nm) under the same 
conditions and does not interfere with the absorption at 530 nm [298]. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
66 
 
 
Figure 3.2. Structures of 5–formylfuroic acid, the major colour contributor to the uronic acid–
carbazole colorimetric assay as well as 2,5–diformylfuran and hydroxymethylfurfural (HMF). 
 In 2007, Li et al. confirmed Bowness’ findings when it was demonstrated that 5–formylfuroic 
acid was the major contributor to the coloured complex with carbazole, however, it was also 
shown that another derivative of carbohydrates – hydroxymethylfurfural (HMF) – absorbed in 
the 530 nm spectrum when complexed with carbazole as shown in Figure 3.2 [299], this 
however is not a hydrolysis product of uronic acid and should not interfere in the analysis of 
Pn1. 
Bitter and Muir, 1962, published a modified method of the Dische carbazole reaction where 
borate was added to the concentrated sulfuric acid to increase the intensity of the colour 
change allowing for an increase in sensitivity to a concentration as low as 4 µg/ml [198].  
3.3.1.1 Assay optimisation 
According to the European Pharmacopeia, glucuronic acid (GlcA) is used as the reference 
standard to produce the standard curve [294]. However, in the development of the 
colorimetric assay it was determined that glucuronic acid produces a more intensely 
coloured complex than galacturonic acid (GalA) which is the major component of Pn1 [197, 
198]. This result indicated that GalA would result in a far more accurate calculation of the 
uronic acid concentration than GlcA. Therefore both uronic acid monosaccharides were 
subjected to the colorimetric assay and the absorbances compared. Figure 3.3 shows the 
difference in absorbance between GlcA and GalA. Both standards gave a linear response 
over the concentration range (0 – 50 µg/ml) with a correlation coefficient (R2) for the 
regression for Glc = 0.9996 and 0.9983 for GalA, however the GlcA standards produced on 
average a 71 % greater absorbance than those of the GalA standards. This proved the 
hypothesis that GalA gives a more accurate representation of the uronic acid concentration 
in Pn1 PS. 
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Figure 3.3. Comparison between glucuronic acid (blue) and galacturonic acid (red) for use as a 
standard in the uronic acid colorimetric assay. 
3.3.1.2 Correction factor 
As Pn1 is not solely constructed of GalA residues, a correction factor needed to be 
determined. The correction factor would account for the difference in the total mass of the 
polysaccharide not accounted for by the assay itself. Pn1 comprises of three sugars, two of 
which are galacturonic acid moieties and one modified amino sugar, and thus the theoretical 
uronic acid composition was determined by Equation 3.1. 
 
  c omposition  
∑  W  component
∑  W  repeating unit
  100 Equation 3.1 
Hence, the percentage composition of uronic acid residues in Pn1 is equal to  
[(240.14+198.10)/660.92] × 100 = 66.3 %. (Molecular weight of Pn1 repeating unit = 660.92 
taking into account two sodium counter–ions for the carboxyl groups and chloride counter–
ion for the amino grouping). The WHO state that Pn1 polysaccharide should theoretically 
consist of 55.17 % uronic acid [162, 300], with the European Pharmacopoeia suggesting a 
typical specification of above 45 % [294]. The value of 66.3 % far exceeds the recommended 
minimum value and corresponds to a purity of 68 %. To correct for the amino residue not 
accounted for by the uronic acid assay (total composition is 100 %), a correction factor is 
required. The correction factor for this assay was assessed by dissolving 5 mg pure Pn1 PS 
in 100 ml water (50 µg/ml) and performing a further two–fold serial dilution (from 50 µg/ml to 
6.25 µg/ml) of these solutions. The polysaccharide concentration was determined by the 
uronic acid assay. The data generated suggested that the uronic acid contribution to the total 
polysaccharide is 66.8 % (average uronic acid concentration for an accurately prepared 50 
µg/ml solution of Pn1 is 33.425 µg/ml). Hence, the correction factor for the assay was 
experimentally calculated using Equation 3.2 and determined to be 1.50.  
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 Theoretical correction factor   
100
  c omposition accounted for by uronic acid assay
 Equation 3.2 
This corresponded well with the theoretical uronic acid composition. Applying this calculated 
correction factor, the average Pn1 concentration was 50.32 with a standard deviation of 0.68 
(compared to the originally prepared concentration of 50 µg/ml) (Table 3.1). The calculated 
percentage relative standard deviation (RSD) for samples was all within specification limits 
of ≤ 2 % at 1.36 %. 
Table 3.1. Values for determination of the correction factor for Pn1 polysaccharide. 
Dilution Average Absorbance (530 nm) 
Calculated uronic acid 
concentration (µg/ml) 
Calculated Pn1 
concentration (µg/ml) 
1 0.415 33.02 49.53 
2 0.208 33.44 50.16 
4 0.104 34.12 51.18 
8 0.049 33.60 50.40 
3.3.1.3 Assay validation 
Linearity shows that the method can produce results that are directly proportional to the 
concentration of the analyte in samples within a given range. The linearity of the assay was 
assessed by preparing and analysing a number of standards including 0, 10, 20, 30, 40, 50, 
100, 200, 500 and 1000 µg/ml, in triplicate, and plotting the mean absorbance against 
concentration (µg/ml).  
The results were shown to be linear across the tested range of 0 – 50 µg/ml using D–
galacturonic acid as standard (Figure 3.4). The slope and intercept of regression line 
obtained were 0.0123 and –0.0011 respectively with correlation coefficient (R2) = 0.9954.  
Non–linearity was evaluated for the assay and found to be at concentrations greater than 
100 µg/ml. The slope and intercept of the regression line obtained were 0.0032 and 0.5325 
respectively with correlation coefficient (R2)   0.8435. It’s important to note that although 
linearity for this assay continues at concentrations greater than 50 µg/ml and up to 200 
µg/ml, standards 100 µg/ml and 200 µg/ml were excluded from the standard curve because 
the respective OD’s are above 1.000. Thus, 0 – 50 µg/ml was the working concentration 
range for the D–galacturonic acid standards. 
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Figure 3.4. Graph of absorbance vs. concentration of GalA to determine linearity and working range 
of the uronic acid colorimetric assay.  
The precision experiments were carried out using a standard Pn1 saccharide concentration 
of 50 µg/ml. Ten replicates of this standard were assessed resulting in an average 
concentration of 50.02 µg/ml and a standard deviation of 0.412. The relative standard 
deviation was calculated to be 0.82 %, well under the specification of ≤ 2 %. 
The accuracy of the assay was assessed by analysing a sample of known concentration at 
the lower, middle and upper level of the linearity curve. The percentage recovery was 
calculated as shown in Equation 3.3 and found to be within acceptable limits of 90 – 110 % 
as shown in Table 3.2. 
 
   ec overy 
Calculated concentration
Actual concentration
  100 Equation 3.3 
Table 3.2. Calculation of percentage recoveries to determine the accuracy of the uronic acid assay 
using different concentrations of Pn1 polysaccharide. 
Theoretical 
concentration (µg/ml) 
Experimental 
concentration (µg/ml) 
Percentage 
recovery (%) 
12.5 11.29 90 
25 23.86 95 
50 50.83 102 
100 103.15 103 
The limit of detection of this assay was determined to be less than 5 µg/ml and LOQ of this 
assay was calculated to be 10 µg/ml. Finally the specificity of the uronic acid colorimetric 
assay was evaluated by analysing for matrix interferences including buffers, reagents and 
water (Table 3.3). To this end, a reference standard was prepared by diluting 75 µl of a 50 
µg/ml Pn1 PS solution with 75 µl of purified water to yield a final sample volume of 150 µl 
(1:2 dilution; 25 µg/ml final concentration). Testing samples were prepared with 75 µl of the 
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interfering substance (analyte) and 75 µl of a 25 µg/ml Pn1 PS standard solution. The 
acceptance criterion was that no optical difference should be observed between the 
reference sample and the testing samples. 
Table 3.3. Analysis of potential interfering species in the uronic acid assay.  
Blank/Analyte Optical difference Blank/Analyte 
Optical 
difference 
Pn1 PS N/A 5 % EtOH in 0.05 M NaOAc N 
0.2 M NaCl N 10 % EtOH in 0.05 M NaOAc N 
10 mM PBS N 15 % EtOH in 0.05 M NaOAc N 
10 % CTAB N 30 % EtOH in 0.05 M NaOAc N 
Saturated ammonium sulfate Y 60 % EtOH in 0.05 M NaOAc N 
Saturated ammonium sulfate was the only reagent found to interfere in the uronic acid 
assay. Therefore, if saturated ammonium sulfate is used during any processing, it would 
have to be completely removed in order to ensure no interference when assaying for uronic 
acid content. 
3.3.2 O–Acetyl assay 
The Hestrin protocol is the preferred method for determining the concentration of O–acetyl 
groups present on a long–chain polysaccharide repeating unit [199, 301]. O–acetyl groups 
are released from the polysaccharide under alkaline conditions by hydroxylamine and 
converted to hydroxamic derivatives. These derivatives are reacted with ferric chloride to 
give a yellow complex that is detected using a spectrophotometer at 540 nm. In order to 
account for interferences, a correction blank is also employed. In this case, the 
polysaccharide is reacted with hydroxylamine under acidic conditions. As hydroxamic 
derivatives are only formed under alkaline conditions, the generation of colour from the 
addition of ferric chloride will be indicative of interfering substances which can be corrected 
for.  
3.3.2.1 Assay optimisation 
When first performing the colorimetric assay, absorbance values for the same sample 
changed over a short period of time. Upon further examination bubbles were visible in the 
solution. This was later determined to be due to the nitrous oxide gas released as 
hydroxylamine has the ability to reduce ferric ions into ferrous ions according to Equation 
3.4. The ferrous ions do not however complex with hydroxamic acids [200, 302]. 
 2NH2OH + 4Fe
+3 → 4Fe+2 + N2O + 4H
+ + H2O Equation 3.4 
Dissipation of the gas bubbles by means of shaking seemed to work over a short period of 
time but bubbles would continue to form. The time between the addition of ferric chloride to 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
71 
 
the hydroxamic acid derivatives and the absorbance reading was investigated. Samples 
were mixed thoroughly after ferric chloride addition and allowed to stand for a maximum of 
60 min. Absorbance readings were taken at 0, 10, 20, 30 and 60 minutes and are plotted in 
Figure 3.5. It was determined that all bubbles had dissipated after 10 minutes but 
absorbance values only stabilised after a period of 20 minutes. This lag time between 
addition and absorption reading was taken into account for all further testing. 
 
Figure 3.5. Comparison of reaction time after the addition of the ferric chloride colour reagent. 
3.3.2.2 Assay validation 
There is no specific correction factor for the O–acetyl assay as the WHO specification is 
based on dry weight [162]; rather, the percentage O–acetylation on the polysaccharide is 
calculated. For this determination, the concentration of the polysaccharide in the solution 
must be confirmed using an appropriate colorimetric assay (For serotype 1 the uronic acid 
assay is employed) and the percentage O–acetylation determined using Equation 3.5. 
 
    acetylation   
concentration of   acetyl groups
concentration of the polysaccharide
   100 Equation 3.5 
In order to determine the linearity of the assay, standards containing a range of 
concentrations from 0 – 6000 µg/ml of acetylcholine were prepared in triplicate as per the 
method reported and the resultant mean absorbance against concentration of the standard 
were plotted. The results were shown to be linear across the test range of 0 – 500 µg/ml 
using acetylcholine as the standard as shown in Figure 3.6 The slope and intercept of the 
regression line obtained were found to be 0.0009 and –0.0024 respectively with a correlation 
coefficient (R2) value of 0.9998. Non–linearity was observed for concentrations greater than 
1000 µg/ml. The slope and intercept of the graph with these absorbances included change 
to 0.0005 and 0.1215 respectively with the correlation coefficient decreasing to 0. 3 82. It’s 
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important to note that although linearity for this assay continues at concentrations greater 
than 600 µg/ml and up to 1000 µg/ml (R2 = 0.9998) and even to 3000 µg/ml (R2 = 0.9981), 
standards 1000 µg/ml and above have been excluded from the standard curve because the 
respective OD’s are close to 1.00. Thus, 0 – 600 µg/ml is the working concentration range 
for the acetylcholine standards. 
 
Figure 3.6. Graph of absorbance vs. concentration of acetylcholine to determine linearity and working 
range of the O–acetyl colorimetric assay. 
The concentration working range of the acetylcholine standard was determined from the 
linearity testing, where after (i) assay precision; (ii) assay accuracy; and (iii) assay specificity 
was performed. The precision experiments were carried out using a 1 mg/ml Pn1 PS 
solution. The O–acetylation pattern of this standard was determined to be 23.74 %. Ten 
replicates of the 1 mg/ml Pn1 PS standard were analysed and returned an average            
O–acetylation percentage of 23.73 % with a standard deviation of 0.446. The range of these 
samples (calculated as ± twice the standard deviation) was determined to be within 22.84 – 
24.62 % and the relative standard deviation was calculated at 1.88 % that was within the 
acceptable specification limits of ≤ 2 %. 
The accuracy of the assay was assessed by analysing a sample of known concentration at 
the lower, middle and upper level of the linearity curve. The percentage recovery was 
calculated as shown in Equation 3.6 and found to be within acceptable limits of 90 – 110 % 
as shown in  
Table 3.4. 
 
   ec overy  
Calculated concentration
Actual concentration
   100 Equation 3.6 
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Table 3.4. Accuracy results used in the O–acetyl assay. 
Dilution O–acetylation groups on Pn1 (%) 
Percentage 
recovery (%) 
1 22.15 93 
1.67 22.77 96 
2.5 22.06 93 
5 22.91 97 
By calculating the ratio between the blanks and the samples the detection limit of this assay 
was determined to be 4 µg/ml and the limit of quantification was calculated at 15 µg/ml. 
The specificity of the test method was evaluated by analysing for matrix interferences 
including buffers, reagents and water. To this end, a reference standard was prepared by 
diluting 250 µl of a 1 mg/ml (polysaccharide) standard with 250 µl of purified water to yield a 
final sample volume of 500 µl (1:2 dilution; 500 µg/ml final Pn1 concentration). Testing 
samples were prepared with 250 µl of the interfering substance (analyte) and 250 µL of the 1 
mg/ml (polysaccharide) standard. The acceptance criterion is that no optical difference 
should be observed between the reference sample and the testing samples (Table 3.5). 
Table 3.5. Substances tested in determining assay specificity. 
Blank/Analyte Optical difference Blank/Analyte 
Optical 
difference 
Pn1 PS N/A 5 % EtOH in 0.05 M NaOAc N 
0.2 M NaCl N 60 % EtOH in 0.05 M NaOAc Y 
0.05 M sodium phosphate N 0.1 M MES Y 
10 % CTAB N Saturated Ammonium sulfate Y 
It should be noted that a high percentage of ethanol, saturated ammonium sulfate and MES 
buffer were found to interfere in the O–acetyl assay. Therefore, if any of these reagents are 
used during the process, they would have to be completely removed in order to ensure no 
interference when assaying for O–acetylation content.  
3.3.3  Summary of colorimetric methods 
Two colorimetric assays were optimised from the European Pharmacopoeia methods to 
enable the accurate quantification of Pn1 polysaccharide. The colorimetric assays were 
validated in terms of linearity, precision, accuracy, LOD, LOQ and specificity. The standard 
used in the uronic acid assay was changed to galacturonic acid, as it provided a better 
correlation to Pn1 PS than glucuronic acid. A correction factor to enable the accurate 
quantification of Pn1 PS was calculated to be 1.5 for the uronic acid assay. No correction 
factor was needed for the O–acetyl assay, and it was determined that in order to achieve 
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stable absorbance readings, the complexed solution had to be vigorously mixed and left to 
stand for 20 minutes for complete dissipation of any bubbles.  
3.4 Polysaccharide hydrolysis 
While colorimetric assays give an indication of the identification and quantitation of certain 
functional groups (uronic acids, methylpentoses, O–acetyl groups) they cannot accurately 
determine the identity and quantity of the total number of monosaccharides in the repeating 
unit without the use of a correction factor. For this, more sensitive and specific detection 
methods are needed. The conventional method of identifying and quantifying 
polysaccharides is first to hydrolyse the material and then separate and quantify the 
constituent monosaccharides on a chromatographic column.  
There are many different methods to hydrolyse a polysaccharide into its monosaccharide 
components. Both chemical and enzymatic approaches are commonly used for a variety of 
polysaccharides. Enzymatic methods make use of the specificity of enzymes to target their 
substrates present in complex mixtures. There are two main types of enzymes which 
promote the hydrolysis of polysaccharides: endohydrases which will hydrolyse the internal 
glycosidic linkages, and exohydrases which will hydrolyse terminal glycosidic linkages [303]. 
Enzymatic methods are fast, very sensitive and highly specific [304]. 
The most common chemical approach for polysaccharides is acid hydrolysis. The rate of 
hydrolysis of polysaccharides is dependent on many different factors including ring structure, 
anomeric configuration, type of glycosidic linkage, chain length and the type of 
monosaccharide residues contained in the polysaccharide [303]. Many different acids have 
been investigated for use in the hydrolysis of polysaccharides, including sulfuric acid 
(H2SO4) [305, 306], hydrochloric acid (HCl) [306, 307], hydrofluoric acid (HF) [308] and 
trifluoroacetic acid (TFA) [306, 309]. TFA has many advantages over the aforementioned 
acids. Reaction times are shorter with TFA and, due to its volatility, there is no need for 
neutralisation as TFA can be removed by evaporation [310, 311].  
The acid hydrolysis reaction can follow one of two different mechanisms. Both the ring 
oxygen as well as the glycosidic oxygen can be protonated. If the glycosidic oxygen is 
protonated, Figure 3.7, the glycosidic linkage is cleaved and a carbocation is formed on the 
anomeric carbon. This carbocation can react with water to give a mixture of both α and β 
anomers of the original ring form. If the ring oxygen is protonated, a ring conversion can 
occur yielding a mixture of α,β–pyranose and α,β–furanose ring forms [312]. However, 
different polysaccharides behave differently during hydrolysis due to their monosaccharide 
composition: on the Pn1 PS repeating unit the uronic acid and 2–acetamido saccharides will 
not be fully hydrolysed. 
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The carboxylic acid functional group on the uronic acid has an electron–withdrawing, 
inductive effect on the sugar. This group creates an electron deficient C1, slowing down 
hydrolysis reaction mechanism which produces a hydrolysis resistant sugar. The acetamido 
group will be deacetylated and then protonated in the acidic medium, this provides the 
functional group with a stronger electron withdrawing inductive effect than the carboxylic acid 
functional group. 
As with other deoxy–sugars, the 2–acetamido–4–amino–2,4,6–trideoxygalactopyranose 
residue of Pn1 was found to be very sensitive to acid hydrolysis and completely degraded 
during analysis [313].  
In 1992, Yu Ip et al. investigated acid hydrolysis of the pneumococcal serotypes 6B, 14, 18C 
and 23F with hydrofluoric acid (HF) followed by trifluoroacetic acid (TFA) and TFA on its own 
and separated and identified on HPAEC–PAD [308]. The hydrolysis with HF and TFA was 
found to be optimal in hydrolysing the pneumococcal serotypes that contained a 
phosphodiester bond (6B, 18C and 23F). For Pn14, optimal hydrolysis conditions were 
determined to be a 16 hour reaction at 98 °C with 2 N TFA.  
Methanolysis is an alternate method of cleaving glycosidic bonds and produces O–methyl 
glycosides. Methanolysis is less destructive than acid hydrolysis for neutral 
monosaccharides, acetamido–sugars, uronic acids and sialic acids as methyl glycosides are 
more stable than the open chain or reducing sugars formed by hydrolysis with acid [304, 
312, 314].  
While the reaction mechanism (Figure 3.8) is similar to the acid hydrolysis procedure, the 
methanol is a much stronger nucleophile than water. Protonation of the glycosidic oxygen is 
followed by the glycosidic cleavage and formation of the anomeric carbocation; the reaction 
with methanol results in a mixture of α– and β–anomers of a 1–O–methylated saccharide. 
The protonation of the ring oxygen may also occur which would result in the observed 
formation of mixtures of α and β anomers of both pyranose and furanose ring forms [312, 
315].  
Carboxyl groups can be converted into methyl esters and N–acyl groups are cleaved during 
methanolysis [312, 314]. The AAT sugar in the Pn1 PS is destroyed during the methanolysis 
procedure and hence a re–N–acetylation step is not needed. The resultant products can be 
directly analysed by HPAEC or derivatized and analysed on GC.  
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Figure 3.7. Simplified reaction mechanism of the acid catalysed hydrolysis of a model (β–1,4) – 
galactan [312]. 
 
Figure 3.8. Simplified reaction mechanism of the cleavage of a glycosidic linkage (model (β–1,4) – 
galactan) using the methanolysis procedure [312]. 
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Sweeley and Walker, in 1964, used methanolysis and GC to analyse a number of different 
glycolipids and gangliosides and determined that a 0.5 N methanolic HCl (HCl/MeOH) at    
75 – 80 °C for 24 hours was sufficient enough to form the methyl glycosides of hexoses, 
neuraminic acid and hexosamines [316]. It was Sweeley and Walker that determined in 
order to detect hexosamines, a re–N–acetylation step would need to be included in the 
procedure before derivatization. Chambers and Clamp, determined the stability of 
monosaccharides in HCl/MeOH and found them to be unstable in 4 M and 6 M HCl/MeOH at 
100 °C [307]. The methanolysis of glycopeptides and oligosaccharides was found to be 
complete within 3 hours at 85 °C. Bleton et al. studied the characterisation of neutral sugars 
and uronic acids with Sweeley’s methanolysis in 1  6  and determined their mass spectral 
fragments [263]. The methanolysis of hyaluronic acid [317], agarose [318], and pectins [319, 
320] amongst other polysaccharides have also been studied. 
Kim et al. investigated a GC method to quantify Streptococcus pneumoniae polysaccharides, 
activated polysaccharides and polysaccharide–protein conjugates (Table 3.6) [242]. The 13 
serotypes found in Prevnar–13 were subjected to methanolysis followed by re–N–acetylation 
and trimethylsilylation. Peaks were confirmed by comparing the retention times against 
monosaccharide standards as well as mass spectral analysis. Pn1 PS could not be fully 
hydrolysed due to the acid resistant glycosidic bonds which was first reported by Talaga et 
al. in 2002 [235]. Kim hypothesised that the extra peaks in the hydrolysed Pn1 
chromatogram shown in Figure 3.9 were due to disaccharides and trisaccharides that could 
not be hydrolysed (based on retention time comparison with model di– and tri–saccharides). 
The presence of these saccharide units was always reproducible and were used in 
conjugation with the GalA monosaccharide residues, to quantify the saccharide and 
compared well (102 %) with the colorimetric method. 
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Table 3.6. Summary of hydrolysis and methanolysis work performed on pneumococcal serotype 1 
polysaccharides. 
Author Serotype  Reagents Temperature (°C) 
Time 
(min) 
Talaga et al. 
[235] 1, 3, 4, 5, 6B, 7F, 9V, 
14, 18C, 19F, 23F 
a) 
2 N HCl/MeOH 
+ 2 M TFA 
80 
121 
24 hr. 
120 
 b) 2 M TFA 121 120 
  c) 
48 % HF 
+ 2 M TFA 
65 
121 
120 
120 
Kim et al. 
[242] 
1, 3, 4, 5, 6A, 6B, 7F, 
9V, 14, 18C, 19A, 
19F, 23F 
 
3 N HCl/MeOH 
MeOH, py, Ac2O 
TMS 
121 
RT 
80 
120 
30 
20 
 
Figure 3.9. GC chromatogram of hydrolysed Pn1 from Kim et al. [242]. 
The combination of methanolysis followed by hydrolysis with TFA has been successfully 
applied by both De Ruiter et al. and Talaga et al. [235, 311]. De Ruiter et al. investigated the 
hydrolysis of various polysaccharides from fungi, plants and animals that contained uronic 
acid residues [311]. Comparisons of methanolysis followed by TFA hydrolysis with H2SO4 
and TFA acid hydrolysis were made using HPAEC analysis. The method used a 16 hr. 
methanolysis at 80 °C followed by hydrolysis conditions of 2 M TFA, at 121 °C for 1 hour. In 
this way the polysaccharide was converted into methyl glycosides through the methanolysis 
and subsequently into the monosaccharide residues after hydrolysis. This resulted in the 
complete hydrolysis of most of the polysaccharides when compared to acid hydrolysis alone 
as shown in Figure 3.10 with respect to citrus pectin. Only monosaccharides could be 
detected from this method compared to the presence of oligomers in the TFA hydrolysed 
sample. 
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Figure 3.10. Chromatograms of citrus pectin after a) TFA hydrolysis and b) methanolysis followed by 
TFA hydrolysis [311]. 
Talaga et al. [235] applied a combination technique of acid hydrolysis and methanolysis to 
eleven pneumococcal serotypes and cell wall polysaccharide using three different methods; 
TFA hydrolysis, methanolysis followed by TFA hydrolysis and HF followed by TFA hydrolysis 
(Table 3.6). The hydrolysed samples were separated and identified by HPAEC–PAD. It was 
determined that the best results were achieved with the TFA hydrolysis for most of the 
polysaccharides. Serotypes 3, 5 and 9V which contained glucuronic acid (GlcA) were best 
hydrolysed with methanolysis followed by TFA hydrolysis. Pn1, however, proved difficult to 
fully hydrolyse as the AAT sugar is known to be destroyed during acid hydrolysis [292, 321] 
and the linked GalA disaccharide residue that remains after the AAT sugar had been 
destroyed was very resistant to acid hydrolysis. Although the methanolysis/hydrolysis 
method produced a superior hydrolysis of Pn1 PS, Figure 3.11, it was not suitable to be 
used as a quantitative method for Pn1 due to the low recovery of GalA. 
 
Figure 3.11. HPAEC–PAD chromatograms of hydrolysis of Pn1 PS by a) TFA hydrolysis and b) 
methanolysis and TFA hydrolysis. Fucose (Fuc) was used as the internal standard [235]. 
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The advantage of methanolysis and TFA hydrolysis over other hydrolysis methods is that 
both reactants can be removed by evaporation and thus both reactions can be performed in 
the same reaction vessel, eliminating major losses and improving the reproducibility of the 
reactions.  
3.4.1 Microwaves 
Due to the resistance of Pn1 PS to conventional hydrolysis, an alternate strategy was 
sought. Microwaves and microwave heating were investigated as the techniques have been 
applied to many different chemistry–related fields [322-331]: from protein and peptide 
analysis [332-335] to glycosylations [336, 337], methylation [338] and esterifications [339]. 
Microwaves have also been used to derivatize compounds for GC analysis [340]. Much work 
has recently been performed on the extractions and hydrolysis of compounds [341-350] as 
well as degradation studies on hyaluronic acid [351-353]. 
Microwave energy comprises of electromagnetic waves in the range 300 MHz to 300 GHz 
that corresponds to wavelengths of 1 cm to 1 m and is found between infrared and radio 
frequencies. They consist of oscillating magnetic and electric fields at right angles to each 
other (Figure 3.12). The fluctuation of the electric field causes liquids to heat when exposed 
to microwave energy. Liquid can be heated by two different mechanisms; polar molecules 
align their dipole moments to the changing electric field which cause them to rotate back and 
forth as well as colliding with the nearest molecules generating heat. The other mechanism 
is based on ions in solution that migrate to the oppositely charged side of the electric field. 
The consequence of this movement is collisions between the ions and other molecules in 
solution which again, generates heat. These two mechanisms contribute simultaneously to 
the rate of heating [332, 335, 354]. 
 
Figure 3.12. Schematic representation of a microwave [354]. 
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The use of microwaves in chemical synthesis became popular after published articles by 
Giguere and Gedye in 1986 [322, 355]. The authors identified that microwave heating results 
in faster reaction times of a few minutes, compared to the hours of traditional thermal 
heating. The difference between conventional thermal heating and microwave heating is the 
way in which the heat is transferred to the sample. In conventional heating the thermal 
energy must first heat the heating mantel which in turn heats the outer surface of the 
container. The hot outer surface of the container transfers the heat onto the reaction mixture. 
The heat transfer is very slow and inefficient, and can result in some parts of the reaction 
mixture heating up before the ideal temperature is reached.  When the heat source is 
switched off, the heat is still being transferred from the reaction container to the reaction 
mixture.  
The energy that comes with microwave heating, on the other hand by–passes the heating 
mantel and container as most mantels and containers are permeable to microwaves. The 
energy interacts directly with the reaction mixture. This allows for the heat to be transferred 
quicker and more evenly than thermal heating. Due to the by–passing of the reaction vessel, 
when the heat source is switched off, the reaction does not continue to heat and therefore 
reduces the risk of overheating. Figure 3.13 shows the difference between conventional and 
microwave heating. 
 
  
Figure 3.13. a) Conventional thermal heating compared to microwave heating [354] and b) inverted 
temperature gradient in conventional heating and microwave heating [323]. 
The use of microwaves in the hydrolysis of carbohydrates has been gaining popularity. The 
hydrolysis of starch was one of the first carbohydrates investigated and Yu et al. found that 
the microwave hydrolysis of starch in dilute acid was complete within 5 min instead of 60 min 
by conventional heating. The effects of salt on the acid hydrolysis of oligomers and glucose 
was also investigated and it was found that the addition of some inorganic salts could further 
decrease the hydrolysis time of starch [344, 356]. 
a) b) 
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Plant seed gums, consisting of galactomannans have also been the subject of microwave 
assisted acid hydrolysis. Hydrolysis was shown to be complete within two minutes using a 
very dilute (0.00625 N) sulfuric acid solution compared to the conventional acid hydrolysis of 
over 40 hours with either 2 N H2SO4 or 4 hr. with 1 M TFA solution [343]. This demonstrated 
the superiority of microwaves when compared to thermal conventional heating and resulted 
in the use of milder reaction conditions and reactants, higher yields, enhanced selectivity, 
faster reactions and purer products [325, 327, 342, 346]. 
Pn1 PS has not been the subject of microwave assisted hydrolysis investigations. As the 
monosaccharide components of Pn1 render it acid resistant it was thought that stronger 
conditions would be able to fully hydrolyse the sample. The two known methods of analysis 
of Pn1, namely TFA hydrolysis and methanolysis were investigated with microwave heating 
and analysed on both HPAEC and GC. Optimisations of reaction time, temperature, acid 
concentrations and power were investigated and the resultant method was compared to the 
classical heating methods. 
3.4.2 Chromatographic methods 
The two most widely used chromatographic methods in the structural identification and 
characterisation of polysaccharides are high performance anion exchange chromatography 
(HPAEC) and gas chromatography (GC). HPAEC makes use of the weakly acidic nature of 
monosaccharides to separate them at high pH using a strong anion exchange stationary 
phase [231]. GC is a much more sensitive method of analysis and is less susceptible to 
interferences from salts and proteins [303], however saccharides do need to be derivatized 
in order to be volatile enough to be used in this method. 
3.4.2.1 HPAEC–PAD 
There have been many different high performance liquid chromatographic systems used to 
analyse hydrolysed saccharides. However, it was only after the quaternary ammonium resin 
anion–exchange columns, with pulsed amperometric detection, were developed that the 
method was able to be applied to all carbohydrates [210, 212, 303, 314]. 
Carbohydrates are weakly acidic, at high pH these carbohydrates are partially ionised and 
can be separated with a strong anion exchange stationary phase (Table 3.7). In most cases, 
the sequence of elution is based on the pKa value of the monosaccharide, due to the acidic 
nature of uronic acids these residues are retained on the column the longest and need the 
help of acetate to enable its elution. 
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The detection of these separated saccharide residues is based on the electric current 
generated by their oxidation on a gold electrode [231]. The oxidation on the surface of the 
electrode slowly covers the electrode, decreasing its sensitivity. The electrode is therefore 
continuously regenerated by raising the potential on the surface so as to oxidise the gold. 
This in turn causes desorption of the carbohydrate oxidised products, and once this is 
accomplished the electrode potential is the lowered to reduce the surface back to gold [231, 
233, 314]. 
Table 3.7. Dissociation constants of common carbohydrates (in water at 25 °C) [231]. 
Sugar pKa 
Fructose 12.03 
Mannose 12.08 
Xylose 12.15 
Glucose 12.28 
Galactose 12.39 
Galacturonic acid 3.51 
The advantage of HPAEC–PAD over GC is that no derivatization is needed prior to injection 
and samples can be in aqueous solutions. The analysis run time is also shorter compared to 
GC. While the instrument itself is expensive, eluents such as sodium hydroxide and sodium 
acetate are relatively inexpensive. 
3.4.2.2 GC–FID 
Gas chromatography has been used in sugar analysis for many years due to its superior 
resolution and robustness. GC analysis requires very small amounts of sample and is a very 
sensitive technique, although the sample preparation is time consuming as samples need to 
be made volatile enough through derivatization [304, 315]. There are two main derivatization 
procedures; in the first a single derivative is produced from each saccharide (e.g. alditol 
acetates), the second procedure produces several derivatives (e.g. methyl glycosides) 
depending on the anomeric configuration of the saccharide [303]. The alditol acetate 
derivatives produce a simple chromatogram that is easy to quantify. Having a number of 
peaks is advantageous as the methyl glycoside peaks always form in the same ratios; this 
pattern is therefore reproducible and can be used as a ‘fingerprint’ for a specific compound 
[303].  
Sample loss due to derivatization must be taken into account and the use of an internal 
standard allows for this as the loss of sample and the loss of internal standard will be of the 
same proportion so the ratio of sample to internal standard will remain the same. Internal 
standards are also used to account for the difficulty to inject a reproducible proportion of the 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
84 
 
sample onto the column [314]. Internal standards should be a compound similar to the 
analyte being investigated but should not normally be present in the sample and it should 
elute at a completely different time from the saccharide of interest. In these investigations, 
myo–inositol was used. 
The simplest detector used in carbohydrate GC analysis is a flame ionisation detector. The 
mobile phase delivers the separated components to the flame whose ionisation changes as 
the molecules pass through it, producing an electrical current. This detection method can be 
used for all carbohydrates however identification is based on the comparison of standards 
that are run separately. Another detector that is used in saccharide analysis is the mass 
spectral detector. This detector measures the mass to charge (m/z) ratio of the compound 
and is reproduced as a mass fragmentation pattern which is unique to each compound. Thus 
a comparison of the mass fragmentation patterns of the sample to a library of standards will 
help identify the saccharide without the need to run a separate standard. 
3.4.3 TFA hydrolysis of Pn1 
The microwave assisted acid hydrolysis technique has been compared to its conventionally 
heated hydrolysis in many investigations. A comparison of the TFA hydrolysis of bacterial 
cell carbohydrates using conventional and microwave heating was undertaken in 2008 by 
Zhao and Monteiro [346]. The 4 M TFA hydrolysis took 5 hours at 105 °C in a heating block 
(conventional) but only 5 min at 120 °C with the assistance of microwave heating. The 
qualitative results, in Figure 3.14, show that the peak area percentage of each 
monosaccharide obtained via conventional and microwave heating are comparable.  
 
Figure 3.14. Comparison of the data of TFA hydrolysis by conventional and microwave heating [346]. 
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As HPAEC–PAD was the analysis method of choice in literature for TFA hydrolysis, it was 
used to investigate the best conditions for hydrolysis of Pn1 polysaccharide with 
microwaves. Figure 3.15 illustrates the typical chromatograms resulting from the TFA 
microwave hydrolysis of Pn1 on the HPAEC–PAD where the internal standard fucose eluted 
at approximately 2.8 min and the peak corresponding to the GalA monosaccharide eluted at 
31 min. A peak, at approximately 10 min, was hypothesised to be due to the degradation of 
the AAT sugar and was detected in all hydrolysed Pn1 samples. Literature suggests that the 
response factor of GalA is a fraction of the response factor of fucose [235] and hence 
recoveries were determined relative to the fucose peak area.  
 
Figure 3.15. Representative chromatogram of hydrolysed Pn1 PS using HPAEC–PAD (microwave 
conditions: 2 M TFA, 150 W, 1 min). 
The concentration of TFA (2 M vs. 5 M), reaction times (1, 2, 5 min) and power output (100, 
150 W) of the microwave were determined on a 2 mg polysaccharide scale (Table 3.8). The 
temperature of the reaction is maintained automatically by the instrument and rises to a set 
point except when the pressure maximum is reached which causes a halt in the increase of 
temperature until the pressure is decreased to within the prescribed limits. This meant that 
the temperature of the reaction had to be monitored at all times but throughout the 
investigations, the temperature did not increase above 123 °C. 
As the same amount of polysaccharide was used for all microwave variations, a comparison 
between the internal standard and the resultant GalA peak areas were used to determine the 
optimised parameters. From the comparison, it was determined that 2 M TFA gave a better 
recovery of 46 % than the 5 M concentration (7 %). It was thought that the lower recovery of 
GalA was due to the destruction of the saccharide before hydrolysis could be achieved. This 
effect was confirmed when the results of the different hydrolysis times were compared. The 
highest recovery was found in the one minute hydrolysis and the recovery then decreased 
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and extra peaks detected as the reaction time increased which again suggested the 
destruction of the polysaccharide. A concentration of 2 M TFA, a reaction time of one minute 
and 2 mg Pn1 PS were subjected to different power outputs of 100 or 150 W. Lower 
recoveries of GalA occurred in the lower power setting. The 150 W samples did not show 
complete recovery of GalA and a higher microwave power was attempted but due to the 
volatility of the TFA, the reaction tube reached its maximum pressure and the sample could 
not be analysed.  
Table 3.8. Comparison of variables investigated for optimised microwave conditions. 
TFA 
conc. (M) 
Reaction time 
(min) 
Power setting 
(W) 
HPAEC–PAD peak 
area (%) of GalA 
5 1 100 7 
2 1 100 46 
2 1 150 55 
2 2 150 42 
2 5 150 18 
It was determined from the above investigations that the optimised hydrolysis method aided 
by microwave heating was 150 W power output, 2 M TFA and a reaction time of one minute. 
This was compared to the hydrolysis method which made use of conventional heating of 2 M 
TFA at 121 °C for 2 hours. The highest temperature reached during microwave analysis was 
123 °C.  
Figure 3.16 shows the superiority of the microwave method compared to the conventional 
heating method; a much smaller peak corresponding to GalA was found in the conventional 
method along with many extra peaks. This was either due to incomplete hydrolysis (peaks 
after the GalA at 29 min) or degradation of the saccharide residues found before the GalA 
elution. The GalA peak of the microwaved sample appeared much larger in the 
chromatogram as did the peak at 10 min which was hypothesised to be due to the degraded 
AAT sugar. The recovery of GalA using the microwave method was much higher at 76 % 
compared to the 8 % achieved with conventional heating (Table 3.9). This shows the 
superiority of the microwave method both in terms of recovery as well as reaction times.  
Table 3.9. Comparison of variables between microwave and conventional heating. 
Source of 
heat TFA (M) 
Temperature 
(°C) 
Reaction 
time (min) 
GalA peak 
area (%) 
Heating block 2 121 120 8 
Microwave 2 123 1 76 
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Figure 3.16. Chromatograms of hydrolysed Pn1 using conventional (black) and microwave (red) 
heating analysed on HPAEC–PAD. Microwave conditions: 2 M TFA, 150 W, 1 min. Conventional 
conditions: 2 M TFA, 120 min, 121 °C. 
3.4.4 Methanolysis of Pn1 PS 
There have been few reported investigations into the microwave assisted methanolysis of 
polysaccharides. Nakanishi et al. cleaved phenylbenzylsaccharides in 15 minutes using a 
household microwave instead of the overnight procedure that is usually employed [357]. In 
2004, Itonori et al. found that the methanolysis of carbohydrates from glycosphingolipids was 
complete in under two minutes [325, 358]. Microwave assisted methanolysis has also been 
used for fatty acids with complete esterification achieved in one minute compared to the 
traditional heating times of 6 – 8 hr. [359]. Two diterpene molecules extracted from green 
coffee oil underwent methanolysis by microwave and conventional means. A 99 % recovery 
of the diterpenes was achieved after 3 min at 100 °C compared to only a 26 % recovery after 
2 hours of conventional heating [360]. This demonstrates not only that microwave assisted 
methanolysis speeds up reaction times but that it results in higher recoveries when 
compared to traditional methods. 
In this investigation, GC–FID was used to determine the optimal microwave conditions 
including: acid concentration, reaction temperature, reaction time and power values. Figure 
3.17 displays the typical chromatogram of the trimethylsilyl– (TMS) derivatives of 
microwave–hydrolysed Pn1 PS, (the reaction to produce volatile derivatives is detailed in 
Figure 3.18). 
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Figure 3.17. Representative chromatogram of hydrolysed Pn1 PS using GC–FID (microwave 
conditions: 3 N HCl/MeOH, 100 W, 121 °C, 1 minute). 
The internal standard (myo–inositol) eluted at 27 min, and four peaks were detected for the 
GalA portion of Pn1. The peaks corresponded to the ɑ and β conformations of the furanose 
(17.4 and 18.5 min) and pyranose (20.8 and 21.2 min) methyl glycosidic ring forms of GalA; 
the order of which was β–furanose, α–furanose, α–pyranose, β–pyranose [361]. These 
peaks were confirmed with GC–MS (Figure 3.19). In determining the optimised microwave 
conditions and the comparisons with the conventional methods, the recoveries of GalA were 
determined as a percentage of the total area of peaks in the chromatogram relative to the 
internal standard.  
 
Figure 3.18. Derivatization procedure producing volatile derivatives for GC–FID analysis. 
The fragmentation patterns of the furanose and pyranose ring forms are very similar; both 
contain fragments of 73, 133, 147, 159, 217 and 234 m/z. The difference in the patterns, 
which is used to identify the furanose and pyranose ring forms is the 204 m/z fragment: in 
the pyranose ring form this fragment is the base peak and the ratio of 204:217 is greater 
than 1. In the furanose fragmentation pattern the 217 fragment is the base peak and the 204 
fragment peak is present only in trace amounts and the ratio of 204:21  is ˂˂˂1 [312, 362]. 
The fragments at 73, 89, 103 are all known TMS derivatives [312, 362]. 
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Figure 3.19. Mass spectral data for a) furanose (17.4 and 18.5 min) and b) pyranose ring forms (20.8 
and 21.2 min) of GalA from GC–MS. 
Two different power outputs: 100 W and 150 W were compared however, due to the high 
volatility of methanolic HCl, 150 W was too powerful which led to the upper pressure limit of 
the reaction vessel and microwave instrument being reached and the instrument terminated 
the reaction. The preferred concentration (2 N vs. 3 N) of methanolic HCl was determined 
when the 3 N HCl/MeOH produced the better results (1.8 fold increase in recovery) 
compared to the 2 N HCl/MeOH sample which revealed evidence of incomplete hydrolysis 
as the presence of disaccharides at 34 – 36 min (Figure 3.20) was identified, this has been 
described by Kim et al. when conventional thermal heating was applied [242].  
 
Figure 3.20. GC–FID chromatogram of Pn1 polysaccharide after microwave methanolysis (2 N 
HCl/MeOH, 121 °C, 100 W, 1 minute). 
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The reaction variables and resulting peak areas are collected in Table 3.10. The percentage 
of GalA as a total of the GC peak area was determined to be 21 % in the case of 2 N 
HCl/MeOH but increased to 60 % for 3 N HCl/MeOH. The percentage of peak area 
dominated by the disaccharides was 41 % in 2 N HCl/MeOH. This suggested that the 
stronger acid would be best suited to the hydrolysis of Pn1 PS. With a power output of     
100 W, the temperature reached a maximum of 121 °C, therefore two different temperatures 
were examined, 100 °C and 121 °C. The higher temperature again produced a better 
recovery of GalA. As most investigations into microwave assisted methanolysis suggested a 
maximum recovery of the components after 2 minutes, the optimal reaction time was also 
studied. In the case of Pn1 PS, the best recovery was determined after a one minute 
reaction (60 %) with only 38 % of GalA recovered after a two minute reaction.  
Table 3.10. Reaction variables tested in the optimisation of microwave assisted methanolysis of Pn1 
PS. 
Conc. 
HCl/MeOH (N) Temp (°C) 
Reaction 
time (min) Power (W) 
% GalA  
(% GC peak area) 
2 121 1 100 21 
3 121 1 100 60 
3 100 1 100 18 
3 121 2 100 30 
3 121 1 150 – 
The optimal conditions for microwave assisted methanolysis were found to be a 3 N 
concentration of methanolic HCl with a reaction time of one minute, reaction temperature at 
121 °C and a power output of 100 W. These optimised conditions were compared to the 
conventional methanolysis method and reaction conditions are detailed in  
Table 3.11. The reaction time for the conventional method was 2 hours compared to the 
much faster one minute reaction using microwaves. An increase in recovery was also found 
in the microwave sample, no peaks corresponding to disaccharides were detected and the 
chromatogram was relatively clean (Figure 3.21). Peaks were detected before 10 minutes 
but were superimposable to the conventional method; a number of these peaks were 
identified as plasticisers by their mass fragmentation patterns (not shown). The mass 
fragmentation of a few peaks suggested that they were of some carbohydrate origin and 
were hypothesised to be due to the degradation of the AAT sugar. The conventional method 
produced a chromatogram with peaks eluting in the region of 36 min which corresponded to 
disaccharides and a recovery of 26 % of GalA compared to the 61 % recovery from the 
microwave method was calculated.  
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Table 3.11. Comparison of conventional and microwave assisted methanolysis of Pn1 PS. 
Source of Heat Conc. HCl/MeOH (N) Temp (°C) 
Reaction 
time (min) % GalA 
Heating block 3 121 120 26 
Microwave 3 121 1 61 
 
Figure 3.21. Chromatograms of Pn1 after methanolysis using conventional (black) and microwave 
(red) heating analysed on GC–FID. Microwave conditions: 3 N HCl/MeOH, 100 W, 1 min, 121 °C. 
Conventional heating: 3 N HCl/MeOH, 120 min, 121 °C. 
3.4.5 Combination of methanolysis and TFA hydrolysis 
The Talaga et al. investigation [235] investigated the alternate method of hydrolysis during 
which methyl glycosides were created, followed by the use of TFA to hydrolyse the 
remaining glycosidic linkages. Although this did not lead to a quantifiable method for Pn1 in 
the literature, it did produce the best results and a comparative investigation was undertaken 
between the conventional and microwave assisted combination hydrolysis using both 
HPAEC–PAD and GC–FID analysis. 
3.4.5.1 HPAEC–PAD 
The reaction details were taken from the optimised methods in the GC analysis section and 
details of the reactions are given in Table 3.12. The order of methanolysis and acid 
hydrolysis was also investigated; whether the acid resistant glycosidic bond should be 
broken first with methanolysis followed by acid hydrolysis into the monosaccharide 
components or acid hydrolysis should first be performed and methanolysis should follow as 
a gentler method to break any remaining glycosidic linkages.  
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Table 3.12. Reaction conditions for comparison of a combination of methanolysis and hydrolysis 
using microwave and conventional heating. 
 Microwave Conventional 
 Methanolysis TFA hydrolysis Methanolysis TFA hydrolysis 
Concentration of reagents 3 N 2 M 3 N 2 M 
Reaction time (min) 1 1 120 120 
Reaction temperature (°C) 121 121 121 121 
Power (W) 100 150 – – 
The HPAEC–PAD comparison was made of the two methods as depicted in Figure 3.22. 
The first noticeable difference was determined with the appearance of extra peaks at 2.8 and 
3.4 min in the sample that underwent methanolysis first. These peaks were hypothesised to 
be due to the degradation of the AAT sugar as it has been shown that amino sugars are 
more sensitive to acid hydrolysis conditions after methanolysis [235]. 
 
Figure 3.22. HPAEC–PAD chromatograms comparing the order of methanolysis and acid hydrolysis 
of Pn1. 
Low recoveries were determined in both methods when compared to just TFA hydrolysis. 
Additional degradation products were also detected for these two methods. As microwave 
assisted TFA hydrolysis on its own was able to achieve a 76 % recovery on HPAEC–PAD, it 
was theorised that the additional step is not needed and causes destruction of the 
saccharides. These samples were repeated three times and compared to the conventional 
combination methods of both methanolysis followed by acid hydrolysis and the hydrolysis 
followed by methanolysis. The relative peak areas when compared to the internal standard 
show the two heating methods to be comparable for both combinations with the conventional 
heating producing an average of 15 % recovery of GalA which is in accordance with the 
values determined by Talaga et al. The microwave heating gave slightly higher recoveries 
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but these were not significant (Table 3.13). In this case, the advantage of the microwave 
method is purely one of reaction time. 
Table 3.13. Comparison of relative peak areas of GalA after methanolysis and TFA hydrolysis. 
Source of Heat MEOH–TFA TFA–MEOH 
Heating block 12 17 
Microwave 19 23 
3.4.5.2 GC–FID 
Whilst the combination literature methods were analysed on HPAEC–PAD, a derivatization 
step was added and the samples were analysed on GC–FID. Since the methanolysis with 
GC analysis had been optimised, the TFA hydrolysis was investigated. As before, reaction 
time, reaction temperature and microwave power were investigated, details of which can be 
found in Table 3.14. The concentration of TFA was kept constant at 2 M throughout the 
investigations. Reaction times of 20, 30 and 60 were compared with recoveries of GalA, 
based on peak area, increasing with increasing reaction time with a one minute reaction 
producing the highest recovery at 61 %. Power output levels were tested with 150 W 
showing an increase in recovery compared to that at 100 W. Finally, three different reaction 
temperatures were examined with the conventional temperature of 121 °C producing the 
highest GalA peak area of 65 % of the total peak area of the chromatogram, the higher 
temperatures led to the degradation of the GalA peaks as described in the literature [235, 
242]. From the data, the optimised conditions were found to be a 2 M TFA solution, at a 
temperature of 121 °C, a reaction time of one minute and a power output of 150 W. 
Table 3.14. Comparison of variables for the optimisation of TFA conditions in combination with 
methanolysis. 
Conc. TFA 
(M) Temp (°C) 
Reaction 
time (sec) Power 
% GalA 
(peak area) 
2 121 20 150 38 
2 121 30 150 44 
2 121 60 150 61 
2 121 60 150 65 
2 130 60 150 60 
2 150 60 150 51 
2 121 60 150 69 
2 121 60 100 27 
This method was compared to the combination method described by Talaga et al. in which 
conventional thermal heating was used. Whilst the concentration of the reagents, the 
temperature and the order in which the methanolysis and hydrolysis were performed 
remained the same when using conventional or microwave heating, the reaction time was 
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much faster with microwave heating only requiring one minute for the methanolysis and one 
minute for the TFA hydrolysis compared to two hours each for the conventional heating. The 
chromatogram (Figure 3.23) details much larger peaks for the microwaved sample in 
comparison to the conventionally heated sample. The relative peak area of the GalA peaks 
for the microwave sample was determined to be 64 % whereas the conventionally heated 
sample was only 17 %. Extra peaks were detected in the conventionally heated sample, 
which indicated that the product had degraded. Both the methanolysis procedure and the 
combination procedure performed better in the microwave heated sample than the 
conventionally heated samples in terms of reaction times and recoveries of GalA. 
 
Figure 3.23. Comparison of conventional (black) and microwave assisted (red) hydrolysis of Pn1 
polysaccharide. 
3.4.6 Summary 
The hydrolysis of Pn1 by conventional methods proved difficult due to the inductive effects of 
the carboxylic acid functional group. Alternate means of hydrolysis utilising microwave 
assisted heating were investigated with both methanolysis and acid hydrolysis yielding a 
greater recovery of GalA than the conventional hydrolysis. For HPAEC–PAD hydrolysis, the 
optimal hydrolysis method involved microwaving the Pn1 polysaccharide in 2 M TFA for one 
minute at 121 °C using 150 W power which produced a recovery of 76 % compared to only  
8 % with conventional thermal heating. Microwave–assisted methanolysis proved to be 
successful for GC–FID analysis with an increase in recovery from 26 % to 61 %. The 
optimum method to produce methyl glycosides consisted of 3 N MeOH/HCl microwaved at 
121 °C for 60 seconds, compared to 2 hours for conventional heating (with all other 
conditions kept constant). A combination of methanolysis and TFA hydrolysis was also 
investigated and was found to be successful with GC–FID analysis with a highest recovery 
of 69 % achieved.  
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3.5 Nuclear magnetic resonance spectroscopy 
Nuclear magnetic resonance (NMR) is a technique widely used in analysing the structure of 
a polysaccharide including: the identity of the monosaccharides in the repeating units, their 
relative amount and their connectivities. In NMR analysis, the nuclear spin levels of an atom 
are split by a strong magnetic field and by inducing transitions between different energy 
levels a signal is formed and recorded. The nucleus of an atom behaves like a magnet when 
exposed to magnetic fields and has an inherent angular momentum which is also known as 
spin. Every elementary particle (electrons, protons etc.) has an associated spin quantum 
number that is either an integer or half integer for example, protons have a quantum number 
of one and electrons have a quantum number of ½. NMR spectroscopy can only be 
performed on nuclei if the total spin is not equal to 0. Table 3.15 lists the most common 
elements used in NMR spectroscopy. 
Table 3.15. List of abundance of most common elements used in NMR spectroscopy. 
Isotope Spin number Abundance (%) 
1H ½ 99.9 
13C ½ 1.1 
15N ½ 0.37 
31P ½ 100 
As organic molecules are mainly composed of carbon and hydrogen they are the two most 
common forms of NMR spectroscopy and since hydrogen is more abundant than 13C, it is by 
far the most common element monitored with NMR. 
Each proton in a molecule is affected by the chemical environment that surrounds it. Any 
change in the chemical environment can change the degree of shielding on the proton and 
hence its chemical shift. The electronegativity of a neighbouring group will reduce the 
electron density of the proton and the nucleus is therefore deshielded and can be found 
further downfield. The methyl protons on an acetate functional group can be shifted as much 
as 1 ppm due to the neighbouring oxygen or nitrogen atom. 
In this way 1H NMR can be used to elucidate the number of different environments that 
protons exist in. If, however, two or more protons are in the exact same chemical 
environment they have the same chemical shift, but the intensity of the peak will integrate for 
more than one proton. The chemical shift of the proton reflects its molecular structure and 
can be used in the clarification of a compound’s structure [195].  
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The proton NMR spectra of polysaccharides can often be complex with overlapping peaks 
especially in the ring proton region (3.5 – 4.5 ppm). Some characteristic signals can be 
identified; the most important of these are the anomeric protons (H1). Anomeric protons are 
usually found with a chemical shift of 4.4 – 5.5 ppm depending on their configuration (Table 
3.16). The number of signals in this anomeric region is indicative of the number of 
saccharides contained in the polysaccharide repeating unit. Other distinctive signals include 
the methyl protons of acetyl (O– and N–) functional groups (2.2 – 2.0 ppm) and the H6 
proton of 6–deoxysugars (1.15 – 1.35 ppm). 
Table 3.16. Proton chemical shifts and coupling patterns of commonly found resonances in the NMR 
spectra of polysaccharides [363]. 
 Chemical Shift range (ppm) 
Coupling 
pattern 
H1 of α sugars 5.5 – 5.0 d, 3 – 5 Hz 
H1 of β sugars 5.0 – 4.4 d, 8 Hz 
H1 of α–manno sugars 5.5 – 4.9 d, ˂2 Hz 
H1 of β–manno sugars 5.0 – 4.6 d, ˂2 Hz 
ManNAc H2 4.7 – 4.3 d, 3 – 5 Hz 
α–manno H2 4.4 – 3.9 d, 4 Hz 
α–GalA H5 5.0 – 4.6 d, ~1 Hz 
N–acetylamino sugar 
methyl 2.15 – 2.00 s 
H6 of 6–deoxysugars 1.35 – 1.15 d, 6 Hz 
The anomeric signals can be determined in the 13C NMR spectra with signals appearing 
between 90 – 110 ppm. 13C NMR has the added advantage of being able to distinguish 
between methyl (CH3), methylene (CH2) and methine (CH) carbon groupings through the 
Distortionless Enhancement by Polarization Transfer (DEPT) experiment. Three different 
DEPT spectra are needed in order to fully differentiate between the different carbon 
multiplicities: DEPT–45, DEPT–90 and DEPT–135 (where the number is indicative of the flip 
angle of the proton pulse). In a DEPT–45 experiment all three carbon groups are shown. In 
the DEPT–90 signal only CH groups are visible and in the DEPT–135 experiment the CH2 
groups are shown in a different phase to the CH3 and CH groups and therefore appear as 
negative peaks on the spectrum. Since methine groups are found in a different part of the 
spectra, using just the DEPT–135 experiment may allow for the identification of the three 
carbon multiplicities. Other distinguished signals can be identified in the carbon spectra, 
these are tabulated in Table 3.17. 
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Table 3.17. Common chemical shifts in the 13C NMR spectra of polysaccharides [363]. 
 Chemical shift, ppm 
Uronic acid C6 170 – 180 
N–acetylaminosugar carbonyl carbon 170 – 180 
Furanose sugar C1 (α,β) 101 – 111 
Pyranose sugar C1 α 
                              β 
91 – 101 
95 – 105 
Unsubstituted furanose ring carbons 70 – 85 
Unsubstituted pyranose ring carbons 65 – 75 
Glycosylated hydroxymethyl groups 65 – 68 
Unsubstituted hydroxymethyl groups 61 – 64 
C–N in amino sugars 48 – 55 
N–acetyl methyl carbons 23 – 25 
6–deoxyhexoses C6 15 – 19 
As ring protons in carbohydrates are often broad and overlap in the 1H NMR ring region and 
not distinguishable. Two dimensional NMR methods are used to identify these protons. The 
simplest of these 2D methods is 1H–1H correlated spectroscopy (COSY). COSY is used to 
identify neighbouring protons, however cross peaks are only seen with correlations due to 
geminal and vicinal coupling only. 
Protons in a single spin system can be assigned using 1H–1H Total Correlation Spectroscopy 
or TOCSY experiments [195]. Correlations can be made over five or six bonds in the same 
ring system as long the J couplings are large enough. Small or zero J couplings and the 
presence of heteronuclear atoms such as oxygen or nitrogen can disrupt this correlation. 
The Heteronuclear Single–Quantum Correlation (HSQC) spectrum is the heteronuclear 
equivalent of the COSY spectrum and consists of a plot of the 1D proton spectrum along one 
axis and the 1D carbon spectrum of the molecule along the other axis and hence linkages 
between protons and carbons can be determined [195]. This method is particularly useful if 
the proton spectrum of the molecule is very crowded and not well resolved. Correlating the 
carbon spectrum to the proton spectrum will also identify if or when two protons are attached 
to the same carbon.  
Heteronuclear Multiple Bond Correlations (HMBC) connects carbons and protons that are 
separated by two or three bonds and is thus considered a long–range correlation. For 
carbohydrates this is important as it allows for glycosidic linkages to be identified by 
comparing the chemical shifts of the carbons in the polysaccharide to that of the 
monosaccharide standard a difference is revealed. Glycosylation causes a large downfield 
shift in the α–carbons, in the range of 6 – 8 ppm and a much smaller upfield shift of between 
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1 – 2 ppm in the β–carbons [363]. Using this technique allows for the determination of both 
the attachment position on the sugar residues as well as the position of the sugar in the 
repeating unit as correlations can be seen from one saccharide to its neighbour through the 
glycosidic linkage. 
While many polysaccharides contain only protons, carbons and oxygens, many will also 
contain nitrogen (as amino or N–acetylated sugars) and phosphorus (phosphate group). 
These can be determined by recording either the 15N or 31P NMR and using 2D methods 
(e.g. HSQC or HMBC) to correlate the linkages to the protons. 
3.5.1 Cell wall polysaccharide contaminant 
The presence of phosphocholine in cell wall polysaccharide was determined in 1968 by 
Brundish and Baddily and confirmed by Watson and Baddily in 1974 [364]. Structurally wise 
it was thought to contain a single phosphocholine group on the repeating unit. Kulakowska 
et al. determined that there were two phosphocholines on the CWPS of a non–encapsulated 
S. pneumoniae strain [365] and in 1999 Karlsson et al. investigated the cell wall 
polysaccharide of one non encapsulated and three encapsulated (serotypes 18B, 32A and 
32F) strains of S. pneumoniae with proton, carbon and phosphorus NMR [366]. It was found 
that the non–encapsulated strain and serotype 18B contained CWPS with only one 
phosphocholine residue but both serotypes 32A and 32F were found to have two 
phosphocholine residues on their CWPS. Therefore the amount of phosphocholine found on 
CWPS seemed to be strain and serotype dependant. In 1980 Jennings et al. investigated the 
CWPS of Pn1 and found only one phosphocholine present, this was confirmed with proton 
and carbon NMR spectra [18] however Vialle et al. showed with 31P NMR that the CWPS of 
Pn1 contained two phosphocholine residues (Figure 3.24) [248].  
As Pn1 PS does not contain any phosphate groupings, the 31P spectrum should represent 
the CWPS and simply by counting the number of peaks found in this spectrum, the number 
of phosphocholine residues can be determined [248]. Three peaks were identified in the 31P 
spectrum (Figure 3.25) that corresponded to the one ribitol phosphate (1.3 ppm) on the 
CWPS, the other two peaks at –0.3 and –0.8 ppm confirmed the presence of two 
phosphocholine residues. This was confirmed with 1H–31P HMBC NMR experiment (not 
shown).  
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Figure 3.24. Structure of pneumococcal cell wall polysaccharide (CWPS), containing two 
phosphocholine groups as found for Pn1.  
 
Figure 3.25. 31P NMR spectrum of Pn1 polysaccharide detailing the peaks from the phosphocholine 
group on the CWPS molecule.  
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As cell wall polysaccharide is considered to be a contaminant it must be quantified. This was 
calculated from the proton NMR spectra. The methyl peak of the phosphocholine residue at 
3.23 ppm was integrated and compared to the methyl group of the AAT sugar at 1.30 ppm 
and the N–acetyl peak of the AAT sugar at 2.05 ppm. As there are two phosphocholine 
residues on the CWPS found in Pn1 this peak integrated for 18 protons. As CWPS also 
contains signals which overlap with the H6 methyl signal N–acetyl signal of the AAT sugar 
these must be corrected for before a calculation can be performed. The corrected methyl 
and N–acetyl peaks integrate for three protons each. Taking this into account the mol 
percent CWPS was determined using the following equation: 
 
  CW PS  
IPCho/18
INAc/3
x 100 Equation 3.7 
Where IPCho is the peak integration of the phosphocholine peak and INAc is the integration of 
the N–acetyl peak. The same equation can be applied when using the methyl peak of the 
amino sugar by substituting the integration of the methyl peak for the N–acetyl peak. An 
alternate method of comparison to calculate the percentage of CWPS contamination would 
be to use the anomeric signal for the unacetylated GalA residue. However due to the 
viscosity of the sample and the resultant broad spectral peaks, this cannot be achieved. The 
WHO has not released guidelines for the amount of CWPS contamination allowed in a 
purified batch of polysaccharide however Marburg et al. suggested a value of less than 3 % 
(w/w) [217, 367]. Whilst this was the initial limit suggested, all purified polysaccharides 
described were found to contain more than 3 % CWPS contamination and this was only 
decreased to below 3 % after hydrolysis was performed. 
3.5.2 Extent of O–acetylation  
The effect on immunogen city of Pn1 PS by removing the O–acetyl functional group was 
shown in the very first studies of the polysaccharide, before the full structural 
characterisation of Pn1 was known [286, 288, 368, 369]. Due to the importance of the O–
acetyl group, the WHO determined specifications for the levels of O–acetylation on the 
polysaccharide. Already discussed is the colorimetric assay based on the Hestrin method 
[199], however NMR is also able to quantify the levels of O–acetylation. The advantage of 
using NMR to determine O–acetylation is that it can be used to determine the position(s) of 
the O–acetylation. 
The introduction of an O–acetyl group in any position on the saccharide will result in a large 
downfield shift on the α–proton in the 1H spectra but only small shifts in the 13C NMR spectra 
[363]. The proton which is linked to the acetylated carbon is shifted to such a degree that it 
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appears in the anomeric proton region and with the help of HSQC can be easily recognised 
and identified. 
Jansson et al performed an in–depth investigation into the shifts in the 13C NMR spectra in 
1987 [370]. The authors determined that the deshielding of the substituted carbon (α–
carbon) is between 0.7 – 3.5 ppm when an O–acetyl group is added in any position. The 
carbon next to the substituted carbon (the β carbons) experience a shift upfield of 1.2 – 2.8 
ppm with shift effects becoming smaller the further away the carbon is situated. D–
Galactopyranosyl derivatives show a greater shift in their ring protons due to the acetylation, 
than D–glucopyranosyl derivatives [370].  
As Pn1 PS is often O–acetylated on two different positions (C2 and/or C3 of GalA (residue 
B)) two peaks are identified in the 1H NMR spectrum. These two peaks were integrated and 
compared to the integration of the peak at 2.05 ppm corresponding to the N–acetyl peak and 
the ratio of the two (Equation 3.8) determined the percentage of O–acetylation of the 
polysaccharide. 
 
  acetylation  
IOAc
INAc
 x 100 Equation 3.8 
3.5.3 NMR structural analysis of Pn1 polysaccharide 
The structural analysis of Pn1 polysaccharide by NMR has been performed by Stroop et al. 
in 2002 [293]. The authors had difficulty assigning spectral peaks for the native 
polysaccharide due to the wide, poorly resolved lines – and thus removed the O–acetyl 
group resulting in the sharpening of the signals which allowed for assignment of the 1H and 
13C spectra. In order to assign the native polysaccharide it was degraded by periodate 
oxidation followed by treatment with base which lead to an oligosaccharide fragment of three 
repeating trisaccharide units. This treatment allowed for the location of the O–acetyl groups 
to be identified on the 2– and 3– position of the 4–linked galacturonic acid residue (residue 
B) of the polysaccharide. 
In this investigation, the structure of the polysaccharide produced by Streptococcus 
pneumoniae serotype 1 was investigated using both 1D and 2D NMR spectroscopic 
techniques.  
As reported by Stroop et al., the 1D proton spectra of native polysaccharide (Figure 3.26) 
produced very broad, overlapping peaks which made identification of the anomeric and ring 
regions impossible. Only the peaks with unique chemical shifts could be identified by 
inspection. These were the phosphocholine peak at 3.23 ppm of the CWPS contaminant, 
which was used as a reference for all other assignments. The N–acetyl peak of the AAT 
sugar was assigned at 2.05 ppm. Two peaks corresponding to the methyl peak (1.30 ppm) 
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of the AAT sugar and two peaks equivalent to the O–acetyl peak of the GalA sugar (2.20 
ppm) were also identified.  
 
Figure 3.26. 1D 1H NMR spectrum of Pn1 polysaccharide. 
Due to this complexity of the O–acetylation pattern on the polysaccharide, other peak 
assignments were not possible; therefore a de–O–acetylated Pn1 PS was first used to fully 
identify the structural backbone of the polysaccharide.  
3.5.3.1 De–O–acetylated Pn1 polysaccharide 
Removing the O–acetyl group on the GalA sugar residue provided NMR spectra with much 
narrower peaks and enabled further peak identifications (Figure 3.27a). Identification of the 
signals in the NMR spectra was made by comparison to the related saccharide monomer. 
Three peaks were identified in the anomeric region that corresponded to H1 of α–AAT and 
two α–GalA sugars at 5.00 (A), 5.08 (C) and 5.22 (B) ppm respectively. Further assignments 
for the AAT sugar could be made for signals at 2.05, 3.67 and 4.74 ppm analogous to the 
NAc group and H4 and H5 respectively. The absence of the O–acetyl grouping resulted in a 
single peak for the methyl group of the AAT sugar (1.27 ppm) which suggests that the O–
acetyl group of the GalA moiety has an influence on the methyl environment. Cell wall 
polysaccharide contamination was confirmed with the peak at 3.23 ppm in the 1H and 55 
ppm in the 13C spectra, corresponding to the methyl peak of the phosphocholine residue. 
The 13C NMR spectrum (Figure 3.28), whilst complex, did show the presence of the 
trisaccharide repeating unit with signals at 100.0, 97.9 and 100.1 ppm corresponding to C1 
of AAT, and the two GalA residues respectively. Characteristic signals at 16.6 ppm (NAc) 
and 23.3 ppm (C6) of the AAT sugar were also observed. There are two amino resonances 
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that are more upfield than the rest of the ring resonances which correspond to amino groups 
linked in the C2 and C4 position of AAT sugar. 
These assignments were confirmed by 2D 1H–1H (TOCSY) (Figure 3.29) and 1H–13C 
(HSQC) (Figure 3.30) correlation experiments and allowed for the full elucidation of the AAT 
and two GalA spin systems. The methyl to H5 coupling of the AAT sugar is clearly visible in 
the 2D TOCSY spectrum. From the expanded spectrum, the correlations of the de–O–
acetylated sugar could be identified from the anomeric protons of each sugar residue to the 
H2, H3 and H4. Additional cross peaks are labelled. The glycosylation linkages were 
identified by their change in chemical shift from the monomeric standards and confirmed the 
linkages as 3–linked AAT (residue A), 4–linked GalA (residue B) and 3–linked GalA (residue 
C). The complete assignments of the NMR signals are collected in Table 3.18 and were in 
close agreement with the literature assignments by Stroop et al. Unlabelled signals in the 
TOCSY spectrum correlating to near 4.6 ppm were attributed to the β–GalNAc and β–Glc 
spin systems of the CWPS. Other signals corresponding to CWPS were identified in the 
HSQC where the H1/C1 and H2/C2 of the phosphocholine (Cho–P–(O→) group were 
assigned at 4.33/59.9 ppm and 3.68/66.5 ppm respectively.  
 
Figure 3.27. 1D 1H pre–sat NMR spectra of a) de–O–acetylated and b) O–acetylated Pn1 
polysaccharide. 
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Figure 3.28. 1D 13C NMR spectra of a) de–O–acetylated and b) O–acetylated Pn1 polysaccharide. 
 
Figure 3.29. Expanded 1H–1H TOCSY spectrum of de–O–acetylated Pn1 polysaccharide. 
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Figure 3.30. Expanded 1H–13C HSQC spectrum of de–O–acetylated Pn1 polysaccharide. 
Table 3.18. Proton and carbon assignments for deOAc of Pn1 polysaccharide, (Underlined figures 
represent glycosylation shifts). Chemical shifts are reported in ppm. 
Residue 
H1 H2 H3 H4 H5 H6 NAc 
C1 C2 C3 C4 C5 C6  
3)–α–D–AAT–(1→    
(A) 
5.00 4.16 4.28 3.67 4.74 1.27 2.05 
100.0 48.6 74.2 53.5 63.8 16.4 23.3 
4)–α–D–GalA–(1→  
(B) 
5.22 3.92 4.06 4.40 4.58   
97.9 68.8 69.7 80.4 71.9   
3)–α–D–GalA–(1→   
(C) 
5.08 3.98 4.01 4.47 4.13   
100.1 66.7 76.9 68.9 73.3   
3.5.3.2 O–acetylated Pn1 polysaccharide 
The native polysaccharide was size reduced, which resulted in narrower, and better resolved 
peaks in the 1D 1H NMR spectra (Figure 3.27). The sharpness in resolution of the peaks 
was most prominent in the anomeric region where four or more anomeric peaks could be 
detected. The additional peaks in the anomeric region corresponded to new H1 signals due 
to the acetylation patterns. Signals, corresponding to the proton attached to the carbon at 
which acetylation took place, have shifted to the anomeric region due to the deshielding of 
the proton by the O–acetyl group. Further differences were observed due to the O–
acetylation on (B) GalA. Signals at 2.19 and 2.23 ppm corresponded to the O–acetyl group. 
Literature suggests that this O–acetylation can occur on either the C2 or C3 position [293]. 
This would then give rise to two different peaks for H1 of the residue. The other noticeable 
signal is an additional peak at 1.35 ppm which is assigned to H6 of the AAT residue due to it 
being in a different chemical environment when the repeating unit is acetylated. Due to the 
acetylation, the 13C was more complex and no further assignments could be made by 
inspection and hence 2D spectroscopic techniques were needed. 
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1D TOCSY experiments, using along mixing times, enabled the identification of all the 
protons belonging to an isolated spin system. This procedure was applied to certain peaks to 
determine the spin system connectivities and proved to be useful in identifying the O–
acetylation linkages on either C2 or C3 of GalA (structure B), as well as identifying the 
twinning phenomenon experienced by the methyl group of the AAT sugar due to the O–
acetylation pattern. The spin system associated with the methyl peak of AAT, with a shift of 
1.35 ppm, showed a strong correlation to H5 of AAT sugar (Figure 3.31). Negative peaks in 
the 1D TOCSY spectrums were assigned to dipolar coupling. It was therefore theorised that 
the O–acetyl peak at 2.23 ppm was acetylated to the C3 position. The anomeric signals of 
the AAT sugar and the GalA residue (structures A and C) were also subjected to 1D 
TOCSY. The anomeric signal from the AAT sugar correlated to H2, H3, and H4 of the AAT 
sugar. A small correlation to the N–acetyl protons as well as to certain protons on the GalA 
residues was identified. The anomeric signal from the C3 O–acetylated GalA residue 
showed correlations to H3 and H4 of GalA residue C and H2, H4 of the C3 acetylated GalA 
residue (Figure 3.32). 
 
Figure 3.31. 1D TOCSY spectrum of Pn1 PS from methyl protons on AAT residue showing 
correlation to acetylation position C3 (B) GalA. 
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Figure 3.32. 1D TOCSY spectrum of Pn1 PS from anomeric proton on (B) GalA acetylated at position 
C3. 
2D TOCSY of the acetylated Pn1 PS showed similar cross peak correlations to the de–O–
acetylated Pn1 (Figure 3.33). The (C) GalA residue can be traced from the anomeric proton 
at 5.08 ppm through to the H2, H3 and H4 residues. The polysaccharide is a mixture of de–
O–acetylated and O–acetylated at position C2 and C3 of the (B) GalA residue, and 
complicates not just this residue but also that of the AAT sugar. From the anomeric signal 
the AAT sugar can be traced to H2, H3 and H4, however cross correlations also occurred 
from two different H4 through to H5 as well as H2 and H3. It is theorised that the acetylation 
on the (B) GalA residue influences the peaks in the AAT sugar spin system. The (B) GalA 
residue with no acetate, acetate on C2 and on C3 brings up three unique spin systems, 
some of which could be correlated in the TOCSY spectrum. 
The acetylated HSQC was more complicated due to the three different acetylation patterns 
on the (B) GalA residue; however assignments made from the de–O–acetylated PS aided in 
the full spectral elucidation (Figure 3.34). As with glycosylation linkages, the position of O–
acetylation could be determined from the change in chemical shift when compared to the 
monomeric related saccharide. The acetylation on either the C2 or C3 of the residue caused 
a shift upfield in the spectrum with peaks at 5.04 and 71.7 ppm corresponding to the C2 
acetylated residue and 5.27 and 73.1 ppm corresponding to the C3 acetylated residue. For 
the acetylation on C2, the shift for the α–carbon (C2) was calculated to be a shift downfield 
of 2.  ppm and shifts of the β–carbons (C1 and C3) were upfield shifts of 2.8 and 0.7 ppm 
respectively. For the C3 acetylated GalA residue; a shift of C3 was determined to be 3.4 
ppm and for the β–carbons (C2 and C4) shifts upfield of 1.6 and 2.6 ppm were measured. 
Full spectral assignments for the polysaccharide acetylated on both positions are collected in 
Table 3.19 and Table 3.20. The assignments made in this study are similar to those 
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described by Stroop et al. however some differences were identified. The shifts for some 
atoms in the AAT sugar change with the addition of the acetylation, apart from the methyl 
group, other shifts have not been described in literature. C5 shifts from 4.74 ppm in the de–
O–acetylated polysaccharide to 4.62 ppm in the acetylated spectra. C4 and C3 of the AAT 
sugar also showed a shift in the O–acetylated spectra from 4.28 and 4.67 ppm to 4.19 and 
3.80 ppm respectively. The GalA on which the O–acetylation is found (residue B) showed a 
number of different chemical shifts than those seen in the de–O–acetylated spectra as well 
as the literature. The main changes in chemical shift observed in the O–acetylated HSQC 
spectrum were due to the points of attachment of the O–acetate groups. Literature identified 
these points as 4.99/70.4 ppm and 5.23/77.8 ppm, although this investigation showed similar 
chemical shifts for the acetylation on C2 of 5.04/71.7 ppm, different shifts of 5.27/73.1 ppm 
were determined for acetylation on C3. The proton chemical shift was found at 5.27 ppm 
compared to 5.23 ppm of the literature value, whereas a greater difference was noted for the 
carbon chemical shift values: 73.1 ppm compared to 77.8 ppm identified by Stroop et al. 
[293]. The change in chemical shift between the acetylated and non–acetylated carbon 
corresponds to 3.4 ppm for the present study and 8.3 ppm for the study by Stroop et al. The 
shift difference should be in the range of 0.7 – 3.5 ppm [370]; the large shift of 8.3 ppm is 
indicative of a glycosylation linkage rather than O–acetylation and hence may have been 
incorrectly assigned. 
Literature has not reported any other chemical shifts on residue B due to the acetylation 
however this investigation determined a number of shifts relating to the acetylation patterns 
as presented in Table 3.19 and Table 3.20. The anomeric signals for the acetylated 
polysaccharide shifted and were identified at 5.38/95.1 ppm for the PS with C2 acetylation 
and 5.29/97.5 ppm for the PS with C3 acetylation. The protons and carbons on either side of 
the acetylation point were also affected and experienced shifts. Residue C (GalA) was not 
affected by the O–acetylation. 
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Figure 3.33. Expanded 1H–1H TOCSY spectrum of O–acetylated Pn1 polysaccharide. 
 
Figure 3.34. Expanded 1H–13C HSQC spectrum of O–acetylated size reduced Pn1 polysaccharide. 
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Table 3.19. Proton and carbon assignments for Pn1 polysaccharide acetylated on C2 GalA (B). 
(Underlined figures represent glycosylation shifts; the bold figures represent points of O–acetylation). 
Chemical shifts are reported in ppm. 
Residue 
H1 H2 H3 H4 H5 H6 NAc OAc 
C1 C2 C3 C4 C5 C6   
3)-α-D-AAT-(1→    
 (A) 
5.02 4.16 4.19 3.80 4.62 1.35 2.05  
99.3 48.6 74.6 54.0 63.9 16.8 23.3  
4)-α-D-GalA(2OAc)-(1→  
(B) 
5.38 5.04 4.36 4.45 4.58   2.19 
95.1 71.7 69.0 60.7 71.9   21.3 
3)-α-D-GalA-(1→    
 (C) 
5.08 3.98 4.01 4.47 4.13    
100.1 66.7 76.9 68.9 73.3    
Table 3.20. Proton and carbon assignments for Pn1 polysaccharide acetylated on C3 GalA (B). 
(Underlined figures represent glycosylation shifts; the bold figures represent points of O–acetylation). 
Chemical shifts are reported in ppm. 
Residue 
H1 H2 H3 H4 H5 H6 NAc OAc 
C1 C2 C3 C4 C5 C6   
3)-α-D-AAT-(1→     
(A) 
5.02 4.16 4.19 3.80 4.62 1.27 2.05  
99.3 48.6 74.6 54.0 63.9 16.4 23.3  
4)-α-D-GalA(3OAc)-(1→  
(B) 
5.29 4.17 5.27 4.59 4.67   2.23 
97.5 67.2 73.1 77.8 71.8   21.6 
3)-α-D-GalA-(1→   
 (C) 
5.08 3.98 4.01 4.47 4.13    
100.1 66.7 76.9 68.9 73.3    
3.5.4 Summary 
Both 1D and 2D NMR techniques were employed to fully assign the proton and carbon 
spectra for the Pn1 polysaccharide. The native polysaccharide displays a poorly resolved 
spectrum with wide, overlapping peaks that made identification of any signals, apart from 
methyl and acetyl groups, very difficult. The possibility of two different points of O–
acetylation could be determined from this spectrum. De–O–acetylation of the polysaccharide 
produced a proton spectrum that allowed for the further identification of the anomeric protons 
as well as some protons on the AAT sugar. From the carbon spectrum, the anomeric signals 
were assigned by inspection but it was the 2D methods that allowed for full identification of 
the signals. The assignments from the de–O–acetylated PS were then used to assign 
signals for the fully acetylated spectrum. By size reducing the native polysaccharide, the 
proton and carbon 1D spectra became clearer however no extra assignments could be 
made. The advantage of size reducing the polysaccharide became apparent in the 1D 
TOCSY and 2 D methods where spectra was obtained that allowed for correlations and 
identifications to be assigned. The 1D TOCSY experiments allowed for the identification of 
the points of O–acetylation and definitely showed that the polysaccharide was a mixture of 
de–O–acetylated and O–acetylated (on either C2 or C3, residue B) GalA. For the first time in 
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the investigation, the HSQC of the now size reduced polysaccharide displayed crosspeaks 
that could be identified. Shifts seen at 5.04/71.7 ppm and 5.27/73.1 ppm were indicative of 
the O–acetylation points on C2 and C3 of the GalA residue B. The two signals 
corresponding to the methyl group of the AAT sugar on the de–O–acetylated and acetylated 
polysaccharide were also identified. By comparison with the monosaccharide standards and 
the literature on the Pn1 PS, the peaks relating to each different acetylated polysaccharide 
could be assigned and the full structural elucidation of Pn1 polysaccharide was achieved. 
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CHAPTER 4. PURIFICATION OF PN1 POLYSACCHARIDE 
4.1 Purification methodology 
Pneumococcal bacteria have a polysaccharide capsule surrounding each cell. This capsular 
polysaccharide is known to be a major virulence factor as it prevents antibodies from 
attaching to the cell and therefore blocks the immune system’s phagocytic response [13, 14]. 
The major component of the pneumococcal polysaccharide vaccine is the capsular 
polysaccharide whereas the pneumococcal conjugate vaccine contains the capsular 
polysaccharide conjugated to a protein. In order to utilise the capsular polysaccharide in a 
conjugate, it must be separated from the killed bacteria and cell debris and other 
contaminants such as proteins, nucleic acids and cell wall polysaccharide [371-373]. This is 
achieved through a purification process which must take into account the physical and 
chemical properties of the polysaccharide, and those of all the impurities. A sufficiently pure 
product is usually only achieved in a multi–step purification process. In the case of both the 
seven and thirteen valent Prevnar conjugate vaccines, the purification process for the 
polysaccharides contains 16 different steps including multiple different chromatographic 
systems and numerous membrane separations to obtain the pure polysaccharide [374].  
The purification procedure for pneumococcal serotype 1 polysaccharide used in this 
investigation makes use of a quaternary ammonium detergent (CTAB) to precipitate 
negatively charged polymers. This is useful as most bacterial polysaccharides are anionic 
(exceptions include pneumococcal serotypes Pn14 which is neutral and Pn1 which is 
zwitterionic), however, the structure of Pn1 has an unusual repeating motif. Each repeating 
unit has a minimum of one positive and one negative charge leading to the common three 
dimensional configuration characterised by a right–handed helix with negatively charged 
grooves, the positive charges being on the outer surface of the lateral boundaries [82]. 
Polysaccharides exhibiting this motif are referred to as zwitterionic capsular polysaccharides 
shown below in Figure 4.1. If it is assumed that one carboxyl and one amino moiety occupy 
the zwitterionic nature of Pn1, then there is a second carboxyl group available for the 
precipitation with CTAB. 
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Figure 4.1. Zwitterion capsular polysaccharide structural motif of Pn 1 with the negatively charged 
carboxyl groups shown in red and the positively charged amino sugar shown in blue. 
Once a precipitate has formed, Celite is added to the CTA+ precipitated polysaccharide 
solution in order to trap the insoluble polysaccharide. The solution is stirred at high speed to 
ensure complete mixing and trapping of the polysaccharide. Once the Celite slurry 
containing the trapped Pn1 PS in its CTA+ salt form has settled, the excess supernatant is 
removed and the Celite slurry is packed onto a chromatography column, in this case the 
 illipore VANTAGE™ Chromatography column.  
 
Figure 4.2. Schematic (not to scale) of the purification set–up including elution buffers, column and 
collection flask. 
The apparatus and arrangement for the purification is detailed in Figure 4.2. After the column 
has been loaded, the elution buffers are connected via a 4–way manifold and sequentially 
passed onto and through the column. The following buffers are used to elute the 
polysaccharide and fractions of elution collected: 
 0.05 % CTAB in 0.05 M NaOAc (pH 6.0): This is the first buffered solution and it is 
introduced to wash media components from the Celite cake whilst still maintaining a 
low level of CTAB to ensure that the polysaccharide remains in its insoluble CTA+ 
salt form. 
 5 % Ethanol (EtOH) in 0.05 M NaOAc (pH 6.0): As certain media components are 
only slightly soluble in aqueous solutions, a low concentration of ethanol was 
introduced to remove these components. 
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 10 % EtOH in 0.05 M NaOAc (pH 6.0): Small quantities of nucleic acids and proteins 
are removed in this step. 
 15 % – 30 % EtOH in 0.05 M NaOAc (pH 6.0): Increasing EtOH concentrations are 
used to elute the polysaccharide. As Pn1 PS is very viscous, once it starts to elute, 
the pressure on the column increases and the flow rate decreases. The 
polysaccharide elutes as a viscous, opaque solution and elution is terminated when 
the flow rate increases and the pressure decreases. 
The fractions collected are tested for the presence of Pn1 PS with the uronic acid 
colorimetric assay. A sample containing Pn1 polysaccharide changes from colourless to 
purple to indicate the presence of Pn1 PS. The positive fractions are pooled together. 
Solid NaCl is added to these pooled fractions in order to precipitate the polysaccharide. 
Sodium chloride is used to change the counter ion of the Pn1 PS from CTA+ to sodium, the 
polysaccharide is then insoluble in ethanol and will precipitate in an alcoholic solution. While 
a final concentration of 2 M NaCl is sufficient to allow for full counter ion exchange, the EtOH 
concentration of the solution must be maintained at a concentration of approximately 60 % in 
order to achieve complete precipitation. This is achieved with the addition of 96 % ethanol to 
the point where precipitation occurs. An equivalent volume of ethanol to the volume of the 
pooled fractions is sufficient for precipitation to occur. 
The precipitated polysaccharide is collected by centrifugation and re–dissolved in a minimum 
volume of water. In order to remove any excess ethanol and CTA+, the polysaccharide is 
diafiltered against seven volumes of 0.5 M NaCl followed by seven volumes of water using 
two 100 kDa MWCO membranes in parallel. The diafiltration set–up is shown in Figure 4.3. 
 
Figure 4.3. Diafiltration set–up for the final step in the purification of Pn1 polysaccharide. 
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Each batch of purified polysaccharide must be fully characterised with validated test 
methods to determine the identity, purity and molecular size of the polysaccharide. Whilst 
there are numerous analytical methods available, they only provide complementary 
information and thus a combination of methods must be applied to achieve a more complete 
description of the polysaccharide. There are combinations of colorimetric tests that 
characterise the polysaccharide in terms of total nitrogen, phosphorus, hexosamine, 
methylpentose, uronic acid and O–acetyl groups. NMR is also used to identify and 
characterise the polysaccharide as well as to check for any impurities [10, 375].  
The analytical tests used to characterise the purified Pn1 PS are summarised below and the 
WHO – accepted criteria is reported in Table 4.1: 
 Polysaccharide identity and composition – These tests include colorimetric 
assays and NMR that provide information on the identity and purity of the 
polysaccharide as well as any impurities, such as CWPS, that may be present. For 
the identity and composition to be confirmed the WHO have defined specifications for 
each serotype and colorimetric test. For Pn1 the theoretical value for the uronic acid 
colorimetric assay is 55.17 % and the O–acetyl assay should give a theoretical value 
of 5.47 % [162]. The CWPS impurity is best determined through NMR as described in 
Chapter 3, Section 3.5.1 and while there is no recommended limit on contamination, 
it must be kept to as low as possible. 
 Protein impurity – The protein content is determined using the Bradford Coomassie 
assay for Pn1 with bovine serum albumin used as a reference. According to the 
WHO, protein contamination should not be greater than 3 % by dry weight [14, 162].  
 Nucleic Acid impurity – Each batch of polysaccharide should contain, by the WHO 
recommendations, a nucleic acid contamination of not more than 2 %. This is 
calculated from the measurement of the absorbance of the polysaccharide solution at 
260 nm [162, 375]. 
 Molecular size distribution – This is used as a test of manufacturing between each 
batch of Pn1 PS purified. While the WHO does not set a limit on the distribution, as it 
is a strain and serotype dependant characteristic, it does suggest the use of size 
exclusion chromatography with a refractive index detector [162, 375]. 
Table 4.1. Defined criteria to determine Pn1 polysaccharide identity and purity. All values are based 
on mass percentage calculations. 
 Uronic acid O–acetyl Protein Nucleic acid 
Accepted criteria (%) 55.17 5.47  3 2 
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The general method for the purification of Pn1 PS is described in Chapter 2. To establish 
and optimise the process, the general method was applied to small scale cultivations to 
determine whether this purification process could be applied to Pn1. This process was 
optimised by investigations into the following areas: 
 The inactivation of the fermentation process was explored to determine whether 
phenol or DOC inactivation gave the best recoveries of high quality, high purity 
polysaccharide. 
 The optimal pH of the clarified fermentation broth was determined resulting in the 
maximum precipitation of the polysaccharide after the addition of CTAB. 
 The concentration of ethanol required to elute the pure polysaccharide from the 
Celite filtration compound packed into a chromatography column. 
Fermentation of Pn1 was performed 19 times; 14 of which were carried out in the fermentor 
and 5 in the WAVE bioreactor. Batch and fed–batch methodologies were evaluated and all 
batches were clarified and proceeded through to the purification downstream process. 
4.1.1 Purification optimisation 
4.1.1.1 Establishment of process parameters 
Three small scale cultivations of Pn1 were used to determine the optimum pH needed to 
achieve maximum CTA+ precipitation. All three batches were cultivated over 4 hours before 
inactivation with phenol. The initial pH was measured and the polysaccharide content was 
determined by ELISA. Differences in the cultivation such as optical density as well as the 
length of time used for inactivation account for the differences in polysaccharide content as 
the optimisation of the culti ation process occurred simultaneously. The pH of each batch 
was adjusted to 8.0, 7.8 and 5.5 in order to determine which pH would allow for maximum 
polysaccharide precipitation. Table 4.2 details the data for the three batches.  
The fermentation broth was clarified by centrifugation to remove any dead cells and 
particulates in the broth. A final concentration of 18 g/L CTAB for each batch was used to 
precipitate out all of the polysaccharide in solution. A sample was taken before as well as 5 
min after the CTAB was added and rate nephelometry was used to shown that only trace 
amounts of Pn1 PS were left in the supernatant after CTAB addition (Figure 4.4).  
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Table 4.2. Initial values for three cultivations of Pn1 to determine the optimum pH for CTAB 
precipitation. 
Batch Initial polysaccharide content (mg) Initial pH Adjusted pH 
1 595 7.65 8.0 
2 234 7.13 5.5 
3 340 7.15 7.8 
 
Figure 4.4. Rate nephelometry for the determination of PS concentration in the fermentation broth 
(blue) and the supernatant after CTAB precipitation (red). 
Celite was added to achieve a final concentration of 93 g/L. This ‘slurry’ was packed onto a 
column and washed with 0.05 % CTAB in 0.05 M NaOAc to elute all the remaining media 
components from the fermentation. Increasing concentrations of ethanol were passed 
through the column to elute out the polysaccharide. As it was not known when the 
polysaccharide would precipitate out, the first batch was eluted with only two different 
concentrations of ethanol (20 % and 30 %), but a more thorough examination of the optimal 
concentration to elute the polysaccharide was performed for batches 2 and 3. Fractions were 
collected and tested with the uronic acid assay for the presence of polysaccharide. The 
results of this assay, (Table 4.3), revealed that the polysaccharide eluted in ethanol 
concentrations of between 10 % and 30 % for all three batches.  
Fractions that tested positive for uronic acid were pooled together and sodium chloride was 
added in its solid form to obtain a final concentration of 2 M NaCl. NaCl precipitates the 
polysaccharide as a counter ion exchange takes place with the CTAB forming the sodium 
salt of the polysaccharide. This sodium form of polysaccharide is insoluble in ethanol and 
therefore precipitates out. This however, did not occur so an equivalent volume of 96 % 
EtOH was added to reduce the polarity sufficiently to enable precipitation. 
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Table 4.3. Results from the uronic acid assay in determination of the elution profile of Pn1 with 
increasing concentrations of EtOH. 
Batch 
Polysaccharide elution* (Y/N) 
0.05 % 
CTAB 5 % EtOH 
10 % 
EtOH 
15 % 
EtOH 
20 % 
EtOH 
30 % 
EtOH 
60 % 
EtOH 
1 N n/a n/a n/a Y Y n/a 
2 N N Y Y Y N N 
3 N N N Y Y Y N 
*Uronic acid assay used to test for polysaccharide elution. Purple colour change suggests Pn1 elution. 
The precipitated polysaccharide was pelleted out by centrifugation, dissolved in 250 ml water 
and diafiltered against seven volumes of 0.5 M NaCl followed by seven volumes of water 
using a Labscale™ TFF system fitted with 2 x 100 K  WCO 50 cm2 membranes fitted in 
parallel. This purified Pn1 PS was analysed on the SEC–HPLC (Figure 4.5) as well as with a 
range of analytical assays to determine the amount of polysaccharide purified as well as the 
percentage O–acetylation (Table 4.4).  
 
Figure 4.5. SEC–HPLC RID chromatogram of a representative purified Pn1 polysaccharide (red, 
dashed). The profile of a reference Pn1 PS is shown (black, solid) for comparison. 
Table 4.4. Analytical results to determine identity and purity of the polysaccharide. 
Analytical calculations Batch 1 Batch 2 Batch 3 Acceptance criteria 
PS Content (UA assay) (mg)* 133 62 64 – 
O–acetylation (colorimetric 
assay) (mass %) 5.16 19.33 31.13 
˃5.47 
Nucleic acid (%) Not performed 0.65 0.69 ˂2 
Protein (%) Not performed 4.34 3.45 ˂3 
% Recovery 22 27 19  
*Based on dry weight 
The recoveries of the three batches (22 %, 27 % and 19 % for batches 1, 2 and 3 
respectively) were within the range seen in previous polysaccharide purifications, with the 
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lower pH range providing the higher recovery value. However, with Pn1 PS, the O–
acetylation value is important. The first batch was only analysed for uronic acid and O–acetyl 
percent and the results revealed only a small amount of O–acetylation. This could have been 
due to the adjusted pH of 8.0 which could cause de–O–acetylation. The other two batches 
were subjected to a full colorimetric assessment. The results confirm that Pn1 PS can be 
purified at both pH values (7.8 and 5.5). Cell wall polysaccharide and O–acetylation patterns 
were not determined with NMR for the three batches. A purification pH of 7.8 was 
determined to be the optimal pH for purification for allowing the CTA+ polysaccharide salt to 
form and precipitate out of solution. The ethanol fractionation range was determined to be 
between 10 – 30 % with low nucleic acid contamination; however, the levels of protein 
contamination were high and above the suggested range.  
4.1.1.2 Inactivation strategies 
Streptococcus pneumoniae is a Biological safety level (BSL) 2 pathogen and represents a 
particular hazard to health through infection by the respiratory route [162]. The bacteria is 
fermented under BSL2 conditions but must be killed before it can proceed to purification in 
an ungraded room, therefore the inactivation of Streptococcus pneumoniae is an important 
linkage between the upstream (fermentation) and downstream (purification). This inactivation 
step should be able to inactivate the bacterial cells and to aid in the release of the capsular 
polysaccharide into the fermentation media with minimum cell lysis, without affecting the 
composition and structure of the polysaccharide. 
Two different inactivation strategies were investigated where both phenol and sodium 
deoxycholate were compared as methods of inactivation. These two different strategies have 
been used to inactivate S. pneumoniae for the production of the two licensed conjugate 
vaccines [164, 376]. The DOC process has been shown to reduce protein contamination yet 
still preserves the integrity of the polysaccharide. DOC also facilitates the release of 
autolysin which is known to be responsible for cleaving the CWPS from the capsular 
polysaccharide [10, 13, 371]. 
Both cultivations were 4 hours long and reached the same optical density. Table 4.5 details 
the initial conditions of each batch. The fermentation broth was clarified by centrifugation and 
the pH of both batches was adjusted to 7.8 with 3.5 M NaOH. 
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Table 4.5. Initial conditions for two cultivations of Pn1 to determine the optimum inactivation strategy. 
Batch Inactivation method Initial PS content (mg) Initial pH 
1 1 % Phenol 187 7.3 
2 0.12 % DOC 197 5.3 
CTAB was added to each batch and rate nephelometry was used to determine if all the 
polysaccharide had precipitated. All of the polysaccharide had precipitated out when the final 
concentration of CTAB in the solution was at 18 g/L when phenol was used as the method of 
inactivation (Figure 4.6), this was not the result seen with DOC inactivation. The rate 
nephelometry showed that no polysaccharide had precipitated out of solution when 18 g/L 
CTAB was added. The amount of CTAB in solution was raised to 30 % and then 50 % 
however the rate nephelometry showed that the polysaccharide concentration increased 
when increasing amounts of CTAB were added. It was hypothesised that the sodium 
deoxycholate was interfering with the assay, by the co–precipitation between the CTA+ and 
DOC salts.  
  
Figure 4.6. CTAB precipitation monitored by rate nephelometry of a) the phenol inactivated batch – 
comparison between fermentation broth (blue) and the supernatant after CTAB addition (red) and b) 
the DOC inactivated batch – comparison between fermentation broth (blue) and the supernatant after 
CTAB addition of 18 g/L (red), 30 % (green) and 50 % (purple). 
Whilst the nephelometry result of the DOC inactivation was noted, purification of both 
batches continued. Celite was added and the polysaccharide was eluted with increasing 
concentrations of ethanol. The ethanol elution pattern for the phenol inactivation was similar 
to previous batches with elution taking place in 5 % – 30 % EtOH fractions. The uronic acid 
colorimetric assay was used to determine where the polysaccharide eluted (as shown in 
Table 4.6). For the phenol inactivated batch, the fractions that tested positive for PS were 
pooled together and solid NaCl added to precipitate out the polysaccharide. As before, the 
precipitation process was aided by the addition of the equivalent volume of 96 % EtOH, 
before centrifugation and diafiltration were performed to obtain the purified polysaccharide.  
a) b) 
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Table 4.6. Polysaccharide elution patterns with increasing concentrations of ethanol. 
Batch 
Polysaccharide elution* (Y/N) 
0.05 % 
CTAB 5 % EtOH 
10 % 
EtOH 
15 % 
EtOH 
20 % 
EtOH 
30 % 
EtOH 
60 % 
EtOH 
1 N Y Y Y Y Y N 
2 N N N N N N N 
*Uronic acid assay used to test for polysaccharide elution. Purple colour change suggests Pn1 elution. 
No polysaccharide was found in any of the fractions collected from the DOC–inactivated 
batch. After this result, further literature investigations were performed and a publication on 
the optimisation of conditions for the PS production of Pn23F was found which suggested 
that in order to obtain polysaccharide from DOC inactivated cultivations, the fermentation 
broth was diafiltered and concentrated by tangential filtration to remove the excess sodium 
deoxycholate [373]. The supernatant that was left after CTAB/Celite precipitation was 
diafiltered against 1.5 volumes 0.2 M NaCl followed by 1.5 volumes of 5 M NaCl using a 
Labscale™ TFF system fitted with 2 x 50 K  WCO 50 cm2 membranes in parallel. 18 g/L 
CTAB was added to precipitate out the polysaccharide. Precipitation did not occur and was 
hypothesised to be due to the high levels of sodium in the solution, which prevented a 
counter ion exchange with the CTA+. An alcohol precipitation was attempted where 96 % 
EtOH was added to the solution until precipitation w s seen. The precipitate was extracted 
by centrifugation, re–dissolved in water and diafiltered as performed in previous batches. 
The analytical results for both batches are tabulated in Table 4.7. 
Table 4.7. Analytical results of purified Pn1 after undergoing phenol or DOC inactivation. 
Analytical calculations Batch 3 Phenol Batch 4 DOC Acceptance criteria 
PS Content (UA assay) (mg)* 128.3 83.2 – 
O–acetylation    
Colorimetric assay (mass %) 23.8 32.7 ˃5.47 
 NMR (mol %) 87.7 – – 
Impurities  
Nucleic acid (%) 0.646 – ˂2 
Protein (%) 5.3 – ˂3 
CWPS (mol %)** 1.5* – – 
CWPS (mass %)** 3.0* – – 
% Recovery 69 42 – 
*Based on dry weight 
**Average of calculations with CH3 and NHAc groups of amino sugar as reference. 
The phenol inactivated batch gave a high recovery of 69 % compared to 42 % recovery of 
the DOC inactivated batch. Due to the potential loss of polysaccharide trapped in Celite, the 
DOC result may not be a true reflection of the purification process. The analytical results for 
the phenol inactivated batch confirmed the identity of the purified Pn1 PS which resulted in 
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an O–acetylation level of 24 % by colorimetric assay and approximately 88 % as determined 
by NMR. The CWPS contamination was determined to be 3.0 % (w/w) which is the limit 
suggested by Merck for their purified polysaccharide [217]. Protein contamination was found 
to be 5.3 % which is above the specified limit of 3 %. It was hypothesised that this was due 
to the inclusion of early eluted fractions with low polysaccharide concentrations but high 
protein concentrations. 
The proton NMR spectrum of the purified polysaccharide is shown in Figure 4.7. The purified 
polysaccharide was compared to a reference sample to confirm the identity of the 
polysaccharide. The CWPS contamination was confirmed with a peak at 3.23 ppm 
corresponding to the methyl groups on the phosphocholine residue [366]. All other peaks 
compared well with the reference spectrum. 
 
Figure 4.7. 1H NMR spectrum of purified Pn1 PS (black) with phenol inactivation. A reference Pn1 PS 
spectrum is shown for comparison (red). 
As the initial purification of the DOC inactivated batch did not prove successful, four batches 
were fermented with two inactivated using phenol and two with DOC. These four batches 
were used as a comparison for the optimal inactivation strategy. Preliminary data for the four 
batches before purification was performed are compiled in Table 4.8. 
All batches were clarified by centrifugation before CTAB precipitation. After clarification the 
pH of the phenol inactivated batches were adjusted to 7.8 using 3.5 M NaOH before CTAB 
was added. The DOC inactivated batches were first diafiltered against 7 volumes of 25 mM 
NaOAc using a 100 kDa MWCO Pellicon 2 membrane.  
CTAB and Celite precipitation, column loading and fractionation using ethanol was 
performed with the uronic acid assay used to determine PS elution as shown in Table 4.9. 
Purification continued as previously described. 
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Table 4.8. Initial conditions for two cultivations of Pn1 to determine the optimum inactivation strategy. 
Batch Inactivation strategy Volume (L) 
Initial PS 
content (mg) 
Initial PS 
concentration 
(mg/L) 
Initial pH 
5 1 % phenol 6 924 154 6.44 
6 1 % phenol 4 720 180 6.84 
7 0.12 % DOC 2 310 155 5.31 
8 0.12 % DOC 4 608 152 5.30 
Table 4.9. Polysaccharide elution patterns with increasing concentrations of ethanol. 
Batch 
Polysaccharide elution (Y/N) 
0.05 % 
CTAB 
5 % 
EtOH 
10 % 
EtOH 
15 % 
EtOH 
20 % 
EtOH 
30 % 
EtOH 
60 % 
EtOH 
5 N N Y Y Y Y N 
6 N N Y Y Y Y N 
7 N N Y Y Y N N 
8 N N Y Y Y N N 
*Uronic acid assay used to test for polysaccharide elution. Purple colour change suggests Pn1 elution. 
For the phenol batches, elution of the polysaccharide took place between 10 – 30 % EtOH 
and elution in the DOC batches was completed within the ethanol concentration range of   
10 – 20 %. The purified polysaccharides were diafiltered using 100 kDa MWCO regenerated 
cellulose membranes with 7 volumes of 0.5 M NaCl followed by 7 volumes of water. Full 
analysis to determine the purity of the polysaccharide was performed (Table 4.10).  
The phenol batches produced an average of 463 mg Pn1 PS compared to the 221 mg from 
the DOC batches, however the fermentation volumes were different in each case and thus, 
simply comparing polysaccharide amounts do not give a clear indication of superiority. The 
average recovery for the phenol batches was calculated at 56 % compared to 46 % for the 
DOC inactivated batches. It must be noted that as the fermentation volume increased so did 
the PS content which was expected, but the recovery also increased with increasing 
volumes: the recovery from the 2L batch was only 40 % whereas 59 % of the PS in the 6 L 
fermentation batch was recovered. This is a known occurrence as the same amount lost in 
the 6 L and 2 L batches would have a different impact on the recoveries for the two batches 
with the smaller batch impacted the most and hence revealed a lower recovery.  
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Table 4.10. Analytical results of purified Pn1 after undergoing phenol or DOC inactivation. 
Analytical calculations Batch 5 Phenol 
Batch 6 
Phenol 
Batch 7 
DOC 
Batch 8 
DOC 
Acceptance 
criteria 
Initial fermentation volume (L) 6 4 2 4 – 
UA content (%) 71.6 70.1 78.8 67.8 ˃ 55.17 
PS Content (UA assay) (mg)* 548.2 378.1 126.2 315.5 – 
O–acetylation 
Colorimetric assay (mass %) 23.6 23.4 22.4 23.7 ˃ 5.47 
NMR (mol %) 90 75 89 70 – 
Impurities 
Nucleic acid (%) 0.69 0.53 1.22 0.61 ˂2 
Protein (%) 5.15 0.94 13.7 0.97 ˂3 
CWPS (mol %)** 2.0 2.7 2.6 2.5 – 
CWPS (mass %)** 4.0 5.4 5.2 5.0 – 
% recovery 59 53 40 52 – 
*Based on dry weight. 
**Average of calculations with CH3 and amino groups of amino sugar as reference. 
The analytical results show that the levels of O–acetylation were approximately 23 % for 
both inactivations according to the colorimetric assay. Nucleic acid and protein 
contamination were all within the acceptable limits. CWPS contamination was determined to 
be within the range of 4 – 5.5 % (w/w). The NMR of each batch confirms the identity of the 
purified polysaccharide as being pneumoc ccal serotype 1 as shown in Figure 4.8 and 
Figure 4.9. It was interesting to note that both batches of Pn1 PS that were inactivated with 
DOC show O–acetylation mainly on C2 of the middle GalA residue (75 %) whereas the 
batches inactivated with phenol show a more evenly spread O–acetylation pattern between 
C2 (60 %) and C3 (40 %). This was theorised to be due to the fermentation pH, an increase 
in the pH brings about a migration of the O–acetyl group from C2 to C3 of the GalA residue. 
This also suggested that the bacteria may acetylate at only one position (C2) and not at both 
as previously suggested [293]. The mechanism for the O–acetyl migration is intramolecular 
via an ortho–ester intermediate as depicted in Figure 4.10 [164]. 
Small traces of acetate buffer were identified in the phenol inactivated batches but apart 
from CWPS, no other contaminants were found in the NMR analysis. The chromatograms 
from the SEC–HPLC data of each purified batch show that the molecular weight range of the 
batches were approximately 1000 kDa compared to Pullulan standards (Figure 4.11). 
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Figure 4.8. 1H NMR overlays of batches inactivated with a) phenol and b) DOC. 
 
Figure 4.9. 1H NMR overlays of batches inactivated with phenol (blue, top) and DOC (black, bottom). 
 
 
Figure 4.10. Migration of O–acetyl group from C2 to C3 on GalA residue in Pn1 PS. 
a) b) 
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Figure 4.11. Size comparison of four batches of either DOC (red and green) or phenol (blue and 
purple) inactivation. A known Pn1 PS (black) is shown for reference. 
From the last four batches the results confirm the phenol inactivation to be superior to DOC 
in polysaccharide yield and O–acetyl content. The phenol inactivated batches were purified 
to a greater extent in terms of protein, nucleic acid and CWPS contaminants. It is important 
to note that the protein contamination was reduced significantly by not collecting the 10 % 
EtOH fractions (which is high in nucleic acid contaminants). The PS produced from both 
phenol batches were within WHO specification for protein, nucleic acid and CWPS. Thus, 
phenol was chosen as the preferred inactivation method for future fermentation and 
purification batches.  
4.1.2 Large scale fermentation batches 
With an inactivation strategy and purification process parameters established following the 
small scale cultivations; the next step was to scale up the fermentation volume. The 
purification volumes were 6 L, 15 L or 30 L: the 15 and 30 L batches were fermented in a 
fermentor and the 6 L batches were fermented using disposable technology, namely a Wave 
Bioreactor. The results of all these purifications can be found in the Appendix. Three batches 
are explained in some detail; Pn1–007 was fermented using disposable bag technology, 
Pn1–019 is included as a representative sample and the Pn1–018 provided a unique 
outcome. Before purification commenced, initial PS content was determined (Table 4.11).  
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Table 4.11. Initial conditions for three cultivations of Pn1 using disposable technology and traditional 
fermentation methods. 
Batch No: Pn1–007 Pn1–018 Pn1–019 
Fermentation mode Wave Fermentor Fermentor 
Fermentation volume (L) 6 15 15 
Method of inactivation phenol phenol phenol 
Initial pH 7.91 7.05 7.09 
Initial PS content (g) 2.40 9.04 5.12 
Initial PS concentration 
(mg/L) 400 602 341 
As with previous batches, the fermentation broth was first clarified to remove any cell debris 
and insoluble media components. Following clarification the pH of the solution was adjusted 
to 7.8 followed by CTAB/Celite addition. Again, rate nephelometry was used to confirm that 
the polysaccharide had precipitated in the CTA+ salt form. The purificatio  continued with the 
ethanol elution of the polysaccharide from the Celite column. During the purification 
investigation, it was decided to reduce the number of EtOH concentrations to three; the 5 % 
EtOH which elutes out the nucleic acids and proteins, the 15 % and 30 % which elutes off 
the polysaccharide and 60 % EtOH was added as a final wash to remove any remaining 
polysaccharide trapped in the Celite. Table 4.12 det ils the fractions that tested positive in 
the uronic acid assay for the presence of polysaccharide and Figure 4.12 shows graphically 
the percentages of polysaccharide and CWPS eluted in each ethanol fraction. Nucleic acid, 
protein and aggregate percentages are also shown for each fraction. The positive fractions 
were pooled; NaCl and EtOH added to promote precipitation, and subsequent centrifugation 
and diafiltration were carried out. Full analysis of each batch was performed and detailed in 
Table 4.13. 
Table 4.12. Polysaccharide elution patterns with increasing concentrations of ethanol. 
Batch 
Polysaccharide elution 
0.05 % 
CTAB 5 % EtOH 
15 % 
EtOH 
30 % 
EtOH 
60 % 
EtOH 
Pn1-007 N N Y Y N 
Pn1-018 N N Y Y Y 
Pn1-019 N N Y Y N 
*Uronic acid assay used to test for polysaccharide. Purple colour change suggests Pn1 
elution. 
The Pn1–018 purified batch produced the highest levels of Pn1 polysaccharide out of all the 
fermented and purified batches in this study; however the recovery from batch Pn1–007 was 
much higher at 69 % compared to approximately 51 % for Pn1–019 and only 43 % for Pn1–
018. The O–acetylation assays gave an unusual result for Pn1–018 which was that no O–
acetylation was present on the polysaccharide after purification. The results from the 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
128 
 
colorimetric assay were confirmed by NMR analysis (Figure 4.13), however it was not known 
why this would have occurred as fermentation proceeded as per previous batches and no 
contamination was seen. The NMR gave an acetylation level of 67 % for both Pn1–007 and 
Pn1–019. The pattern of O–acetylation between the two batches was different with Batch 
Pn1–019 showing a position ratio between C2 and C3 of 65:35 where Pn1–007 gave a 
position ratio of 49:51 C2:C3. The difference in position of O–acetylation was hypothesised 
to be due to the pH of the inactivated fermentation broth. From the NMR it was concluded 
that the bacteria acetylates at the C2 position of the GalA residue and an increase in pH 
causes a migration to the C3 position, the extent of migration depends on the pH of the 
fermentation batch, the temperature and the time since fermentation to analysis. 
 
Figure 4.12. Total amounts of nucleic acid, protein, aggregates, CWPS and PS during EtOH fractions 
on a representative purification. 
The nucleic acid contamination in Pn1–007 was not significant but was found to be 
approximately 1 % in Pn1–018 and Pn1–019, which was still within acceptable limits. The 
protein contamination of Pn–018 was higher than acceptable limit at 3.1 % whilst the other 
two batches were within specification. This high value for Pn1–018 could be attributed to the 
inclusion of the 60 % ethanol fraction in the pool. This fraction tested positive for a large 
amount of polysaccharide and hence was included in the pooled fractions but since each 
fraction was not tested for protein, it was possible that this fraction may have been 
contaminated with a large amount of protein.  
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Table 4.13. Analytical results of three purified Pn1 polysaccharide batches. 
Analytical calculations Pn1-007 Pn1-018 Pn1-019 Acceptance criteria 
UA content (%) 66.6 70.2 74.1 ˃ 55.17 
PS Content (UA assay) (g)* 2.3 7.6 4.0 – 
O–acetylation     
Colorimetric assay (mass %) 23.7 0 23 ˃5.47 
NMR (mol %) 67 0 67 – 
Impurities     
Nucleic acid (%) 0.004 1.2 1.1 ˂2 
Protein (%) 0.6 3.1 1.7 ˂3 
CWPS (mol %)** 2.2 1.2 1.9 – 
CWPS (mass %)** 4.4 2.4 3.8 – 
% recovery 69 43 51 – 
*Based on dry weight 
**Average of calculations with CH3 and NHAc groups of amino sugar as reference. 
 
 
Figure 4.13. 1H NMR overlays of three batches of purified Pn1 polysaccharide, a) Pn1–019 and b) 
Pn1–018 and c) Pn1–007. 
4.1.3 Summary 
A strategy for the purification of Pn1 was successfully implemented. The inactivation strategy 
developed was based on a patent by Liveyns et al. and it was determined that phenol 
inactivation provided the optimum amount of polysaccharide when compared to DOC 
inactivation. The inactivated fermentation broth was transferred to downstream processing 
after clarification. The CTAB/Celite “slurry” was generated and packed into a column and 
washed with a low concentration of CTAB to remove excess media components before the 
polysaccharide was eluted with increasing concentrations of ethanol. Polysaccharide 
fractions eluted with low ethanol concentrations were not included as the levels of protein 
and nucleic acid were too high. Counter ion exchange with NaCl was followed by 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
130 
 
precipitation with 96 % ethanol before final separation by centrifugation and diafiltration to 
obtain the purified Pn1 PS. Figure 4.14 details the final process flow for the purification of 
Pn1 along with all analytical tests performed throughout the process. This polysaccharide 
conformed to all specifications determined by the World Health Organisation in terms of 
identity, structural integrity and purity. The polysaccharide was deemed sufficiently pure to 
be further conjugated to a carrier protein in the preparation of a conjugate vaccine for animal 
testing.  
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Figure 4.14. Final process flow for the purification of Pn1 polysaccharide including diafiltration steps as well as all analytical assays performed. 
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4.2 Polysaccharide size reduction 
There are two different molecular weight distributions for polysaccharides that are used in 
commercially available vaccines: 
1. Full sized or size–reduced bacterial polysaccharides that are randomly activated at 
various sites along the chain with or without a linker. A cross linked, lattice–like 
structure is formed when the polysaccharide is coupled to a protein [107, 164, 377]. 
These conjugates have a very high molecular mass, and are difficult to characterise 
on a molecular level.  
2. Shorter polysaccharide fragments (oligosaccharides) that are either attached to the 
protein at one singular point that generally corresponds to their terminal or cross–
linked to the protein [107, 378-380]. 
There is evidence that shows that the shorter chain fragments of polysaccharides are able to 
elicit a greater T cell–dependent antibody response than the longer chain PS; they optimise 
T cell help by bringing antigen specific B cells and helper T cells into a more favourable 
physical relationship for cell–cell interactions [381]. Conjugates that contain saccharides as 
small as a disaccharide have been shown to elicit antibodies to some bacterial 
polysaccharides or the corresponding bacteria itself [380]. However, the size of the 
saccharide must be sufficiently large to be effective in raising antibody immunity by 
expressing the complete epitope of the native antigen [10, 107, 380, 381].  
The relationship between immunogenicity and polymer chain length has been shown for a 
variety of polysaccharides in both animal and human studies [382-385]. The studies have 
provided direct evidence that a reduction in the polysaccharide size below a certain 
minimum can result in a reduced immunogenicity. These studies [383, 384] formed the 
historical basis for the introduction of molecular size specifications that would provide 
confidence that the potency of pneumococcal polysaccharides used in vaccine formulations 
remains, however these were based on polysaccharide vaccines and not conjugate vaccines 
[385]. 
Anderson et al. carried out detailed studies of the effects of oligosaccharide chain length on 
the immunogenicity of PRP for Hib conjugate vaccines [380, 381]. The investigations 
compared conjugates containing saccharides with 8 and 20 ribose–ribitol phosphate 
repeating units. The conjugate containing the 20 repeating units was found to prime infants 
for a secondary response better than the 8 repeating unit conjugate. However, a later study 
of conjugates with 4–, 6– and 12– repeating unit conjugates showed no difference in animal 
antibody response [381]. 
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Despite the opposing thoughts with respect to immunogenicity and chain length, an 
advantage of size reduction is a reduction in the viscosity of the polysaccharide in solution. 
Due to the number of hydroxyls and other functional groups in the polysaccharide, inter– and 
intra–molecular forces, including hydrogen bonding and van der Waals forces, are present 
which gives the polysaccharide a very high apparent hydrodynamic size. By interrupting 
these forces, the viscosity of the polysaccharide in solution decreases, making the solution 
easier to work with and allowing a more efficient conjugation.  
Table 4.14 best describes the variability of polysaccharide size and size reduction methods 
of some licensed conjugate vaccines. Synthetic (Quimi–Hib), full length (ActHIB) and size 
reduced (HibTITER) PRP has been used in conjugate vaccines against Hib. Both chemical 
and mechanical means of size reduction have been applied to different serotypes in 
pneumococcal conjugate vaccines with GlaxoSmithKline making use of microfluidization as 
described in this chapter. The conditions used in the GSK process are a maximum of 50 
passes through a M110S Microfluidics machine for a period of two minutes at a maximum 
pressure of 12 328 psi [386]. 
Table 4.14. Currently licensed vaccines using various polysaccharide sizes. 
Serotype Conjugate Vaccine 
Method of polysaccharide 
size reduction Manufacturer 
Hib conjugates 
B HibTITER® Periodate oxidation Pfizer 
B ActHIB® Native PS used Sanofi Pasteur 
B Quimi–Hib® Synthetically produced Heber Biotech 
Meningococcal conjugates 
A MenAfriVac® Periodate oxidation Serum Institute of India Limited (SIIL) 
C NeisVac–C® Periodate oxidation GlaxoSmithKline 
Tetravalent Menveo® Acid hydrolysis Novartis 
Pneumococcal vaccines 
7 valent Prevnar® Acid hydrolysis and periodate oxidation Pfizer 
10 valent Synflorix® Microfluidization GlaxoSmithKline 
13 valent Prevnar13® Acid hydrolysis and periodate oxidation Pfizer 
The traditional methods of size reduction are: 
1. Acid and base catalysed hydrolysis where either an acid or base is added to the 
sample to be hydrolysed and the sample is heated to a desired temperature over a 
period of time. 
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2. Chemical manipulation of a reactive group on the polysaccharide that leads to 
fragmentation, e.g. oxidation of the diols on the ribitol chain of PRP to form 
aldehydes and resulting in fragmentation of the polysaccharide. 
The use of chemical size reduction has distinct disadvantages, including: 
 Many of the pneumococcal polysaccharides are unstable at extreme pHs. For 
example Pn1 contains a very labile O–acetyl grouping that will be removed at a basic 
pH (above 8.0). 
 The ability to obtain and control the size of the polysaccharide is very difficult using 
traditional methods and even if the desired size is achieved it is very difficult to 
reproduce. 
 As they are chemically selective, these methods may break susceptible bonds and 
leave the more resistant bonds intact. 
 It is specific to certain groups of saccharide and not generally applicable to all 
polysaccharides. 
 Side reactions may occur. 
Alternatives to the use of chemicals are sonication and microfluidization. Although these 
methodologies require specialised instrumentation, they have the advantage of yielding 
suitable fragmentation that: (i) is reproducible, (ii) requires minimal post fragmentation work–
up (iii) is relatively quick to perform and; (iv) does not require additional chemicals or 
reagents. 
4.2.1 Mechanical size reduction 
Two different types of mechanical size reduction were investigated in this study, namely 
sonication and microfluidization.  
Sonication is a process by which an electrical signal is converted into a mechanical vibration. 
This vibration, in the case of polysaccharides, causes the glycosidic bonds between the 
different saccharides to break. The essential component of a sonicator is the generator: it 
creates an ultrasonic electrical signal that powers a transducer which, in turn, changes the 
electrical signal to a mechanical vibration using piezoelectric crystals. This mechanical 
vibration is amplified to the required power output before transferring it to the probe which 
vibrates through the solution when placed in the sample. The amplitude or power output 
(that controls the rate of vibration) and the time a sample is sonicated can be controlled 
depending on the sample requirements [387].  
Sonication works by creating an effect known as cavitation that occurs as a result of liquids 
not moving as fast as the movement of the probe, so the vibrations create a series of 
microscopic bubbles in the solution, pockets (cavities) of space wedged between the 
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molecules form and collapse again under the weight of the solution, sending out tiny 
shockwaves into the surrounding substance. Thousands of these bubbles forming and 
collapsing constantly create powerful waves of vibration that cycle into the solution and 
break the polymeric chains [387].  
One consequence of high power output focused in the tip of a probe is that sonication can 
generate substantial and rapid heat. A burst of a sonicator probe for just a few (1 – 2) 
seconds can cause water to boil. Consequently, when heat labile samples are processed, 
the samples must be kept cold and the sonication must be performed in short bursts 
interspersed with cooling periods. A further consequence of the high power output is that the 
tip itself disintegrates posing a contamination issue. Although particles can be removed by 
introducing a filtration step post–sonication, this potential contamination issue renders the 
method not suitable for manufacturing processes. An alternative method for size reduction, 
namely microfluidization, allows for the control and reproducibility of the sonication without 
the contamination. 
Microfluidization involves the use of an interaction chamber containing fixed geometry 
micro– channels and a pump. The pump in the instrument amplifies hydraulic pressure to the 
selected level which, in turn, imparts this pressure to the sample. The pressure is 
controllable in the range of 2 500 to 30 000 psi that the pump delivers at a constant rate to 
the sample. As the pump travels through its pressure stroke it drives the sample through the 
interaction chamber. The sample travels at a very high velocity through the micro–channels 
that are designed to create high shearing and impact forces that disrupt (break) any non–
branching glycosidic bonds in the polysaccharide. As the pump completes its pressure 
stroke it reverses direction and draws through the next volume of sample. At the end of the 
intake stroke it again reverses direction, drives the sample into the interaction chamber and 
the process is repeated. This allows for the processing of large volumes of sample in a 
repeatable procedure. The sample can be recirculated through the chamber if the desired 
size is not achieved from the first pass [388].  
In order to investigate the application of microfluidization the M–110PS model was acquired 
that permits a minimum sample volume of 25 ml. By utilising the specifically designed fixed 
geometry diamond interaction chamber technology, and a ceramic (Zirconia) plunger, the M–
110PS is capable of processing a wide variety of applications such as particle size–reduction 
and cell disruptions including the most difficult yeast and plant cells in as few as 1 – 2 
passes. The process is repeatable and scalable to pilot and/or production volumes. The 
microfluidizer has a pressure operating range of 0 – 30 000 psi and the return coil has to be 
cooled to between 2 – 6 °C to avoid the sample heating up. 
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Two different methods; namely sonication and microfluidization, were investigated in order to 
initiate and develop a simple and general fragmentation strategy that could be applied to a 
wide variety of polysaccharides, irrespective of their chemical structure. 
4.2.2 Sonication 
During the investigation into the sonication technique, Pn1 polysaccharide was in limited 
supply and a model compound was sought. Hyaluronic acid (HA) (Figure 4.15) is composed 
of a disaccharide repeating unit of glucuronic acid and N–acetylglucosamine, which is 
structurally similar to the galacturonic acid and the AAT amino saccharide of Pn1 and was 
thus chosen as a model compound for the initial sonication investigations. 
The main objective of the experiments described below was to determine if the degree of 
depolymerisation could be consistently controlled by changing time or power variables, 
without altering the structure of the polysaccharide. The targeted molecular size range post 
sonication was 50 – 100 kDa for all polysaccharides. 
 
Figure 4.15. Structures of a) HA and b) Pn1. 
10 ml of an HA solution in water (at 5.00 mg/ml concentration) was placed in a 50 ml beaker 
and cooled in an ice bath before the sample was subjected to sonication with varying power 
outputs as described in Table 4.15. 
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Figure 4.16. SEC–HPLC RID chromatograms of hyaluronic acid samples. Comparison of full size 
(black) HA with 85 kDa HA1 (red), 67 kDa HA2 (blue) and 56 kDa HA3 (green). 
Table 4.15. Summary of sonication conditions and the resultant size distribution of HA. 
Sample Time (min) 
Power output 
(kJ) 
Retention time 
(min) Size (kDa) Size reduction 
HA 0 0 12.868 3360 – 
HA1 30 71.64 17.792 85 39.5 fold 
HA2 60 37.77 18.101 67 50 fold 
HA3 45 104.58 18.332 56 60 fold 
The HA samples were significantly reduced in size with the molecular size decreasing from 
3000 kDa to 50 – 100 kDa, a 40 – 60 fold size reduction when the higher power outputs 
were applied. Higher power outputs were required due to the larger size of the native 
polysaccharide (Figure 4.16). Both HPAEC and NMR analysis were performed on sample 
HA2 to investigate if the integrity of the sample had been maintained after sonication and 
that no epimerization occurred.  
The resulting HPAEC–PAD chromatograms (Figure 4.17) before and after sonication both 
display a peak eluting at 16 min, corresponding to N–acetylglucosamine. With this 
chromatographic method the glucuronic acid moiety was not seen. A peak that eluted at 9.0 
min was due to the presence of glycerol; this was expected due to the filtering of the sample 
to remove any traces of metal shavings. As the GlcA peak was not observed NMR was 
needed to confirm that the structural integrity of the polysaccharide remained in place. 
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Figure 4.17. HPAEC analysis of HA a) full length and b) HA2: sonicated – 67 kDa. 
Figure 4.18 details the proton (1H) and carbon NMR spectra respectively of the sonicated 
sample (HA2). The fully characterised 2D proton–carbon correlation (HSQC) spectrum is 
displayed in Figure 4.19. The anomeric signals of both N–acetyl glucosamine and glucuronic 
acid in the 1H NMR were found with chemical shifts of 4.56 and 4.46 ppm respectively. The 
methyl peak at 2.02 ppm corresponded to the acetate peak of N–acetyl glucosamine. Peaks 
due to the presence of glycerol were seen in the proton spectrum (insert in Figure 4.18) and 
confirmed in the 13C spectrum. All peaks identified in both the 1H and 13C spectra confirmed 
that no epimerization had taken place during sonication. 
 
  
Figure 4.18. 1H and 13C NMR spectra of sonicated HA. The insert in the 1H NMR is of a glycerol 
overlay confirm the presence of the impurity.  
a) b) 
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Figure 4.19. Expanded proton–carbon correlation spectrum (HSQC) of sonicated HA.  
The 2D HSQC spectrum (Figure 4.19) further confirmed the identity of the hyaluronic acid 
with all peaks from the proton and carbon spectra correlated and identified. No epimerization 
had taken place as the peaks identifying both glucuronic acid and N–acetyl glucosamine 
were confirmed.  
With the knowledge that the structural integrity of the polysaccharide is maintained after 
sonication, attention turned to the size reduction of Pn1 PS by means of sonication. 
Pneumococcal polysaccharide serotype 1 was made available from two sources: 
1.  Chengdu Institute of Biological Products (CDIBP). 
2.  Pn1 fermented and purified at The Biovac Institute, (Biovac).  
20 ml of Pn1 from both sources were separately solubilised in water (at 5 mg/ml 
concentration), placed in a 50 ml beaker and cooled with an ice bath. Pn1 was subjected to 
various power outputs for between 30 and 60 min. The data generated from the analysis of 
the polysaccharide is presented in Table 4.16 and the SEC–HPLC chromatograms are 
displayed in Figure 4.20. 
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Figure 4.20. SEC–HPLC RID chromatograms of full length (grey) and sonicated (purple) Pn1 Biovac 
batch sample, as well as the chromatograms of CDIBP full length (black), CDIBP–1 (blue), CDIBP–2 
(red) and CDIBP–3 (green) samples. 
Table 4.16. Summary of sonication conditions and the resultant size distribution of Pn1 from CDIBP 
as well as a sample from TBI. 
Source Sample Time (min) 
Power 
(kJ) 
Retention time 
(min) 
Size 
(kDa) 
Size 
reduction 
CDIBP 
Pn1 0 0 12.823 1188 – 
1 45 68.22 15.400 178 6.7 fold 
2 60 77.74 15.485 169 7.0 fold 
3 60 98.24 16.166 110 10.8 fold 
Biovac 
Pn1  0 0 12.947 1061 – 
1 30 54.32 16.060 118 9.0 fold 
A reduction in size was achieved with all samples of Pn1 that underwent sonication. A small 
power output of 54.32 kJ produced a size reduction to 118 kDa from 1061 kDa (9 fold 
reduction) for the Biovac sample, whereas a CDIBP sample was subjected to a 68.22 kJ 
power output yet a size reduction from 1188 kDa to only 178 kDa (7 fold reduction) was 
achieved. While the reduction in size of the two different samples are similar (7 vs. 9 fold 
reduction) differences between the levels of size reduction could be explained in two ways. 
Firstly, due to the shedding of the metal tip on the sonicator, the size reductions of the 
samples will never be completely reproducible, the same power and time could be used for 
different samples, and the outcome will not be exactly the same. Secondly, the purity of the 
samples should be taken into account when comparing size reduction. It was thought that 
the Pn1 from CDIBP contained more contaminants (protein and nucleic acid) than that 
purified at Biovac. Therefore, more energy may have been used to break up the 
contaminants than the actual polysaccharide. 
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Proton NMR spectra were recorded for the native (full sized) and sonicated (size reduced) 
Pn1 from both CDIBP and Biovac. The CDIBP sample contained an extra peak at 1.91 ppm 
corresponding to the methyl group of free acetate from trace amounts of acetate buffer. It 
was observed that the NMR spectrum for both samples (Figure 4.21) were sharper post 
sonication, especially in the ring proton and anomeric region. The observed broad lines in 
the parent NMR spectrum were due to the lack of molecular motion. Increasing either the 
temperature, or in this case, reducing the size of the polysaccharide resulted in an increase 
in the molecular motion and therefore a better resolved spectrum with sharper peaks.  
Figure 4.21. 1H NMR analysis from (a) CDIBP and (b) Biovac detailing the full sized and sonicated 
Pn1 polysaccharide. (c) 1H–13C HSQC of sonicated Pn1 polysaccharide (CDIBP sample). 
The anomeric region revealed four proton signals post sonication corresponding to the 
acetylation at two different positions. The sharper signals were possibly due to the disruption 
of the intramolecular forces (hydrogen bonding) in the polysaccharide. The most labile bond 
on Pn1 is the O–acetyl bond on the GalA residue. It is thought that the O–acetyl functional 
group is important for the polysaccharide’s immunogenicity and therefore needs to remain 
attached to the polysaccharide. No loss of the O–acetyl peak was observed after size 
reduction as the O–acetyl peak can still be seen at 2.20 ppm. The N–acetyl peak of the 
amino saccharide was identified at 2.05 ppm and was seen before and after size reduction. 
The peak at 3.23 ppm corresponded to the cell wall polysaccharide (CWPS) which was 
  
 
a) b) 
c) 
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present in small quantities in all samples. The methyl peak of the amino saccharide at 1.29 
ppm along with the O– and N– acetyl peaks confirmed that the conformation Pn1 remained 
intact after sonication. The HSQC spectrum was used to fully characterise the 
polysaccharide (Figure 4.21c).  
4.2.3 Microfluidization 
The microfluidizer technology was investigated with the pneumococcal polysaccharides Pn1, 
Pn6B and Pn14. The primary aim of this investigation was to achieve a reduction in 
polysaccharide size to the smallest size possible without affecting the integrity of the 
polysaccharide or its polydispersity. Pn14 polysaccharide was used to further evaluate 1) the 
conservation of area under the peaks before and post microfluidization and 2) the 
polydispersity of the polysaccharide peaks in the chromatograms to quantitate the 
heterogeneity of molecular size. Molecular weights under 200 kDa for P 6B and Pn14 and 
under 400 kDa for Pn1 were the size targets decided upon at the beginning of the 
investigation. 
4.2.3.1 Pn6B 
To investigate the reduction in size that the microfluidizer can induce on a molecule, 25 ml of 
Pn6B, solubilised in water (at 10 mg/ml concentration), was loaded into the sample reservoir. 
The polysaccharide was exposed to 15 000 psi for an increasing number of passes, 2, 4, 6 
and 8, through the chamber. After the desired number of passes a sample was taken and 
analysed on SEC–HPLC, with the remainder of the solution returned to the glass reservoir 
for more passes.  
 
Figure 4.22. SEC–HPLC RID chromatograms of Pn6B full length (black) and after microfluidization at 
15 000 psi and 2 cycles (red), 4 cycles (green), 6 cycles (blue) and 8 cycles (purple). 
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Table 4.17. Summary of the resultant size distribution of Pn6B whilst increasing the number of passes 
through the microfluidization chamber. 
Number of Passes Retention time (min) Molecular weight (kDa) Size reduction 
0 12.958 1050 – 
2 13.556 635 1.7 
4 14.033 443 2.4 
6 14.684 283 3.7 
8 14.862 248 4.2 
The results in Table 4.17 and Figure 4.22 illustrate the effect on size reduction that the 
increasing number of passes at a specific pressure had on the polysaccharide. The 
polydispersity of the PS increased with the amount of times the polysaccharide was 
subjected to microfluidization. The decrease in molecular weight was most noticeable during 
the first pass, with additional passes having less and less impact on the apparent molecular 
weight and it was hypothesised that the pressure exerted on the sample would have greater 
size reducing power than the number of times the sample is exposed to microfluidization. 
The Pn6B sample was exposed to 22 000 psi for 3 and 4 passes, and the size of the PS 
reduced from 1050 kDa to 206 kDa and 196 kDa after 3 or 4 passes respectively. A 
summary of the results for Pn6B is shown in Table 4.18. 
Table 4.18. Summary of the microfluidization variables and the resultant size distribution of Pn6B.  
Initial molecular 
weight (kDa) 
Pressure 
(psi) 
Number of 
passes 
Final molecular 
weight (kDa) Size reduction 
1050 
15 000 
2 635 1.7 
4 443 2.4 
6 283 3.7 
8 248 4.2 
22 000 
3 206 5.1 
4 196 5.4 
The sample subjected to a pressure of 22 000 psi and 4 passes through the instrument was 
found to be in the required size range. This sample was subjected to full proton, carbon, 
phosphorus and 2D HSQC analysis for structural confirmation. The structure of Pn6B 
polysaccharide is shown in Figure 4.23. 
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Figure 4.23. Structure of serotype Pn6B. 
 
  
Figure 4.24. 1H and 31P spectra of full length (blue) and microfluidized (black) Pn6B polysaccharide. 
 
 
Figure 4.25. Expansion of 1H–13C HSQC spectrum of microfluidized Pn6B. 
The Pn6B microfluidized sample was less viscous than the native polysaccharide and 
yielded well–resolved spectra containing the same proton, carbon and phosphorus 
resonances as the parent polysaccharide which was indicative that microfluidization had no 
impact of the structural integrity of the Pn6B saccharide. The three alpha anomeric protons 
a) b) 
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from galactose (Gal), rhamnose (Rha) and glucose (Glc) were detected at 5.67, 5.16 and 
5.15 ppm respectively (Figure 4.24). One signal for a methyl group at 1.32 ppm 
corresponded to C6 of Rha. The 31P spectra confirmed that the ribitol phosphate structure 
was retained after size reduction with a single peak at 1.09 ppm [389]. The 2D HSQC 
(Figure 4.25) again confirmed that structural integrity was maintained after size reduction. 
4.2.3.2 Pn14 
Pneumococcal serotype 14 was subjected to the same conditions as described for Pn6B. 
The sample was solubilised in water at a concentration of 10 mg/ml and exposed to 2, 4 and 
6 passes through the microfluidizer at 10 000 psi. After each set number of passes, a 
sample was taken and analysed on SEC–HPLC. The pressure employed for the Pn14 
polysaccharide was slightly lower than that used for Pn6B (10 000 instead of 15 000psi) due 
to the relative initial size of the polysaccharide. During the Pn6B investigations it was seen 
that the polydispersity of the polysaccharide increased significantly after 8 passes so the 
maximum number of passes that Pn6B was subjected to was 6 passes. The results of these 
investigations can be seen in Figure 4.26. Elution times and corresponding molecular 
weights can be found in Table 4.19. 
Table 4.19. Changes in Pn14 molecular weight as the number of passes through the microfluidizer is 
increased, the pressure remained constant at 10 000 psi. 
Number of Passes Retention time (min) Molecular weight (kDa) Size reduction 
0 13.128 904 – 
2 13.549 639 1.4 fold 
4 13.843 509 1.8 fold 
6 14.509 290 3.1 fold 
 
Figure 4.26. SEC_HPLC RID chromatograms of Pn14 full length (black) and after microfluidization at 
10 000 psi with 2 cycles (red), 4 cycles (blue) and 6 cycles (green). 
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As with Pn6B, the results demonstrated the effects of an increasing number of cycles at a 
constant pressure to which the polysaccharide was subjected. The molecular weight 
decreased from 904 kDa before size reduction to 290 kDa after 6 passes at 10 000 psi. 
Table 4.19 details the increase in elution time and hence the decrease in size dependant on 
the number of passes through the system. Molecular polydispersity was seen to increase 
with increasing number of passes which was in agreement with the findings of the Pn6B 
study. The results in Figure 4.26 also illustrated that the area under the curve remained 
constant and there was no apparent loss in molecular mass irrespective of the number of 
passes the sample was exposed to. This was expected using the microfluidizer processor as 
the interaction chamber has a very small void volume and the system loop is also of low 
volume, thus losses should be low.  
As with Pn6B, the molecular weight of the polysaccharide was not reduced to within the 
desired range. By increasing the amount of times that the solution is passed through the 
machine, it is the polydispersity, and not the size, of the polysaccharide that changes. Thus 
a change in the pressure applied throughout the microfluidizer was increased to determine 
whether it would elicit a decrease in the polysaccharide siz . The pressure was increased to 
16 000 and to 22 000 psi, and the sample was subjected to 3 and 4 passes through the 
instrument. The reduction in molecular weight of this sample is shown below in Table 4.20. 
Table 4.20. Summary of the changes in variables and the resultant change in molecular weight for 
Pn14. 
Initial molecular 
weight (kDa) 
Pressure 
(psi) 
Number of 
passes 
Final molecular 
weight (kDa) Size reduction 
904 kDa 
 
10000 
2 639 1.4 fold 
4 509 1.8 fold 
6 290 3.1 fold 
16 000 
3 271 3.3 fold 
4 238 3.8 fold 
893 kDa 22 000 
3 192 4.7 fold 
4 173 5.2 fold 
With a pressure of 16 000 psi, a size reduction to under 200 kDa was not achieved. The 
increase in pressure to 22 000 psi was able to reduce the size of Pn14 to 192 after 3 passes 
and 173 kDa after 4 passes. 
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Figure 4.27. Structure of Pn14. 
The structure of Pn14 is depicted in Figure 4.27. The Pn14 microfluidized samples were less 
viscous than the native polysaccharides and yielded well–resolved NMR spectra, Figure 
4.28, containing the same proton and carbon resonances as the parent (full length) 
polysaccharide, indicating that microfluidization had no impact of the structure of Pn14 
saccharide. Less CWPS and no peak corresponding to the acetate buffer could be detected 
in the microfluidized spectrum as ultrafiltration was performed after microfluidization. A single 
peak at 2.05 ppm in the proton spectrum was identified as the N–acetyl peak from the N–
acetylglucosamine (GlcNAc) saccharide residue. It was presumed that the 4 peaks would be 
seen in the anomeric region of the NMR spectrum due to the four saccharide residues found 
in Pn14. This, however, was not the case as only three clear signals could be seen. These 
three peaks at 4.75, 4.50 and 4.40 were identified as the anomeric protons of GlcNAc, a 
mixture of one Gal and the Glc residue and the remaining Gal residue respectively. 
Confirmation of the four saccharides was determined with the HSQC spectra recorded in 
Figure 4.29.  
 
Figure 4.28. 1H NMR analysis of Pn14 a) full length and b) microfluidized. 
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Figure 4.29. Expanded 1H–13C HSQC analysis of Pn14.  
4.2.3.3 Pn1 
Pn1 PS, that was fermented and purified at The Biovac Institute was solubilised in water at a 
concentration of 5 mg/ml and loaded into the microfluidizer reservoir. Following the 
experience gained from Pn6B and Pn14 investigations, Pn1 was exposed to a high pressure 
of 20 000 psi for a maximum of 4 passes. Samples were taken after 3 and 4 passes and 
analysed on SEC–HPLC. 
 
Figure 4.30. SEC–HPLC RID chromatograms of Pn1 microfluidization (20 000 psi) of three (red) and 
four (blue) passes. A Pn1 (full size) chromatogram is shown (black) for reference. 
As seen in both Figure 4.30 and Table 4.21, a 2.8 fold decrease in molecular weight from 
1137 kDa to 400 kDa occurred after 4 passes at 20 000 psi. The size reduction after 4 
passes was within the required molecular weight of 400 kDa.  
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Table 4.21: Microfluidization variables resulting in molecular weight changes in Pn1. 
Initial 
molecular 
weight (kDa) 
Pressure 
(psi) 
Number of 
passes 
Retention time 
(min) 
Final molecular 
weight (kDa) 
Size 
reduction 
1137 20 000 
0 12.888 1137 – 
3 13.881 495 2.3 fold 
4 14.178 400 2.8 fold 
 
Figure 4.31. 1H NMR spectrum of microfluidized Pn1. 
The proton NMR spectrum was recorded for the microfluidized Pn1 (Figure 4.31) and a 
comparison was made with a reference Pn1 PS (a full set of spectra can be found in Chapter 
3, Section 3.5). The O–acetyl signals at 2.2 ppm were present, as well as the N–acetyl peak 
at 2.05 ppm. Three anomeric signals corresponding to the H1 of the ATT (amino) saccharide 
as well as the two GalA residues could be seen at approximately 5.0 ppm. As with the 
previous samples, a peak at 3.23 ppm corresponded to the CWPS. The methyl peak of the 
amino saccharide at 1.3 ppm along with the O– and N– acetyl peaks confirm that Pn1 had 
not changed in any way after sonication. HSQC (not shown) confirmed the structural identity 
of the polysaccharide. 
4.2.4 Consistency 
Pn1 was used to determine consistency of the microfluidization process. Three different 
batch samples of Pn1 were exposed to 22 000 psi for four cycles. The results are 
summarised in Table 4.22.  
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Table 4.22: Results for 3 batches of Pn1 before and after microfluidization at 22 000 psi for 4 cycles. 
Pn1 batch 
Before Microfluidization After Microfluidization 
Retention 
time (min) 
Molecular 
size (kDa) 
Retention 
time (min) 
Molecular 
size (kDa) 
Size 
reduction 
1 12.723 1305 14.497 320 4.1 fold 
2 12.888 1120 14.339 357 3.1 fold 
3 12.847 1162 14.260 377 3.1 fold 
From the table it can be seen that microfluidization can produce consistent size reduction 
from 1100 – 1305 kDa to achieve sizes of between 320 and 380 kDa using the same 
microfluidization conditions.  
4.2.5 Summary 
Size reduction using sonication was achieved for two polysaccharides. The experiments with 
HA demonstrated that the degree of depolymerisation could be controlled by sonication 
conditions such as time or power output. For HA, a decrease a 40 – 60 fold reduction was 
achieved with a power output of over 100 kJ. This proof of concept was applied to Pn1 to 
yield a decrease in size of 6.7 – 10.8 fold. 
Size reduction using microfluidization was achieved for three different pneumococcal 
polysaccharides. Investigations with Pn6B and Pn14 showed that an increase in pressure, 
rather than an increase in the number of passes through the microfluidizer, produced an 
increase in the size reduction. For Pn1 to achieve a reduction in size as specified, it was 
determined that 22 000 psi was required. Pn1 PS from three different batches (and hence 
three different molecular weights) was subjected to the same conditions in order to 
determine consistency. A size reduction to less than 400 kDa was achieved. A comparison 
of the reduction in size between the two techniques is detailed for Pn1 in Table 4.23.  
Table 4.23. Comparison of size reduction between sonication and microfluidization for pneumococcal 
serotypes 6B and 1. 
Polysaccharide Sonication Microfluidization 
Pn1 6.7 – 10.8 fold 2.3 – 2.8 fold 
A simple and general fragmentation method was developed using mechanical means that 
has been applied to a variety of polysaccharides irrespective of their chemical structure. Size 
reduction using methods such as sonication and microfluidization, described above, have 
been shown to be successful in creating polysaccharide fragments for conjugation. The 
polysaccharides were analysed by chromatographic and spectroscopic means to determine 
that the structural integrity was maintained. No epimerization was seen in any of the 
samples. Table 4.24 compares the two techniques.  
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Table 4.24. Comparison of sonication and microfluidization.  
 Sonication Microfluidization 
Polysaccharide recovery √ √ 
Scalability X √ 
Polydispersity √ X 
Degree of size reduction √ X 
Preservation of integrity √ √ 
Control X √ 
GMP X √ 
Time X √ 
*a tick is indicative of a superiority, a cross indicates an inferiority 
Polysaccharide recovery as well as the integrity of the samples is maintained with both 
techniques. The advantages of the sonicator are that the polydispersity of the sample is 
maintained throughout size reduction and much smaller sizes are achievable. Due to the 
shedding of metal particles on the sonicator probe, the sonication results are not repeatable 
and it is therefore not able to be used in a good manufacturing practice (GMP) environment. 
The control and consistency of the microfluidizer as well the scalability and use in a GMP 
process makes the microfluidizer the preferred method. 
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CHAPTER 5. PROTEIN DERIVATIZATION FOR CONJUGATION 
A carrier protein is a protein used for coupling with saccharides or peptides that are not 
sufficiently large or complex on their own to induce an immune response and produce 
antibodies [120]. Ideally, a carrier protein induces a strong helper effect to a conjugated B 
cell epitope without inducing an antibody response against itself. Many proteins can be used 
as carriers and are chosen based on safety, immunogenicity, solubility, and availability of 
useful functional groups through which conjugation with the desired molecule can be 
achieved [120, 175, 390]. 
There are many suitable proteins available that can function as carrier proteins. The earliest 
and most widely used group of proteins are the bacterial toxoids which are toxins that have 
been altered either by chemical or genetic means to be non–toxic. Proteins can be isolated 
from natural sources, or produced by recombinant or synthetic means. Inactivating a toxic 
protein, which could be as simple as substituting one amino acid in the sequence for another 
or chemically inactivating the toxin with formaldehyde or heat, provides a non–toxic protein 
that retains its interactive binding capacity and effectiveness [391-395]. Examples of 
chemically inactivated bacterial toxins include; diphtheria toxoid (DT), tetanus toxoid (TT), 
and the genetically inactivated cross–reactive material CRM197. Bacterial outer membrane 
proteins such as outer membrane complex C (OMPC) (derived from Neisseria meningitidis 
b) and pneumococcal adhesion protein (PsaA) can also be used. In general the albumin 
protein class, consisting of ovalbumin, human serum albumin (HSA), bovine serum albumin 
(BSA), could be used as protein carriers although issues with autoimmune responses have 
resulted in this class of proteins only being used in laboratory testing. Carrier proteins need 
to be non–toxic, non–reactogenic and should be available in large amounts at high purity 
[390, 396-398].  
5.1 Background to derivatization strategies 
Whilst the concept of attaching saccharides to proteins was first developed in 1929 by Avery 
and Goebel [109, 110] whereby p–aminophenol β–glucoside and p–aminophenol β–
galactoside were synthesised and conjugated to serum albumin, it took until 1980 before 
Schneerson et al. [114] made use of this technology to prepare Hib conjugates by first 
derivatizing four different proteins, BSA, HSA, hemocyanin and DT with a 6 carbon spacer 
adipic acid dihydrazide (ADH) in the presence of 1–[3–(dimethylamino)propyl]–3–ethyl 
carbodiimide hydrochloride (EDC) (Table 5.1) and subsequently chemically linking the 
derivatized proteins to the PRP capsular polysaccharide. The polysaccharide was also 
activated as most saccharides do not have the necessary functional groups (aldehydes, 
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carboxyl groups) to form direct, covalent linkages with the amino groups of the proteins. 
While the conjugation was successful, the conjugate showed solubility problems, and hence 
this method was modified in 1986, so that the polysaccharides (Hib and pneumococcal 
serotype 6A) were first activated with the addition of cyanate groups on the hydroxyls of the 
saccharide followed by conjugation to TT (not derivatized) with the addition of ADH in the 
presence of EDC [115]. This modification (using non derivatized TT and activating in situ 
with the activated polysaccharide) improved the conjugation efficiency and the stability of the 
product. Derivatization of the carboxyls on the carrier protein to hydrazides is needed for a 
number of reasons. Firstly, the hydrazide groups have a lower pKa (pKa = 4 – 5) than the 
lysine amino groups (pKa = 10.5) [390, 399] which makes the protein more reactive at the 
neutral/mildly acidic conditions used in conjugations, this pH is also required to prevent the 
protein from aggregating and cross reacting with other protein molecules. Secondly, 
toxoiding a protein blocks the amino groups; the toxoids would therefore contain a limited 
number of lysine groups available for conjugation [390]. 
Table 5.1. List of reaction conditions for derivatization of protein. 
Author Protein ADH EDC pH Reaction time (hr.) Temp. Dialysis 
Schneerson 
et al.[114] 
BSA, 
HSA, DT 3.45 (w/w) 
0.1, 0.3, 
0.6 (w/w) 4.7 3 RT 0.2 M NaCl, 
Lee, Frasch 
[390] TT 0.42 M* 20 mM 6.5 4 RT 
NaCl/Na2CO3 
(pH 10.5) 
*Hydrazine could also be used at the same concentration as ADH. 
Lee and Frasch, in 2005, modified the derivatization procedure to use with the tetanus toxoid 
protein by adjusting the concentration of the reagents, the pH as well as the dialysis 
conditions [390]. 
The novelty of the Schneerson et al. publication, modified by Lee and Frasch in 2005 is 
based on derivatization of the carboxylic groups on acidic amino acids of toxoid protein 
carriers ADH (or hydrazine) in the presence of EDC to form hydrazide–derivatized proteins 
(Figure 5.1) with the reaction conditions compiled in Table 5.1 [114, 390]. This approach to 
derivatizing proteins relies on the carbodiimide molecule reacting with the carboxyl group of 
the aspartic and glutamic acids on the protein. The electron deficient carbon atom in EDC is 
attacked by the carboxylate and a highly reactive O–acylisourea is formed, which reacts with 
nucleophiles, such as the hydrazine functional grouping on ADH or hydrazine itself, to form a 
hydrazone bond. If no nucleophile is present, the carbodiimide will rearrange to form a stable 
N–acylurea. The reaction is performed in aqueous solutions at room temperature, which is 
especially important for manipulations with biological molecules. An acidic environment is 
needed to catalyse the reaction, presumably through the protonation of the carbodiimide 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
154 
 
nitrogen. In this acidic environment, coupling to hydrazide is advantageous over primary 
amines due to the low pKa of hydrazides in comparison to other primary amines.  
In the patent by Lee and Frasch, after derivatization, the reaction is quenched with sodium 
hydroxide to hydrolyse any unreacted EDC or its stable by–product, N–acylurea [400]. EDC–
catalysed proteins have a propensity to polymerize or precipitate: this is due to the change of 
the protein’s isoelectric point (pI) after derivatization. Proteins carry positive, negative and 
zero net electrical charges depending on the pH of the surrounding environment. The net 
charge of a protein is the sum of all its positive and negative charges which are determined 
by the acidic and basic side chains of the amino acids of the protein. If the protein contains 
more acidic than basic groups the isoelectric point of the protein is found at a low pH value, 
hence the protein is classified as acidic. A basic protein will thus contain more basic groups 
and will therefore have a higher pI. Most pIs of proteins are found in the pH range of 4 – 7. 
By derivatizing the carboxyl groups on the protein with hydrazide groups, the pI and hence 
the solubility of the protein will change. 
This aggregation and subsequent precipitation of the protein is largely due to its pH 
environment. Through controlling the pH by buffer exchanging the solution after 
derivatization, the derivatized protein will remain soluble and stable until needed for 
conjugation [400]. The derivatized protein is diafiltered against a sodium carbonate/sodium 
chloride (Na2CO3/NaCl) buffer at pH 10.7 using a 50 KDa MWCO membrane; the high pH 
keeps the protein (in this case, TT) soluble and stable for conjugation. The diafiltration step 
also removes residual hydrazine/hydrazide, EDC break–down products and salts which 
would all affect the pH of the solution.  
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Figure 5.1. Schematic representing the mechanism of protein derivatization. 
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Table 5.2. Licensed conjugate vaccines that make use of DT, TT, OMPC or CRM197 as protein carriers [175, 375, 386, 390, 401-405]. 
Serotype Licensed Name Date licensed WHO prequalified [406] Protein Manufacturer 
Haemophilus influenzae type b 
 ProHIBIT® 1987 – DT Sanofi Pasteur 
 HibTITER® 1988 – CRM197 Pfizer 
 PedvaxHIB® 1989 2003 OMPC Merck 
 Vaxem–Hib® 1990 1997 CRM197 Novartis 
 ActHIB® 1993 1998 TT Sanofi Pasteur 
 Quimi–Hib® 2003 (Cuba) 2010 TT Heber Biotech 
 Sii HibPro® 2007 (India) 2008 TT Serum Institute of India Ltd  
Combination Hib and meningococcal 
C Menitorix® 2009 – TT GlaxoSmithKline 
C, Y MenHibrix® 2012 – TT (Hib) GlaxoSmithKline 
Meningococcal 
C Meningitec® 1999 (UK) – CRM197 Pfizer 
C NeisVac–C® 2000 (UK) – TT Baxter International* 
C Menjugate® 2000 (UK) – CRM197 Novartis 
A MenAfriVac® 2009 (India) 2010 TT Serum Institute of India Ltd 
A, C, W–135, Y Menactra® 2005 – DT Sanofi 
A, C, W–135, Y Menveo® 2010 (FDA) – CRM197 Novartis 
A, C, W–135, Y Nimenrix® 2012 (EU) – TT GlaxoSmithKline 
Pneumococcal 
4, 6B, 9V, 14, 18C, 19F, 23F Prevnar® 2000 (FDA) – CRM197 Pfizer 
1,4,5,6B,7F,9V,14,18C,19F,
23F Synflorix
® 2009 2010 Protein D, TT–18C, DT–19F GlaxoSmithKline 
1, 3, 4, 5, 6 (A&B) 7F, 9V, 
14, 18C, 19(A&F), 23F Prevnar13
® 2010 (FDA) 2010 CRM197 Pfizer 
*Used under licensed for distribution by GlaxoSmithKline. 
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5.2 Protein carriers in conjugate vaccines 
Of all the protein carriers mentioned, only five; TT, DT, CRM197, OMPC and Protein D have 
been licensed for use in vaccines (Table 5.2) [407, 408]. Pneumococcal, meningococcal and 
Hib licensed conjugate vaccines all make use of protein carriers either in their native or 
derivatized form. 
5.2.1 Hib vaccines 
A summary of the four licensed Hib conjugate vaccines is given in Table 5.3 and are 
explained in the subsequent sections. 
Table 5.3. Characteristics of the four Hib conjugate vaccines. Modified from Eskola [409]. 
 PRP-DT PRP-TT PRP-CRM197 PRP-OMPC 
Carbohydrate length sized Full sized Oligosaccharide Full sized 
Carbohydrate dose 
(µg) 25 10 10 15 
Protein DT TT CRM197 OMPC 
Protein dose (µg) 18 24 25 250 
Conjugation chemistry ADH/EDC ADH/EDC reductive amination 
bigeneric 
space 
5.2.1.1 Native protein carriers 
The first conjugate vaccine was licensed in 1987 by Sanofi Pasteur to protect against 
Haemophilus influenzae type b (ProHIBIT) and employed DT as the carrier protein [390, 
409]. This was followed in 1 88 by Pfizer’s (then Wyeth) conjugate HibTITE  which 
employed CRM197 as the carrier protein. HibTITER used the reductive amination conjugation 
method to couple the polysaccharide of Hib directly to the CRM197 protein. Sanofi Pasteur 
released another Hib conjugate vaccine onto the market in 1993 where they changed the 
protein carrier from DT to TT in ActHIB. This conjugate vaccine employed the modified 
Robbins conjugation chemistry where the ADH spacer was first added to the polysaccharide 
followed by conjugation with the underivatized TT in the presence of EDC. This vaccine 
improved the conjugation efficiency as well as the product stability compared to the Hib–DT 
conjugate [390, 409].  
5.2.1.2 Derivatized protein carriers 
Merck licensed their Hib conjugate vaccine, Pedvax, in 1989 where OMPC was used as the 
carrier. Both the polysaccharide and the protein were derivatized separately before 
conjugating the two via a bigeneric spacer, i.e. a spacer molecule that is made from parts of 
the derivatized protein and polysaccharide (Figure 5.2). The protein was derivatized with a 
thioether (N–acetylhomocysteine thiolactone) and the polysaccharide was separately 
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activated with carbonyldiimidazole to form an imidazolylurethane (I) which was susceptible to 
nucleophilic substitution with a 1,4–butanediamine producing a stable urethane with pendant 
amine is produced (II). The final activation step was to bromoacetylate the polysaccharide 
with p–nitrophenyl bromoacetate before conjugation under nitrogen (6hr, RT) to the 
derivatized protein could be achieved [217, 410]. 
 
Figure 5.2. Modified representation of the formation of a bigeneric spacer conjugate as used in the 
conjugate vaccine against Hib (Merck) [410].  
Comparison studies on the four main Hib conjugates (Table 5.4) showed that the ProHIBIT 
conjugate (PRP–DT) was found to be the least immunogenic of the four vaccines [73, 411-
413] however, it was found to be highly immunogenic in Finnish children (7 – 24 months old) 
[414]. The Merck Pedvax vaccine that used OMPC as the carrier protein, was found to 
stimulate the highest antibody concentration of the four with a 94 % reduction of Hib related 
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diseases after just a single dose in infants [411, 413]. A study by Schlesinger and Granoff 
compared the TT, CRM197 and OMPC conjugated vaccines and showed that the CRM197 
vaccine elicited the most antibodies, followed by the vaccine with TT as the carrier protein 
with the least antibodies against the OMPC conjugated Hib vaccine [415], this was 
confirmed in 1995 by Lucas and Granoff in rat models where the CRM197 vaccine showed a 
10–fold higher bactericidal and protective activity than Merck OMPC vaccine [412, 416]. The 
Hib–TT vaccine gave the highest mean antibodies after 3 doses as well as a greater booster 
response and higher antibody concentrations in children 2.5 years after immunisation [417].  
Table 5.4. Immunogenicity comparison of Hib conjugate vaccines in children at 7 and 15 months 
(Finland) [409]. 
Vaccine GMT (µg/ml) 
 7 months 15 months 
PRP–DT 0.68 33.73 
PRP–TT 10.59 29.26 
PRP–OMPC 1.68 11.16 
PRP–CRM197 4.12 58.29 
This study showed that it is not only the carrier protein, the type of conjugation chemistry, or 
the size of polysaccharide that is important in producing an immunogenic conjugate vaccine, 
rather a combination of many different factors; however there is a clear superiority of the 
vaccines using TT and CRM197 as the carrier proteins. 
5.2.2 Meningococcal vaccines 
5.2.2.1 Native protein carriers 
The second type of conjugate vaccines that employ DT, TT and CRM197 as carrier proteins 
are those that protect against disease caused by Neisseria meningitides. In the late 1990s, 
two CRM197 conjugate vaccines, Meningitec, (Wyeth Pharmaceuticals) and Menjugate, 
(Novartis Vaccines) were developed against meningococcal disease caused by serogroup 
C. Baxter International licensed the NeisVac–C in 2000 that made use of TT as the protein 
carrier, also against serogroup C. Both Meningitec and NeisVac–C made use of the same 
general conjugation chemistry where the polysaccharide was first activated using periodate 
oxidation and with subsequent coupling directly onto the carrier protein via reductive 
amination without the need for derivatization [375]. However NeisVac–C was first de–
acetylated as it was found that the de–O–acetylated conjugate produced higher antibody 
titres than the acetylated conjugate [418-420]. Menjugate followed a different path with the 
use of a spacer molecule (N–hydroxysuccinimidodiester) between the activated 
polysaccharide (via acid hydrolysis) and the CRM197 protein molecule [375]. 
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A tetravalent vaccine against meningococcal serogroups A, C, W–135, and Y conjugated to 
DT was first licensed in 2005 (Menactra). CRM197 was used in the meningococcal vaccine 
licensed in 2010 by Novartis (Menveo) and Nimenrix, the tetravalent meningococcal 
conjugate vaccine licenced by GlaxoSmithKline in 2012 contains TT as the carrier protein. 
As Menactra was the first licensed tetravalent vaccine, both Menveo and Nimenrix used 
Menactra as the comparison for non–inferiority in order to be granted licensure.  
Non–inferiority was achieved for Menveo in comparison to Menactra where all four 
serogroups showed higher immunogenicity levels in adolescents and adults when 
vaccinated with Menveo [421, 422]. The immunogenicity of Nimenrix was compared to 
Menactra in terms of the percentage of subjects that produced antibody titres above a 
certain level, with three of the serotypes (MenA, MenW–135 and MenY) showing a 
superiority with Nimenrix with no statistical difference seen with MenC when compared to 
Menactra [423]. The comparison, in terms of immunogenicity, of all three tetravalent 
conjugate vaccines has not yet been published. 
5.2.2.2 Derivatized protein carriers 
To date there is only one commercially available monovalent conjugate vaccine against 
meningococcal serogroup A. This vaccine made use of TT as the protein carrier and 
received WHO prequalification in 2010. The protein was first derivatized with hydrazine in 
the presence of 20 mM EDC and 0.1 M 2–morpholinoethanesulfonic acid (MES) at a pH of 
6.5 [404].  
5.2.3 Pneumococcal vaccines 
5.2.3.1 Native protein carriers 
Until the introduction of Protein D, CRM197 held the market share as a protein carrier for 
Streptococcus pneumoniae conjugate vaccines. In 2000, Pfizer developed the first conjugate 
vaccine protective against Streptococcus pneumoniae, Prevnar (PCV7). PCV7 is a 
conjugate vaccine that consists of the capsular polysaccharide of seven different serotypes 
individually conjugated to CRM197 via reductive amination. In 2009, GSK licensed a 10–
valent conjugate vaccine with additional serotypes 1, 5 and  F  to Pfizer’s seven valent. All 
but one of the serotypes was conjugated to the native Protein D via polysaccharide 
activation with CDAP [386]. The following year, Pfizer licensed the 13-valent vaccine 
(serotypes 3, 6A and 19A additional to the 10 serotypes of GSK) Again, CRM197 was the 
choice for protein carrier and the reductive amination conjugation methodology was used 
[175].  
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5.2.3.2 Derivatized protein carriers 
Of the 10 serotypes found in the GSK conjugate vaccine, only serotype 18C was conjugated 
to TT (all other serotypes were conjugated to Protein D except 19F which was conjugated to 
DT). The TT was first derivatized using the ADH/EDC procedure and conjugated to Pn18C 
using CDAP technology. TT was chosen as the carrier protein for 18C instead of Protein D 
as the immune response was shown to be much stronger in mice with TT as the protein 
carrier compared to Protein D (for the same reason, Pn19F was conjugated to DT) [164]. 
5.2.4 Immune response interference among carrier proteins 
In recent years, the efficacy of TT as a protein carrier has been brought into question. TT is 
itself used as a vaccine against tetanus (lockjaw) as well as being used as a carrier protein 
in vaccines for Hib, MenC, and pneumonia. Its frequency of use and large dosage amount 
may overload the immune system, which could result in a higher occurrence of adverse 
reactions due to pre–existing antibodies in targeted populations [160, 397, 407, 424-426]. 
Simultaneous immunisations of PRP–TT and pneumococcal–TT vaccines were tested 
following the standard American infant schedule. As the dosage of the pneumococcal 
vaccine was increased, the immune response to the Hib vaccine showed decreasing levels 
that suggested immune interference of the polysaccharide, possibly because of the protein 
carrier [426]. 
TT and CRM197 were compared for safety and immunogenicity in 2 year old children in the 
form of a tetravalent pneumococcal conjugate vaccine (making use of serotypes 6A, 14, 19F 
and 23F). The vaccines used identical conjugation chemistries (reductive amination), and 
the protein to polysaccharide ratios remained the same at 0.50 ± 0.18. The final vaccine 
formulation consisted of 50 µg of the carrier protein and approximately 20 µg of total 
polysaccharide. The children were injected with a mixture of the two vaccines (25 µg of each 
protein) or either of the two vaccines (containing 50 µg of the carrier). This was followed 2 
months later by an identical secondary injection. Sera were taken before each injection as 
well as 1 month after the second injection and the ELISA IgG serum responses were 
determined. The results showed that the differences were based on serotypes rather than 
protein carrier, however the children immunised with the mixture of the two carrier protein 
vaccines showed higher ELISA responses than those immunised with a single protein carrier 
[426]. 
In order to develop an affordable and effective Pn1 conjugate vaccine a suitable protein 
carrier would have to be determined. The objective of this investigation was to activate a 
protein carrier, that, when conjugated to pneumococcal serotype 1, would form a conjugate 
vaccine that could be tested in vivo in an animal model. The proteins investigated were BSA, 
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TT, CRM197 and pneumolysoid (PLD). The BSA protein was used as a model carrier protein 
to investigate whether the conjugation methods were successful as it was readily available, 
cost effective and of a similar size to the CRM197 and PLD proteins. Due to the potential 
interference of the immune response, TT was investigated as a carrier protein for use in a 
monovalent conjugate vaccine. As PCV7, PCV13 and PCV15 (in development) make use of 
CRM197 as a carrier protein, conjugation methodologies would have to be performed with 
CRM197 to allow for a direct comparison with the commercially available multivalent vaccines. 
The added protection offered by PLD (described in Section 5.6) made it an attractive protein 
carrier to study as a carrier for pneumococcal conjugate vaccines. The relative molecular 
weights (Mw), number of carboxyls as well as the approximate isoelectric points of each 
protein investigated are compiled in Table 5.5.  
Table 5.5. Comparison of proteins used in this study.  
Protein Molecular Weight (kDa) 
Number of amino 
acid residues 
Number of 
carboxyl groups* 
pI 
(approximate) 
BSA 67 606 99 4.7 
TT 150 1314 160 5.8 
CRM197 58 535 65 5.8 
PLD 53 471 64 5.2 
*Carboxyl groups from aspartic acid and glutamic acid. 
The general derivatization method was modified to suit each of the four proteins tested. The 
derivatization levels were investigated as each protein would have an optimal level of 
derivatization for successful conjugation to occur. It was thought that the smaller protein 
carriers would not have to be derivatized to the higher levels of the larger proteins as too 
many derivatization sites would result in cross reactions on the protein that would decrease 
the solubility of the protein in aqueous solutions. Before derivatization, the isoelectric points 
of the carrier proteins are all below the pH used in subsequent conjugations however 
derivatization leads to an increase in the pI of the protein. This level of derivatization and 
ensuing pI change must be monitored as solubility will become an issue if the pI of the 
derivatized protein corresponds to the pH at which conjugation takes place. 
5.3 Bovine Serum Albumin 
Bovine serum albumin (BSA) belongs to the class of serum proteins called albumins, which 
make up about half of the protein in plasma and are the most stable and soluble proteins in 
plasma. BSA has a molecular weight of 67 kDa and contains 99 carboxyl groups and it is 
these that are targeted in the derivatization procedure [427, 428]. 
BSA is one of the most commonly used protein carriers in the laboratory due to its stability, 
low cost, wide availability and its non–reactivity in a wide range of biochemical reactions. 
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However, BSA has been known to cross–react immunologically with other serum albumin 
proteins (found in human serum) and thus is no longer used in vaccines [429-431]. Another 
reason for not using BSA in clinical trials and vaccines is due to the fact that most albumins 
are sourced from either human or bovine serum which presents regulatory concerns over 
blood borne contaminants (mycoplasma, viruses and prions). BSA is generally utilised as a 
model protein to set up immunoassays in the lab as well as to test the chemistry and 
biochemistry of a reaction. 
According to literature, BSA has been used in conjugations in both its native, underivatized 
form as well as its ADH derivatized form. Table 5.6 details the reaction conditions used when 
derivatizing BSA with ADH and EDC. In 1980, Schneerson and Robbins derivatized different 
proteins, including BSA, with ADH in one of the first licensed uses of a protein carrier in 
vaccines when they conjugated the derivatized protein to Hib polysaccharide PRP. These 
conjugates showed an increase in immunogenicity in both mice and rabbits. The proteins 
were solubilised at a concentration of 25 mg/ml. To these solutions, ADH was added 
followed by varying concentrations of EDC. The reaction proceeded at room temperature for 
3 hours at a constant pH of 4.7 ± 0.2. The derivatized protein was dialysed at 3 – 8 °C 
against 0.2 M NaCl [114, 432].  
In 1997, Kossaczka et al. used ADH derivatized BSA as a protein carrier in the conjugation 
with the Vi polysaccharide of Salmonella typhi. Different EDC to protein ratios were tested 
for the derivatization of BSA but it was found that concentrations of EDC above 0.2 mg per 
mg of protein did not result in a higher final ratio of ADH to protein [433]. In 2000, the 
derivatization of BSA with ADH was again published, this time by Shafer et al. [434] This 
derivatized BSA was used to test the 1–cyano–4–methylaminopyridinium tetrafluoroborate 
(CDAP) conjugation methodology and conjugated to various polysaccharides.  
Table 5.6. Hydrazide derivatization details for BSA. 
Author 
ADH 
(mg/mg 
protein) 
EDC 
(mg/mg 
protein) 
pH Reaction time Dialysis 
Derivatization 
levels 
Schneerson et 
al. [114]  3.45  
0.1, 0.3, 
0.6  4.7 ±0.2 3 hr. 0.2 M NaCl n/a* 
Kossaczka et 
al. [433] 3.5  0.1  4.9 –5.1 1 hr. 0.15 M NaCl 2.3 
Shafer et al. 
[434]  1.8 0.96 5.5 overnight saline 15.9 
*Not available. 
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5.3.1 Derivatization of BSA 
BSA was used as a model protein in developing a proof of concept to test the derivatization 
chemistry before it was applied to other proteins. BSA was first derivatized with ADH and 
EDC over a period of four hours and the derivatization levels measured as a percentage of 
the carboxylic acid substitution (% CS) using the TNBS colorimetric assay (Table 5.7). The 
derivatized protein was analysed on SEC–HPLC and compared to the native form as shown 
in Figure 5.3. 
 
Figure 5.3. SEC–HPLC UV 280 nm chromatogram of BSA (black) and derivatized BSA (red). 
A shift in retention time, for the derivatized BSA that eluted at 18.9 min was compared to that 
of the underivatized protein eluting an apparent smaller molecular weight protein at 18.2 min. 
It is hypothesised that the free hydrazide group from the ADH molecule interacted with the 
polyhydroxymethacrylate stationary phase of the columns, resulting in prolonged interaction 
and retention within the column, and hence a shift to an apparent lower molecular weight 
was observed.  
Table 5.7. Summary of derivatization results of BSA with ADH. 
Reaction Reaction time (hr.) 
Protein concentration 
(mg/ml) 
Hydrazide 
concentration (mM) 
Carboxylic acid 
substitution (%) 
1 4 17.94 3.81 20 
2 4 10.80 3.61 22 
3 1.5 12.25 2.58 14 
The pH of the derivatized protein was lowered to 6.5 to determine if the protein was stable at 
the pH used for conjugation. Aggregation occurred at this pH and was theorised to be due to 
over derivatization of the protein resulting in a shift of the protein’s pI causing the protein to 
be insoluble at this pH. The derivatization levels of the protein were investigated to see if 
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lower levels of derivatization would prevent this precipitation occurring at the pH needed for 
conjugation. This lower level of derivatization was achieved by lowering the reaction time 
whilst keeping the reactant ratios the same.  
By halving the reaction time from 3 hours to 1.5 hours, a decrease was seen in the levels of 
derivatization from 20 and 22 % to only 14 %. This showed that derivatization levels could be 
controlled to some effect by controlling the amount of time the reaction is allowed to 
proceed. However a linear relationship was not found between the levels of derivatization 
and the reaction time.  
5.4 Tetanus Toxoid 
Tetanus toxoid is a non–toxic, chemically detoxified (with formaldehyde) tetanus toxin. 
Tetanus toxin is produced from Clostridium tetani bacterium and is composed of 1314 amino 
acid residues and has a molecular weight of approximately 150 kDa [394]. The toxoid form 
has been shown to maintain a high degree of secondary and tertiary structure when 
compared to the native toxin [393]. There are 160 carboxyl groups from the aspartic and 
glutamic acid residues of the toxoid that are available for derivatization with ADH.  
As tabulated in Table 5.2, TT has been used as a carrier protein in conjugate vaccines 
licensed for a variety of diseases. It has mainly been applied in its underivatized form, 
although vaccines against meningococcal and pneumococcal diseases have utilised 
derivatized tetanus toxoid in preparation of conjugates. Underivatized TT was used in the 
early 1980s by Beuvery et al. in the investigation into conjugate vaccines against 
meningococcal group C [435-437].  
TT has been conjugated in its derivatized form as a protein carrier. In 2000, Pawlowski et al. 
used an alternative derivatization method for TT via a bromoacetylation pathway (Figure 5.4) 
with the N–hydroxysuccinimide ester of bromoacetic acid (0.7 mg ester/mg TT). The pH 
remained at 8.3 and the reaction proceeded for 2 hours at room temperature. This 
derivatized TT was conjugated to previously thiolated pneumococcal serotypes 14 and 23F 
[438]. 
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Figure 5.4. Alternative derivatization of TT, via bromoacetylation, described by Pawlowki et al. [438].  
The majority of the conjugates that utilised derivatized TT as the carrier protein, summarised 
in Table 5.8, followed the method of Lee and Frasch [390]. The MenA vaccine, licensed in 
2009, made use of this chemistry when TT was derivatized with hydrazine and EDC followed 
by conjugation to an oxidised MenA polysaccharide. GSK also made use of the Lee–Frasch 
method in their 10 valent pneumococcal vaccine; however it was modified by reacting the 
protein with ADH for an hour [386]. In 2007, Silveira et al. derivatized TT using the hydrazine 
technology, conjugated it to MenC polysaccharide using reductive amination and tested it in 
mice [439]. The conjugate gave a 10 to 20–fold rise in immunoglobulin G (IgG) response in 
mice compared to the pure polysaccharide.  
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Table 5.8. Reaction conditions for the derivatization of TT for use in conjugate vaccines. 
Author Source of hydrazide  
EDC 
(mM) pH 
Reaction 
time (hr.) Dialysis 
Lee et al. [404]  Hydrazine (0.42 M) 20 6.5 4 30 mM NaCl, 3 mM Na2CO3 (pH 10.5) 
Biemans et al. [386] ADH (0.2 M) 20 6.2 1 n/a 
Silveira et al. [439]  Hydrazine (0.42 M) 20 6.1 4 
0.02 M PBS  
(pH 7.4) 
5.4.1 Derivatization of TT 
Results from the derivatization of BSA indicated that a decrease in reaction time led to a 
decrease in derivatization levels. This change in reaction time was applied to TT to 
determine if these results could be repeated. In previous studies, a 4 hour reaction time led 
to TT derivatization levels of between 18 and 23 % [440]. Reaction times were decreased 
from the usual 4 hours to 1.5 hours, before the reaction was quenched with NaOH. Post 
diafiltration (to remove excess ADH), hydrazide concentration and carboxylic substitution 
levels were assayed (Table 5.9) and chromatographic profiles were obtained before and 
after derivatization.  
Table 5.9. Summary of derivatization results of TT with ADH. 
Reaction 
time (hr.) 
Protein concentration 
(mg/ml) 
Hydrazide 
concentration (mM) 
Carboxylic acid 
substitution (%) 
4 9.26 2.06 21 
4 15.81 3.11 18.6 
4 17.49 4.26 23 
1.5 17.40 1.75 13.4 
1.5 17.49 3.07 16.6 
1.5 23.48 4.02 16.2 
1.5 27.84 4.75 16.1 
The UV chromatogram illustrated a shift in retention time between the native and the 
derivatized TT (Figure 5.5). As with the derivatization of BSA, a shift to an apparent lower 
molecular weight compound occurred. The derivatization studies confirmed that decreasing 
the reaction time from 4 hours to 1 hour decreased the derivatization levels; however this 
decrease was not as large as the difference realised with BSA. Due to Pn1 containing both 
reactive amino and carboxylic functional groups, it was hypothesised that a lower 
derivatization level for TT would be more appropriate in order to minimize cross linking and 
subsequent precipitation.  
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Figure 5.5. SEC–HPLC, UV 280 nm chromatograms of TT (black) and derivatized TT (red) in water. 
5.5 CRM197 
Different mutant forms of the diphtheria toxin were isolated during the 1  0 ’s, including the 
cross–reactive material 197 (CRM197). CRM197 is a non–toxic DT mutant that resulted from a 
single substitution of glycine to glutamic acid at position 52 in the amino acid sequence 
(Figure 5.6). CRM197 shows no enzymatic activity, is therefore nontoxic to humans, and is 
known to function as an exceptional carrier for polysaccharides in conjugate vaccines [407, 
441]. CRM197 has a molecular weight of 58 kDa and contains 65 carboxyl groups available 
for derivatization with ADH [442].  
 
Figure 5.6. Structures of DT (left) and CRM197 (right). The accessible lysine residues are highlighted 
(purple spheres) for CRM197 that are available for conjugation. The mutation of the glycine residue in 
position 52 of DT to the glutamic acid residue at position 55 on CRM197 is also depicted [443]. 
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As CRM197 is non–toxic, it escapes the need for chemical detoxification that is required for 
DT (TT is also detoxified, usually by formaldehyde). Chemical detoxification can cause 
extensive cross linking and epitope modification and may interfere with the immunogenicity 
of the vaccine [391, 392]. Since detoxification is not required, the lysine residues on the 
protein are accessible and therefore no derivatization is needed for successful conjugation. 
At present no conjugate vaccines have been licensed make use of derivatized CRM197, 
however, as previously described, there are licensed vaccines that contain CRM197 as the 
carrier protein in its native form [443]. 
A conjugate vaccine against Salmonella Typhi under development uses derivatized CRM197 
as the carrier protein. The derivatization was performed at a higher pH than used with TT in 
order to minimise protein precipitation, otherwise the method used to derivatize the protein 
was as per previously described [444].  
As the main objective of the investigation was to compare the conjugation chemistries 
developed against the commercially available conjugate vaccines; a head to head 
comparison was to be performed. To reduce the number of variables in the comparison, the 
carrier protein should be kept constant. The decision to investigate the derivatization of 
CRM197 was due to the successful use of the protein in PCV7 and PCV13.  
5.5.1 Derivatization of CRM197 
The known ADH/EDC method used to activate proteins such as TT and BSA was employed. 
The derivatization procedure was modified by raising the pH to 6.2 as described by Micoli et 
al. (2011) in order to prevent potential protein aggregation [444]. Reaction times were 
investigated to provide a range of derivatization levels for evaluation in conjugation 
reactions.  
CRM197 was purchased from Pfenex by the Program for Appropriate Technology for Health 
(PATH) and made available for use in these experiments. A vial of CRM197, containing 20 mg 
of lyophilized CRM197 protein, (other additives included sucrose, sodium phosphate and 
polysorbate 80), was dissolved in a 60 mM MES buffer, solution pH 6.2, to give a final 
concentration of 10 mg/ml (0.345 µM). The sample was dialysed against 60 mM 2–(N–
morpholino)ethane–sulfonic acid (MES) buffer in order to remove the additives. The 
derivatization reaction procedure followed was the same as previously described (Chapter 2, 
Section 2.8.1), where ADH was added in a 3.5 mg ADH/mg protein excess at room 
temperature. Once dissolved, EDC was added to the reaction mixture as an aqueous 
solution containing a 55 fold molar excess (0.15 mg EDC/mg protein). The reaction 
proceeded for a defined period of time (Table 5.10) after which the reaction solution was 
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dialysed against 3 x 2 L solutions of 0.2 M NaCl / 10 mM MES buffer at pH 7.2 using 10 kDa 
MWCO dialysis cassettes. The derivatized protein was assayed for hydrazide concentration 
and protein concentration, as well as analysed by SEC–HPLC.  
Table 5.10. Summary of derivatization results of CRM197 with ADH/EDC. 
Reaction Reaction time (hr.) 
Protein 
concentration 
(mg/ml) 
Hydrazide 
concentration (mM) 
Carboxylic acid 
substitution (%) 
1 1 2.13 0.060 2.5 
2 3 2.61 0.176 5.9 
3 16 2.84 0.710 24.5 
4 16 2.58 0.797 27.1 
5 24 2.96 0.802 27 
 
  
Figure 5.7. SEC–HPLC a) RID and b) UV chromatograms of CRM197 before (black) and after (red) 
derivatization. 
Representative chromatograms (Figure 5.7) show the elution time for the native and 
derivatized protein. No significant shift was seen in either the RID or UV280 signals. The 
article by Micoli et al. also showed that no real difference in retention time was seen before 
and after derivatization [444]. While Micoli et al. used mass spectrometry to determine the 
level of derivatization, the TNBS assay, was employed in this investigation. By increasing the 
reaction time from 60 minutes to 3 hours the carboxylic acid substitution more than doubled. 
However, this percentage derivatization was still low and hence an additional derivatization 
of 16 hours was performed to increase derivatization levels. An increase in reaction time 
from 3 hours to 16 hours to 24 hours achieved an increase in percentage carboxylic acid 
substitution from 6 % to 25 % to 27 % respectively. While 27 % may be over derivatized 
when using TT as a protein carrier, it was not known what effect this would have on the 
conjugation of CRM197 to polysaccharide.  
a) b) 
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5.6 Pneumolysoid 
Pneumolysin (PLY), a sulfhydryl–activated cytolytic toxin, is produced by all serotypes of S. 
pneumoniae and is assumed to be a virulence factor in pneumococcal infections. Patients 
with pneumococcal pneumonia have been reported to elicit an antibody response to PLY. 
Therefore, pneumolysin itself is a potential vaccine candidate to induce species–specific 
anti–pneumococcal immunity based on anti–PLY antibody and, more importantly, may be a 
useful protein carrier for the preparation of the conjugate vaccine [445]. 
The genetically toxoided form of PLY; pneumolysoid (PLD) is used as a carrier protein. 
Investigations of this protein have been performed extensively with Pn19F polysaccharide. 
Table 5.11 and Table 5.12 summarise the use of PLD in its native and derivatized form in 
conjugate investigations. Paton et al., 1991, conjugated activated Pn19F to PLD using EDC 
coupling through the use of linker, 6–aminocaproic acid [446]. When tested in animal 
systems, the anti–polysaccharide and anti–pneumolysin titres were significantly higher in 
immunised mice than non–immunised mice. When the mice were challenged with Pn19F 
bacteria, the bacteria were eliminated more efficiently from the immunised mice. Survival 
rates in mice were also higher for the immunised mice [446]. 
In 1996, Kuo et al. patented the conjugation of pneumococcal serotypes Pn14 and Pn18C to 
PLD [447]. Serotype 14 was first oxidized and conjugated to either ADH–derivatized or non–
derivatized PLD. Pn18C was first size–reduced followed by oxidation and conjugated to both 
underivatized and ADH–derivatized PLD. All conjugations employed reductive amination 
methodology with cyanoborohydride. PLD was derivatized in 0.1 M potassium phosphate 
buffer (pH 5.5) by adding a 676 molar excess of ADH, followed by a 614 molar excess of 
EDC and leaving the solution to react for 3 hours. The derivatized protein was dialysed with 
0.1 M potassium phosphate buffer (pH 7.0) to remove any traces of unreacted ADH before 
being characterised and stored at 4 °C until use [447].  
Table 5.11. Use of underivatized PLD in conjugate vaccines. 
Author Pneumococcal serotypes Modification Conjugation to PLD 
Paton et al. 
[446] 19A 
Cyanogen bromide or 
6-aminocaproic acid EDC coupling 
Kuo et al. [447] 18C Periodate oxidation Reductive amination  
Michon et al. 
[445]  6B,14,19F,23C Periodate oxidation Reductive amination  
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Table 5.12. Use of derivatized PLD in conjugates. 
Author ADH (w/w) 
EDC 
(w/w) 
Reaction 
time (hr.) Dialysis % CS 
Kuo et al. [447]  2.2 2.2 3 0.1 M potassium phosphate (pH 7.0) n/a* 
Michon et al. conjugated four different pneumococcal serotypes, namely 6B, 14, 19F and 
23F, to non–derivatized PLD via reductive amination. The four polysaccharides required 
derivatization with periodate oxidation prior to protein coupling. Mice studies were performed 
with the monovalent, as well as multivalent conjugates, at two different doses. The lower 
dose and the multivalent conjugate gave the best responses in the mice. When compared to 
a TT conjugate vaccine, produced using the same conjugation methodology, the PLD 
conjugate elicited equivalent or better capsular polysaccharide–specific response. The mice 
produced high levels of pneumolysin–specific IgG antibodies which have been shown to 
neutralise pneumolysin induced haemolytic activity in vitro [445].  
PATH purchased PLD from St Jude’s Children’s  esearch Hospital in the United States and 
supplied it to The Biovac Institute for investigation as a protein carrier for Pn1. Due to a 
limited supply of PLD; small–scale (20 mg) derivatizations were performed. The established 
ADH/EDC derivatization method was applied to PLD, although small changes in ratios and 
buffers were made according to the Kuo et al. [447] paper due to the large difference in the 
pI between PLD (5.2) and CRM197 (5.8) or TT (5.8). 
5.6.1 Derivatization of PLD 
As it was not made known what additives, if any, were present in the lyophilised 
pneumolysoid sample, a dialysis step was employed prior to derivatization to remove any 
excipients that may have been introduced. Two different buffers were tested, namely: 0.1 M 
potassium phosphate (KH2PO4) (pH 5.4) and 0.1 M MES (pH 6.0) as described in Table 
5.13. A sample of PLD was dialysed extensively using 5 K MWCO membranes against both 
buffers before the general method for protein derivatization was applied, i.e. 3.5 mg ADH / 
mg protein was added followed by 0.11 mg EDC / mg protein. The reaction proceeded for 3 
hours at room temperature after which it was extensively dialysed in either 0.1 M KH2PO4 
(pH 7.0) or 3 mM Na2CO3/30 mM NaCl (pH 7.2).  
Table 5.13. Dialysis buffers used before and after derivatization of protein PLD. The pH of the buffers 
is shown. 
Reaction Dialysis buffer before derivatization 
Buffer 
pH 
Dialysis buffer after 
derivatization Buffer pH 
1 0.1 M KH2PO4 5.4 0.1 M KH2PO4 7.0 
2 0.1 M MES 6.0 3 mM Na2CO3/30 mM NaCl 7.2 
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Figure 5.8. SEC–HPLC UV 280 nm chromatograms of a) PLD before (black) and after (red) dialysis 
with 0.1 M MES buffer and b) PLD before (black) and after (red) derivatization. Dialysis buffer used: 3 
mM Na2CO3/ 30 mM NaCl. 
The derivatized PLD was found to be very unstable in the diafiltration buffer, KH2PO4 (pH 
7.0), and precipitated out during the three hour reaction. The protein was stable in the 
Na2CO3/NaCl buffer and a sample was analysed on SEC–HPLC as well as being assayed 
for protein concentration and derivatization levels. 
The results of the SEC–HPLC analysis in Figure 5.8 demonstrate that the PLD may have 
contained an impurity, detected in the UV280 chromatogram, which was removed by means 
of dialysis. Post derivatization, there seems to be no significant shift in the PLD profile on 
UV280 which confirmed the findings presented by Kuo et al. [447]. Employing the Kuo 
method for derivatization of PLD gave consistent results of 24 % carboxylic acid substitution 
with greater than 80 % recoveries.  
5.7 Electrophoretic comparison of protein carriers 
Three of the four carrier proteins used in the course of the investigation were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) under denaturing 
conditions to determine the molecular weight of the proteins, and whether the molecular 
weight of PLD had been maintained post–derivatization. The gel was loaded and run with a 
two–fold dilution of: (1) BSA, (2) CRM197 and (3) PLD (pre–/post–derivatization), starting with 
a concentration of 400 µg/ml. The gel was stained to allow visualization of the proteins 
(Figure 5.9). 
a) 
b) 
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Figure 5.9. SDS–PAGE (reducing) gel with molecular weight marker (Lane 1); BSA protein (Lane 2, 
3); PLD protein (Lane 5, 6); derivatized PLD (Lane 8, 9); and CRM197 protein (Lane 11, 12). 
The SDS–PAGE gel shows the PLD to be slightly smaller than the BSA and CRM197 carrier 
proteins (56 kDa compared to 64 and 66 kDa respectively). The observed size distribution of 
the various native proteins is in order with literature. The PLD protein post–derivatization 
was slightly larger in size than the native PLD and showed no dimerization or trimerization to 
have occurred during the derivatization process.  
5.8 Summary 
All four carrier proteins were successfully derivatized using the ADH/EDC derivatization 
method. For BSA and TT, the SEC–HPLC 280 nm chromatogram revealed a shift in 
retention time post–derivatization to a lower molecular weight which was hypothesised to be 
a result of the hydrazides interacting with the column packing. No shift in elution time was 
seen for either the derivatized CRM197 protein or the derivatized PLD protein. Derivatization 
for all four proteins was confirmed with the colorimetric TNBS assay. Table 5.14 shows the 
deviations from the Lee, Frasch patent that were successfully used in this investigation. As 
shown in the BSA experiments, derivatization levels were lowered by decreasing the 
reaction time of the derivatization procedure. This was confirmed with TT. The reaction times 
for CRM197 had to be extended due to low levels of derivatization seen (below 10 %) after 4 
hrs. To achieve derivatization levels of approximately 20 %, a reaction time of between 16 
and 24 hours was required. Both derivatizations of PLD gave consistent results with a 24 % 
carboxylic acid substitution, however the PLD derivatized in KH2PO4 (pH 7.0) buffer was 
found to be unstable and this was substituted with a Na2CO3/NaCl buffer at neutral pH. This 
was shown to stabilise the protein and prevent any aggregation. 
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Table 5.14. Deviations from the original method for different carrier proteins investigated. 
Protein ADH (w/w) EDC (w/w) pH 
Reaction 
time (hr.) Dialysis 
Dialysis 
pH % CS 
Model 3.5 0.15 4.75 4 30 mM NaCl/   3 mM Na2CO3 
10.7 N/A 
BSA 3.5 0.15 4.75 1.5 NaCl/Na2CO3 10.5 14 
TT 3.5 0.15 4.75 1.5 NaCl/Na2CO3 10.5 13–17 
CRM 3.5 0.15 6.2 16–24 NaCl/ MES 7.2 24–27 
PLD 2.5 0.11 6.0 3 NaCl/Na2CO3 7.2 24 
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CHAPTER 6. CONJUGATION 
6.1 Introduction 
Pn antigens can be converted from a T–cell independent antigen to a T–cell dependent 
antigen by covalently linking the polysaccharide to a protein. There are many considerations 
to take into account when producing a conjugate vaccine that is immunogenic: the chemistry 
used to couple the saccharide to the protein is amongst the most important. The size and 
functional groups of the saccharide and protein, the type of carrier protein, and the amount 
of saccharide conjugated to each protein carrier are also aspects that need to be considered 
to produce a successful conjugate [375, 448, 449].  
Conditions such as the time, temperature and pH of the reaction need to be carefully 
monitored in order to maintain the structural chemistry of the polysaccharide as the creation 
or destruction of epitopes and the chance of unwanted depolymerisation may lead to a 
destruction of the saccharide’s immunogenicity. The optimised conditions would also prevent 
cross linking within the saccharide or carrier protein or cross reactivity between conjugates 
[10, 375, 400]. 
There are different approaches to the preparation of conjugates, two of which are shown in 
Figure 6.1. The polysaccharide (either full length or size reduced) can be i) randomly 
activated, ii) activated at only one terminal, or iii) partially degraded to form activated groups 
at both terminals. The former is mainly used for the conjugation of large polysaccharides 
with the latter two being used for oligo– or shorter polysaccharides. The final structure of the 
conjugate depends on which approach is chosen [375].  
Three main functional groups are available for conjugation on the saccharide: the hydroxyl 
(OH), carboxyl (COOH) and amino (NH2) groups. However, aldehyde functional groups can 
be generated via periodate oxidations as well as acid hydrolysis.  
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Figure 6.1. Various conjugate structures can be formed depending on how the polysaccharide is 
activated. I) random activation of the polysaccharide leads to a cross linked lattice type conjugate 
whereas II) terminal activation produces a single carrier protein with attachment points for each 
activated polysaccharide. 
There are approximately seven different functional groups on a protein that can be 
considered for conjugations, however due to the number of each of these groups on a 
protein, the first two groups are the most widely used in conjugation reactions. The seven 
different groups are: 
 Amino groups (lysine) which can be conjugated directly to the carboxyl groups on the 
saccharide. 
 Carboxyl (via aspartic or glutamic acid) which can be conjugated either directly to 
amino groups or first derivatized with ADH followed by conjugation to the carboxyl 
groups on the saccharide. 
 Hydroxyl groups (threonine, serine tyrosine). 
 Sulfhydryl groups (cysteine). 
 Imidazole groups found on histidine residues. 
 Indole functional groups on tryptophan. 
 Guanidine groups found on arginine amino acids [166]. 
While there are many different chemistries available for conjugations of polysaccharides and 
proteins only a few different approaches have been used in licensed pneumococcal 
conjugate vaccines – using the hydroxyl and amine functional groups on the polysaccharide 
and protein respectively. The general approaches that are used by the manufacturers for the 
pneumococcal vaccine are based on the same procedures that achieved success with the 
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licensed Hib conjugate vaccines. In doing so, the manufacturers have a chemistry that has 
been well defined and they also retain ownership of the proprietary information so as to 
avoid any intellectual property disputes. 
Pfizer used reductive amination chemistry for both the seven and thirteen valent conjugate 
vaccines [120, 175]. In order for reductive amination to be successful, aldehyde functional 
groups are needed on the polysaccharide. As the pneumococcal polysaccharides do not 
contain aldehydes, the saccharides need to be modified; this is usually achieved by oxidising 
any available diols with sodium periodate (Figure 6.2A). This oxidation usually results in ring 
opening and could also lead to cleavage of the polymer thus providing simultaneous size 
reduction and activation of the polysaccharide. In the case of Pn1, there are no available 
diols so a de–O–acetylation step must first take place to remove the O–acetyl functional 
group on the GalA residue to create the diol. Once the aldehydes have been created, they 
are reacted with the amines on the CRM197 carrier protein to form an imine linkage (Figure 
6.2B). This process is slow and reversible and an in situ reduction with sodium 
cyanoborohydride to a secondary amine must occur for a stable linkage to form (Figure 
6.2C). Any unreacted aldehydes are subsequently reduced with sodium borohydride. 
GSK’s pneumococcal conjugate vaccine is based on the activation of the hydroxyl groups of 
the saccharide with 1–cyano–4–dimethylaminopyridium tetrafluoroborate (CDAP) forming a 
cyanate ester [386]. This activated saccharide can be coupled directly or through a spacer 
group to the amino group on the carrier protein. Hydroxyl groups themselves do not react 
spontaneously with CDAP as they have pKas of approximately 12, thus a strong base is 
needed to transform the stable hydroxyl groups into more reactive alkoxide ions (–O-). These 
alkoxide ions are more nucleophilic and are able to react with CDAP. However, the use of a 
strong base has a negative effect as both CDAP and the resultant active cyanate esters are 
rapidly hydrolysed to inert carbamates, resulting in a lesser amount of active intermediates 
to efficiently couple to the desired compound. It was determined that instead of increasing 
the nucleophilicity of the hydroxyl groups; it was more useful to enhance the electrophilicity 
of CDAP with the addition of a “cyano–transfer” reagent. To this end, as an alternative to 
NaOH, triethylamine (TEA) was utilised; it reacts with the CDAP forming a N–cyanotriethyl–
ammonium (CTEA) complex that is more electrophilic than CDAP by itself and is therefore 
more susceptible to attack by the hydroxyl functional groups (Figure 6.3) [450]. The use of 
TEA also allowed for the reaction to occur at neutral pH thus avoiding the formation of the 
inactive carbamate compounds. Table 6.1 shows a comparison of the two conjugation 
chemistries for Prevnar and Synflorix. 
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Table 6.1. Comparison of the conjugation chemistries of the three commercially available 
pneumococcal conjugate vaccines. 
 Pfizer GlaxoSmithKline 
Licensed vaccine(s) Prevnar7 and Prevnar13 Synflorix 
Carbohydrate activation Periodate CDAP 
Conjugation 
Reductive amination via 
Schiff’s base with sodium 
cyanoborohydride 
Cyanylation via isourea 
Quenching sodium borohydride glycine 
There are many different analytical tools available to show conjugate formation. Size 
exclusion chromatography can indicate a variance in elution time between the unconjugated 
and conjugated material due to the shift in molecular weight. SDS–PAGE is another method 
for depicting conjugate formation and works in a similar fashion to SEC. The large molecular 
weight conjugate is generally shown as a smear in the high molecular weight region as 
opposed to the lower molecular weight neat bands seen for most unconjugated proteins [10]. 
The solution containing conjugate often contains unconjugated polysaccharide and protein 
present in varying amounts [451]. As it is the conjugate that will directly contribute to the 
immune response, the unconjugated polysaccharide, protein and any remaining reagents 
must be removed or at least minimised. This is achieved through conjugate purification. 
There are various methods available to purify the conjugate including ultrafiltration, 
chromatographic and precipitation methods. Whilst saccharides can be a few hundred 
kilodaltons in size, they have an extended structure in solution and thus a large 
hydrodynamic volume. This apparent large size makes it difficult to separate from the 
conjugate vaccine using conventional chromatographic techniques, however, by taking 
advantage of the carrier protein, a method involving the selective precipitation of the 
conjugate with ammonium sulfate can be utilised [452]. After this separation, the free sugar 
still present in the conjugate can be quantified by further selective precipitation of the 
conjugate with deoxycholate [255, 256] followed by either colorimetric or HPAEC–PAD 
analytical methods [10, 235, 256].  
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Figure 6.2. Conjugation method used for the production of PCV13. A) Periodate oxidation followed by 
the formation of a Schiff’s base (B) and subsequent reduction (C) to an amine (reductive amination). 
R1, R2, R3 = remainder of polysaccharide, R4 = protein. 
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Figure 6.3. Reaction mechanism for CDAP activation of a polysaccharide and subsequent 
conjugation to a protein. 
Both Pfizer and GSK have taken the conjugation approach used for their preparations of the 
Hib vaccine and applied it to the pneumococcal serotypes, by making use of the hydroxyl 
and amino groups on the polysaccharide and protein respectively. Several potential issues 
arise with these conjugation methodologies when applied specifically to the Pn1 PS. The 
Pfizer conjugation requires diol functional groups available for periodate oxidation to oxidise 
to aldehydes, hence the Pn1 would need to be de–O–acetylated. However, literature 
indicates the importance of the O–acetyl group in terms of its immunogenicity [286, 368, 
369], thus modification of this group could potentially lead to a decrease in immunogenicity. 
GSK’s CDAP conjugation methodology activates the hydroxyl functional groups on the 
polysaccharide; however, the amino group on the AAT saccharide has a greater propensity 
to react with CDAP than the hydroxyl groups, thus resulting in modification of the amine 
group. The addition of a strong base in the CDAP conjugation reaction may lead to a loss of 
the labile groups such as the O–acetyl group of the GalA residue which is important for 
immunogenicity. 
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As both Pfizer’s PCV13 and GSK’s PCV10 have only recently been introduced into 
vaccination programs around the world, information on the efficacy of these vaccines is still 
being gathered and comparisons cannot yet be determined. It has been revealed in an 
article by Prymula and Schuerman, in 2009, that the OPA activity against Pn1 had the lowest 
recorded value at 65.7 % compared to all other serotypes contained in the 10 valent vaccine 
[164, 165]. The OPA results for Prevnar13 also show Pn1 to have the one of the lowest 
responses (along with Pn3) [178, 453]. 
The modification of the O–acetyl and amino groups on Pn1 polysaccharide may play a role 
in the reduced immunogenicity of the serotype in the conjugate vaccines, however, this can 
only be concluded if a conjugate, prepared using an alternate functional group, resulted in 
higher immunogenicity levels when compared to the commercial vaccines. One of the 
unique features of Pn1 PS is the more reactive carboxyl function groups on the GalA 
residues. With two carboxyl groups available for conjugation on each Pn1 PS repeating unit, 
random activation of either of these groups and subsequent coupling to a carrier protein 
could produce a conjugate that is immunogenic in mice studies by virtue of ELISA and OPA 
assay results. To activate the carboxyl group, the most common reagent 1–ethyl–3–(3–
dimethylaminopropyl)carbodiimide (EDC) was investigated. Alternate methods of activation 
of the carboxyl group were also determined that applied activators; namely HOBt and 
triazine mediated activation. This activated polysaccharide would subsequently be 
conjugated to the hydrazide–derivatized protein carriers. The successful conjugates would 
then be formulated and the chemistries and protein carriers compared to commercial 
conjugate vaccines. 
6.2 EDC Chemistry 
Carbodiimides are used to mediate the formation of linkages between amines and either 
carboxylates (amides) or phosphates (phosphoramides) [454, 455]. Carbodiimides are one 
of the most widely used zero length cross linkers as they are efficient in forming conjugates 
between two protein molecules, between a peptide and a protein, between an 
oligonucleotide and a protein, between a biomolecule and a surface or particle, or any 
combination of these with small molecules. There are two basic types of carbodiimides: 
water–soluble and water–insoluble. The water–soluble carbodiimides are the most common 
choice for biochemical conjugations, because most macromolecules of biological origin are 
soluble in aqueous buffer solutions. Not only is the carbodiimide itself able to dissolve in the 
reaction medium, but the by–product of the reaction, an isourea, is also water–soluble, 
facilitating easy purification [400].  
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Figure 6.4. Molecular structure of EDC.  
EDC (or EDAC; 1–ethyl–3–(3–dimethylaminopropyl)carbodiimide hydrochloride) shown in 
Figure 6.4 is the most common carbodiimide used for conjugating biological substances 
containing carboxylates and amines [456]. EDC is water–soluble, which allows for its direct 
addition to a reaction without prior organic solvent dissolution. Both the reagent itself and the 
isourea formed as the by–product of the crosslinking reaction are water–soluble and may be 
easily removed by dialysis or gel filtration [457, 458]. The reagent is, however, labile in the 
presence of water and therefore the bulk chemical should be stored desiccated at –20 °C. A 
concentrated solution of EDC in water may be prepared to facilitate the addition of a small 
molar amount to a reaction, but the stock solution should be dissolved rapidly and used 
immediately to prevent extensive loss of activity [400]. A variety of chemical conjugates may 
be formed using EDC, provided one of the molecules contains an amine and the other a 
carboxylate group. N–substituted carbodiimides can react with carboxylic acids to form 
highly reactive, O–acylisourea intermediates (Figure 6.5). Consequently this active species 
can react with a nucleophile such as a primary amine to form an amide bond [459]. 
Other nucleophiles are also reactive – oxygen atoms, such as those in water molecules, may 
act as the attacking nucleophile. In aqueous solutions, hydrolysis by water is the major 
competing reaction, cleaving off the activated ester intermediate, forming an isourea, and 
regenerating the carboxylate group [460]. Nakajima and Ikada (1995) investigated EDC 
amide bond formation in aqueous solution using hydrogels of acrylic acid– or maleic acid–
containing polymers and ethylenediamine or benzylamine. Their results indicated that 
carboxylate activation occurred most effectively with EDC at pH 3.5 – 4.5, while amide bond 
formation occurred with the highest yield in the range of pH 4 – 6. When working with 
proteins and peptides, experience indicates that EDC–mediated amide bond formation 
effectively occurs between pH 4.5 and 7.5. Beyond this pH range, however, the coupling 
reaction occurs more slowly with lower yields. Most references to the use of EDC describe 
the optimal reaction medium to be at a pH from 4.7 to 6.0 [461]. However, the carbodiimide 
reaction occurs effectively up to at least pH 7.5 without significant loss of yield [400]. 
Conjugations performed under mildly alkaline pH conditions (e.g. pH 8.5) may be conducted 
to limit the polymerization of proteins, while still facilitating the coupling of a carboxylate–
containing molecule at a low substitution level per protein [462]. Some procedures 
recommend the use of water as the solvent in an EDC reaction, while the pH is maintained 
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constant by the addition of HCl. Buffered solutions are more convenient, as the pH would not 
have to be monitored during the course of the reaction.  
Table 6.2 details a summary of some of the reactions that make use of EDC as the method 
of conjugation. Beuvery et al., in 1983, prepared Neisseria meningitidis group C 
polysaccharide–tetanus toxoid conjugates by using high molecular weight polysaccharide 
and purified tetanus toxoid with EDC as a coupling reagent. It was determined that the 
composition of the conjugate was not homogeneous and at least 10 % unconjugated 
polysaccharide was present. The conjugation was performed by the slow addition of a 
solution of EDC in water to a solution of polysaccharide and protein in equal mass ratios. 
The EDC was used as the zero length linker between the carboxyl groups on the 
polysaccharide and the amine functional groups on the carrier protein. The pH was 
maintained at 4.7 with the addition of HCl and the reaction was stopped after 4 hours with 
the addition of ethanolamine. The conjugate was dialysed against PBS buffer [435]. 
Table 6.2. Summary of some conjugations in literature that make use of EDC as a conjugation 
method. 
Author PS PS activation Protein 
Protein 
derivatized 
(Y/N) 
EDC reaction 
conditions 
Beuvery et 
al. [435] 
Meningococcal 
group C None TT N 
2.5 mM, 4 hr.,  
pH 4.7 
Schneerson 
et al. [115] Hib, Pn6A CNBr TT N 
0.1 M, 3 hr.,  
pH 5.0 
Hale et al. 
[463] Vi None rP40 Y 
5 mM, 3 hr.  
pH 5.6–5.9 
Cabrera et 
al. [68] 
Meningococcal 
group A, B,C NaOH TT N 
0.1 M, 4 hr.  
pH 5–6 
Biemans et 
al. [386] Pn22F CDAP/ADH Protein D N 
1 mg/mg PS, 2.5 hr.,  
pH 5–7 
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Figure 6.5. Mechanism of the reaction between a carboxyl and an amino functional group with EDC 
to form a stable amide linkage. A) Reaction between carboxylate functional group with EDC to form 
active ester intermediate. B) Reaction between active ester intermediate with amine functional group 
to form amide bond and isourea by–product. Modified from Hermanson [400]. 
Schneerson et al. (1986) used the EDC methodology to couple Pn6A to TT that was injected 
into human adult volunteers. The hydroxyls on the polysaccharide were first activated with 
cyanogen bromide (CNBr) and ADH to form the activated PS–ADH compound that was 
conjugated to TT with EDC at a final concentration of 0.1 M EDC for 3 hours at pH 5.0, 
before extensive dialysis with 0.2 M NaCl. The Pn6A–TT conjugate elicited an 8 fold 
increase in antibodies after one injection. A Hib–TT conjugate, produced with the same 
carbodiimide method was introduced concurrently with the pneumococcal conjugate. A cross 
reaction was noted with the Pn6A conjugate eliciting Hib antibodies in 13 of 20 volunteers, 
however, only 4 of 59 volunteers injected with the Hib–TT conjugate produced an increase in 
Pn6A antibodies [115].  
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Hale et al. (2006) used the carbodiimide–coupling methodology to conjugate carboxyl 
groups on the capsular polysaccharide of Vi to the ADH–derivatized outer membrane protein 
of Klebsiella pneumoniae (rP40). A final concentration of 5 mM EDC was used in the 
reaction that proceeded for 3 hours at room temperature within the pH range of 5.6 – 5.9. 
Immunogenicity studies in mice showed an increase in antibody response compared to the 
native polysaccharide [463].  
Cabrera et al. (2006) produced conjugates against Neisseria meningitides serogroups A, B, 
C, Vibrio cholera and Salmonella typhi, and tested their immunogenicity in mice. These 
activated saccharides were linked to the carboxyl groups on TT via EDC coupling. The 
conjugates all elicited higher anti–polysaccharide titres than the unconjugated saccharide 
[68, 464]. 
In the investigation by GSK into their 10 valent licensed pneumococcal vaccine, the EDC 
coupling methodology was evaluated with respect to Pn22F (not used in the vaccine). The 
polysaccharide was first derivatized with ADH in the presence of CDAP. This ADH–
derivatized polysaccharide was conjugated to Protein D using EDC coupling [386] and 
compared to a Pn22F conjugate prepared using their general CDAP method.  
Table 6.3. Comparison of Pn22F–Protein D conjugates using different conjugation methodologies 
[386]. 
Polysaccharide Conjugation Protein:PS Free PS (%) 
Pn22F 
CDAP 0.46 5.8  
EDC 0.27 – 0.23 ˂1 
The conjugates were compared with respect to the ratio of protein to polysaccharide and 
free polysaccharide levels (Table 6.3) with the EDC conjugate, showing a lower protein–
polysaccharide ratio and a much lower percentage of free polysaccharide levels than the 
CDAP conjugate. The immunogenicity of the polysaccharide and protein were determined in 
terms of both IgG levels as well as opsonophagocytic titres (Figure 6.6), and revealed that 
the conjugate prepared with the ADH linker showed superiority over the CDAP conjugate 
both in the ELISA and in the OPA results [386].  
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Figure 6.6. Antibody response of Pn22F conjugates prepared using two different conjugation 
methods modified from Biemans et al. [386]. 
6.2.1 EDC conjugations to BSA 
As EDC is one of the most widely used reagents for activating the polysaccharide and 
subsequent conjugations to protein carriers, it was the first conjugation method to be 
investigated. BSA was used as a protein carrier to determine if conjugation via EDC coupling 
was a viable method. The formation of the conjugate was also monitored in two different 
solutions; NaCl and MES buffer and the results of these investigations could be used as a 
foundation when alternate protein carriers are used. 
In order to determine if conjugation was successful, Pn1 was dissolved in 0.2 M NaCl with a 
1:1 molar ratio of derivatized BSA. EDC was added in excess (2 mol EDC for every mol PS) 
and the reaction was monitored on SEC–HPLC at 30 and 90 min. 
  
Figure 6.7. SEC–HPLC RID (a) and UV 280 nm (b) chromatograms of Pn1_EDC_BSA in 0.2 M NaCl 
after 30 (red) and 90 min (blue) compared to Pn1 polysaccharide (a) and BSA (b) (black). 
The RID profiles (Figure 6.7a) detail the formation of the conjugate over time. After 30 
minutes a shoulder appeared on the higher molecular weight side of the chromatogram 
where the polysaccharide eluted. After 90 minutes this shoulder had become the major peak 
at 13.5 min; however, the double humped peak suggested that unconjugated Pn1 may still 
have been present. The UV signals at 280 nm mimicked the RID signals. At 30 minutes, a 
a) b) 
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large shift in elution time from the derivatized BSA at 19.0 min to the conjugate peak at 13.4 
minutes was shown. This peak was double humped, which in the RID signal suggested that 
unconjugated saccharide was present, but with the UV signal it was hypothesised that either 
two different molecular weight conjugates had formed or that the protein or conjugate had 
aggregated. The smaller molecular weight peak seen in the 30 min chromatogram 
decreased significantly after 90 minutes confirming that conjugation was still in progress with 
more saccharide fragments conjugating to the protein. The peak shown at approximately 20 
minutes in the 30 minute sample was from unreacted derivatized BSA and disappeared in 
the 90 minute sample suggesting that all the protein had reacted. 
The size exclusion purification method was tested using the Sephacryl S500 packing, on an 
ÄKTA chromatographic system, to determine if it was a viable method of purification. The 
resulting chromatogram (Figure 6.8) showed two overlapping peaks, which suggested that 
the incorrect packing material was used as significant separation could not be obtained. An 
alternate packing, the Sephacryl S400, was also tested (see molecular weight ranges in 
Table 6.4) however, the separation did not improve (data not shown). Fractions were 
collected and analysed on the SEC–HPLC to test for conjugate and unbound saccharide. 
Table 6.4. Molecular weight working range for dextrans using Sephacryl size exclusion column 
packing [465]. 
Packing Dextran Mw fractionation range (Da) 
S400 1x104 – 2x106 
S500 4x104 – 2x107 
 
Figure 6.8. UV 280 nm chromatogram of the separation of the Pn1_EDC_BSA conjugate. 
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Figure 6.9. SEC–HPLC a) RID and b) UV 280 nm chromatograms of Fractions 1 (black), 2 (blue), 3 
(red), 4 (purple) and 5 (green) of Pn1_EDC_BSA conjugate. 
Table 6.5. Saccharide and protein content in fractions from Pn1_EDC_BSA. 
Fraction number Total saccharide (mg) Total protein (mg) 
1 1.68 3.96 
2 6.39 13.68 
3 9.15 17.15 
4 3.67 8.80 
5 0.23 1.42 
Total 21.12 45.00 
From the RID chromatogram (Figure 6.9a) the polysaccharide was observed to have eluted 
in Fractions 2 – 4 with three different molecular weight species. It was observed that only 
Fractions 2 and 3 contained protein. The colorimetric assays, Table 6.5, gave positive 
results for saccharide and protein in every fraction. Recoveries of 90 % protein and 42 % 
polysaccharide were obtained. The low recovery of saccharide could be due to unconjugated 
Pn1 eluting later on the column or interacting with the N,N'–methylenebisacrylamide found in 
the column packing thus not eluting. As Pn1 is not UV active, the polysaccharide elution 
could not be monitored. Table 6.5 confirms the pictorial representation in the chromatograms 
where Fractions 2 and 3 contained the majority of the polysaccharide and the protein. The 
protein assay suggested that 17 % of the original amount of protein was found in Fraction 4 
although the HPLC chromatogram did not show this. The sample volume injected onto the 
column was insufficient to allow for full analytical testing. 
As conjugation between Pn1 and BSA was shown to be successful, the reaction solution 
was investigated further to determine whether NaCl or 2–(N–morpholino)ethanesulfonic acid 
(MES) may affect the conjugation reaction. 
Two reactions were investigated with ratios of Pn1, BSA and EDC detailed in Table 6.6. The 
only difference was that the Pn1 was dissolved in either 0.2 M NaCl or 1 M MES. After the 
reaction was stopped the mixture was centrifuged to pellet out any precipitate and the 
a) b) 
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supernatant was analysed by SEC–HPLC. Precipitation was observed during both 
conjugation reactions, however the conjugate in NaCl produced much less visible precipitate 
than that of the MES buffered reaction.  
Table 6.6. Reaction variables for EDC conjugation of Pn1 with derivatized BSA. 
Pn1/Protein 
molar ratio 
Reaction 
solution 
Pn1/EDC 
molar ratio 
pH 
adjustment 
Reaction 
time (hr.) 
1:1 0.2 M NaCl 1:2 6.0 2 
1:1 1 M MES 1:2 6.0 2 
  
  
Figure 6.10. SEC–HPLC RID (a) and UV 280 nm (b) chromatograms comparing Pn1 polysaccharide 
(black) to the Pn1_EDC_BSA conjugate in NaCl (blue) and MES (red) buffer. 
The RID profile, Figure 6.10, showed a shift in elution times for both reactions from the Pn1 
PS peak at 15.4 min to a higher molecular weight range, eluting at 13.3 min for the NaCl 
reaction and 13.5 min for the MES conjugate. Both conjugate peaks were double humped, 
suggesting either that unconjugated saccharide remained in both reactions and/or the 
presence of two populations of conjugate. The UV chromatograms also showed a large shift 
in retention time from the derivatized protein at 18.9 min to the new elution time of the 
conjugate at 13 min. Both conjugate peaks exhibited a slight shouldering that suggested the 
formation of a lower molecular weight conjugate (as unconjugated saccharide is not UV 
active). The intensity and area under the conjugate peaks suggested that a greater amount 
of conjugate was formed in the NaCl solution than in the MES buffer. Both conjugate 
chromatograms revealed that trace amounts of unconjugated protein remained after the two 
hour reaction, with a peak elution at 18.9 min.  
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6.2.2 EDC conjugations to TT 
As conjugation to BSA was successful, investigations focussed on the conjugation of Pn1 
PS to tetanus toxoid. 
Tetanus Toxoid is currently one of the few proteins used clinically as a carrier in 
commercially available conjugate vaccines as well as in several vaccines undergoing clinical 
trials. In terms of Streptococcus pneumoniae, GSK have used TT as a carrier protein for 
serotype 18C in their 10 valent conjugate vaccine: Synflorix [386]. TT is also widely used in 
commercially available Hib vaccines as well as conjugate vaccines against MenC including 
GSK’s tetravalent meningococcal vaccine Nimenrix [407, 423].  
With the successful activation of the tetanus toxoid determined (Chapter 5, Section 5.4.1); 
the EDC conjugation method was applied to the derivatized TT in order to develop a Pn1–TT 
conjugate. 
The conjugation reaction was carried out as described with BSA where size reduced Pn1 
and derivatized TT were combined, followed by the addition of EDC. Derivatized TT must be 
kept at a high pH to avoid precipitation and as such the pH of the PS:protein combination 
was lowered to 6.85 with 0.1 M HCl (pH 6.85 is at the upper working range of EDC). The 
conjugation was monitored by SEC–HPLC at 1, 2 and 5 hours. Reaction variables are 
summarised in Table 6.7.  
 Table 6.7. Reaction variables for the EDC conjugation of Pn1 and derivatized TT. 
Pn1/protein 
mass ratio Pn1:TT pH 
Pn1/EDC 
molar ratio 
Reaction time 
(hr.) 
1:2 6.85 1:10 5 
The RID chromatograms in Figure 6.11 track the conjugation reaction over a period of five 
hours. Pn1 PS eluted at 14.2 min and the conjugate formation was seen with small shifts in 
elution time to 13.9, 13.9 and 14.0 minutes seen for the 1 hour, 2 hour and 5 hour reactions 
respectively, thereby indicating that no significant amounts of conjugation had formed. The 
peak eluted at 17.7 min in all three conjugate samples corresponded to unreacted TT 
protein. The UV chromatograms showed a large amount of free protein remaining after a 
reaction time of 5 hours. A small amount of higher molecular weight compound eluted at 
13.3 min. This peak increased in intensity and area over time which was indicative of the 
slow formation of conjugate. Whilst the species eluted in the range of the conjugate (13 – 14 
min) it could not be identified conclusively as conjugate or as aggregated protein without 
further analysis. 
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Figure 6.11. SEC–HPLC a) RID and b) UV 280 nm chromatograms of Reaction 2, Pn1_EDC_TT, 
traced over a period of time: 1 hr. (blue), 2 hr. (red) and 5 hours (green). Pn1 polysaccharide (black) 
is shown as a comparison in the RID chromatogram. 
The conjugate was left to react over 24 hours where a large amount of precipitate was seen 
to have formed. The sample was centrifuged to pellet out the precipitate and the clear 
supernatant was analysed by SEC–HPLC. The chromatograms for the supernatant of the 
overnight conjugate are shown in Figure 6.12. The RID chromatogram compared the 
conjugate with unconjugated Pn1 PS; a small shift in elution time from the polysaccharide at 
14.2 min to 14.0 min occurred, this was suggestive of conjugation, however, a large amount 
of free protein was present in the RID signal at 17.9 min. The UV profile confirmed the 
suggestions made in the RID chromatograms; a small peak was seen at 14 min that 
suggested either a small amount of conjugation had taken place or aggregation of the 
derivatized protein had occurred. In order to analyse the pellet by SEC–HPLC, different 
solvents were used to dissolve it; a low pH (0.1 M MES, pH 5.5), pH neutral (water) and high 
pH buffer (30mM NaCl/3mM Na2CO3, pH 10.5) were tested. The pellet was barely soluble in 
any of the solvents but the high pH buffer partially dissolved the pellet and this was analysed 
by SEC–HPLC. The RID and UV chromatograms for the pellet in the three different solvents 
are displayed in Figure 6.12c and d. 
a) 
b) 
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Figure 6.12. SEC–HPLC a) RID and b) UV 280 nm chromatograms of Pn1_EDC_TT supernatant 
(red) compared to Pn1 polysaccharide (black) as well as the a) RID and b) UV 280 nm 
chromatograms of pellet dissolved in various buffered solutions. Black–0.1 M MES buffer pH 5.5, 
blue–in water, and red–30 mM NaCl/3 mM Na2CO3 pH 10.5. 
The RID chromatograms of the pellet dissolved in the low or high pH buffers showed no 
trace of polysaccharide or protein. The pellet dissolved in water showed trace amounts of 
conjugate and unconjugated protein. Minimal conjugate was observed in the UV 
chromatogram of the MES buffer and trace amounts of protein and reagents were eluted in 
the additional two solutions.  
As seen from the results above, significant conjugation was not achieved with tetanus toxoid 
as a protein carrier and alternative strategies had to be investigated to achieve a successful 
conjugation of Pn1 PS and TT. 
6.3 Activator chemistry 
There are a number of reasons hypothesised as to why EDC was not successful in the TT 
conjugation reactions:  
 Pn1 has both carboxyl and amine groups on its repeating unit and cross linking of the 
polysaccharide could account for a small amount of precipitation (seen both in the 
BSA and TT reactions). TT itself has a large number of carboxyl groups and 
a) b) 
c) d) 
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derivatization is not fully complete, thus carboxyl groups may still be found on the 
surface of the protein. These groups could react with the amino groups or the 
derivatized hydrazide groups also found on the protein which will cause the protein to 
precipitate out.  
 The active ester formed by the reaction of the carboxyl group on the polysaccharide 
with EDC reacts very slowly with amines and can hydrolyse in aqueous solutions 
[455]. If the amine target is not reacted with the activated carboxylate before it 
hydrolyses the desired conjugate cannot form. This is especially the case when the 
amine target is in low concentrations in water as is the case with most protein 
molecules.  
 In addition to reacting with carboxyl groups, EDC is known to form stable complexes 
with any exposed sulfhydryl groups [466] as well as tyrosine residues, most likely 
through the phenolate ionized form of its side chain [467].  
 Hydrolysis by water is a major competing reaction as it both inactivates the EDC itself 
and it can also cleave the activated ester thereby forming an isourea and 
regenerating the carboxylate group [460].  
Alternate reaction methodologies were sought in order to circumvent the problems of EDC 
conjugations. The addition of an activator would produce a more stable active ester as well 
as generating a better electrophile that is more susceptible to nucleophilic attack by the 
hydrazide–derivatized protein [400, 456]. The concentration of the added activator is usually 
much greater than that of the amine containing compound hence the reaction will proceed 
through the active ester intermediate, however, the final product of this two–step reaction is 
identical to that obtained with EDC alone in that a stable amide bond is formed between the 
carboxylate group on one compound with the amine group on another [400]. 
6.3.1 HOBt activator chemistry 
 
Figure 6.13. Molecular structure of 1–hydroxybenzotriazole (HOBt). 
1–Hydroxybenzotriazole (HOBt) (Figure 6.13) is a widely used activating group for the 
construction of an amide bond during peptide and β–lactam antibiotic synthesis [333, 468, 
469]. HOBt works by creating an active ester intermediate of the polysaccharide which would 
react with the amine groups on a protein carrier creating a conjugate. Active esters of HOBt 
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have also been employed in the formation of a C–C bond during the preparation of the 
antibiotic malonomicin [470]. Chan and Cox (2008) determined that the reaction rates of 
conjugation were independent of HOBt and that the rate limiting step was the reaction 
between the carboxylic acid group and EDC during the formation of the O–acylisourea. 
However it was determined that a high yields of amide formation was found in the presence 
of HOBt and very poor conversion rates to the amide in HOBt’s absence [468]. 
The decision to make use of HOBt mediated coupling came from the article by Bulpitt and 
Aeschlimann (1999) when they used HOBt/EDC to couple hyaluronic acid (HA) to different 
amines [471]. The degree of derivatization of HA could be controlled and varied in the range 
of 10 – 70 % depending on the nature of the amine containing nucleophile. The derivatized 
HA compounds were reacted together to form hydrogels using gluteraldehyde, hydrazide 
and N–hydroxysuccinimide esters to a degree of between 10 % and 25 %. These hydrogels 
were infiltrated by cells and supported growth factor – induced remodelling in the rat ectopic 
bone formation. Hydrogels formed with the highly derivatized HA compounds were found to 
be anti–adhesive to cells and could be used to generate tissue separations and prevent 
adhesions following surgery [471].  
The mechanistic details of a HOBt mediated conjugation (Figure 6.14), begin with the 
formation of the reactive O–acylisourea intermediate is by reacting EDC with the carboxyl 
functional group on one compound. This intermediate is reacted almost instantaneously with 
the HOBt to form a HOBt active ester and the EDC by–product. Two different active esters 
can be formed with HOBt. The two different esters, one being the O–acyl derivative and the 
other the N–acyl derivative were investigated by Brink et al. [472]. The kinetics of the 
reaction suggested that the O–acyl active ester is more likely to form and the mixture will 
isomerise almost completely into the N–acyl derivative over time [470]. Sterically hindered 
molecules also mainly produced the O–acyl derivative which suggested that the N–acyl 
isomer has greater steric limitations on its formation, and therefore bulkier substrates would 
favour the extra atom between the HOBt rings and form the O–acyl isomer. The initial 
formation of the O–acyl isomer proposes that the reaction at the oxygen atom goes through 
a lower activation energy path than the ring nitrogen due to the more available steric 
approach, while the eventual formation of the more stable N–acyl derivative is suggestive of 
the thermodynamic product [473].  
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Figure 6.14. Representative reaction steps taken in the HOBt mediated conjugation between a 
carboxyl and amine group. I) Creation of an O–acylisourea intermediate, II) formation of the HOBt 
active ester, III) creation of the amide bond linkage. 
The preference for O–acylation corresponds to the change in relative tautomerization of the 
HOBt nucleophile in solution during the course of the reaction [474]. This is an example of 
the Curtin–Hammett principle (Figure 6.15) which states that the relative energies of the 
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transitions states control the selectivity of the reaction rather than the relative energies of the 
starting materials [472, 475]. It is also theorised that the O–acyl derivative is more 
electrophilic and hence more susceptible to nucleophilic attack than the N–acyl derivative 
[473, 476]. 
 
Figure 6.15. The Curtin–Hammett equilibrium of HOBt tautomers and acylated HOBt adducts [472]. 
With the unsuccessful conjugation of derivatized TT with Pn1 using the EDC coupling 
technology, an EDC mediated coupling conjugation procedure using HOBt was investigated. 
As the conjugation with BSA using the EDC coupling technology was successful it was 
thought that the formation of an active ester with the carboxyl groups found in Pn1 would 
drive the reaction between an amine group and the active ester intermediate.  
Three protein carriers were investigated, i.e. TT, CRM197 and PLD; the majority of the 
reactions were carried out using TT. Most investigations were performed on small scale (25 
– 50 mg) and involved establishing whether the use of HOBt would significantly enhance 
conjugate formation. Once this was established, investigations into the initial polysaccharide 
and protein mass ratios were performed, the pH of the mixture of Pn1 and protein was 
optimised to reduce precipitation and the pH of the EDC/HOBt reactant mixture was also 
optimised to reduce precipitation. Once the process parameters were established with TT as 
the carrier protein the methodology was applied to other protein carriers with the view of 
comparing the highest yielding protein carrier with commercially available conjugate 
vaccines in animal studies. 
6.3.1.1 HOBt mediated conjugations to TT 
Nine conjugates were prepared using Pn1, TT and EDC/HOBt. Table 6.8 details the process 
parameters. Derivatized and underivatized protein was compared as well as different 
polysaccharide to protein ratios, polysaccharide to EDC/HOBt mass ratios and pH 
adjustments.  
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Table 6.8. Polysaccharide and protein variables for Reactions 1 – 9 employing HOBt mediated 
coupling. 
Reaction 
PS –
Protein 
mass 
ratio 
Protein 
derivatized 
(Yes/No) 
Protein 
pH 
pH of 
protein
– Pn1 
mixture 
Pn1/HOBt 
molar ratio 
EDC/HOBt 
molar ratio 
EDC/HOBt 
pH 
1 1:5 No 6.80 n/a 1:6.4 1:1 None 
2 1:5 
Yes 
(16.1 %) 
6.80 n/a 1:6.4 1:1 None 
3 1:3 
Yes 
(17.2 %) 
8.00 7.03 1:6.6 1:1 None 
4 1:3 
Yes 
(17.2 %) 
8.00 7.12 1:12.9 1:1 7.10 
5 1:1 Yes 8.5 8.04 1:6.2 1:1 6.70 
6 2:1 Yes 8.5 7.84 1:6.2 1:1 6.70 
7 0.5:1 Yes 8.5 7.84 1:6.2 1:1 6.70 
8 1:1 
Yes 
(16.2 %) 
9.62 7.54 1:6.3 1:1 6.80 
9 2:1 
Yes 
(16.6 %) 
7.56 7.44 1:6.5 1:1.3 6.80 
The first two reactions were performed in order to investigate whether the carrier protein 
could be conjugated to the polysaccharide without protein derivatization. Reactions 1 and 2 
were performed using the same process parameters, differing only in the use of native 
(Reaction 1) and derivatized (Reaction 2) protein. The pH of the derivatized protein was first 
lowered from 10.5 to 6.8 before addition to the polysaccharide. In a separate reaction vessel 
EDC and HOBt were dissolved in a 1:1 solution of water and dimethylsulfoxide (DMSO). The 
EDC and HOBt mixture was added drop–wise to the polysaccharide–protein solution and the 
reaction was left to proceed overnight with slow, continuous mixing. Small amounts of 
precipitation were seen during the addition of the reagents. Samples of each reaction were 
taken for SEC–HPLC analysis before the reactions were dialysed with 0.2 M NaCl. 
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Figure 6.16. SEC–HPLC RID (a) and UV 280 nm (b) chromatograms of Pn1_HOBt_TT using 
underivatized TT (Reaction 1 – red) and derivatized TT (Reaction 2 – blue). Pn1 polysaccharide 
(black) is shown for comparison.  
The RID profiles of both Reactions 1 and 2 (Figure 6.16a) exhibit a shift in elution time of the 
Pn1 PS from 14.2 min to 13.6 min and 13.2 minutes for the underivatized and derivatized TT 
reactions respectively, thus indicating the presence of conjugate. The conjugate prepared 
using underivatized TT exhibited a broad shoulder to the right that is an indication of the 
presence of unconjugated saccharide. There was also a peak eluting at 17.8 min which is 
indicative of unconjugated TT present in the sample. The conjugate prepared with the 
derivatized protein displayed a much sharper peak eluting at 13.2 min thus suggesting a 
larger molecular weight conjugate had been formed when compared to that of the 
underivatized protein. The conjugate peak also displayed a shoulder towards the lower 
molecular weight range which was suggestive of unconjugated polysaccharide. The peak 
eluting at 11.1 min seen in the derivatized protein conjugate was considered an artefact as it 
was not seen in the dialysed sample. 
The UV profiles of the conjugates are presented in Figure 6.16b. Both conjugates exhibited a 
main peak at 13 min corresponding to the conjugate. The conjugate prepared with the 
underivatized protein (Reaction 1) did indicate the presence of unconjugated protein with a 
peak seen at 17.3 min. Reaction 2, using the derivatized protein showed a sharp peak at 
12.9 with a small shoulder on the low molecular weight (right–hand) side which suggested a 
lower molecular weight conjugate could have formed. It may also suggest that the reaction 
had not proceeded to completion. As the Pn1 PS is not UV active this shoulder was not 
indicative of unconjugated saccharide. Trace amounts of unconjugated protein could be 
seen at 17.5 min and the peak eluting at 10.89 min was removed with dialysis. SEC–HPLC 
analysis of these two reactions suggested that higher conjugation efficiencies had occurred 
using derivatized protein. 
The next two reactions were performed to determine whether adjustment of pH of the 
EDC/HOBt mixture would play a role before addition to the polysaccharide/protein mixture as 
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well as if the reagents were added in sufficient excess. The water/DMSO solution, which 
lowered the pH of the EDC/HOBt mixture, has a low pH (± 5.18) and was thought to 
contribute to the instability of the derivatized TT. Reaction 3 was performed with no 
adjustment of the reagents’ pH where the pH of Reaction 4’s reagents was adjusted to pH 
7.10 before its addition to the polysaccharide/protein mixture. The reagents in Reaction 4 
were added at twice the molar value than in Reaction 3. Full details of the reaction variables 
are found in Table 6.8. 
  
Figure 6.17. SEC–HPLC RID (a) and UV 280 nm (b) chromatograms of Pn1_HOBt_TT conjugates 
from Reactions 3 (blue) and 4 (red) to determine whether a pH adjustment of the EDC/HOBt mixture 
was necessary. Pn1 PS (black) is shown for comparison. 
Figure 6.17 (a and b) show the RID and UV 280 nm chromatographic signals of Reactions 3 
and 4. For Reaction 3 the RID signal showed a slight shift to higher molecular weight 
material and the UV signal confirmed this with a peak eluting at 12.9 min. The large shoulder 
on the right of Reaction 3’s conjugate peak for the RID signal and the absence of this 
shoulder in the UV signal suggested that there was unconjugated saccharide or a lower 
molecular weight conjugate present. A large amount of precipitate was formed during the 
addition of the reagents as a result of a drop in pH and further analysis was not possible. 
Reaction 4 displayed a shift in the RID signal to the higher molecular weight range when 
compared to the Pn1 PS. As with Reaction 3, a shoulder was present on the lower molecular 
weight side of the conjugate peak which was confirmed to be unconjugated saccharide by 
the absence of this shoulder in the UV spectrum. The conjugate however, did remain in 
solution which confirmed that the final pH adjustment of the reaction mixture must be made, 
after the addition of the activating species.  
Purification of Reaction 4 was through a size exclusion S500 column (as performed 
previously in EDC experiments). Two main peaks eluted in the UV profile of the conjugate 
(Figure 6.18) which were collected and analysed for conjugated and free saccharide.  
a) b) 
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Figure 6.18. Sephacryl S500HR: UV 280 nm chromatogram of Reaction 4. The UV (blue) and 
conductivity (red) profiles of the conjugate are shown. 
Table 6.9. Colorimetric analysis of total and free saccharide levels in Reaction 4. 
Peak 
Saccharide 
Total (mg) Free (mg) 
1 8.47 1.52 (18.0 %) 
2 1.12 0.53 (47.3 %) 
As shown in Table 6.9, the first peak contained the highest percentage of conjugated 
saccharide with 82 % of the saccharide eluted as conjugated Pn1. The unconjugated 
saccharide, eluted in the second peak, was determined with the DOC preparation and 
subsequent uronic acid assay and found to be 47.3 %.  
The initial mass ratio of polysaccharide to protein was investigated to determine which initial 
ratio would result in the optimal polysaccharide–protein ratio. Reactions 5, 6 and 7 were 
performed in order to create consistency in the reaction conditions and to evaluate the 
polysaccharide–protein ratio. In Reaction 5, the polysaccharide to protein mass ratio was 
1:1, in Reaction 6 this was 2:1 and Reaction 7 had a 0.5:1 polysaccharide protein mass ratio 
(Table 6.10).  
Table 6.10. Initial polysaccharide and protein mass ratios used in Reactions 5,6 and 7. 
Reaction PS – Protein mass ratio 
5 1:1 
6 2:1 
7 0.5:1 
The pH of the protein solution (87.5 mg) was lowered from 10.5 to 8.5 before being divided 
between the three reactions, according to the initial ratio needed, and added to the 
polysaccharide. In a separate vial the EDC and DMSO were mixed together and the pH of 
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the collective activating mixture was raised from 5.11 to 6.70 before being added in equal 
proportions to the three polysaccharide–protein mixtures. The reaction was left at room 
temperature for 24 hours, followed by dialysis against 0.2 M NaCl to remove any unreacted 
reagents.  
  
Figure 6.19. SEC–HPLC RID (a) and UV 280 nm (b) chromatograms of Reactions 5 (green), 6 (blue) 
and 7 (red) producing the Pn1_HOBt_TT conjugates. Pn1 PS (black) serves as a comparison. 
The peaks in the RID chromatograms in Figure 6.19 exhibited the formation of the 
conjugates for all three reactions. They showed a large shift in the elution time compared to 
the size reduced Pn1 elution. The broad shape of Reaction 6 (2:1 Pn1:TT mass ratio) 
suggested that either a large quantity of polysaccharide remained unreacted or that the 
molecular weight range of the conjugate was broad. The peak shapes for Reactions 5 and 7 
were identical and a small amount of unconjugated saccharide remained. The peaks 
displayed in the UV chromatogram at 280 nm all depicted the formation of the conjugate at 
approximately 12.8 min. The difference in the intensity of the three peaks was due to the 
concentration of polysaccharide and protein present in each reaction. The peaks all showed 
similar shapes with a slight broadening suggestive of the formation of a range of different 
molecular weight conjugates. Purification using a Sephacryl S500 HR column and 
subsequent saccharide and protein analysis was performed on all three reactions.  
The representative elution profile, monitored at 280 nm for the three reactions (Figure 6.20) 
revealed one large peak of higher molecular weight with a shoulder to the right and one peak 
of smaller molecular weight. It was previously shown that the small peak was most likely due 
to unconjugated polysaccharide, and/or unreacted reagents so as a result, Fraction 4 was 
not subjected to testing. The large, shouldered peak was collected in three fractions and 
assayed for protein and saccharide composition.  
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Figure 6.20. Sephacryl S500 HR: UV 280 nm representative profile of Reactions 5 – 7. 
Table 6.11. Saccharide and protein results of fractions collected for Reactions 5, 6 and 7. 
Reaction  
Initial 
PS:Protein 
ratio 
Fraction 
Total 
saccharide 
(mg) 
Free 
saccharide 
Protein 
(mg) 
PS:Protein 
ratio 
5 
 1 2.92 0.45 mg (15 %) 4.14 0.60 
1:1 2 4.67 1.34 mg (29 %) 1.78 1.87 
 3 0.31 0.23 mg (74 %) 0.24 0.33 
6 
 1 1.62 0.49 mg (30 %) 2.61 0.43 
2:1 2 4.60 1.37 mg (30 %) 0.68 4.75 
 3 0.73 0.09 mg (12 %) 0.18 3.56 
7 
 1 3.14 0.25 mg (8 %) 10.41 0.28 
0.5:1 2 5.32 0.54 mg (10 %) 5.63 0.85 
 3 0.74 0.34 mg (46 %) 0.95 0.72 
The results in Table 6.11 confirmed that the majority of the polysaccharide and protein 
eluted in the first two fractions for all three reactions with the majority of the protein found in 
the first fraction and the bulk of the polysaccharide in the second fraction. The levels of free 
saccharide were also lower in the first two fractions than the third suggesting that the third 
fraction mainly contained unreacted polysaccharide. A summary of the free saccharide and 
conjugation efficiencies can be found in Table 6.12. The final protein to polysaccharide ratio 
of all three reactions were comparable to their initial ratios with Reaction 5 exhibiting a final 
protein to polysaccharide ratio of 0.95:1, Reaction 6 presenting a final ratio of 1.44:1 and 
Reaction 7 resulted in a final ratio of 0.47 mg polysaccharide to every mg of protein. In terms 
of conjugation efficiency, Reaction 7 gave the best conjugation efficiency of 32.3 %, with the 
lowest efficiency of 20 % resulting from Reaction 6 It is hypothesised that the greater the 
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amount of polysaccharide, the greater the potential for cross–linking within the saccharide 
and hence less is available for conjugation to the protein. 
Table 6.12. Conjugation efficiencies and final Ps: Protein ratios for Reactions 5, 6 and 7. 
Reaction Ps: Protein ratio (initial) 
Total 
saccharide 
(mg) 
Free 
saccharide 
Protein 
(mg) 
PS:Protein 
ratio (final) 
Conjugation 
efficiency 
(%) 
5 1:1 7.90 2.02 mg   (26 %) 6.16 0.95 23.5 
6 2:1 6.95 1.95 mg   (28 %) 3.47 1.44 20.0 
7 0.5:1 9.20 1.13 mg   (12 %) 16.99 0.47 32.3 
Reactions 8 and 9 were performed on a larger scale than the preceding reactions in order to 
investigate the issues with precipitation as well as to confirm that the conjugation reaction 
was scalable. As the protein supply was limited, a large scale reaction with a polysaccharide 
to protein ratio of 1:2 was not performed. Reaction 8 was performed on a 1:1 
polysaccharide: protein mass scale with both EDC and HOBt added in a 6.3 molar excess. 
Reaction 9 was performed on a 2:1 polysaccharide–protein mass scale as this was 
determined to be the optimal ratio used in other conjugation strategies. EDC and HOBt were 
added in a 5 and 6.5 molar excess respectively and the pH of both activating mixtures was 
raised to 6.8 before addition to the polysaccharide and protein mixture. 
  
Figure 6.21. SEC–HPLC RID and UV 280 nm chromatograms of the Pn1_HOBt_TT conjugate 
Reaction 8 (red) compared to Reaction 9 (blue) and the Pn1 PS (black). 
The RID profile for Reaction 8 together with the UV280 signal (Figure 6.21) presented a 
peak at 12.8 min that is attributed to the formation of a conjugate. The results also confirmed 
that not all the protein had been consumed during the course of the reaction. Reaction 9 
contained an initial polysaccharide to protein mass ratio of 2:1 and again, both the RID and 
UV280 profile revealed the formation of a conjugate peak; the RID elution time slightly later 
at 13.6 min than the UV280 peak at 12.9 min. The peak at approximately 18 min indicates 
the presence of free protein. No precipitation was observed and this was attributed to the 
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reaction conditions employed. The relative small volume of protein at high pH and much 
larger volume of buffered Pn1 solution at a lower pH, meant that the addition of the two did 
not lead to a drastic change in pH and hence precipitation of the protein. These results 
suggest that the precipitate was a result of the smaller scale reactions. Continuous 
monitoring of the pH must be observed as conjugation is favourable at a pH under 7.  
Both reaction products were subjected to purification using the S500 HR packing material 
connecting to the ÄKTA FPLC system. The UV profile of Reaction 8 (Figure 6.22a) revealed 
a small peak between 20 – 40 ml and a large peak between 60 – 100 ml. Fractions 2 – 7 
were analysed on the SEC–HPLC as well as with colorimetric assays to determine the total 
protein, total saccharide as well as the percentage free saccharide in each fraction. The UV 
profile of Reaction 9 (Figure 6.22b) also displayed two peaks, but, due to the intensity of the 
second peak, the first peak in the chromatogram appears insignificant. Fractions were 
collected and analysed as per Reaction 8. 
  
Figure 6.22. Sephacryl S500 HR UV 280 nm elution profile of a) Reaction 8 and b) Reaction 9. 
  
Figure 6.23. SEC–HPLC a) RID and b) UV280 chromatograms of the Fractions 2 (blue), 3 (red), 4 
(green), 5 (orange), 6 (purple) and 7 (black) of Reaction 8, collected on Sephacryl S500HR column. 
The results of the chromatographic analysis (Figure 6.23) and colorimetric assays (Table 
6.13) for Reaction 8 revealed the presence of polysaccharide and protein in all fractions. The 
highest percentage saccharide concentration was found in Fractions 4, 5 and 6. The protein 
a) b) 
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concentrations confirm the higher levels of proteins in the first peak. The second peak was 
theorised to contain a mixture of HOBt and free protein as the protein assay result could not 
account for the very intense UV peak following S500 purification. The DOC preparation for 
free saccharide was performed and the resulting assay confirmed the presence of free 
saccharide in all fractions. Fractions 2 and 3 exhibited a very small amount of free 
saccharide, with Fractions 4, 5 and 6 each containing a free saccharide percentage of above 
30 %.  
Table 6.13. Analytical assay results to determine final polysaccharide–protein ratios and conjugation 
efficiency for Reaction 8.  
Fraction 
Elution Time 
(min) 
Total 
saccharide 
(mg) 
Free 
saccharide 
(mg) 
Protein 
(mg) 
PS:Protein 
ratio 
Conjugation 
efficiency 
(%) RID UV 
2 12.76 12.40 8.35 0.40 (5 %) 44.11 0.18  
3 12.85 12.56 14.98 2.53 (17 %) 37.72 0.33  
4 12.92 12.69 22.33 7.09 (32 %) 18.95 0.80  
5 13.37 12.82 33.43 16.34 (49 %) 14.38 1.18  
6 14.18 13.08 33.00 17.99 (55 %) 9.70 1.54  
7 14.83 13.00 17.57 9.78 (56 %) 5.76 1.35  
TOTAL – 129.66 54.13 (42 %) 130.62* ** 38 
*Overestimation as only 100 mg protein used (unreacted matrix interference). 
**Not determined as incorrect value for protein calculated. 
 
 
  
Figure 6.24. SEC–HPLC a) RID and b) UV 280 nm chromatogram of Reaction 9 (black) and the 
fractions collected after purification on S500 HR. Fraction 1 (blue), Fraction 2 (red) and Fraction 3 
(green) are shown. 
Figure 6.24 details the SEC–HPLC RID and UV profiles of Reaction 9 as well as the 
fractions collected after separation on the S500 HR column. Fractions 1, 2 and 3 were the 
only fractions to show any trace of saccharide or protein where Fraction 1 contained the 
highest molecular weight material although not enough conjugate was eluted to assay for 
free and total saccharide content. Fraction 2 was hypothesised to contain most of the 
conjugate as it had showed a significant elution in both the RID and UV traces.  
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The results of the colorimetric assays for the two main fractions are tabulated in Table 6.14. 
Fractions 1 – 3 tested positive for saccharide with no saccharide present in Fractions 4 and 
5. The UV chromatogram (absorbance at 279 nm) was positive for all fractions however 
Fractions 4 and 5 suggest the presence of HOBt. The DOC preparation for free saccharide 
was performed on Fractions 2 and 3 and the resulting assay confirmed free saccharide in 
both fractions. The percentage free saccharide in both these fractions was very high. This, 
along with the HPLC profiles, suggested that the reaction may not have worked. The total 
conjugation efficiency for this reaction was 27.25 %, however, the final PS:protein ratio was 
approximately 1.1 which was an optimal conjugation ratio. 
Table 6.14. Analytical assays for the collected fractions of Reaction 9, with calculated conjugation 
efficiency and polysaccharide–protein ratios. 
Fraction Total saccharide (mg) 
Free saccharide 
(mg) 
Protein 
(mg) 
PS:Protein 
ratio 
Conjugation 
efficiency (%) 
2 26.82 10.19 (38 %) 14.67 1.13 – 
3 24.96 14.34 (58 %) 9.94 1.06 – 
Total 51.78 24.53 (48 %) 24.61 1.10 27.25 
6.3.1.2 Summary of HOBt conjugations with TT 
The conjugations of Pn1 to the TT were successful only when HOBt was added to the EDC 
conjugation technique. By visual comparison of the chromatograms of the EDC and HOBt 
reactions a clear shift in retention time in both the RID and UV signals can be seen for the 
HOBt reactions. It was found that the HOBt/EDC mixture had to be pH controlled as when it 
was added to the reaction mixture the pH of the reaction mixture was lowered past the 
isoelectric point of TT resulting in precipitation. When this pH was controlled in the 
subsequent TT all reactants r mained in solution and no precipitate was observed. On the 
small scale, the optimal reaction (Reaction 7) showed the lowest free saccharide (12 %) and 
highest conjugation efficiency (32.3 %). The protein to polysaccharide ratio was on the low 
side (0.47) due to the larger amount of protein used. In the larger scale reactions, the limited 
amount of protein meant that only two reactions could be performed. Reactions 8 and 9 
showed similarities in the free saccharide amount (42 % vs. 48 %) but accurate protein 
values could not be determined for Reaction 8 due to matrix interferences. The conjugation 
efficiency of Reaction 8 was 38 %, higher than that of 27 % for Reaction 9 but due to the 
interferences in Reaction 8, this may be inaccurate. These investigations showed that 
conjugation of Pn1 to a derivatized carrier protein can be achieved using HOBt mediated 
EDC coupling technology. 
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6.3.1.3 HOBt mediated conjugations to CRM197 
CRM197 is licensed for human use in several efficacious conjugate vaccines commercially 
available [175] and used routinely in children. The HOBt conjugation method proven 
effective with TT as a protein carrier was applied to CRM197. 
The reaction variables for the conjugations of Pn1 and derivatized CRM197 using the HOBt 
mediated conjugation methodology are found in Table 6.15. Reaction 1 was performed with 
a 2:1 initial polysaccharide to protein mass ratio. The protein was derivatized to a very low 
level of 2.5 %. Reaction 2 was performed on a 2:1 polysaccharide–protein mass ratio with 
CRM197 derivatized to 24.5 %. Both reactions were allowed to proceed overnight followed by 
extensive dialysis with 10 mM MES/ 0.2 M NaCl (pH 7.2).  
Table 6.15. Reaction variables for the conjugation of Pn1 to derivatized CRM197 using the HOBt 
mediated conjugation methodology. 
Reaction Pn1/Protein mass ratio 
CRM197 
derivatization levels 
EDC/HOBt 
molar ratio 
Pn1/HOBt 
molar ratio 
1 2:1 2.5 1:1.1 1:12 
2 2:1 24.5 1:1 1:6 
  
Figure 6.25. SEC–HPLC a) RID and b) UV chromatograms of Pn1 (RID – black) and CRM197 (UV – 
black) and Reaction 1: Pn1_HOBt_CRM197 (red). 
For Reaction 1 the RID profile in Figure 6.25 did not show a difference in the shift in elution 
time (and therefore molecular weight) between the polysaccharide and the conjugate. 
However, a shift was seen in the UV chromatogram with the formation of a conjugate peak 
at 12.9 min and the disappearance of the peak at 18.1 min. This shift was hypothesised in 
the TT conjugations to signify successful conjugation. Whilst the disappearance of the peak 
at 18.3 min is confirmation of the complete consumption of protein, the lack of shift in the 
RID signal was theorised to be due to unconjugated polysaccharide and required further 
investigation.  
Hydrophobic interaction column (HIC) was investigated as an alternate means of conjugate 
purification as size exclusion chromatography did not prove to be successful with the TT 
a) b) 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
209 
 
conjugations. Underivatized CRM197 protein was used in order to explore the optimal 
conditions for HIC. These investigations are summarised in Table 6.16 (solution A – 1 M 
(NH4)2SO4, and solution B – 0.05 M sodium phosphate buffer (pH 7.0)). Purification of the 
conjugate was performed on HiTrap 5 ml columns. In the first experiment, step 1 consists of 
0.5 M ammonium sulfate but as shown in Figure 6.26a, this was insufficient to successfully 
bind all of the protein. In the second experiment (Figure 6.26b) 1 M ammonium sulfate binds 
the protein to the column; this is shown by the absence of the early peak. At a gradient of 50 
% B, the protein was released from the column and detected; however, the concentration of 
the protein (amount loaded) was too small to obtain an adequate profile. The three UV 
profiles suggest that conditions used in experiment 3, a step–wise elution, reveal the best 
separation parameters. The initial concentration of ammonium sulfate, determined in 
experiment 2 to be suitable to allow for binding of the protein to the column, was used. A 
step–wise elution from 0 to 100 % solution B, was introduced.  
Table 6.16. Summary of HIC investigations with solution A: 1 M (NH4)2SO4 and solution B: 0.05 M 
sodium phosphate buffer (pH 7.0). The protein concentration was ~ 2 mg/ml. 
Experiment 
Step 1 
Step 2 
Step 3 Injection vol. 
(µl) Solution A Solution B Solution A Solution B 
1 50 % 50 % Gradient 0 % 100 % 100 
2 100 % 0 % Gradient 0 % 100 % 100 
3 100 % 0 % – 0 % 100 % 500 
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Figure 6.26. UV profile (blue) of HIC experiments 1(a), 2(b) and 3 (c). The red trace shows the 
gradient elution of solution B. d) the UV profile of the Pn1_HOBt_CRM197 conjugate as well as the 
fractions collected. 
In order to separate sufficient product for further investigation a sample of 1 ml (0.87 mg 
Pn1) was loaded on the HIC column as shown in Figure 6.26d and the fractions were 
subsequently analysed for total and free saccharide and protein (Table 6.17). 
Table 6.17. Assay results for fractionated Reaction 1 conjugate (1 ml conjugate, 0.87 mg Pn1) 
showing saccharide and protein results. 
Fraction Total Saccharide (mg) Free Saccharide Protein (mg) 
1 0.18 77 %  0.200 
2 0.19  82 %  0.079 
3 0.07 n/a 0.141 
4 0.04 n/a 0.189 
Total 0.48 (55 %) 62.5 %  0.609 
Saccharide and protein were detected in all four fractions collected. Approximately 77 % of 
the polysaccharide eluted was unconjugated in the first fraction. The large second peak 
(Fractions 2 and 3) was theorised to contain conjugate with the third peak (Fraction 4) 
containing only unconjugated protein. The analytical assays revealed that Fraction 4 
contained the bulk of the protein with polysaccharide in trace amounts. This indicated that 
a) b) 
c) 
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not all the protein was conjugated, which is in contradiction to the SEC–HPLC 
chromatogram that proposed that no unconjugated protein was present, although the 
broadness of the conjugate peak is likely shielding any unconjugated protein. The larger 
peak contained both polysaccharide and protein although a large amount (82 %) of the 
polysaccharide eluted was unconjugated.  
The profiles (Figure 6.27) of the SEC–HPLC analysis of Reaction 2 show a shift in elution 
time as previously seen with TT conjugations. The double hump of the conjugate profile in 
the RID profile indicated either the presence of free saccharide or a bi–modal conjugate of 
two different molecular weights. The UV profile showed a large shift in elution time from 
CRM197 at 18.12 min to the conjugate at 12.92 min. This served as a further confirmation that 
conjugation has taken place. 
  
Figure 6.27. SEC–HPLC a) RID and b) UV 280 nm chromatograms of Reaction 2, 
Pn1_HOBt_CRM197 (blue/red) before ammonium sulfate precipitation. Pn1 PS (black) is shown for 
comparison. 
As neither size exclusion (Sephacryl S500 column) nor HI chromatography provided 
adequate separation of unconjugated and conjugated saccharide, ammonium sulfate 
precipitation was investigated. It was hypothesised that the conjugate would precipitate in 
saturated ammonium sulfate if the protein were able to do so without polysaccharide 
conjugated to it. Two volumes of saturated ammonium sulfate were added to the derivatized 
CRM197 however no precipitation was observed. It was hypothesised that the solution of 1 
mg/ml CRM197 was too dilute to facilitate precipitation. The derivatized protein was 
concentrated down approximately 10–fold using a 50 kDa MWCO filter and centrifugation at 
4000 rpm (actual concentration not determined due to volume size). Approximately a two 
volume equivalent of saturated ammonium sulfate was added. A precipitate was observed 
which confirmed that the conjugate could be precipitated with ammonium sulfate. 
A portion of the conjugate formed in Reaction 2 (containing 50 mg polysaccharide and 25 
mg protein) was concentrated down to a gel like solution and approximately two volumes of 
ammonium sulfate were added. The mixture was stirred and left to precipitate overnight at   
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2 – 8 °C. This mixture was centrifuged to pellet out the conjugate and the clear ammonium 
sulfate supernatant was discarded. This pelleted conjugate was subjected to a second round 
of precipitation before being reconstituted in PBS buffer (pH 7.2) and colorimetric analysis 
for protein as well as free and unconjugated saccharide was performed. The results are 
shown in Table 6.18.  
Table 6.18. Analytical assay results of saccharide and protein content for Reaction 2. 
Total saccharide 
(mg) 
Free saccharide 
(mg) 
Total protein 
(mg) 
PS:Protein 
ratio 
Conjugation 
efficiency (%) 
12.80 1.17 (3.6 %) 7.83 1.48 23.4 
Low recoveries of saccharide (25.6 %) and protein (31.3 %) were achieved with ammonium 
sulfate precipitation. As no saccharide was detected in the waste of the concentration step, 
or in the supernatant following the ammonium sulfate precipitation, it was hypothesised that 
the conjugate remained on the membrane filters during the concentration step. As the 
conjugate was concentrated down 10–fold (approximately 1 ml), it was too viscous to 
analyse for saccharide to determine if any had remained on the membrane filter. The results 
from the ammonium sulfate precipitation showed that only 3.59 % of the saccharide retained 
was unconjugated. This is below the minimum of 5 % agreed upon by The Biovac Institute at 
the beginning of the investigation. A final ratio of 1.48 mg polysaccharide to every mg protein 
was achieved with a conjugation efficiency of 23.4 %. The conjugation efficiency was 
calculated by taking the final result of the conjugated polysaccharide (11.63 mg) as a 
percentage of the total polysaccharide that underwent ammonium sulfate precipitation (50 
mg). Due to the loss of polysaccharide and protein during the concentration step, this 
conjugation efficiency could potentially be a lot higher.  
6.3.1.4 Summary of HOBt conjugations to CRM197 
Conjugation of Pn1 PS to CRM197 carrier protein was effectively performed using HOBt 
mediated EDC coupling chemistry. The two reactions investigated the derivatization levels of 
the carrier protein as well as different purification methods. The CRM197 with the lower levels 
of derivatization underwent HIC purification and was found to contain high levels of 
unconjugated polysaccharide. The conjugate with the higher derivatization levels showed a 
shift in retention time in the RID signal indicative of conjugation. This conjugate was purified 
by ammonium sulfate precipitation, and a free saccharide level of less than 5 % was 
determined. This conjugate was formulated and put forward for in vivo mice studies to 
compare with the triazine conjugate as well as two commercially available vaccines.  
The conjugations of Pn1 to both TT and CRM197 carrier proteins were found to be successful 
when using the HOBt mediated conjugation technique. Table 6.19 compares the analytical 
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results of the conjugates prepared. The free saccharide was determined to be the lowest 
when CRM197 was used as the protein carrier. In terms of conjugation efficiency the TT 
conjugate was the highest of all three conjugates and the saccharide to protein ratio of the 
TT conjugate was closest to the ideal value of 0.75 – 1.0.  
Table 6.19. Comparison of three different carrier proteins in conjugates prepared using the HOBt 
methodology. 
Derivatized 
protein 
Free saccharide 
(%) 
PS:Protein 
ratio 
Conjugation efficiency 
(%) 
TT 47.4 1.10 27.25 
CRM197 3.59 1.48 23.4 
6.3.2 Triazine activator conjugations 
2–Chloro–4,6–dimethoxy–1,3,5–triazine (CDMT), shown in Figure 6.28, is known to be a 
useful non–carbodiimide condensing agent for the synthesis of esters and acid anhydrides,  
especially in the formation of peptide bonds between a carboxylic acid and an amine.  
 
Figure 6.28. Structure of CDMT. 
The standard method for making amide bonds using CDMT consists of two main steps; the 
formation of the activated carboxyl group and the conjugation of the active species to the 
amino group on the protein. The carboxylic acid on the polysaccharide reacts with the CDMT 
in the presence of N–methylmorpholine (NMM) to form a CDMT–activated intermediate, an 
active ester depicted in Figure 6.29. The second step involves the coupling of the carboxylic 
acid to the DMTMM (prepared in situ) followed by nucleophilic displacement of the triazine 
moiety by the amine resulting in the formation of an amide bond. Preliminary studies by 
Kaminski showed that for the activation of sodium, silver or quaternary ammonium salts of 
carboxylic acids to successfully occur, the presence of a base was required. This base had 
to come from a very select group including tetramethylguanidine, N–methylmorpholine 
(NMM), dimethylaminopyridine or pyridine, although the best results were obtained with 
NMM [477]. The NMM base is used to neutralise the chloride ions which are released from 
the CDMT during the activation. The activation takes place in a non–polar/polar (acetonitrile 
and water) solvent as this allows for the dissolution of both the polysaccharide (water) and 
CDMT (acetonitrile or any solvent less polar than water) to occur. An advantage of using this 
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non–polar/polar solvent mixture is that both hydrophobic and hydrophilic amines can be 
used. Once the reaction is completed, Dowex H+ /Na+, which are cation exchange resins or 
a dilute acid, can be used to remove the main morpholinium by–product [478].  
When the CDMT was added to the carboxylic acid, followed by the NMM, left to stir for an 
hour followed by the addition of the amine compound, significant racemization occurred via 
the formation of a azlactone formed via the cyclization of N–acetyl–α–amino acids that 
contain both a nitrogen and oxygen in the ring where the oxygen is adjacent to a carbonyl. 
Garret et al. (2002) first showed this occurrence when amino acid analogues were coupled 
with CDMT to create peptide bonds. The coupling took place over 22 hours where the acidic 
compound was dissolved in ethyl acetate before the addition of 1.45 molar excess of CDMT. 
This was cooled to 15 °C and a 2.4 fold molar excess of NMM was added. The mixture was 
warmed to room temperature and left to react overnight. However, the authors noted that the 
intermediate formed was not the active ester, but instead an azlactone. It was theorised that 
by adding the amine in the beginning of the reaction as it would prevent the cross–linked 
azlactone from forming. The authors repeated the experiment but added the amine in the 
beginning creating a one–step reaction. The amide bond was formed to completion in less 
than 60 min [479].  
The CDMT coupling reaction was first used to prepare hyaluronic acid (HA) conjugates in 
2007 when Bergman et al. coupled HA to a number of compounds with differing functional 
groups [478]. The general procedure that was applied to HA is described as follows: HA, 
containing 0.2 mmol carboxylic acid groups was first dissolved in water. To this acetonitrile 
was added to a ratio of 3:2 with respect to water. NMM was added in a molar equivalent to 
the amount of carboxylic acid on the HA. The solution was cooled to 4 °C and CDMT was 
added and the reaction left to stir for one hour at room temperature. The resulting active 
ester was mixed with a molar equivalent of the amine and stirred for a further 20 hours at 
room temperature before 1 ml Dowex H+ was added to quench the reaction. The reaction 
mixture was stirred, filtered and dialysed against water. Many methods published before 
Bergman et al. coupled HA in organic solvents, namely DMSO and dimethylformamide but 
the authors had to change the counter ion on the carboxylic acid groups on the HA from 
sodium to tetrabutylammonium in order to make the HA soluble in the organic solvents. 
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Figure 6.29. Mechanistic detail of the conjugation of a carboxyl group with an amine functional group 
through the use of CDMT and NMM. 
In 2011, Schanté et al. compared three HA derivatives synthesised using three different 
methods. The first was the classic carbodiimide–coupling (EDC) in water; the second was 
the triazine coupling method in acetonitrile and water, and the third using 2–chloro–1–
methylpyridinium iodide (CMPI) in anhydrous DMF. The synthesis of the HA alanine 
compound using CDMT was adapted from Bergman et al. (2007) [478]. The HA sodium salt 
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was first dissolved in a water–acetonitrile solution (3:2). A 3 molar excess of CDMT was 
added and the solution was left to react, forming the HA–dimethoxytriazine intermediate, for 
1 hour in an ice bath. A 4.5 molar excess of NMM was added along with the alanine 
derivative and the reaction was left overnight at room temperature with constant stirring. 
Dowex–H+ and Dowex–Na+ were added to remove any excess amines. The results of these 
three couplings; the EDC, triazine and CMPI reactions, showed that the coupling in the 
anhydrous DMF solvent gave substitutions of the carboxyl groups of up to 100 % [480, 481]. 
Whilst this was what the authors were looking for, for the pneumococcal type 1 
polysaccharide, lower activation levels are preferable due to the presence of both carboxylic 
acid and amino groups on the repeating unit that could lead to cross linking. 
In 1999, Kunishima synthesised the 4–(4,6–dimethoxy–1,3,5–triazin–2–yl)–4–methyl–
morpholinium chloride (DMTMM) salt by reacting CDMT with N–methylmorpholine (NMM) in 
THF at room temperature for 30 minutes [482]. As DMTMM is simply the reaction between 
CDMT and NMM it reacts with carboxyl groups in the same way. It activates the carboxyl 
group of the polysaccharide forming a reactive triazinyl ester which is capable of reacting 
with an amine (or any nucleophile).  
The advantages of the DMTMM reagent over the classical CDMT and NMM reagents are 
numerous. DMTMM is water soluble and is compatible with many other solvents including 
alcohols, ethyl acetate and diethyl ether. No tertiary amine base is needed as NMM is 
liberated during the reaction of DMTMM with the carboxylic acid grouping. The main by–
product 2–hydroxy–4,6–dimethoxy–1,3,5–triazine which is generated during the reaction as 
well as any excess reagent can be easily removed and recycled for the manufacture of 
DMTMM. DMTMM is also reactive over a wide pH range and in some cases pH control is not 
necessary [483, 484]. 
Pneumococcal polysaccharides undergoing coupling reactions using the DMTMM salt had 
previously been reported by Esser and Schlottmann in 2006. The polysaccharides were 
coupled to Luminex spheres for use in serological assays. A 200 mg/ml solution of DMTMM 
was added to the polysaccharides and the reaction mixture was left to react at room 
temperature for between 40 and 60 minutes before purification and subsequent conjugation 
to the Luminex amino–microspheres. The reaction was left to proceed overnight in the dark 
after which the pneumococcal polysaccharide microspheres were washed to remove any 
free polysaccharides before storage in blocking buffer, available for use in serological 
assays. The conjugation method was found to be reproducible and stable for at least 3 
months [485].  
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The decision to use CDMT and NMM instead of the DMTMM salt in the investigations was 
made after various factors were considered. Firstly the cost involved: at the time of writing, 5 
g of CDMT was nearly one sixth of the cost of the DMTMM salt and NMM was one tenth of 
the cost of the salt, so it would thus prove cheaper to make the salt than to purchase the salt 
form. Secondly, it has been reported that the reactions all require longer times to proceed to 
completion. The formation of the activated ester occurs after 1.5 hours, and the conversion 
rate of conjugation is much lower with the DMTMMM salt than with that of the classical 
CDMT/NMM method. The type of carboxylic acid is also limited with DMTMM where only 
sterically hindered pivalic or benzoic acids with electron withdrawing groups seemed to work 
successfully with DMTMM [486]. 
The objective of this study was to develop an alternative method for the conjugation of Pn1 
PS other than the known carbodiimide approach. The structural similarities of Pn1 PS and 
HA support the investigation into triazine conjugations. In the case of Pn1, there are two 
galacturonic acid residues available for triazine activation which would be coupled to the 
derivatized protein. The pH and subsequent precipitation issues surrounding EDC 
conjugations would be avoided as triazine conjugations tak  place at neutral pH. 
The conjugation group at The Biovac Institute investigated this new conjugation 
methodology with Pn1 polysaccharide. Conjugations of Pn1 and four (derivatized) carrier 
proteins; BSA, TT, CRM197 and PLD were found to be successful when using the triazine 
methodology. The activating species was formed separately in an organic solvent, before 
addition to the polysaccharide solution. An initial polysaccharide–protein mass ratio of 2:1 
was determined to be the optimum mass ratio needed in order to achieve a final mass ratio 
in the conjugate of 1. Ammonium sulfate precipitation was the preferred method of removing 
free saccharide instead of size exclusion chromatography.  
Table 6.20. Comparison of the conjugation results between conjugates containing derivatized TT, 
CRM197 and PLD as protein carriers. 
Derivatized 
protein 
Free saccharide 
(%) 
Saccharide: protein 
ratio 
Conjugation efficiency 
(%) 
TT 2.1 0.5 21.4 
CRM197 7.2 1.32 21.9 
PLD 15.8 0.91 32 
Table 6.20 compares the analytical results of the conjugates prepared with derivatized TT, 
CRM197 and PLD as protein carriers. The PLD conjugate gave the best polysaccharide–
protein final mass ratio of 0.91 compared to 1.32 for the CRM197 conjugate and 0.5 for the 
TT conjugate. The conjugation efficiency of the PLD conjugate was also the highest, 
followed closely by the CRM197 and TT conjugates. 
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6.4 Formulation with adjuvant 
In the current regulatory environment, there is an increasing necessity to develop vaccines 
that are well defined in molecular terms. The first vaccines available used whole, inactivated 
pathogens which presented a complex range of antigens, whereas the recent vaccines are 
based instead on selected antigens which in some cases may be single molecules or 
fragments thereof which can be derived from bacteria, tumour cells, allergens or an auto–
antigen [487]. These molecular vaccines are often poorly immunogenic and an adjuvant is 
often needed to enhance the cellular and/or humoral immune response to an antigen [192, 
488]. 
The word ‘adjuvant’ is derived from the Latin verb adjuvare which means “towards help” 
[489]. They were first described as “substances used in combination with a specific antigen 
that produced a more robust immune response than the antigen alone” by Gaston  amon 
[490]. There are a number of characteristics that the ideal adjuvant should exhibit. Adjuvants 
should first and foremost be safe, and non–toxic with no occurrences of local or systemic 
responses. They should be chemically defined, stable in a formulation with the antigen,  they 
should, most importantly, not confer immunity on their own but  improve the potency of the 
immune response when formulated with an antigen in a vaccine, and must be effective in 
infants and young children [192, 490, 491]. These characteristics of an adjuvant promote an 
earlier, longer lasting and more potent immunological reaction against the antigen. This 
advantage leads to the use of reduced quantities of the antigen to elicit the same 
immunological response [192, 492].  
While there are a number of adjuvants in use in clinical studies, the main adjuvant, used in 
the majority of licensed conjugate vaccines, are the aluminium based adjuvants: aluminium 
hydroxide and aluminium phosphate. The adjuvant effect of aluminium compounds were first 
investigated in 1926, when Glenny et al. precipitated a diphtheria toxoid with potassium alum 
(AlK(SO4)2.12H2O). When compared in immunological studies in rabbits and guinea pigs, to 
the toxoid alone, this adjuvanted toxoid produced a significant increase in the immune 
response [493, 494]. The work by Glenny, led to the thought that for an antigen to produce 
an immune response it must be adsorbed onto the aluminium adjuvant. This observation led 
to the hypothesis of the mechanism of action of these adjuvants in that the antigen is slowly 
released from the adjuvant once injected into physiological fluid, due to the difference in 
makeup of the physiological fluid from that of the formulated vaccine that would affect the 
adsorption of the antigen on the adjuvant [192, 494, 495]. The World Health Organization 
recommends adsorption of 80 % or more of tetanus and diphtheria toxoids to aluminium–
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containing adjuvants. The United States Minimum Requirement also specifies that at least 
75 % of the diphtheria toxoid be adsorbed by aluminium–containing adjuvants [496, 497].  
Aluminium adjuvants are most widely used as they have a very long safety record [498]. 
Regulatory requirements mean that any new adjuvant must be put through a number of 
investigations to determine if its benefits of being an adjuvant outweigh any tolerability or 
safety issues. This long and arduous process has already been performed for the aluminium 
adjuvants, making the use of these adjuvants much more inviting [499]. 
There are however, several disadvantages of aluminium adjuvants. They are known to only 
stimulate the humoral immune response. Another major drawback of these adjuvants is that 
they cannot be lyophilised nor frozen as both of these processes would destroy the gel–
based structure [192].  
The major mechanism that allows for the adjuvants to adsorb the antigen is electrostatic 
interaction. Electrostatic interaction takes advantage of the differences of the isoelectric point 
of the two aluminium adjuvants. If the isoelectric point of the antigen is known, the adjuvant, 
with the opposite surface charge, can be used [500]. This was best illustrated by Seeber et 
al. when it was shown that lysozyme, with a high isoelectric point of 11.0 was poorly 
adsorbed by the aluminium hydroxide adjuvant which also has a high pI, but the lysozyme 
was adsorbed strongly by the aluminium phosphate adjuvant that has a low pI of 5.5 [501].  
Adjuvants are not the only additions to a vaccine formulation. Preservatives, such as phenol, 
2–phenoxyethanol and thiomersal (not used in children’s’ vaccinations due to safety 
concerns [502]), are added mostly to multi–dose vials to combat the potential risk of 
contamination [9]. Additives are added in order to buffer, stabilise, and prevent the 
formulation from aggregating and from sticking to the vial; these can include certain sugars 
such as sucrose, lactose and sorbitol. Salts, such as sodium chloride and succinic acid, 
along with surfactants (Tween–80), are also commonly used in formulations not just to buffer 
the vaccine, but also to reduce the injection pain and to normalise the vaccine with the 
physiological fluid at a rapid rate, as well as to prevent the vaccine from sticking to the glass 
vial and stopper [502].  
The ionic strength of the formulation will also affect the adsorption of the antigen to the 
adjuvant. Al–Shakhshir et al. investigated this when they monitored the amount of lysozyme 
adsorbed onto aluminium phosphate at pH 7.4 by varying the salt concentration. It was 
found that the best adsorption occurred in the presence of 0.06 M NaCl, adsorption was 
greatly reduced at 0.15 M NaCl and no adsorption was seen with a concentration of 0.25 M 
NaCl [503]. It is now common practice to keep the ionic strength of the vaccine formulation 
as low as possible when electrostatic interaction is the mode of adsorption [500]. 
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6.4.1 Formulation study 
The devised Pn1 vaccine formulation was based on the Pfizer product utilising in–house 
methodology for preparing aluminium phosphate in situ. A comparison between the 
proposed formulation and that of Pfizer’s is summarised in Table 6.21. The only difference 
between the components in the formulation was the amount of NaCl added but the amount 
used was still low enough not to inhibit the adsorption as shown by Al–Shakhshir [503].  
Table 6.21. Proposed formulation for the Pn1 experimental conjugates and Pfizer’s Prevnar 13 
vaccine formulation (volume = 1 000 ml). 
Component Pfizer Proposed 
AlPO4 (as Al
3+) (mg) 0.125 0.125 
NaCl (mg) 4.250 4.500 
Succinic acid (mg) 0.295 0.295 
Polysorbate 80 (Tween–80) (mg) 0.100 0.100 
The formulation of the conjugates involved the slow formation of aluminium phosphate from 
aluminium chloride and sodium phosphate. After the aluminium phosphate had formed, the 
pH was adjusted and the antigen added. Adsorption of the antigen to the aluminium 
phosphate occurred over a number of hours. Succinate buffer was included to provide pH 
control and improve the process control. Polysorbate 80 improves the robustness of the 
manufacturing process [376]. 
All five conjugates used in the animal studies (two in Round I and three in Round II, 
described later) were prepared using this formulation, only the type and volume of antigen 
was changed between formulations. All antigens were formulated to a final concentration of 
2 μg/ml. After each formulation was complete, a competition ELISA was performed in order 
to determine the percentage absorption of the antigen (conjugate) onto the aluminium 
adjuvant. A 2 μg/ml Pn1 antigen was used as a positive control with a blank formulation (not 
containing the antigen) used as a negative control. The five conjugates that were prepared 
are shown in Table 6.22 with specific volumes of each component used is shown in Table 
6.23. 
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Table 6.22. Conjugate formulations in animal studies. 
Conjugate 
formulation number Protein 
Chemistry 
utilised 
Round of 
animal study 
Form001 CRM197 HOBt I 
Form002 CRM197 Triazine* I 
Form003 CRM197 Triazine* II 
Form004 TT Triazine* II 
Form005 PLD Triazine* II 
*Triazine conjugates prepared by the conjugation team at The Biovac 
Institute. 
Table 6.23. Specific volumes used in formulations prepared for animal studies. 
Formulation AlCl3 (ml) 
Na3PO4 
(ml) 
Succinic 
acid (ml) 
Tween 
(ml) 
NaCl 
(ml) 
Antigen 
(ml) 
WFI 
(ml) P/Al 
Final 
pH 
Form001 138.20 42.47 25.0 10 63.03 1.54 719.76 1.41 7.02 
Form002 138.20 42.47 25.0 10 63.03 1.32 719.98 1.42 7.10 
Form003 82.92 29.16 15.0 6 37.82 0.94 428.16 1.31 6.90 
Form004 138.20 45.26 25.0 10 63.03 3.26 715.25 1.22 6.76 
Form005 138.20 45.86 25.0 10 63.03 1.45 716.46 1.24 6.83 
The absorption efficiencies of the antigen onto the adjuvant were determined by quantifying 
the amount of unbound conjugate in the formulation solution. This is therefore inversely 
proportional to the amount of conjugate that has been absorbed onto the aluminium 
phosphate adjuvant. The ATCC Pn1 PS was used as a reference standard. Figure 6.30 
displays the ELISA results graphically with both the amount of free conjugate and the 
amount of conjugate that was absorbed onto the adjuvant. 
  
Figure 6.30. Competition ELISA results of all Pn1 formulations quantifying a) the amount of Pn1 
polysaccharide and b) the percentage absorption of Pn1. 
A variable amount of absorption for all the conjugates was revealed through the ELISA 
results. The highest absorption values were seen for the conjugates with CRM197 as the 
protein carrier (Form001, Form002 and Form003). Absorptions of between 58 and 65 % 
were seen for this protein carrier. Pneumolysoid conjugates (Form005) showed much lower 
a) b) 
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adjuvant absorption of only 33 % and the TT conjugate (Form004) showed no absorption at 
all. The lack of adsorption of the TT conjugate is hypothesised to be due to a pH issue as 
Kumar et al. suggests that TT absorption onto aluminium phosphate adjuvant is optimal at a 
pH near 5 and decreases when the pH approaches 6.3 – 7 [504]. However, due to time 
constraints, this formulation method could not be optimised for each conjugation. 
6.5 Animal studies 
6.5.1 Animal study design 
All animal procedures used were approved and performed by the University of 
Witwatersrand. Five week old outbred NMRI female mice were obtained from the National 
Health Laboratory Services (NHLS) animal facility based at the NICD in Johannesburg, 
South Africa. The study consisted of two different phases (Round I and II). Round I 
investigated the immunogenicity of the two different conjugation chemistries: EDC mediated 
and triazine. CRM197 was used as the protein carrier for both conjugation chemistries. The 
prepared conjugates were compared to a commercial vaccine that contained CRM197 as the 
protein carrier so that the only difference in the conjugates was the conjugation chemistry. 
The conjugation chemistry that presented with the best results was taken to Round II where 
three protein carriers: CRM197, TT and PLD were conjugated to Pn1 PS using the 
conjugation chemistry of choice from Round I. These three conjugates were compared to 
two commercial conjugate vaccines. For each round the body mass of the mice was 
monitored and recorded on a weekly basis. 
Table 6.24. Sample details for Round I of animal studies. 
Conjugate/Vaccine Carrier protein Conjugation Chemistry 
Placebo* 
Diluent + AlPO4 
– – 
Positive control 
Commercial vaccine I 
CRM197 Reductive amination 
Form001 CRM197 EDC mediated 
Form002 CRM197 Triazine 
*Placebo/negative control consisted of the diluent and aluminium 
phosphate. (Same formulation but no antigen present). 
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Table 6.25. Sample details for Round II of animal studies. 
Conjugate/Vaccine Carrier Protein Conjugation Chemistry 
 Placebo* n/a n/a 
Diluent + AlPO4 +  
unconjugated Pn1 
PLD unconjugated n/a 
Commercial vaccine I CRM197 reductive amination 
Commercial vaccine II Protein D CDAP 
Form003 CRM197 preferred chemistry** 
Form004 TT preferred chemistry** 
Form005 PLD preferred chemistry** 
* Placebo/negative control consisted of the diluent and aluminium phosphate. (Same 
formulation but no antigen present). 
**Preferred chemistry chosen from Round I 
Table 6.24 and Table 6.25 outline the conjugates and samples used in both rounds of 
animal studies. The negative control I (placebo) used in both rounds of animal studies 
contained 100 µl of AlPO4 adjuvant. This adjuvant was the same concentration as that used 
in the conjugate formulations. A second negative control, used in Round II consisted of the 
AlPO4 adjuvant as well as a mixture of unconjugated Pn1 PS and PLD protein in order to 
check that immunogenicity levels were not a result of either the polysaccharide or the protein 
on its own. Two commercially available vaccines were used as positive controls in this study 
and both of the commercial vaccines employ different conjugation chemistries to the ones 
tested. One of the vaccines contained CRM197 as the protein carrier. The second commercial 
vaccine contained Pn1 PS conjugated to Protein D, however, both TT and DT are found in 
this vaccine as carrier proteins for other serotypes. The five conjugates that were 
investigated in this study were injected in a 100 µl formulated dose consisting of 200 ng of 
Pn1 conjugate and AlPO4 as adjuvant. 
Mice however, do not produce a dose dependent response and are not the ideal animal 
model for testing conjugates and these results can only provide an indication of the 
immunogenicity of the conjugates. 
6.5.2 Immunoassays 
As anticapsular antibodies are used by the immune system to prevent invasive bacterial 
diseases, measuring the serotype–specific antibody titres as well as the opsonophagocytic 
(OPA) activities against the serotypes have become the preferred methods to evaluate the 
immunogenicity of conjugate vaccines [129]. The safety and immunogenicity of new 
vaccines are determined through clinical studies. The WHO have determined a number of 
licensure criteria in order to by–pass the difficulties related to clinical efficacy trials [162]. A 
study will fulfil this criteria if immunological non–inferiority to the licensed conjugate vaccines 
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can be shown using specific techniques such as enzyme–linked immunosorbent assay 
(ELISA) and opsonophagocytic (OPA) assays [162, 505]. 
With a large number of samples, the OPA assay becomes labour intensive and difficult to 
perform and therefore many laboratories will measure the antibody binding by ELISA alone 
to form an idea of how the vaccine will perform. Since antibodies to the capsular 
polysaccharide are the mediators against infection, an assay that can measure the antibody 
levels can be used as a substitute for the OPA assay, however a correlation between the 
two assays must first be determined [506]. 
6.5.2.1 ELISA 
The total IgG antibody titres against Pn1 serotype 1 were used to compare the different 
vaccinated mouse groups and were determined by the method first described by Conception 
and Wernette in 2001 [506]. This method was modified to enable it to detect mouse IgG. The 
IgG results were calculated based on an in–house reference serum that was given an 
arbitrarily value of 100 units/ml. Samples that fell below the detection limits were given a titre 
value of half of the detection limit. The ELISA assay was optimised and validated for 
linearity, specificity, sensitivity, background, inter– and intra–assay precision as well as 
coating concentration [507].  
As previously stated, for an ELISA to be used in the place of an OPA assay, there must be a 
strong correlation between the two titres. It has been suggested that a correlation co–
efficient of above 0.8 is a good enough correlation [506]. This was performed during Round 
II of the animal study when the OPA assay was in place. 
6.5.2.2 OPA 
Opsonins are antibodies in the blood serum that make the pneumococcal bacteria more 
susceptible to phagocytosis [10, 508, 509]. These opsonins bind to the capsular 
polysaccharide and phagocytes bind to these antibodies in order to induce the killing of the 
cell in what is known as opsonophagocytosis [10]. As opsonophagocytosis is an essential 
process in the immune system’s defence against S. pneumoniae, a method that allows for 
the measurement of the opsonins is a vital tool in determining whether or not the conjugates 
prepared would be able to illicit an immune response. 
At the WHO consultation meeting in 2003 it was decided that the OPA assay used to 
determine immunogenicity should follow the Romero–Steiner et al. method and such was 
used in the measurement of functional antibodies in his investigation [386, 510]. The 
functionality of the antibodies in the serum samples was expressed as the opsonophagocytic 
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titre, which is the reciprocal dilution at which ≥50   bacterial killing occurred in comparison 
to the control wells [507]. 
6.5.3 Body weight profiles 
One of the variables monitored throughout this investigation was the body weight of all mice. 
An increase in weight during the investigation is an indication of good health (Figure 6.31). 
No differences between the placebo and the vaccine mice groups were observed. One 
mouse, used in the first round of studies did however develop a tumour and was terminated. 
This mouse belonged to the HOBt (EDC mediated) conjugate group however this was an 
isolated, adverse event and was not thought to be related to the conjugate vaccine as it has 
been documented that NMRI mice have a high propensity to develop spontaneous tumours 
[511-513]. 
  
Figure 6.31. Mouse body weight profiles from a) round I and b) round II studies. Body weight curve 
after mice were vaccinated with conjugate vaccines or placebo. The body weight was recorded 
weekly for mice. The mean body weight for each group of mice is shown (n =12 per group). 
6.5.4 Round I results 
The OPA assay had not been fully developed and optimised by the time Round I of the 
animal studies took place and hence only the ELISA results could be reported. Both the 
HOBt as well as the triazine mediated conjugates produced significantly higher titres than 
the commercial vaccine. The data represented graphically in Figure 6.32 detail the values of 
the ELISA assays for the conjugates. All of the mice in the two conjugate chemistry groups 
were able to produce a measurable antibody response, with only 11 out of the 12 from the 
commercial vaccine being able to do the same and as expected, none of the mice from the 
placebo group were able to produce any antibody titres. The placebo was given an arbitrary 
value of 0.1 as they fell below the limit of detection of the assay. It was shown that all the 
values for the commercial vaccine were within the range of 0.1 – 24 µ/ml. Values for the 
HOBt conjugate fell within a range of 3.4 – 207.5 µ/ml with the triazine ranging between    
4.7 – 375.1 µ/ml. A two tailed comparison was performed to determine if there was any 
a) b) 
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significant difference between the two chemistries but they were found not to be statistically 
different.  
 
Figure 6.32. Graphical comparison of the ELISA immunogenicity levels of the two experimental 
conjugate vaccines (Green – HOBt chemistry, and red – triazine chemistry) compared to the 
commercially available vaccine (blue). The negative control is shown for comparison. 
Whilst these results show a large difference between the commercial vaccine and the two 
conjugates investigated, it must be noted that the commercial vaccine is a multivalent 
vaccine including more than 10 different serotypes thus the serotype specific host responses 
of the commercial vaccine may be supressed by the higher antigen load. To date, this has 
not been further investigated.  
6.5.5 Round II 
6.5.5.1 Western blot analysis of conjugates 
Although there was no significant difference between the results of the carbodiimide 
mediated and triazine conjugates, the triazine chemical conjugation method was chosen to 
be the preferred method for Round II animal studies. This round compared three different 
protein carriers (TT, CRM197 and PLD) to the two commercial vaccines to determine 1) if the 
conjugation chemistry was superior to those techniques used in the commercial vaccines 
and 2) the superior protein carrier. 
Before formulation, all conjugates prepared for Round II of the animal study were subjected 
to Western blot analysis to demonstrate conjugate formation and to confirm that the 
structural integrity (epitope) of the protein was retained after conjugation. In separate 
experiments unconjugated Pn1 and Pn1 conjugated to the three different proteins (CRM197, 
TT and PLD) were first subjected to SDS–PAGE followed by electrophoretic transfer onto a 
PVDF membrane and staining. 
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Figure 6.33. Image of PVDF membranes containing A) native TT (lane 1) and Pn1–TT conjugate 
(lane 2), B) native CRM197 (lane 1) and Pn1–CRM197 conjugate (lane 2) and C) native PLD (lane 1) 
and Pn1–PLD (lane 2) post western blot analysis. 
The results of the Western blots, (Figure 6.33), demonstrate that antibodies specific to the 
protein (TT, DT (for CRM197) and PLD) were able to bond to the specific conjugate as shown 
by the second band in each figure. The first lane in each gel depicts the underivatized and 
unconjugated protein that acted as positive controls for antibody recognition. From these 
results it can be concluded that each conjugated protein retained its structural antigenic 
integrity as it was still recognisable to the antibody post derivatization and conjugation. The 
lack of free protein (i.e. no band or streaking observed between 55 – 70 kDa) in both the 
CRM197 and PLD conjugation samples confirm good conjugation efficiency. As the TT was 
run under native (non–reducing) conditions, its tertiary structural conformation prevented it 
from entering the gel. The conjugates were each formulated onto aluminium phosphate 
adjuvant, followed by Round II of the animal investigations. 
6.5.5.2 Animal results 
The immunogenicity of the conjugates was compared to two negative and two positive 
controls. The ELISA results are graphically displayed in Figure 6.34 with the OPA assay 
results revealed in Figure 6.35.  
Two of the three different protein carriers tested resulted in higher antibody titres to both 
commercially available vaccines. As with the first round of animal studies, it must be 
mentioned that the commercial vaccines are both multivalent vaccines of more than 10 
different serotypes and the specific host responses for Pn1 in these vaccines may be 
inhibited by the antigen load. 
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All of the conjugates exhibited higher antibody titres than those of the two negative controls. 
For the ELISA results three of the mice injected with the unconjugated Pn1 negative control 
did show an immune response, and 11 out of the 12 mice injected with commercial vaccine I 
produced antibody titres. All of the other conjugates showed 100 % conversion rates. The 
OPA revealed slightly different seroconversion results when one of the 12 mice in the 
commercial vaccine I and two of the 12 in the PLD conjugate group failed to produce any 
detectable OPA results and were given a value under that of the detectable limit. The 
second commercial vaccine as well as the conjugates with TT and CRM197 as protein 
carriers gave 100 % seroconversion rates.  
The conjugate that employed TT as the protein carrier gave the highest antibody titres with a 
geometric mean concentration (GMC) of 357.4 µ/ml with the CRM197 conjugates resulting in 
the second highest levels with a GMC of 141.1 µ/ml. Interestingly, the conjugates with PLD 
as a carrier protein gave lower titres than one of the commercial vaccines, however, they 
were found not to be statistically different to either commercial vaccine. As PLD is derived 
from PLY, a pneumococcal protein, it should have its own immune protective potential and 
thus, a conjugate with PLD as a protein carrier should have the added advantage of giving a 
broader protective immunity than the other conjugates. This result does not support the 
results released by Michon et al. in 1998 where the pneumococcal–PLD conjugates 
produced similar immunogenic results to the results obtained with pneumococcal–TT 
conjugates, however Michon made use of native, underivatized PLD and used reductive 
amination as a coupling chemistry [445]. These differences could attest to the difference in 
immunogenicity as described here.  
Significantly higher OPA titres were observed for all conjugate vaccines in comparison to the 
placebo and unconjugated controls. As with the ELISA assay, the conjugate with PLD 
resulted in lower titres than one of the commercial vaccines however no significant 
difference was seen in the titres between both the commercial vaccines and the PLD 
conjugate. The conjugates using TT and CRM197 produced GMC titres of up to 10–fold 
higher than the commercial vaccines.  
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Figure 6.34. Graphical comparison of the ELISA immunogenicity levels in Round II of the animal 
studies, comparing three different protein carriers (Purple – PLD, red – CRM197 and pink – TT) with 
two commercially available conjugate vaccines (blue and green). The negative controls are shown for 
comparison. 
 
Figure 6.35: Graphical comparison of the OPA functional antibody responses in mice in Round II. 
Comparisons are made with the three different protein carriers (Purple – PLD, red – CRM197 and pink 
– TT) and two commercially available conjugate vaccines (blue and green). The negative controls are 
shown for comparison. 
6.5.6 Summary of animal results 
All new pneumococcal vaccines need to adhere to certain essential conditions – including 
immunologic non–inferiority to contemporary licensed vaccines. The results demonstrate 
that when the Pn1 PS was coupled to CRM197 using either HOBt or triazine mediated 
chemistries; both novel protein–polysaccharide conjugation chemistries were capable of 
generating considerably more effective immune responses than the commercially available 
vaccines. 
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It must be taken into account that the prepared conjugate vaccine consisted of only one 
serotype whereas the commercially available vaccine were multivalent. It is known that 
whilst combining several different antigens into one vaccine broadens the coverage of the 
vaccine, it does lead to a reduction in the immunogenicity of a single antigen in the 
multivalent vaccine. This has been shown to occur in vaccines against viruses such as flu 
[514], human papillomavirus [515], protein vaccines [516] as well as in pneumococcal 
conjugate vaccines [517]. In the case of conjugate vaccines, Fattom et al. observed a 
reduction of between 30 and 90 % in antibody responses to several serotype of a 12–valent 
Escherichia coli conjugate vaccines. The authors also identified a reduction of 30 % in the 
immunogenicity of S. aureus type 8 antibodies when the conjugate vaccine was combined 
with a type 5 conjugate vaccine.  
With the need to overcome the limitation of carrier overload, attention has turned to the use 
of unique protein carriers. TT and CRM197 have shown to be the most frequently employed 
protein carriers due to their highly immunogenic characteristics and history of safe use within 
humans. In this study, it was found that the immune response of the conjugate with PLD as a 
carrier protein was inferior to that of either the TT or CRM197 conjugates. The conjugation 
strategy for PLD conjugates would need to be optimised as the animal results are in 
opposition to those described by Michon et al. in 1998 [445].  Michon used underivatized 
PLD and reductive amination coupling chemistry which may account for the difference in 
immunogenicity. Further work on the derivatization levels on PLD as well as optimisation of 
the conjugation chemistry need to be investigated as well as both the formulation conditions 
and the stability of the PLD conjugate.  
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CHAPTER 7. CONCLUSIONS  
 
Pneumonia is the leading cause of death in children worldwide and is estimated to kill 1.6 
million children every year. Pneumonia affects children and families everywhere, but is most 
prevalent in sub–Saharan Africa and South–east Asia. The capsular polysaccharide has 
been shown to be the most important virulence factor and over 90 pneumococcal serotypes 
have been recognised. Serotype 1 is responsible for up to 20 % of invasive pneumococcal 
diseases in developing countries and has been the cause of several outbreaks in the African 
meningitis belt. It is ranked among the top three serotypes in GAVI–eligible countries and is 
among the top six ranked serotypes among children under 5 years of age in regions with the 
highest burden of pneumococcal disease.  
The distinctive epidemiology of IPD infections from Pn1, suggested that a monovalent Pn1 
conjugate vaccine would be beneficial to developing countries and would have a significant 
public health value for epidemic control. This led to the aim of the present study: the 
development of a process and quality control methods for the preparation of an 
immunogenic conjugate vaccine against Streptococcus pneumoniae serotype 1 disease. 
The Pn1 polysaccharide was purified following a two–step process utilising a differential 
filtration with ethanol. Small scale purifications were designed in order to investigate 
methods of inactivation as well as pH control. The favoured inactivation method was found to 
be phenol and an optimal pH of 7.8 was needed to ensure the complete precipitation of the 
PS in its CTA salt form. The optimisations determined in the small scale purifications were 
applied to larger fermentation batches to show that the purification method could be scaled 
up to 15 and 30 L batches.  
This purified polysaccharide was subjected to a number of analytical tests in order to confirm 
that the purified polysaccharide batches conformed to the World Health Organisation 
specifications. These assessments were first optimised and validated and included size 
analysis, uronic acid composition, O–acetylation patterns and purity.  
The viscosity of the purified polysaccharide hampered its detailed characterisation and ease 
of manipulation in conjugation reactions. Methods of size reduction were investigated and 
both sonication and microfluidization were successfully applied to model polysaccharides 
and Pn1. Composition and NMR studies confirmed that mechanical sizing had no impact on 
the structural integrity of the saccharides. Whilst sonication was able to achieve higher levels 
of size reduction and maintained the polydispersity of the polysaccharide when compared to 
microfluidization, the latter was found to be more suited to a GMP environment and was 
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advantageous in terms of scalability, control and consistency. The structure of the repeating 
unit of the polysaccharide and size reduced saccharide was fully elucidated by use of 1D 
and 2D NMR spectroscopy. The NMR study confirmed that the partially O–acetylated 
polysaccharide consisted of a mixture of de–O–acetylated Pn1 PS and polysaccharide 
acetylated at two different positions of GalA. NMR analysis of one specific purified Pn1 PS 
batch revealed O–acetylation in only one position (C2 of GalA, residue B), which indicated 
that the bacteria O–acetylates at one position and the fermentation and purification 
parameters such as pH and temperature permit migration to the C3 position. 
Compositional analysis of the purified polysaccharide was also accomplished by means of 
hydrolysis and chromatographic methods. Conventional hydrolysis methods reported in the 
literature were applied but resulted in low recoveries due to the stability of the glycosidic 
linkage between the two galacturonic acid residues. Therefore alternate means of hydrolysis 
that utilised microwaves as a source of heat were investigated. Two different microwave–
assisted hydrolysis methods were successfully developed, namely TFA hydrolysis and 
methanolysis, followed by analysis using anion–exchange and gas chromatography. This 
study showed the potential of microwave–assisted hydrolysis which can be applied to other 
bacterial polysaccharides that are particularly resistant to acid hydrolysis. 
This purified, fully characterised and size–reduced polysaccharide was then successfully 
conjugated to hydrazide–derivatized protein carriers via the polysaccharide’s carboxyl 
groups. The derivatization of four different protein carriers, BSA, TT, CRM197 and PLD, with 
ADH was successfully achieved. The reaction introduced a highly reactive hydrazide 
functional group on some of the carboxyl groups on the protein. The four different proteins 
behaved differently which led to modifications of the derivatization procedure for each 
protein; TT required a shortened reaction time whereas the reaction with CRM197 needed to 
be lengthened to ˃16 hours in order to achieve derivatization levels comparable to TT.  
In order to conjugate the polysaccharide to the hydrazide–derivatized protein, the widely 
used carbodiimide methodology was first attempted and found to be successful only when 
conjugating to the model BSA protein. With the addition of an activating species, two novel 
conjugation methodologies were studied; one of which made use of a triazine activating 
compound and the other, 1–hydroxybenzotriazole, increased the electrophilicity of the 
polysaccharide and enabled conjugation to occur. Two protein carriers; TT and CRM197 were 
successfully conjugated to Pn1 using this HOBt methodology. Precipitation/aggregation was 
observed during small scale reactions but this was later identified as a pH and volume 
problem which was resolved in the larger scale reactions. The conjugates were successfully 
purified by precipitation with ammonium sulfate however further work into the purification of 
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all the conjugates needs to be investigated as some reactions contained high levels of 
free/unconjugated polysaccharide. Problems with the precipitation of PLD during conjugation 
reactions would need to be further investigated with the examination of reaction buffer, 
reaction time and purification methods.  
The successful conjugate vaccine candidates were formulated with an aluminium phosphate 
adjuvant. Owing to time constraints, optimisation of the formulation did not take place. The 
adjuvanted conjugates were compared to two commercially available multivalent 
pneumococcal conjugate vaccines in order to establish non–inferiority. Two separate studies 
in mice were performed; the first compared the two investigated conjugation methodologies 
where Pn1 PS was conjugated to the hydrazide–derivatized CRM197 carrier protein using 
either HOBt or triazine methods. These two conjugates were compared to a commercially 
available conjugate that also used CRM197 as the carrier protein and therefore it was only the 
conjugation chemistry that was compared. No statistical difference between the two 
candidate vaccines was determined and both conjugates produced much higher ELISA titres 
than the commercial vaccine.  
The second round of studies applied the triazine conjugation method to Pn1 and three 
different protein carriers (TT, CRM197 and PLD) and compared which protein carrier would 
provide the best immunogenicity data. Comparisons between the three conjugates and two 
commercial vaccines were performed using both ELISA and OPA data. The results showed, 
on average, 5–fold and 12 fold increases in the ELISA antibody titre and 7–fold and 15 fold 
increases for the OPA data for the CRM197 and TT conjugates respectively when compared 
to the two commercially available vaccines. The PLD conjugate did not show any statistical 
superiority to the commercial vaccines but was shown to be non–inferior. 
By targeting the carboxyl functional groups, of the polysaccharide and using a hydrazide–
derivatized protein carrier, the conjugate was able to induce high levels of antibodies and a 
strong killing potential. These levels of immunogenic and functional antibodies produced by 
the experimental vaccines, as well as the suggested tolerance in mice gave a strong 
indication of the potential of this new conjugation approach for conjugate vaccines against 
pneumococcal type 1 disease.  
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CONFERENCES AND PRESENTATIONS 
Parts of this thesis have been presented at conferences: 
Oral Presentation (2009): University of Trieste 
Talk Entitled: Developing a vaccine against pneumococcal type 1 disease 
Oral and Poster Presentation (2012): 26th International Carbohydrate Symposium in 
Madrid, Spain 
Poster and Talk Entitled: Development of a Streptococcus pneumoniae conjugate vaccine 
against serotype 1 disease. 
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APPENDIX 1: PURIFICATION RESULTS 
Batch 1 2 3 4 5 6 7 8 9 10 
Fermentation mode Fermentor Fermentor Fermentor Fermentor Fermentor Fermentor Wave Fermentor Wave Fermentor 
Fermentation volume (L) 15 15 15 30 15 15 8 15 6 15 
Initial pH 7.20 7.32 7.33 7.05 7.05 7.31 7.91 7.21 7.43 7.20 
Initial PS concentration (mg/L) 535 550 550 530 500 530 400 365 264 391 
Final Analytical Assays                     
PS Content (UA assay) (g) 0.45 2.4 5.4 7.3 
Purification 
failed due to 
improper 
clarification 
Purification 
failed due 
to improper 
clarification 
2.3 
Purification 
failed due to 
improper 
clarification 
1.6 0.71 
O–acetylation (mass %) – 20 20 23 24 23 23 
NMR (mol %) –* – – – 67 80 –  
Nucleic acid (%) 1.570 1.000 1.909 2.181 0.004 0.099 2.181 
Protein (%) 6.40 0.29 0.28 1.68 0.61 0.28 6.40 
CWPS (mol %)  –* 1.4 0.9 1.9 2.2 2.3 1.9 
% recovery 6 29 65 50 –  – 72 – 99 12 
           
           
Batch 11 12 13 14 15 16 17 18 19  
Fermentation mode Fermentor Fermentor Wave Wave Wave Fermentor Fermentor Fermentor Fermentor  
Fermentation volume (L) 15 – 8 8 8.5 – – 15 15  
Initial pH 7.32 – 7.41 7.02 6.75 – – 7.05 7.09  
Initial PS concentration (mg/L) 932 – 642 268 595 – – 602 341  
Final Analytical Assays        
PS Content (UA assay) (g) 3.7 Not 
purified 
due to 
fermentor 
electronics 
offline 
2.1 1.7 2.5 
Not purified 
due to 
problem 
with 
centrifuge 
Not 
purified 
due to 
accident in 
BSL3 
facilities 
7.6 4.0  
O–acetylation (mass %) 23 21 23 18 0 23  
O–acetylation (mol %) 79 77 76 74 0 67  
Nucleic acid (%) 1.271 1.061 0.004 0.099 1.200 1.100  
Protein (%) 0.13 0.86 0.10 1.05 3.10 1.70  
CWPS (mol %) 1.5 1.5 2.0 1.4 1.2 1.9  
% recovery 27  – 41 79 49 –  – 43 51  
* NMR not performed  
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
236 
 
REFERENCES 
1. Austrian, R., Pneumococcal otitis media and pneumococcal vaccines, a historical perspective. 
Vaccine, 2001. 19: p. S71-S77. 
2. Schranz, J., Pneumococcal conjugate vaccines: what do we know and what do we need? 
Procedia in Vaccinology, 2009. 1 (1): p. 189-205. 
3. Pneumonia and diarrhoea: Tackling the deadliest diseases for the world's poorest children,  
2012. UNICEF.    
4. WHO World Health Statistics 2012. Global health indicators,  2012.    
5. WHO/Unicef. Pneumonia: The forgotten killer of children.  2006.   
http://www.unicef.org/mdg/mortalitymultimedia/Pneumonia_The_Forgotten_Killer_of_Children
.pdf  [Accessed on: 12 December 2012]. 
6. Guo, Z. and Boons, G.-J. Carbohydrate-based vaccines and immunotherapies. Wiley Series 
in Drug Discovery and Development, ed. Wang, B. 2009. John Wiley and Sons: New Jersey. 
7. Pneumococcal Disease, in Epidemiology and Prevention of Vaccine-Preventable Diseases: 
The Pink Book: Course Textbook 2012. CDC. 
8. Austrian, R., The first one hundred years. Reviews of Infectious Diseases, 1981. 3 (2): p. 183-
189. 
9. Plotkin, S.A. and Orenstein, W.A., Vaccines. 4 ed 2004. Saunders. 
10. Siber, G.R., Klugman, K.P., and Makela, P.H. Pneumococcal Vaccines: The impact of 
conjugate vaccines.  2008. ASM Press: Washington DC. 
11. Lopez, R., Pneumococcus: the sugar coated bacteria. International Microbiology, 2006. 9: p. 
179-190. 
12. Lund, E. and Henrichsen, J., Laboratory diagnosis, serology and epidemiology of 
Streptococcus pneumoniae, in Methods in Microbiology, Norris, J.R. 1978. Academic Press: 
London. p. 241-262. 
13. Bahler, B., Lee, T.-S., Lotvin, J.A., Ruppen, M.E., and Charbonneau, P. for Wyeth. Separation 
of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation. 2006. 
Organisation, W.I.P. PCT/US2006/12134. WO 2006/110352 A2.  
14. Bahler, B., Lee, T.-S., Lotvin, J.A., Ruppen, M.E., and Charbonneau, P. for Wyeth LLC. 
Separation of contaminants from Streptococcus pneumoniae polysaccharides by pH 
manipulation. 2010. Office, U.S.P. 11/396108. US 7718791 B2.  
15. AlonsoDeVelasco, E., Verheul, A.F., Verhoef, J., and Snippe, H., Streptococcus pneumoniae: 
Virulence factors, pathogenesis and vaccines. Microbiological Reviews, 1995. 59 (4): p. 591-
603. 
16. Lloyd, A.J., Gilbey, A.M., Blewett, A.M., De Pascale, G., El Zoeiby, A., Levesque, R.C., 
Catherwood, A.C., Tomasz, A., Bugg, T.D., Roper, D.I., and Dowson, C.G., Characterization 
of tRNA-dependent peptide bond formation by MurM in the synthesis of Streptococcus 
pneumoniae peptidoglycan. Journal of Biological Chemistry, 2008. 283 (10): p. 6402-6417. 
17. Tillet, W.S., Goebel, W.F., and Avery, O.T., Chemical and immunological properties of a 
species specific carbohydrate of pneumococci. Journal of Experimental Medicine, 1930. 52 
(6): p. 895-900. 
18. Jennings, H.J., Lugowski, C., and Young, N.M., Structure of the complex polysaccharide C-
substance from Streptococcus pneumoniae type 1. Biochemistry, 1980. 19: p. 4712-4719. 
19. Austrian, R., Some observations on the pneumococcus and current status of pneumococcal 
disease and its prevention. Reviews of Infectious Diseases, 1981. 3 (Supplement): p. S1-S17. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
237 
 
20. Rodgers, G.L. and Klugman, K.P., The future of pneumococcal disease prevention. Vaccine, 
2011. 29 (Supplement 3): p. C43-C48. 
21. Henrichsen, J., Six newly recognized types of Streptococcus pneumoniae. Journal of Clinical 
Microbiology, 1995. 33 (10): p. 2759-2763. 
22. Henrichsen, J., Typing of Streptococcus pneumoniae: Past, present, and future. American 
Journal of Medicine, 1999. 107 (Supplement 1A ): p. S50-S54. 
23. Dochez, A.R. and Avery, O.T., The elaboration of specific soluble substance by 
pneumococcus during growth. The Journal of Experimental Medicine, 1917. 26 (4): p. 477-
493. 
24. Heidelberger, M. and Avery, O.T., The soluble specific substance: First paper. Journal of 
Experimental Medicine, 1923. 38 (1): p. 73-79. 
25. Tomasz, A., Surface components of Streptococcus pneumoniae. Reviews of Infectious 
Diseases, 1981. 3 (2): p. 190-211. 
26. Weinberger, D. ., Trzciński, K., Lu, Y.-J., Bogaert, D., Brandes, A., Galagan, J., Anderson, 
P.W., Malley, R., and Lipsitch, M., Pneumococcal Capsular Polysaccharide Structure Predicts 
Serotype Prevalence. PLoS Pathogens, 2009. 5 (6): p. e1000476. 
27. Paton, J.C., Hansman, D.J., Boulnois, G.J., Andrew, P.W., Mitchell, T.J., and Walker, J.A. for 
Pneumolysin mutants and pneumococcal vaccines made therefrom 2004. Office, U.S.P. 
08/378 213. US 6716432.  
28. Pneumococcal vaccines WHO position paper. World Health Organization Weekly 
Epidemiological record, 2012. 87 (12): p. 129-144. 
29. Mehr, S. and Wood, N., Streptococcus pneumoniae – a review of carriage, infection, serotype 
replacement and vaccination. Paediatric Respiratory Reviews, 2012. 13 (4): p. 258-264. 
30. Lloyd-Evans, N., O'Dempsey, T.J.D., I., B., Secka, O., Demba, E., Todd, J.E., McArdle, T.F., 
Banya, W.S., and Greenwood, B., Nasopharyngeal carriage of pneumococci in Gambian 
children and in their families. The Pediatric Infectious Disease Journal, 1996. 15: p. 866-871. 
31. Dagan, R., Melamed, R., Muallem, M., Piglansky, L., and Yagupsky, P., Nasopharyngeal 
colonization in Southern Israel with antibiotic-resistant pneumococcci during the first 2 years 
of life: Relation to serotypes likely to be included in pneumococcal conjugate vaccines. The 
Journal of Infectious Diseases, 1996. 174 (6): p. 1352-1355. 
32. Cardozo, D.M., Nascimento-Carvalho, C.M., Andrade, A.L., Silvany-Neto, A.M., Daltro, C.H., 
Brandao, M.A., Brandao, A.P., and Brandileone, M.C., Prevalence and risk factors for 
nasopharyngeal carriage of Streptococcus pneumoniae among adolescents. Journal of 
Medical Microbiology, 2008. 57 (Pt 2): p. 185-189. 
33. Gray, B.M., Converse III, G.M., and Dillon Jr., H.C., Epidemiologic studies of Streptococcus 
pneumoniae in infants: Acquisition, carriage, and infection during the first 24 months of life. 
The Journal of Infectious Diseases, 1980. 142 (6): p. 923-933. 
34. Vives, M., Garcia, M.E., Saentz, P., Mora, M., Mata, L., Sabharwal, H., and Svanborg, C., 
Nasopharyngeal colonization in Costa Rican children during the first year of life. The Pediatric 
Infectious Disease Journal, 1997. 16: p. 852-858. 
35. Bravo, L.C., Overview of the disease burden of invasive pneumococcal disease in Asia. 
Vaccine, 2009. 27 (52): p. 7282-7291. 
36. Basarab, M., Ihekweazu, C., George, R., and Pebody, R., Effective management in clusters 
of pneumococcal disease: a systematic review. The Lancet Infectious Diseases, 2011. 11 (2): 
p. 119-130. 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
238 
 
37. Davidson, M., Parkinson, A.J., Bulkow, L.R., Fitzgerald, M.A., Peters, H.V., and Parks, D.J., 
The Epidemiology of Invasive Pneumococcal Disease in Alaska, 1986-1990: Ethnic 
Differences and Opportunities for Prevention. The Journal of Infectious Diseases, 1994. 170 
(2): p. 368-376. 
38. Pletz, M.W., Maus, U., Krug, N., Welte, T., and Lode, H., Pneumococcal vaccines: 
mechanism of action, impact on epidemiology and adaption of the species. International 
Journal of Antimicrobial Agents, 2008. 32 (3): p. 199-206. 
39. Kilpi, T., Herva, E., Kaijalainen, T., Syrjanen, R., and Takala, A.K., Bacteriology of acute otitis 
media in a cohort of Finnish children followed for the first two years of life. The Pediatric 
Infectious Disease Journal, 2001. 20 (7): p. 654-662. 
40. Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Haapakoski, J., Herva, E., Takala, A.K., Kayhty, 
H., Karma, P., Kohberger, R., Siber, G.R., and Makela, P.M., Efficacy of a pneumococcal 
conjugate vaccine against acute otitis media. New England Journal of Medicine, 2001. 344: p. 
403-409. 
41. Teele, D.W., Klein, J.O., and Rosner, B., Epidemiology of otitis media during the first seven 
years of life in children in greater Boston: A prospective, cohort study. The Journal of 
Infectious Diseases, 1989. 160 (1): p. 83-94. 
42. Pitsiou, G.G. and Kioumis, I.P., Pneumococcal vaccination in adults: does it really work? 
Respiratory Medicine, 2011. 105 (12): p. 1776-1783. 
43. Meningitis - pneumococcal. National Center for Biotechnology Information. Available from: 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001632/. [Accessed on:12 September 
2012]. 
44. Baraff, L.J., Lee, S.I., and Schriger, D.L., Outcomes of bacterial meningitis in children: a 
meta-analysis. . The Pediatric Infectious Disease Journal, 1993. 12: p. 389-394. 
45. Musher, D.M., Infections caused by Streptococcus pneumoniae: clinical spectrum, 
pathogenesis, immunity and treatment. Clinical Infectious Diseases, 1992. 14: p. 801-809. 
46. Greenberg, D., Givon-Lavi, N., Newman, N., Bar-Ziv, J., and Dagan, R., Nasopharyngeal 
carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a 
means to estimate serotype disease potential. The Pediatric Infectious Disease Journal, 
2011. 30 (3): p. 227-233. 
47. Poolman, J., Kriz, P., Feron, C., Di-Paolo, E., Henckaerts, I., Miseur, A., Wauters, D., 
Prymula, R., and Schuerman, L., Pneumococcal serotype 3 otitis media, limited effect of 
polysaccharide conjugate immunisation and strain characteristics. Vaccine, 2009. 27 (24): p. 
3213-3222. 
48. Hausdorff, W.P., Bryant, J., Klock, C., Paradiso, P., and Siber, G.R., The contribution of 
specific pneumococcal serogroups to different disease manifestations: Implications for 
conjugate vaccine formulation and use. Part II. Clinical Infectious Diseases, 2000. 30 (1): p. 
122-140. 
49. Alanee, S.R., McGee, L., Jackson, D., Chiou, C.C., Feldman, C., Morris, A.J., Ortqvist, A., 
Rello, J., Luna, C.M., Baddour, L.M., Ip, M., Yu, V.L., and Klugman, K.P., Association of 
serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an 
international study. Clinical Infectious Diseases, 2007. 45 (1): p. 46-51. 
50. Kisakye, A., Makumbi, I., Nansera, D., Lewis, R., Braka, F., Wobudeya, E., Chaplain, D., 
Nalumansi, E., Mbabazi, W., and Gessner, B.D., Surveillance for Streptococcus pneumoniae 
meningitis in children aged <5 years: implications for immunization in Uganda. Clinical 
Infectious Diseases, 2009. 48 (Supplement 2): p. S153-S161. 
51. O'Brien, K.L., Wolfson, L.J., Watt, J., Henkle, E., Deloria-Knoll, M., McCall, N., Lee, E., 
Mulholland, E.K., Levine, O.S., and Cherian, T., Burden of disease caused by Streptococcus 
pneumoniae  in children younger than 5 years: global estimates. The Lancet, 2009. 374: p. 
893-902. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
239 
 
52. Zar, H.J. and Madhi, S.A., Pneumococcal conjugate vaccine - a health priority. South African 
Medical Journal, 2008. 98 (6): p. 463-467. 
53. Nunes, M.C. and Madhi, S.A., Safety, immunogenicity and efficacy of pneumococcal 
conjugate vaccine in HIV-infected individuals. Human Vaccines & Immunotherapeutics, 2012. 
8 (2): p. 161-173. 
54. Hausdorff, W.P., The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. 
Vaccine, 2007. 25 (13): p. 2406-2412. 
55. Pneumococcal regional serotype distribution for pneumococcal AMC TPP,  2008. GAVI 
PneumoADIP.    
56. Liu, L., Johnson, H.L., Cousens, S., Perin, J., Scott, S., Lawn, J.E., Rudan, I., Campbell, H., 
Cibulskis, R., Li, M., Mathers, C., and Black, R.E., Global, regional, and national causes of 
child mortality: an updated systematic analysis for 2010 with time trends since 2000. The 
Lancet, 2012. 379 (9832): p. 2151-2161. 
57. Hausdorff, W.P., Bryant, J., Paradiso, P., and Siber, G.R., Which pneumococcal serogroups 
cause the most invasive disease: Implications for conjugate vaccine formulation and use. Part 
I. Clinical Infectious Diseases, 2000. 30 (1): p. 100-121. 
58. Gessner, B.D., Mueller, J.E., and Yaro, S., African meningitis belt pneumococcal disease 
epidemiology indicates a need for an effective serotype 1 containing vaccine, including for 
older children and adults. BMC Infectious Diseases, 2010. 10. 
59. Weir, D.M., Immunology - an outline for students of medicine and biology. 4 ed 1977. 
Edinburgh: Churchill Livingstone. 
60. Immune System. National Institute of Health. Available from: 
http://www.niaid.nih.gov/topics/immunesystem/Pages/default.aspx. [Accessed on:12 
November 2012]. 
61. Janeway, C.A., Travers, P., Walport, M., and Shlomchik, M.J. Immunobiology: The Immune 
System in Health and Disease. . Garland Science. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK27156/. [Accessed on:12 November 2012]. 
62. Wars, D.W., Host defense against Streptococcus pneumoniae: The role of the spleen. 
Reviews of Infectious Diseases, 1981. 3 (2): p. 299-309. 
63. Zandvoort, A. and Timens, W., The dual function of the splenic marginal zone: essential for 
initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-
borne antigens. Clinical and Experimental Immunology, 2002. 130: p. 4-11. 
64. Klosterman, L., Immune system 2009. Marshall Cavendish Benchmark. 
65. Mond, J.J., Vos, Q., Lees, A., and Snapper, C.M., T cell independent antigens. Current 
Opinion in Immunology, 1995. 7: p. 349-354. 
66. Rijkers, G.T., Sanders, E.A.M., Breukels, M.A., and Zegers, B.J.M., Infant B cell responses to 
polysaccharide determinants. Vaccine, 1998. 16 (14/15): p. 1396-1400. 
67. Klein Klouwenberg, P. and Bont, L., Neonatal and infantile immune responses to 
encapsulated bacteria and conjugate vaccines. Clinical and Developmental Immunology, 
2008. 2008: p. e628963. 
68. Cabrera, O., Cuello, M., Soto, C.R., Martínez, M.E., del Campo, J.M., Pérez, O., Infante, J.F., 
and Sierra, G., New method for obtaining conjugated vaccines. Vaccine, 2006. 24 
(Supplement): p. S76-S78. 
69. Rappuoli, R. and De Gregorio, E., A sweet T cell response. Nature Medicine, 2011. 17 (12): 
p. 1551-1552. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
240 
 
70. Pomat, W.S., Lehmann, D., Sanders, R.C., Lewis, D.J., Wilson, J., Rogers, S., Dyke, T., and 
Alpers, M.P., Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in 
children in the highlands of Papua New Guinea. Infection and Immunity, 1994. 62 (5): p. 
1848-1854. 
71. Laferriere, C., The immunogenicity of pneumococcal polysaccharides in infants and children: 
a meta-regression. Vaccine, 2011. 29 (40): p. 6838-6847. 
72. Gonzalez-Fernandez, A., Faro, J., and Fernandez, C., Immune responses to polysaccharides: 
lessons from humans and mice. Vaccine, 2008. 26 (3): p. 292-300. 
73. Kelly, D.F., Moxon, E.R., and Pollard, A.J., Haemophilus influenzae type b conjugate 
vaccines. Immunology, 2004. 113 (2): p. 163-174. 
74. Avci, F.Y. and Kasper, D.L., How bacterial carbohydrates influence the adaptive immune 
system. Annual Review of Immunology, 2010. 28: p. 107-130. 
75. Avci, F.Y., Li, X., Tsuji, M., and Kasper, D.L., A mechanism for glycoconjugate vaccine 
activation of the adaptive immune system and its implications for vaccine design. Nature 
Medicine, 2011. 17 (12): p. 1602-1609. 
76. de Quandros, C.A. Vaccines: preventing disease and protecting health.  2003. Pan American 
Health Organization: Washington, D.C. 
77. Cobb, B.A., Wang, Q., Tzianabos, A.O., and Kasper, D.L., Polysaccharide processing and 
presentation by the MHCII pathway. Cell, 2004. 117 (5): p. 677-687. 
78. Cobb, B.A. and Kasper, D.L., Zwitterionic capsular polysaccharides: thenew MHCII-
dependent antigens. Cellular Microbiology, 2005. 7 (10): p. 1398-1403. 
79. Tzianabos, A.O., Onderdonk, A.B., Rosner, B., R.L., C., and Kasper, D.L., Structural features 
of polysaccharides that induce intra-abdominal abcesses. Science, 1993. 262 (5132): p. 416-
419. 
80. Tzianabos, A.O., Kasper, D.L., and Onderdonk, A.B., Structure and function of bacteroides 
fragilis capsular polysaccharides: Relationship to induction and preventionn of abscesses. 
Clinical Infectious Diseases, 1995. 20 (Supplement): p. S132-S140. 
81. Duan, J., Avci, F.Y., and Kasper, D.L., Microbial carbohydrate depolymerization by antigen-
presenting cells: deamination prior to presentation by the MHCII pathway. Proceedings of the 
National Academy of Sciences, USA, 2008. 105 (13): p. 5183-5188. 
82. Mertens, J., Fabri, M., Zingarelli, A., Kubacki, T., Meemboor, S., Groneck, L., Seeger, J., 
Bessler, M., Hafke, H., Odenthal, M., Bieler, J.G., Kalka, C., Schneck, J.P., Kashkar, H., and 
Kalka-Moll, W.M., Streptococcus pneumoniae serotype 1 capsular polysaccharide induces 
CD8CD28 regulatory T lymphocytes by TCR crosslinking. PLoS Pathogens, 2009. 5 (9): p. 
e1000596. 
83. Truck, J., Lazarus, R., Clutterbuck, E.A., Bowman, J., Kibwana, E., Bateman, E.A.L., and 
Pollard, A.J., The zwitterionic type I Streptococcus pneumoniae polysaccharide does not 
induce memory B cell formation in humans. Immunobiology, 2013. 218 (3): p. 368-372. 
84. Brodie, W.H., Rogers, W.G., and Hamilton, E.T.E., A contribution to the pathology of infection 
by the pneumococcus. South African Medical Journal, 1899. 6: p. 258-264. 
85. Nathan, E.A., A report on pneumonia at the Premier Diamond Mine. The Transvaal Medical 
Journal, 1907. 2: p. 154-159. 
86. Wright, A.E., Parry Morgan, W.P., Colebrook, L., and Dodgson, R.W., Observations on 
prophylactic inoculation against pneumococcus infections, and on the results which have 
been achieved with it. The Lancet, 1914. 1: p. 1-10. 
87. Rijkers, G.T., van Mens, S.P., and van Velzen-Blad, H., What do the next 100 years hold for 
pneumococcal vaccination. Expert Review of Vaccines, 2010. 9 (11): p. 1241-1244. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
241 
 
88. Lister, F.S., An experimental study of prophylactic inoculation against pneumococcal infection 
in the rabbit and in man. Publications of the South African Institute for Medical Research, 
1916. 8: p. 231-287. 
89. Heidelberger, M., MacLeod, C.M., Kaiser, S.J., and Robinson, B., Antibody formation in 
volunteers following injection of pneumococci or their type-specific polysaccharides. Journal 
of Experimental Medicine, 1946. 83 (4): p. 303-320. 
90. Tillet, W.S. and Francis, T., Cutaneous reactions to the polysaccharides and proteins of 
pneumococcus in lobar pneumonia. Journal of Experimental Medicine, 1929. 50 (5): p. 687-
701. 
91. Finland, M. and Sutliff, W.D., Specific cutaneous reactions and circulating antibodies in the 
course of lobar pneumonia. I. Cases receiving no serum therapy. . Journal of Experimental 
Medicine, 1931. 54: p. 637-642. 
92. MacLeod, C.M., Hodges, R., Heidelberger, M., and Bernhard, W.G., Prevention of 
pneumococcal pneumonia by immunization with specific capsular polysaccharides. Journal of 
Experimental Medicine, 1945. 82: p. 445-465. 
93. Heidelberger, M., MacLeod, C.M., and Di Lapi, M.M., The human antibody response to 
simultaneous injection of six specific polysaccharides of pneumococcus. Journal of 
Experimental Biology, 1948. 88 (3): p. 369-372. 
94. Austrian, R. and Gold, J., Pneumococcal bacteremia with especial reference to bacteremic 
pneumococcal pneumonia. Annals of Internal Medicine, 1964. 60 (5): p. 759-776. 
95. Austrian, R., Douglas, R.M., Schiffman, G., Coetzee, A.M., Koornhof, H.J., Hayden-Smith, S., 
and Reid, R.D., Prevention of pneumococcal pneumonia by vaccination. Transactions of the 
Association of American Physicians, 1976. 89: p. 184-194. 
96. Klugman, K.P., Hayden-Smith, S., and Koornhof, H.J., Evidence that prevention of carriage 
by pneumococcal capsular vaccines may be the mechanism of protection from pneumococcal 
pneumonia. South African Journal of Epidemiology and Infection, 2011. 26 (4): p. 221-224. 
97. Butler, J.C., Shapiro, E.D., and Carlone, G.M., Pneumococcal vaccines: History, current 
status, and future directions. American Journal of Medicine, 1999. 107 (Supplement 1A ): p. 
S69-S76. 
98. Robbins, J.B., Austrian, R., Lee, C.J., Rastogi, S.C., Schiffman, G., Henrichsen, J., Mäkelä, 
P.H., Broome, C.V., Facklam, R.R., Tiesjema, R.H., and Jr, J.C.P., Considerations for 
Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with 
Emphasis on the Cross-Reactive Types within Groups. The Journal of Infectious Diseases, 
1983. 148 (6): p. 1136-1159. 
99. Parkinson, A.J., Davidson, M., Fitzgerald, M.A., Bulkow, L.R., and Parks, D.J., Serotype 
distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus 
pneumoniae: Alaska 1986-1990. The Journal of Infectious Diseases, 1994. 170 (2): p. 461-
464. 
100. Hedlund, J., Svenson, S.B., Kalin, M., Henrichsen, J., Olsson-Liljequist, B., Möllerberg, G., 
and Källenius, G., Incidence, Capsular Types, and Antibiotic Susceptibility of Invasive 
Streptococcus pneumoniae in Sweden. Clinical Infectious Diseases, 1995. 21 (4): p. 948-953. 
101. Lee, C.J., Banks, S.D., and Li, J.P., Virulence, immunity, and vaccine related to 
Streptococcus pneumoniae. Critical Reviews in Microbiology, 1991. 18: p. 89-114. 
102. Rozenbaum, M.H., Boersma, C., Postma, M.J., and Hak, E., Observed differences in invasive 
pneumococcal disease epidemiology after routine infant vaccination. Expert Review of 
Vaccines, 2011. 10 (2): p. 187-199. 
103. Ortqvist, A., Henckaerts, I., Hedlund, J., and Poolman, J., Non-response to specific serotypes 
likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. 
Vaccine, 2007. 25 (13): p. 2445-2450. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
242 
 
104. Grabenstein, J.D. and Manoff, S.B., Pneumococcal polysaccharide 23-valent vaccine: Long-
term persistence of circulating antibody and immunogenicity and safety after revaccination in 
adults. Vaccine, 2012. 30 (30): p. 4435-4444. 
105. Moberley, S., Krause, V., Cook, H., Mulholland, K., Carapetis, J., Torzillo, P., and Andrews, 
R., Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal 
polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia. 
Vaccine, 2010. 28 (11): p. 2296-2301. 
106. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. World 
Health Organization Weekly Epidemiological record, 2007. 82 (12): p. 93-104. 
107. Jones, C., Vaccines based on the cell surface carbohydrates of pathogenic bacteria. Annals 
of the Brazilia Academy of Sciences, 2005. 77 (2): p. 293-324. 
108. Goebel, W.F. and Avery, O.T., Chemo-immunological studies on conjugated carbohydrate 
proteins: IV The synthesis of the p-aminobenzyl ether of the soluble specific substance of 
type III pneumococcus and its coupling with proteins. Journal of Experimental Medicine, 1931. 
54 (3): p. 431-436. 
109. Avery, O.T. and Goebel, W.F., Chemo-immunological studies on conjugated carbohydrate 
proteins: II Immunological specificity of synthetic sugar-protein antigens. Journal of 
Experimental Medicine, 1929. 50 (4): p. 533-550. 
110. Goebel, W.F. and Avery, O.T., Chemo-immunological studies on conjugated carbohydrate 
proteins: I. The synthesis of p-aminophenol b-glucoside, p-aminophenol b-galactoside, and 
their coupling with serum globulin Journal of Experimental Medicine, 1929. 50 (4): p. 521-531. 
111. Goebel, W.F., Avery, O.T., and Babers, F.H., Chemo-immunological studies on conjugated 
carbohydrate proteins: IX The specificity of antigens prepared by combining the p-
aminophenol glycosides of disaccharides with proteins. Journal of Experimental Medicine, 
1934. 60 (5): p. 599-617. 
112. Goebel, W.F., Babers, F.H., and Avery, O.T., Chemo-immunological studies on conjugated 
carbohydrate-proteins: VI The synthesis of p-aminophenol a-glucoside and its coupling with 
protein. Journal of Experimental Medicine, 1932. 55 (5): p. 761-767. 
113. Avery, O.T. and Goebel, W.F., Chemo-immunological studies on conjugated carbohydrate 
proteins: V The immunological specificity of an antigen prepared by combining the capsular 
polysaccharide of type III pneumococcus with foreign protein. Journal of Experimental 
Medicine, 1931. 54 (3): p. 437-447. 
114. Schneerson, R., Barrera, O., Sutton, A., and Robbins, J.B., Preparation, characterization and 
immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. The 
Journal of Experimental Medicine, 1980. 152: p. 361-376. 
115. Schneerson, R., Robbins, J.B., J.C., P.J., Bell, C., Schlesselman, J.J., Sutton, A., Wang, Z., 
Schiffman, G., Karpas, A., and Shiloach, J., Quantitative and qualitative analyses of serum 
antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A 
capsular polysaccharide-tetanus toxoid conjugates. Infection and Immunity, 1986. 52 (2): p. 
519-528. 
116. Countries having introduced Hib vaccine and infant Hib coverage - WHO/IVB database, 
September 2011. World Health Organization. Available from: 
http://www.who.int/nuvi/hib/decision_implementation/en/index1.html. [Accessed on:24 
September 2012]. 
117. Dinleyici, E.C., Current status of pneumococcal vaccines: lessons to be learned and new 
insights. Expert Review of Vaccines, 2010. 9 (9): p. 1017-1022. 
118. Rennels, M.B., Edwards, K.M., Keyserling, H.L., Reisinger, K.S., Hogerman, D.A., Madore, 
D.V., Chang, I., Paradiso, P.R., Malinoski, F.J., and Kimura, A., Safety and immunogenicity of 
heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. . 
Pediatrics, 1998. 101 (4): p. 604-611. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
243 
 
119. Dinleyici, E.C. and Yargic, Z.A., Pneumococcal conjugated vaccines: impact of PCV-7 and 
new achievements in the postvaccine era. Expert Review of Vaccines, 2008. 7 (9): p. 1367-
1394. 
120. Anderson, P.W. and Eby, R. for The University of Rochester. Immunogenic conjugates of 
Streptococcus pneumonial capsular polymer and toxin or in toxiad. 1994. Office, U.S.P. 
819305. 5360897.  
121. Dagan, R. and Poland, G., World Pneumonia Day: fighting pneumonia with safe and 
affordable vaccines. Vaccine, 2010. 28 (48): p. 7577-7578. 
122. Black, S., Shinefield, H.R., Fireman, B., Lewis, E., Ray, P., Hansen, J.B., Elvin, L., Ensor, 
K.M., Hackell, J., Siber, G.R., Malinoski, F.J., Madore, D.V., Chang, I., Kohberger, R., 
Watson, W., Austrian, R., and Edwards, K.M., Efficacy, safety and immunogeniicty of 
heptavalent pneumococcal conjugate vaccine in children. The Pediatric Infectious Disease 
Journal, 2000. 19 (3): p. 187-196. 
123. O'Brien, K.L., Moulton, L.H., Reid, R., Weatherholtz, R., Oski, J., Brown, L., Kumar, G., 
Parkinson, A.J., Hu, D., Hackell, J., Kohberger, R., Siber, G.R., and Santosham, M., Efficacy 
and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: 
group randomised trial. The Lancet, 2003. 362: p. 355-361. 
124. Prymula, R., Motlova, J., and Kriz, P., Comparison of Streptococcus pneumoniae serotypes 
causing acute otitis media and invasive disease in young children in the Czech Republic. 
Indian Journal of Medical Research, 2004. 119: p. 168-170. 
125. Hansen, J., Black, S., Shinefield, H., Cherian, T., Benson, J., Fireman, B., Lewis, E., Ray, P., 
and Lee, J., Effectiveness of heptavalent pneumococcal conjugate vaccine in children 
younger than 5 years of age for prevention of pneumonia: updated analysis using World 
Health Organization standardized interpretation of chest radiographs. The Pediatric Infectious 
Disease Journal, 2006. 25 (9): p. 779-781. 
126. Black, S.B., Shinefield, H.R., Ling, S., Hansen, J., Fireman, B., Spring, D., Noyes, J., Lewis, 
E., Ray, P., Lee, J., and Hackell, J., Effectiveness of heptavalent pneumococcal conjugate 
vaccine in children younger than five years of age for prevention of pneumonia. The Pediatric 
Infectious Disease Journal, 2002. 21 (9): p. 810-815. 
127. Adamkiewicz, T.V., Silk, B.J., Howgate, J., Baughman, W., Strayhorn, G., Sullivan, K., and 
Farley, M.M., Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with 
sickle cell disease in the first decade of life. Pediatrics, 2008. 121 (3): p. 562-569. 
128. Kourtis, A.P., Ellington, S., Bansil, P., Jamieson, D.J., and Posner, S.F., Hospitalizations for 
invasive pneumococcal disease among human immunodeficiency virus-1 infected children, 
adolescents and young adults in the United States in the era of highly active antiretroviral 
therapy and the conjugate pneumococcal vaccine. The Pediatric Infectious Disease Journal, 
2010. 29 (6): p. 561-563. 
129. Moffitt, K.L. and Malley, R., Next generation pneumococcal vaccines. Current Opinion in 
Immunology, 2011. 23 (3): p. 407-413. 
130. Black, S., Shinefield, H., Baxter, R., Austrian, R., Bracken, L., Hansen, J., Lewis, E., and 
Fireman, B., Postlicensure Surveillance for Pneumococcal Invasive Disease After Use of 
Heptavalent Pneumococcal Conjugate Vaccine in Northern California Kaiser Permanente. 
The Pediatric Infectious Disease Journal, 2004. 23 (6): p. 485-489. 
131. Hsu, K.K., Shea, K.M., Stevenson, A.E., and Pelton, S.I., Changing serotypes causing 
childhood invasive pneumococcal disease: Massachusetts, 2001-2007. The Pediatric 
Infectious Disease Journal, 2010. 29 (4): p. 289-293. 
132. Singleton, R.J., Hennessy, T.W., L.R., B., Hammitt, L.L., Zulz, T., Hurlburt, D.A., Butler, J.C., 
Rudolph, K., and Parkinson, A.J., Invasive pneumococcal disease caused by nonvaccine 
serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate 
vaccine coverage. The Journal of the American Medical Association, 2007. 297 (16): p. 1784-
1792. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
244 
 
133. Hausdorff, W.P., van Dyke, M.K., and Effelterre, v., Serotype replacement after 
pneumococcal vaccination. The Lancet, 2012. 379 (9824): p. 1387-1388. 
134. Weinberger, D.M., Malley, R., and Lipsitch, M., Serotype replacement in disease after 
pneumococcal vaccination. The Lancet, 2011. 378 (9807): p. 1962-1973. 
135. Jacobs, M.R., Good, C.E., Bajaksouzian, S., and Windau, A.R., Emergence of Streptococcus 
pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to 
introduction of the protein-conjugated pneumococcal vaccine. Clinical Infectious Diseases, 
2008. 47 (11): p. 1388-1395. 
136. Krishnamurthy, T., Lee, C.J., Henrichsen, J., Carlo, D.J., Stoudt, T.M., and Robbins, J.B., 
Characterization of the cross reaction between type 19F (19) and 19A (57) pneumococcal 
capsular polysaccharides: Compositional anallysis and immunological relation determined 
with rabbit typing antisera. Infection and Immunity, 1978. 22 (3): p. 727-735. 
137. Pichichero, M.E. and Casey, J.R., Emergence of a multiresistant serotype 19A pneumococcal 
strain not included in the 7-valent conjugate vaccine as an otophaogen in children. The 
Journal of the American Medical Association, 2007. 298 (15): p. 1772-1778. 
138. Kaplan, S.L., Barson, W.J., Lin, P.L., Stovall, S.H., Bradley, J.S., Tan, T.Q., Hoffman, J.A., 
Givner, L.B., and Mason, E.O., Jr., Serotype 19A Is the most common serotype causing 
invasive pneumococcal infections in children. Pediatrics, 2010. 125 (3): p. 429-436. 
139. Hoberman, A., Paradise, J.L., Shaikh, N., Greenberg, D.P., Kearney, D.H., Colborn, D.K., 
Rockette, H.E., Kurs-Lasky, M., McEllistrem, M.C., Zoffel, L.M., Balentine, T.L., Barbadora, 
K.A., and Wald, E.R., Pneumococcal resistance and serotype 19A in Pittsburgh-area children 
with acute otitis media before and after introduction of 7-valent pneumococcal polysaccharide 
vaccine. Clinical Pediatrics, 2011. 50 (2): p. 114-120. 
140. Picazo, J., Ruiz-Contreras, J., Hernandez, B., Sanz, F., Gutierrez, A., Cercenado, E., 
Meseguer, M.A., Delgado-Iribarren, A., Rodriguez-Avial, I., and Mendez, C., Clonal and 
clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive 
infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid. Vaccine, 2011. 29 
(9): p. 1770-1776. 
141. Choi, E.H., Kim, S.H., Eun, B.W., Kim, S.J., Kim, N.H., Lee, J., and Lee, H.J., Streptococcus 
pneumoniae serotype 19A in children, South Korea. Emerging Infectious Diseases, 2008. 14 
(2): p. 275-282. 
142. Lee, H.J., Park, S.E., and Kim, K.H., Immune response to 19A serotype after immunization of 
19F containing pneumococcal conjugate vaccine in Korean children aged 12-23 months. 
Korean Journal of Pediatrics, 2011. 54 (4): p. 163-168. 
143. What is the Pneumococcus - powerpoint presentation. PneumoAction. Available from: 
http://www.preventpneumo.org/data-tools/slides.cfm. [Accessed on:15 June 2012]. 
144. Hausdorff, W.P., Feikin, D.R., and Klugman, K.P., Epidemiological differences among 
pneumococcal serotypes. The Lancet Infectious Diseases, 2005. 5 (2): p. 83-93. 
145. Aguiar, S.I., Brito, M.J., Goncalo-Marques, J., Melo-Cristino, J., and Ramirez, M., Serotypes 
1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in 
Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine, 2010. 28 (32): p. 5167-
5173. 
146. Brueggemann, A.B. and Spratt, B.G., Geographic distribution and clonal diversity of 
Streptococcus pneumoniae serotype 1 Isolates. Journal of Clinical Microbiology, 2003. 41 
(11): p. 4966-4970. 
147. Saha, S.K., Naheed, A., El Arifeen, S., Islam, M., Al-Emran, H., Amin, R., Fatima, K., Brooks, 
W.A., Breiman, R.F., Sack, D.A., and Luby, S.P., Surveillance for invasive Streptococcus 
pneumoniae disease among hospitalized children in Bangladesh: antimicrobial susceptibility 
and serotype distribution. Clinical Infectious Diseases, 2009. 48 (Supplement 2): p. S75-S81. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
245 
 
148. Romney, M.G., Hull, M.W., Gustafson, R., Sandhu, J., Champagne, S., Wong, T., 
Nematallah, A., Forsting, S., and Daly, P., Large community outbreak of Streptococcus 
pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clinical 
Infectious Diseases, 2008. 47 (6): p. 768-774. 
149. Leimkugel, J., Forgor, A.A., Gagneux, S., Pfluger, V., Flierl, C., Awine, E., Neegeli, M., 
Dangy, J.-P., Smith, T., Hodgson, A., and Plusch, G., An outbreak of serotype 1 
Streptococcus pneumoniae meningitis in Northern Ghana with features that are characteristic 
of Neisseria meningitidis meningitis epidemics. The Journal of Infectious Diseases, 2005. 19 
(192-198). 
150. Imohl, M., Reinert, R.R., Ocklenburg, C., and van der Linden, M., Association of serotypes of 
Streptococcus pneumoniae with age in invasive pneumococcal disease. Journal of Clinical 
Microbiology, 2010. 48 (4): p. 1291-1296. 
151. Ruckinger, S., von Kries, R., Siedler, A., and van der Linden, M., Association of serotype of 
Streptococcus pneumoniae with risk of severe and fatal outcome. The Pediatric Infectious 
Disease Journal, 2009. 28 (2): p. 118-122. 
152. Madhi, S.A. and Klugman, K.P., A role for Streptococcus pneumoniae in virus-associated 
pneumonia. Nature Medicine, 2004. 10 (8): p. 811-813. 
153. Klugman, K.P., Madhi, S.A., Huebner, R.E., Kohberger, R., Mbelle, N., and Pierce, N., A trial 
of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV 
infection. New England Journal of Medicine, 2003. 349 (14): p. 1341-1348. 
154. Cutts, F.T., Zaman, S.M.A., Enwere, G., Jaffar, S., Levine, O.S., Okoko, J.B., Oluwalana, C., 
Vaughan, A., Obaro, S.K., Leach, A., McAdam, K.P., Biney, E., Saaka, M., Onwuchekwa, U., 
Yallop, F., Pierce, N.F., Greenwood, B.M., and Adegbola, R.A., Efficacy of nine-valent 
pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in 
The Gambia: randomised, double-blind, placebo-controlled trial. The Lancet, 2005. 365 
(9465): p. 1139-1146. 
155. Saaka, M., Okoko, B.J., Kohberger, R.C., Jaffar, S., Enwere, G., Biney, E.E., Oluwalana, C., 
Vaughan, A., Zaman, S.M., Asthon, L., Goldblatt, D., Greenwood, B.M., Cutts, F.T., and 
Adegbola, R.A., Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal 
conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. Vaccine, 2008. 
26 (29-30): p. 3719-3726. 
156. Prymula, R., Peeters, P., Ch obok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, 
P., Poolman, J., Prieels, J.-P., and Schuerman, L., Pneumococcal capsular polysaccharides 
conjugated to protein D for prevention of acute otitis media caused by both Streptococcus 
pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy 
study. The Lancet, 2006. 367 (9512): p. 740-748. 
157. Schuerman, L., Prymula, R., Henckaerts, I., and Poolman, J., ELISA IgG concentrations and 
opsonophagocytic activity following pneumococcal protein D conjugate vaccination and 
relationship to efficacy against acute otitis media. Vaccine, 2007. 25 (11): p. 1962-1968. 
158. Lucero, M.G., Nohynek, H., Williams, G., Tallo, V., Simoes, E.A., Lupisan, S., Sanvictores, D., 
Forsyth, S., Puumalainen, T., Ugpo, J., Lechago, M., de Campo, M., Abucejo-Ladesma, E., 
Sombrero, L., Nissinen, A., Soininen, A., Ruutu, P., Riley, I., and Makela, H.P., Efficacy of an 
11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia 
among children less than 2 years of age in the Philippines: a randomized, double-blind, 
placebo-controlled trial. The Pediatric Infectious Disease Journal, 2009. 28 (6): p. 455-462. 
159. Ugpo, J., Lucero, M., Williams, G., Lechago, M., Nillos, L., Tallo, V., and Nohynek, H., 
Reactogenicity and tolerability of a non-adjuvanted 11-valent diphtheria-tetanus toxoid 
pneumococcal conjugate vaccine in Filipino children. Vaccine, 2009. 27 (20): p. 2723-27239. 
160. Dagan, R., Goldblatt, D., Maleckar, J.R., Yaich, M., and Eskola, J., Reduction of antibody 
response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing 
acellular pertussis components. Infection and Immunity, 2004. 72 (9): p. 5383-5391. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
246 
 
161. Expert committee on biological standardization: , in Recommendations to assure the quality, 
safety and efficacy of pneumococcal conjugate vaccines. 2009. World Health Organization 
Relacement of TRS 927 Annex 2.   
162. Annex 2: Recommendations for the production and control of pneumococcal conjugate 
vaccines,  2005. World Health Organization WHO technical report series no 927.   
163. Jódar, L., Butler, J., Carlone, G., Dagan, R., Goldblatt, D., Käyhty, H., Klugman, K., Plikaytis, 
B., Siber, G., Kohberger, R., Chang, I., and Cherian, T., Serological criteria for evaluation and 
licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine, 
2003. 21 (23): p. 3265-3272. 
164. Assessment report for Synflorix,  2009. European Medicines Agency Procedure no: 
EMEA/H/C/000973.   
165. Prymula, R. and Schuerman, L., 10 valent pneumococcal nontypeable Haemophilus 
influenzae PD conjugate vaccine: Synflorix. Expert Review of Vaccines, 2009. 8 (11): p. 1479-
1500. 
166. Biemans, R.L., Denoel, P., Poolman, J., and Prieels, J.P. for GlaxoSmithKline. Vaccine. 2007. 
Organization, W.I.P. PCT/EP2007/053412. WO 2007/116028 A2.  
167. Nurkka, A., Joensuu, J., Henckaerts, I., Peeters, P., Poolman, J., Kilpi, T., and K??yhty, H., 
Immunogenicity and Safety of the Eleven Valent Pneumococcal Polysaccharide-Protein D 
Conjugate Vaccine in Infants. The Pediatric Infectious Disease Journal, 2004. 23 (11): p. 
1008-1014. 
168. Vesikari, T., Wysocki, J., Chevallier, B., Karvonen, A., Czajka, H., Arsene, J.P., Lommel, P., 
Dieussaert, I., and Schuerman, L., Immunogenicity of the 10-valent pneumococcal non-
typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the 
licensed 7vCRM vaccine. The Pediatric Infectious Disease Journal, 2009. 28 (Supplement 4): 
p. S66-S76. 
169. Wysocki, J., Tansey, S., Brachet, E., Baker, S., Gruber, W., Giardina, P., and Arora, A., 
Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate 
vaccines. Vaccine, 2010. 28 (49): p. 7779-7786. 
170. Wysocki, J., Tejedor, J.C., Grunert, D., Konior, R., Garcia-Sicilia, J., Knuf, M., Bernard, L., 
Dieussaert, I., and Schuerman, L., Immunogenicity of the 10-valent pneumococcal non-
typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when 
coadministered with different neisseria meningitidis serogroup C conjugate vaccines. The 
Pediatric Infectious Disease Journal, 2009. 28 (Supplement 4): p. S77-S88. 
171. Bermal, N., Szenborn, L., Chrobot, A., Alberto, E., Lommel, P., Gatchalian, S., Dieussaert, I., 
and Schuerman, L., The 10-valent pneumococcal non-typeable Haemophilus influenzae 
protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus 
vaccines: assessment of immunogenicity. The Pediatric Infectious Disease Journal, 2009. 28 
(Supplement 4): p. S89-S96. 
172. Knuf, M., Pankow-Culot, H., Grunert, D., Rapp, M., Panzer, F., Kollges, R., Fanic, A., Habib, 
A., Borys, D., Dieussaert, I., and Schuerman, L., Induction of immunologic memory following 
primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae 
protein D conjugate vaccine in infants. The Pediatric Infectious Disease Journal, 2012. 31 (1): 
p. 31-36. 
173. Vesikari, T., Karvonen, A., Lindblad, N., Korhonen, T., Lommel, P., Willems, P., Dieussaert, I., 
and Schuerman, L., Safety and immunogenicity of a booster dose of the 10-valent 
pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine 
coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 
months. The Pediatric Infectious Disease Journal, 2010. 29 (6): p. 47-56. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
247 
 
174. Kim, C.H., Kim, J.S., Cha, S.H., Kim, K.N., Kim, J.D., Lee, K.Y., Kim, H.M., Kim, J.H., Hyuk, 
S., Hong, J.Y., Park, S.E., Kim, Y.K., Kim, N.H., Fanic, A., Borys, D., Ruiz-Guinazu, J., 
Moreira, M., Schuerman, L., and Kim, K.H., Response to primary and booster vaccination with 
10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in 
Korean infants. The Pediatric Infectious Disease Journal, 2011. 30 (12): p. 235-243. 
175. Hausdorff, W.P., Siber, G.R., Paradiso, P., and Prasad, A.K. for Wyeth. Multivalent 
pneumococcal polysaccharide-protein conjugate composition. 2007. Office, U.S.P. 
11/644207. US2007/0184072 A1.  
176. Scott, D.A., Komjathy, S.F., Hu, B.T., Baker, S., Supan, L.A., Monahan, C.A., Gruber, W., 
Siber, G.R., and Lockhart, S.P., Phase 1 trial of a 13-valent pneumococcal conjugate vaccine 
in healthy adults. Vaccine, 2007. 25 (33): p. 6164-6166. 
177. Scott, D., Ruckle, J., Dar, M., Baker, S., Kondoh, H., and Lockhart, S., Phase 1 trial of 13-
valent pneumococcal conjugate vaccine in Japanese adults. Pediatrics International, 2008. 50 
(3): p. 295-299. 
178. Kieninger, D.M., Kueper, K., Steul, K., Juergens, C., Ahlers, N., Baker, S., Jansen, K.U., 
Devlin, C., Gruber, W.C., Emini, E.A., and Scott, D.A., Safety, tolerability, and immunologic 
noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent 
pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. 
Vaccine, 2010. 28 (25): p. 4192-4203. 
179. Yeh, S.H., Gurtman, A., Hurley, D.C., Block, S.L., Schwartz, R.H., Patterson, S., Jansen, 
K.U., Love, J., Gruber, W.C., Emini, E.A., and Scott, D.A., Immunogenicity and safety of 13-
valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics, 2010. 126 (3): p. 
493-505. 
180. Kellner, J.D., Halperin, S., Scheifele, D., Connor, D.D., Dionne, M., McDonald, J.C., 
Meekison, W.G., Predy, G., Rubinstein, E., Tapiero, B., Zickler, P., Pride, M., Patterson, S., 
Girgenti, D., Gruber, W., Emini, E.A., and Scott, D. Immunogenicity and safety of a 13-valent 
pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric 
vaccinations in Canada. in 7th Internation Symposium on Pneumococci and Pneumococcal 
Diseases. 2010. Israel. 
181. Vanderkooi, O.G., Scheifele, D.W., Girgenti, D., Halperin, S.A., Patterson, S.D., Gruber, 
W.C., Emini, E.A., Scott, D.A., and Kellner, J.D., Safety and immunogenicity of a 13-valent 
pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric 
vaccinations in Canada. The Pediatric Infectious Disease Journal, 2012. 31 (1): p. 72-77. 
182. Cooper, D., Yu, X., Sidhu, M., Nahm, M.H., Fernsten, P., and Jansen, K.U., The 13-valent 
pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing 
responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine, 2011. 29 
(41): p. 7207-7211. 
183. Nunes, M.C. and Madhi, S.A., Review on the immunogenicity and safety of PCV-13 in infants 
and toddlers. Expert Review of Vaccines, 2011. 10 (7): p. 951-980. 
184. Skinner, J.M., Indrawati, L., Cannon, J., Blue, J., Winters, M., Macnair, J., Pujar, N., Manger, 
W., Zhang, Y., Antonello, J., Shiver, J., Caulfield, M., and Heinrichs, J.H., Pre-clinical 
evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-
rhesus monkey immunogenicity model. Vaccine, 2011. 29 (48): p. 8870-8876. 
185. Musey, L. Safety, Tolerability, and Immunogenicity of 15-Valent Pneumococcal Conjugate 
Vaccine (PCV15) in Healthy Adults. in Infectious Diseases Society of America. 2011. Boston. 
186. Sobanjo, A., Vesikari, T., Malacaman, E., Shapiro, S., Dallas, M., Hoover, P., McFetridge, R., 
Marchese, R.D., Watson, W., and Musey, L. Safety, tolerability, and immunogenicity of 15-
valent pneumococcal conjugate vaccine (PCV15) in toddlers previously immunized with 7-
valent pneumococcal conjugate vaccine (PCV7). in European Society for Pediatric Infectious 
Diseases. 2011. The Haugue, Netherlands. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
248 
 
187. Croucher, N.J., Harris, S.R., Fraser, C., Quail, M.A., Burton, J., van der Linden, M., McGee, 
L., von Gottberg, A., Song, J.H., Ko, K.S., Pichon, B., Baker, S., Parry, C.M., Lambertsen, 
L.M., Shahinas, D., Pillai, D.R., Mitchell, T.J., Dougan, G., Tomasz, A., Klugman, K.P., 
Parkhill, J., Hanage, W.P., and Bentley, S.D., Rapid pneumococcal evolution in response to 
clinical interventions. Science, 2011. 331 (6016): p. 430-434. 
188. Moffitt, K.L., Yadav, P., Weinberger, D.M., Anderson, P.W., and Malley, R., Broad antibody 
and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine, 2012. 30 (29): 
p. 4316-4322. 
189. Antonio, M., Hakeem, I., Awine, T., Secka, O., Sankareh, K., Nsekpong, D., Lahai, G., 
Akisanya, A., Egere, U., Enwere, G., Zaman, S.M., Hill, P.C., Corrah, T., Cutts, F., 
Greenwood, B.M., and Adegbola, R.A., Seasonality and outbreak of a predominant 
Streptococcus pneumoniae serotype 1 clone from The Gambia: expansion of ST217 
hypervirulent clonal complex in West Africa. BMC Microbiology, 2008. 8: p. 198-204. 
190. Mehiri-Zghal, E., Decousser, J.W., Mahjoubi, W., Essalah, L., El Marzouk, N., Ghariani, A., 
Allouch, P., and Slim-Saidi, N.L., Molecular epidemiology of a Streptococcus pneumoniae 
serotype 1 outbreak in a Tunisian jail. Diagnostic Microbiology and Infectious Disease, 2010. 
66 (2): p. 225-227. 
191. Klugman, K.P., Madhi, S.A., Adegbola, R.A., Cutts, F., Greenwood, B., a d Hausdorff, W.P., 
Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster 
dose. Vaccine, 2011. 29 (18): p. 3372-3373. 
192. Walsh, G., Biopharmaceuticals - Biochemistry and Biotechnology. 2 ed 2003. England: Wiley 
and Sons Ltd. 
193. Wave Bioreactor Catalog 2006,  2006. Wave Europe Pvt. Ltd.    
194. Liveyns, R., Gilles, D., and Arickx, M. for SmithKline Process for the preparation of purified 
bacterial capsular antigenic polysaccharides, the obtained products and their use. 1983. 
Office, E.P. EP19820107154 19820807. EP0072513.  
195. Field, L.D., Sternhell, S., and Kalman, J.R. Organic structures from spectra. 4 ed.  2008. John 
WIley and Sons Ltd.: England. 
196. Dische, Z., A new specific color reaction for hexuronic acids. The Journal of Biological 
Chemistry, 1946. 167: p. 189-199. 
197. Dische, Z., A modification of the carbazole reaction of hexuronic acids for the study of 
polyuronides. The Journal of Biological Chemistry, 1949. 183: p. 489-195. 
198. Bitter, T. and Muir, H.M., A modified uronic acid carbazole reaction. Analytical Biochemistry, 
1962. 4 (4): p. 330-334. 
199. Hestrin, S., The reaction of acetylcholine and other carboxylic acid derivatives with 
hydroxylamine and its analytical application. The Journal of Biological Chemistry, 1949. 180 
(1): p. 249-262. 
200. Aksnes, G., The complex between hydroxamic acids and ferric ions, and the use of the 
complex for quantitative determination of hydroxamic acids, acyl derivatives and ferric salts. 
Acta Chemica Scandinavica, 1957. 11: p. 710-716. 
201. Walker, J.M. The protein protocols handbook. 2 ed., ed. Mezzina, D. 2002. Humans Press. 
202. Goldfarb, A.R., Saidel, L.J., and Mosovich, E., The ulltraviolet absorption spectra of proteins. 
The Journal of Biological Chemistry, 1951. 193: p. 397-404. 
203. Creighton, T.E., Proteins: structures and molecular properties. 2 ed 1993. W.H. Freeman. 
207. 
204. Instructions for Coomassie (Bradford) protein assay kit,  2011. Thermo Scientific.    
205. Protein Assay: Technical handbook,  2005. Pierce Biotechnology.    
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
249 
 
206. Snyder, S.L. and Showalter, P.Z., An improved 2,4,6-trinitrobenzenesulfonic acid method for 
the determination of amines. Analytical Biochemistry, 1975. 64: p. 284-288. 
207. Qi, X.-Y., Keyhani, N.O., and Lee, Y.C., Spectroscopic determination of hydrazine, 
hydrazides, and their mixtures with trinitrobenzenesulfonic acid. Analytical Biochemistry, 
1988. 175: p. 139-144. 
208. Stramski, D. and Piskozub, J., Estimation of scattering error in spectroscopic measurements 
of light absorption by aquatic particles from three-dimensional radiative transfer simulations. 
Applied Optics, 2003. 42 (18): p. 3634-3647. 
209. Instructions: TNBSA,  1999. Pierce Chemical Company.    
210. Manz, A., Pamme, N., and Iossifidis, D., Bioanalytical Chemistry 2004. London: Imperial 
College Press. 
211. Mikkelsen, S.R. and Corton, E., Bioanalytical Chemistry 2004. New Jersey: Wiley-
Interscience. 
212. Gault, V.A. and McClenaghan, N.H., Understanding Bioanalytical Chemistry: Principles and 
Applications 2009. Wiley-Blackwell. 
213. Wilson, K. and Walker, J. Principles and techniques of biochemistry and molecular biology. 7 
ed.  2010. Cambridge University Press: Cambridge, United Kingdom. 
214. O'Dell, J.W., Determination of turbidity by nephelometry: Method 180.1, Agency, U.S.E.p., 
Editor 1993. Revision 2.0.   
215. Sadar, M., Introduction to laser nephelometry: an alternative to conventional particulate 
analysis methods,  2005.    
216. Labtech, B., NEPHELOstar plus: Laser based microplate nephelometer that measures light 
scattering,  2012.    
217. Marburg, S., Tolman, R.L., Kniskern, P.J., Miller, W.J., Hagopian, A., Ip, C.C., Hennessey Jr, 
J.P., Kubek, D.J., and Burke, P.D. for Merck & Co Inc. Pneumococcal polysaccharide 
conjugate vaccine. 1997. Office, U.S.P. 246394. 5623057.  
218. Lee, C.-J., Quality control of polyvalent pneumococcal polysaccharide-protein conjugate 
vaccine by nephelometry. Biologicals, 2002. 30 (2): p. 97-103. 
219. Frokjaer, S. and Hovgaard, L. Pharmaceutical formulation: Develoment of peptides and 
proteins. 2000. 
220. BIO-RAD, Criterion precast gels: Instruction manual and application guide,  2011. Bio-Rad 
Laboratories Document number: 4110001 Rev F.   
221. BIO-RAD, Criterion XT precast gel instruction guide,   Bio-Rad Revision B.   
222. BIO-RAD, Protein Blotting guide: A guide to transfer and detection,   Bio-Rad.    
223. BIO-RAD, Immun-Blot PVDF membrane for protein blotting: Instruction manual, Bio-Rad.      
224. Davey, J. and Lord, M., Gel electrophoresis of proteins, in Cell structure: A practical approach 
2003. Oxford University Press. p. 197-268. 
225. Protein Blotting Handbook 2012. Millipore Application Note: TP001ENEU. Available from: 
http://www.millipore.com/publications.nsf/a73664f9f981af8c852569b9005b4eee/bdd070ddcbe
9b90385257a95005ce13e/$FILE/TP001ENEU,_MM.pdf. [Accessed on: 12 December 2012]. 
226. Gunzler, H. and Williams, A. Handbook of Analytical Techniques.  2002. Wiley-VCH: 
Germany. 
227. Amersham, Gel Filtration: Principles and methods,  2002. Amersham Biosciences.    
228. Lee, Y.C., High-performance anion-exchange chromatography for carbohydrate analysis. 
Analytical Biochemistry, 1990. 189 (2): p. 151-162. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
250 
 
229. Hardy, M.R., Townsend, R.R., and Lee, A., Monosaccharide analysis of glycoconjugates by 
anion exchange chromatography with pulsed amperometric detection. Analytical 
Biochemistry, 1970. 170: p. 54-62. 
230. Townsend, R.R., Hardy, M.R., Hindsgaul, O., and Lee, Y.C., High-performance anion-
exchange chromatography of oligosaccharides using pellicular resins and pulsed 
amperometric detection. Analytical Biochemistry, 1988. 174 (2): p. 459-470. 
231. Analysis of carbohydrates by high performance anion exchange chromatography with pulsed 
amperometric detection (HPAE-PAD),  2000. Dionex Corporation: United States.    
232. Product manual for CarboPac Ma1, CarboPac PA1, CarboPac PA10 and CarboPac PA100,  
2010. Dionex Corporation Document number: 031824. Revision: 8.  
233. Liang, C. and Lucy, C.A., Characterization of ion chromatography columns based on 
hydrophobicity and hydroxide eluent strength. Journal of Chromatography A, 2010. 1217 (52): 
p. 8154-8160. 
234. Cataldi, T.R.I., Campa, C., and De Benedetto, G.E., Carbohydrate analysis by high-
performance anion-exchange chromatography with pulsed amperometric detection: The 
potential is still growing. Fresenius Journal of Analytical Chemistry, 2000. 368: p. 739-758. 
235. Talaga, P., Vialle, S., and Moreau, M., Development of a high-performance anion-exchange 
chromatography with pulsed-amperometric detection based quantification assay for 
pneumococcal polysaccharides and conjugates. Vaccine, 2002. 20: p. 2474-2484. 
236. Martin, A.J.P. and Synge, R.L.M., A new form of chromatogram employing two liquid phases. 
Biochemical Journal, 1941. 35: p. 1358-1368. 
237. James, A.T. and Martin, A.J.P., Gas-liquid partition chromatography: The separation and 
micro-estimation of volatile fatty acids from formic acid to dodecanoic acid. Biochemical 
Journal, 1952. 50: p. 679-690. 
238. Golay, M.J.E. for Vapor Fractometer column. 1960. Office, U.S.P. 2920478.  
239. Condon, R.D., Design considerations of a gas chromatography system employing high 
efficiency Golay columns. Analytical Chemistry, 1959. 31 (9): p. 1717-1722. 
240. Ettre, L., Evolution of capillary columns for gas chromatography. LC-GC The Magazine of 
Separation Science, 2001. 19 (1): p. 48-56. 
241. Fox, A., Wright, L., and Fox, K., Gas chromatography-tandem mass spectrometry for trace 
detection of muramic acid, a peptidoglycan chemical marker, in organic dust. Journal of 
Microbiological Methods, 1995. 22: p. 11-26. 
242. Kim, J.S., Laskowich, E.R., Arumugham, R.G., Kaiser, R.E., and MacMichael, G.J., 
Determination of saccharide content in pneumococcal polysaccharides and conjugate 
vaccines by GC-MSD. Analytical Biochemistry, 2005. 347 (2): p. 262-274. 
243. Tsai, C.S., Biomacromolecules: Introduction to Struture Function and Informatics 2007. New 
Jersey: Wiley-Liss. 
244. Purcell, E.M., Torrey, H.C., and Pound, R.V., Resonance Absorption by Nuclear Magnetic 
Moments in a Solid. Physical Review, 1946. 69 (1-2): p. 37-38. 
245. Bloch, F., Hansen, W.W., and Packard, M., Nuclear Induction. Physical Review, 1946. 70 (7-
8): p. 460-474. 
246. Lindley, D. Landmarks: NMR-Grandmother of MRI. Physical Review Focus, 2006. 18,  DOI: 
10.1103/PhysRevFocus.18.18 http://physics.aps.org/story/v18/st18  [Accessed on: 14 August 
2012]. 
247. Balci, M., Basic 1H- and 13C-NMR Spectroscopy 2005. The Netherlands: Elsevier. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
251 
 
248. Vialle, S., Sepulcri, P., Dubayle, J., and Talaga, P., The teichoic acid (C-polysaccharide) 
synthesized by Streptococcus pneumoniae serotype 5 has a specific structure. Carbohydrate 
Research, 2005. 340 (1): p. 91-96. 
249. Melander, W., Salt effect on hydrophobic interactions in precipitation and chromatography of 
proteins: an interpretation of the lyotropic series. Archives of Biochemistry and Biophysics, 
1977. 183 (1): p. 200-215. 
250. O’Farrell, P.A., Hydrophobic interaction chromatography, in Protein purification protocols, 
Cutler, P. 2004. Humana Press: New Jersey. p. 133-138. 
251. Dennison, C., A Guide to Protein Isolation 2003. The Netherlands: Kluwer Academic Publ. 
252. Zhang, Y. and Cremer, P.S., Interactions between macromolecules and ions: The Hofmeister 
series. Current Opinion in Chemical Biology, 2006. 10 (6): p. 658-663. 
253. Lyklema, J., Simple Hofmeister series. Chemical Physics Letters, 2009. 467 (4-6): p. 217-222. 
254. Vlachy, N., Jagoda-Cwiklik, B., Vacha, R., Touraud, D., Jungwirth, P., and Kunz, W., 
Hofmeister series and specific interactions of charged headgroups with aqueous ions. 
Advances in Colloid and Interface Science, 2009. 146 (1-2): p. 42-47. 
255. Guo, Y.-Y., Anderson, R., McIver, J., Gupta, R.K., and Siber, G.R., A simple and rapid 
method for measuring unconjugated capsular polysaccharide (PRP) of Haemophilus 
influenzae type b in PRP-tetanus toxoid conjugate vaccine. Biologicals, 1998. 26: p. 33-38. 
256. Lei, Q.P., Lamb, D.H., Heller, R., and Pietrobon, P., Quantitation of low level unconjugated 
polysaccharide in tetanus toxoid-conjugate vaccine by HPAEC/PAD following rapid 
separation by deoxycholate/HCl. Journal of Pharmaceutical and Biomedical Analysis, 2000. 
21: p. 1087-1091. 
257. Cui, S.W., Structural analysis of polysaccharides, in Food Carbohydrates: Chemistry, physical 
properties and applications, Cui, S.W. 2005. Taylor and Francis: Florida. 
258. Annex 1: Recommendations for the production and control of Haemophilus influenzae type b 
conjugate vaccines,  2000. World Health Orgaization Technical Report Series No 897.   
259. Recommendations to assure the quality, safety and efficacy of Group A meningococcal 
conjugate vaccines,  2006. World Health Organization WHO/BS/06.2041.   
260. Karamanos, N.K., Hjerpe, A., Tsegenidis, T., Engfeldt, B., and Antonopoulos, C.A., 
Determination of iduronic acid and glucuronic acid in glycosaminoglycans after stoichiometric 
reduction and depolymerization using high-performance liquid chromatography and ultraviolet 
detection. Analytical Biochemistry, 1988. 172: p. 410-419. 
261. Brudin, S.S., Shellie, R.A., Haddad, P.R., and Schoenmakers, P.J., Comprehensive two-
dimensional liquid chromatography: ion chromatography x reversed-phase liquid 
chromatography for separation of low-molar-mass organic acids. Journal of Chromatography 
A, 2010. 1217 (43): p. 6742-6746. 
262. Albersheim, P., Nevins, D.J., English, P.D., and Karr, A., A method for the analysis of sugars 
in plant cell-wall polysaccharides by gas-liquid chromatography. Carbohydrate Research, 
1967. 5 (3): p. 340-345. 
263. Bleton, J., P., M., Sansoulet, J., Goursaud, S., and Tchapla, A., Characterization of neutral 
sugars and uronic acids after methanolysis and trimethylsilylation for recognition of plant 
gums. Journal of Chromatography A, 1996. 720: p. 27-49. 
264. Nygren, Y., Fredriksson, S.-A., and Nilsson, B., Identification of sialic acid and related acids 
as acetylated lactones by gas chromatography/mass spectrometry. Journal of Mass 
Spectrometry, 1996. 31: p. 267-274. 
265. Rumpel, C. and Dignac, M.-F., Gas chromatographic analysis of monosaccharides in a forest 
soil profile: Analysis by gas chromatography after trifluoroacetic acid hydrolysis and 
reduction–acetylation. Soil Biology and Biochemistry, 2006. 38 (6): p. 1478-1481. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
252 
 
266. Sassaki, G.L., Souza, L.M., Serrato, R.V., Cipriani, T.R., Gorin, P.A., and Iacomini, M., 
Application of acetate derivatives for gas chromatography-mass spectrometry: novel 
approaches on carbohydrates, lipids and amino acids analysis. Journal of Chromatography A, 
2008. 1208 (1-2): p. 215-222. 
267. Martens, D.A. and Frankenberger Jr., W.T., Determination of saccharides in biological 
materials by high-performance anion-exchange chromatography with pulsed amerometric 
detection. Journal of Chromatography, 1991. 546: p. 293-309. 
268. Cataldi, T.R.I., Campa, C., and Casella, I.G., Study of sugar acids separation by high-
performance anion-exchange chromatography-pulsed amperometric detectio using alkaline 
eluents spiked with Ba, Sr, or Ca as acetate or nitrate salts. Journal of Chromatography A, 
1999. 848: p. 71-81. 
269. Somme, R., Degradation of glucuronic acid-containing exopolysaccharides from Rhizobium 
by the hakomori methylation procedure. Carbohydrate Research, 1986. 152: p. 237-241. 
270. Renard, C.M.G.C. and Jarvis, M.C., Acetylation and methylation of homogalacturonans 1: 
optimisation of the reaction and characterisation of the products. Carbohydrate Polymers, 
1999. 39: p. 201-207. 
271. Kim, J.S., Reuhs, B.L., Michon, F., Kaiser, R.E., and Arumugham, R.G., Addition of glycerol 
for improved methylation linkage analysis of polysaccharides. Carbohydrate Research, 2006. 
341 (8): p. 1061-1064. 
272. Kim, J.S., Laskowich, E.R., Michon, F., Kaiser, R.E., and Arumugham, R.G., Monitoring 
activation sites on polysaccharides by GC-MS. Analytical Biochemistry, 2006. 358 (1): p. 136-
142. 
273. Toukach, F.V., Kocharova, N.A., Maszewska, A., Shashkov, A.S., Knirel, Y.A., and Rozalski, 
A., Structure of the O-polysaccharide of Providenci  alcalifaciens O8 containing (2S,4R)-2,4-
dihydroxypentanoic acid, a new non-sugar component of bacterial glycans. Carbohydrate 
Research, 2008. 343 (15): p. 2706-2711. 
274. Hellerqvist, C.G., Hoffman, J., Lindberg, B., Pilotti, A., and Lindberg, A.A., Anomeric nature of 
the D-mannose residues in the Salmonella typhi  and S. strasbourg lipopolysaccharides. Acta 
Chemica Scandinavica, 1971. 25 (4): p. 1512-1513. 
275. Hoffman, J., Lindberg, B., and Svensson, S., Determination of the anomeric configuration of 
sugar residues in cetylated oligo- and polysaccharides by oxidation with chromium trioxide in 
acetic acid. Acta Chemica Scandinavica, 1972. 26: p. 661-666. 
276. Laine, R.A. and Renkonen, O., Analysis of anomeric configurations in glyceroglycolipids and 
glycosphingolipids by chromium trioxide oxidation. Journal of Lipid Research, 1975. 16: p. 
102-106. 
277. Itasaka, O., Sugita, M., Yoshizaki, H., and Hori, T., Determination of the anomeric 
configurations of Corbicula ceramide di- and trihexose by chromium trioxide oxidation. Journal 
of Biochemistry, 1976. 80: p. 935-936. 
278. Kochetkov, N.K., Chizhov, O.S., and Shashkov, A.S., Dependence of 13C chemical shifts on 
the spatial interactions of protons and its application in structural and conformational studies 
of oligo- and polysaccharides. Carbohydrate Research, 1984. 133: p. 173-185. 
279. Backman, I., Jansson, P.E., and Kenne, L., Synthesis, NMR and conformational studies of 
some 1,4-linked disaccharides. Journal of the Chemical Society, Perkin Transactions 1, 1990. 
(5): p. 1383-1388. 
280. Bush, C.A. and Martin-Pastor, M., Structure and conformation of complex carbohydrates of 
glycoproteins, glycolipids and bacterial polysaccharides. Annual Review of Biophysics and 
Biomolecular Structure, 1999. 28: p. 269-293. 
281. Abeygunawardana, C., Williams, T.C., Sumner, J.S., and Hennessey, J.P., Jr., Development 
and validation of an NMR-based identity assay for bacterial polysaccharides. Analytical 
Biochemistry, 2000. 279 (2): p. 226-240. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
253 
 
282. Wormald, M.R., Petrescu, A.J., Pao, Y.-L., Glithero, A., Elliot, T., and Dwek, R.A., 
Conformational studies of oligosaccharides and glycopeptides: Complementarity of NMR, X-
ray crystallography and molecular modelling. Chemical Reviews (Washington, D. C.), 2002. 
102: p. 371-386. 
283. Clement, M.J., Imberty, A., Phalipon, A., Perez, S., Simenel, C., Mulard, L.A., and Delepierre, 
M., Conformational studies of the O-specific polysaccharide of Shigella flexneri 5a and of four 
related synthetic pentasaccharide fragments using NMR and molecular modeling. Journal of 
Biological Chemistry, 2003. 278 (48): p. 47928-47936. 
284. Fehér, K., Pristovšek, P., Szilágyi, L., Ljevaković, Đ., and Tomašić, J., Modified glycopeptides 
related to cell wall peptidoglycan: conformational studies by NMR and molecular modelling. 
Bioorganic & Medicinal Chemistry, 2003. 11 (14): p. 3133-3140. 
285. Aubin, Y., Jones, C., and Freedberg, D.I., Using NMR Spectroscopy to obtain the higher order 
structure of biopharmaceutical products. BioPharm International, 2010. (Supplement): p. 28-
38. 
286. Heidelberger, M., Goebel, W.F., and Avery, O.T., The soluble specific substance of 
pneumococcus: Third paper. Journal of Experimental Medicine, 1925. 42 (5): p. 727-745. 
287. Avery, O.T. and Goebel, W.F., Chemoimmunological studies on the soluble specific 
substance of pneumococcus: I The isolation and properties of the acetyl polysaccharide of 
pneumococcus type I. Journal of Experimental Medicine, 1933. 58 (6): p. 731-755. 
288. Heidelberger, M., Kendall, F.E., and Scherp, H.W., The specific polysaccharides of types I, II 
and III pneumococcus. Journal of Experimental Medicine, 1936. 64 (4): p. 559-572. 
289. Alberty, R.A. and Heidelberger, M., Fractionation and physical-chemical studies of a 
commercial preparation of the specific polysaccharide of type I pneumococcus. Journal of the 
American Chemical Society, 1948. 70 (1): p. 211-213. 
290. Smith, E.E.B., Galloway, B., and Mills, G.T., The purification and composition of type I 
pneumococcal capsular polysaccharide. Biochemical Journal, 1960. 76: p. 35P. 
291. Guy, R.C.E., How, M.J., Stacey, M., and Heidelberger, M., Capsular polysaccharide of type 1 
pneumococcus: I Purification and chemical modification. The Journal of Biological Chemistry, 
1967. 212 (21): p. 5106-5111. 
292. Lindberg, B., Lindqvist, B., Lonngren, J., and Powell, D.A., Structural studies of the capsular 
polysaccharide from Streptococcus pneumoniae type 1. Carbohydrate Research, 1980. 78: p. 
111-117. 
293. Stroop, C.J.M., Xu, Q., Retzlaff, M., Abeygunawardana, C., and Bush, C.A., Structural 
analysis and chemical depolymerization of the capsular polysaccharide of Streptococcus 
pneumoniae type 1. Carbohydrate Research, 2002. 337: p. 335-344. 
294. European Pharmacopoeia. 6 ed 2007. Strasbourg: Council of Europe. 
295. Guidance for Industry: Q2B validation of analytical procedures: methodology, 1996. FDA.    
296. Riley, C.M. and Rosanske, T.W. Development and Validation Of Analytical Methods. 
Progress in Pharmaceutical and Biomedical Analysis, ed. Riley, C.M. and Fell, A.F. Vol. 3. 
1996. Elsevier Science. 
297. Guideline for Industry: Text on validation of analytical procedures,  1995. FDA ICH-Q2A.   
298. Bowness, J.M., 5-Formylfuroic acid and the carbazole reaction for uronic acids and acidic 
polysaccharides. Biochemical Journal, 1958. 70 (1): p. 107-111. 
299. Li, J., Kisara, K., Danielsson, S., Lindstrom, M.E., and Gellerstedt, G., An improved 
methodology for the quantification of uronic acid units in xylans and other polysaccharides. 
Carbohydrate Research, 2007. 342 (11): p. 1442-1449. 
300. Recommendations for the production and control of pneumococcal conjuugate vaccines,  
2003. World Health Organization.    
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
254 
 
301. Hestrin, S. and Mager, J., Color test for identification of glucose. Analytical Chemistry, 1947. 
19 (12): p. 1032-1035. 
302. Guzowski Jnr., J.P., Golanoski, C., and Montgomery, E.R., A gas chromatographic method 
for the indirect determination of hydroxylamine in pharmaceutical preparations: conversion 
into nitrous oxide. Journal of Pharmaceutical and Biomedical Analysis, 2003. 33: p. 963-974. 
303. Chaplin, M.F. and Kennedy, J. Carbohydrate Analysis: A practical approach. 2 ed. The 
Practical Approach Series, ed. Rickwood, D. and Hames, B.D. 2003. Oxford University Press. 
304. Brummer, Y. and Cui, C., Understanding carbohydrate analysis,  2005. Taylor and Francis. 
305. Englyst, H.N. and Cummings, J.H., Simplified method for the measurement of total non-starch 
polysaccharides by gas-liquid chromatography of constituent sugars as alditol acetates. The 
Analyst, 1984. 109 (7): p. 937-942. 
306. Garna, H., Mabon, N., Nott, K., Wathelet, B., and Paquot, M., Kinetic of the hydrolysis of 
pectin galacturonic acid chains and quantification by ionic chromatography. Food Chemistry, 
2006. 96 (3): p. 477-484. 
307. Chambers, R.E. and Clamp, J.R., An assessment of methanolysis and other factors used in 
the analysis of carbohydrate-containing materials. Journal of Biochemistry (Great Britain), 
1971. 125: p. 1009-1018. 
308. Yu Ip, C.C., Manam, V., Hepler, R., and Hennessey Jr, J.P., Carbohydrate composition 
analysis of bacterial polysaccharides: Optimized acid hydrolysis conditions for HPAEC-PAD 
analysis. Analytical Biochemistry, 1992. 201: p. 343-349. 
309. Arnous, A. and Meyer, A.S., Quantitative prediction of cell wall polysaccharide composition in 
grape (Vitis vinifera L.) and apple (Malus domestica) skins from acid hydrolysis 
monosaccharide profiles. Journal of Agricultural & Food Chemistry, 2009. 57 (9): p. 3611-
3619. 
310. Fengel, D. and Wegener, G., Hydrolysis of cellulose: mechanisms of enzymatic and acid 
catalysis, in Advances in Chemistry 1979. American Chemical Society. p. 145-158. 
311. De Ruiter, G.A., Schols, H.A., Voragen, G.J., and Rombouts, F.M., Carbohydrate analysis of 
water-soluble uronic acid-containing polysaccharides with high-performance anion-exchange 
chromatography using methanolysis combined with TFA hydrolysis is superior to four other 
methods. Analytical Biochemistry, 1992. 207: p. 176-185. 
312. Boons, G.-J., Lee, Y.C., Suruki, A., Taniguchi, N., and Voragen, A.G.J. Comprehensive 
glycoscience: From chemistry to systems biology. ed. Kamerling, J.P. 2007. Elsevier: The 
Netherlands. 
313. Talaga, P., Bellamy, L., and Moreau, M., Quantitative determination of C-polysaccharide in 
Streptococcus pneumoniae capsular polysaccharides by use of high-performance anion-
exchange chromatography with pulsed amperometric detection. Vaccine, 2001. 19: p. 2987-
2994. 
314. Manzi, A.E., Total compositional analysis by high-performance liquid chromatography or gas-
liquid chromatography, in Current Protocols in Molecular Biology 2000. John Wiley and Sons. 
315. Willför, S., Pranovich, A., Tamminen, T., Puls, J., Laine, C., Suurnäkki, A., Saake, B., Uotila, 
K., Simolin, H., Hemming, J., and Holmbom, B., Carbohydrate analysis of plant materials with 
uronic acid-containing polysaccharides–A comparison between different hydrolysis and 
subsequent chromatographic analytical techniques. Industrial Crops and Products, 2009. 29 
(2-3): p. 571-580. 
316. Sweeley, C.C. and Walker, B., Determination of carbohydrates in glycolipides and 
gangliosides by gas chromatography. Analytical Chemistry, 1964. 36 (8): p. 1461-1466. 
317. Jeanloz, R.W. and Jeanloz, D.A., The degradation of hyaluronic acid by methanolysis. 
Biochemistry, 1964. 3 (1): p. 121-123. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
255 
 
318. Quemener, B., Lehave, M., and Metro, F., Assessment of methanolysis for the determination 
of composite sugars of gelling carrageenans and agarose by HPLC. Carbohydrate Research, 
1995. 266: p. 53-64. 
319. Quemener, B., Marot, C., Mouillet, L., Da Riz, V., and Diris, J., Quantitative analysis of 
hydrocolloids in food systems by methanolysis coupled to reverse HPLC. Part 2. Pectins, 
alginates and xanthan. Food Hydrocolloids, 2000. 14: p. 19-28. 
320. Bertaud, F., Sundberg, A., and Holmbom, B., Evaluation of acid methanolysis for analysis of 
wood hemicelluloses and pectins. Carbohydrate Polymers, 2002. 48: p. 319-324. 
321. Poxton, I.R., Tarello, E., and Baddiley, J., The structure of C-polysaccharide from the walls of 
Streptococcus pneumoniae. Biochemical Journal, 1978. 175: p. 1033-1042. 
322. Gedye, R., Smith, F., Westaway, K., Ali, H., Baldisera, L., Laberge, L., and Rousell, J., The 
use of microwave ovens for rapid organic synthesis. Tetrahedron Letters, 1986. 27 (3): p. 
279-282. 
323. Lidstrom, P., Tierney, J., Wathey, B., and Westman, J., Microwave assisted organic synthesis 
- a review. Tetrahedron 2001. 57: p. 9225-9283. 
324. Loupy, A., Perreux, L., Liagre, M., Burle, K., and Moneuse, M., Reactivity and selectivity 
under microwaves in organic chemistry. Relation with medium effects and reaction 
mechanisms. Pure and Applied Chemistry, 2001. 73 (1): p. 161-166. 
325. Corsaro, A., Chiacchio, U., Pistara, V., and Romeo, G., Microwave-assisted chemistry of 
carbohydrates. Current Organic Chemistry, 2004. 8: p. 511-538. 
326. Hayes, B., Recent Advances in Microwave-assisted synthesis. Aldrichimica ACTA, 2004. 37 
(2): p. 66-76. 
327. de la Hoz, A., Diaz-Ortiz, A., and Moreno, A., Microwaves in organic synthesis. Thermal and 
non-thermal microwave effects. Chemical Society Reviews, 2005. 34 (2): p. 164-178. 
328. Kappe, C.O. and Stadler, A. Microwaves in Organic and Medicinal Chemistry. Wiley-VCH. 
Available from: http://onlinelibrary.wiley.c m/book/10.1002/3527606556. [Accessed on:05 
June 2012]. 
329. Wiesbrock, F. and Schubert, U.S., Microwaves in chemistry: the success story goes on. 
Chemistry Today, 2006. 24 (3): p. 30-33. 
330. Horikoshi, S. and Serpone, N., Photochemistry with microwaves. Journal of Photochemistry 
and Photobiology C: Photochemistry Reviews, 2009. 10 (2): p. 96-110. 
331. Richel, A., Laurent, P., Wathelet, B., Wathelet, J.-P., and Paquot, M., Microwave-assisted 
conversion of carbohydrates. State of the art and outlook. Comptes Rendus Chimie, 2011. 14 
(2-3): p. 224-234. 
332. Margolis, S.A., Jassie, L., and Kingston, H.M., The hydrolysis of proteins by microwave 
energy. Journal of Automatic Chemistry, 1991. 13 (3): p. 93-95. 
333. Fara, M.A., Díaz-Mochón, J.J., and Bradley, M., Microwave-assisted coupling with DIC/HOBt 
for the synthesis of difficult peptoids and fluorescently labelled peptides—a gentle heat goes a 
long way. Tetrahedron Letters, 2006. 47 (6): p. 1011-1014. 
334. Paolini, I., Nuti, F., de la Cruz Pozo-Carrero, M., Barbetti, F., Kolesinska, B., Kaminski, Z.J., 
Chelli, M., and Papini, A.M., A convenient microwave-assisted synthesis of N-glycosyl amino 
acids. Tetrahedron Letters, 2007. 48 (16): p. 2901-2904. 
335. Engelhart, W.G., Microwave hydrolysis of peptides and proteins for amino acid analysis. Am. 
Biotechnol. Lab, 1990. 15: p. 31-34. 
336. Bornaghi, L.F. and Poulsen, S.-A., Microwave-accelerated Fischer glycosylation. Tetrahedron 
Letters, 2005. 46 (20): p. 3485-3488. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
256 
 
337. de Paula, V.C., Pinheiro, I.O., Lopes, C.E., and Calazans, G.C., Microwave-assisted 
hydrolysis of Zymomonas mobilis levan envisaging oligofructan production. Bioresource 
Technology, 2008. 99 (7): p. 2466-2470. 
338. Singh, V., Tiwari, A., Tripathi, D.N., and Malviya, T., Microwave promoted methylation of plant 
polysaccharides. Tetrahedron Letters, 2003. 44 (39): p. 7295-7297. 
339. Hirose, T., Kopek, B.G., Wang, Z.H., Yusa, R., and Baldwin, B.W., Microwave oven synthesis 
of esters promoted by imidazole. Tetrahedron Letters, 2003. 44: p. 1831-1833. 
340. Soderholm, S.L., Damm, M., and Kappe, C.O., Microwave-assisted derivatization procedures 
for gas chromatography/mass spectrometry analysis. Molecular Diversity, 2010. 14 (4): p. 
869-888. 
341. Lamble, K.J. and Hill, S.J., Microwave digestion procedures for environmental matrices. The 
Analyst, 1998. 123: p. 103-133. 
342. Cheng, M.-C., Wang, K.-T., Inoue, S., Inoue, Y., Khoo, K.-H., and Wu, S.-H., Controlled acid 
hydrolysis of colominic acid under microwave irradiation. Analytical Biochemistry, 1999. 267: 
p. 287-293. 
343. Singh, V., Sethi, R., Tewari, A., Srivastava, V., and Sanghi, R., Hydrolysis of plant seed gums 
by microwave irradiation. Carbohydrate Polymers, 2003. 54 (4): p. 523-525. 
344. Xing, R., Liu, S., Yu, H., Guo, Z., Wang, P., Li, C., Li, Z., and Li, P., Salt-assisted acid 
hydrolysis of chitosan to oligomers under microwave irradiation. Carbohydrate Research, 
2005. 340 (13): p. 2150-2153. 
345. Orozco, A., Ahmad, M., Rooney, D., and Walker, G., Dilute acid hydrolysis of cellulose and 
cellulosic bio-waste using a microwave reactor system. Process Safety and Environmental 
Protection, 2007. 85 (5): p. 446-449. 
346. Zhao, J. and Monteiro, M.A., Hydrolysis of bacterial wall carbohydrates in the microwave 
using trifluoroacetic acid. Carbohydrate Research, 2008. 343 (14): p. 2498-2503. 
347. Chhatbar, M., Meena, R., Prasad, K., and Siddhanta, A.K., Microwave assisted rapid method 
for hydrolysis of sodium alginate for M/G ratio determination. Carbohydrate Polymers, 2009. 
76 (4): p. 650-656. 
348. Allard, B. and Derenne, S., Microwave assisted extraction and hydrolysis: An alternative to 
pyrolysis for the analysis of recalcitrant organic matter? Application to a forest soil (Landes de 
Gascogne, France). Organic Geochemistry, 2009. 40 (9): p. 1005-1017. 
349. Zhang, Z. and Zhao, Z.K., Solid acid and microwave-assisted hydrolysis of cellulose in ionic 
liquid. Carbohydrate Research, 2009. 344 (15): p. 2069-2072. 
350. Yoshida, T., Tsubaki, S., Teramoto, Y., and Azuma, J.I., Optimization of microwave-assisted 
extraction of carbohydrates from industrial waste of corn starch production using response 
surface methodology. Bioresource Technology, 2010. 101 (20): p. 7820-7826. 
351. Dřímalová, E., Velebný, V., Sasinková, V., Hromádková, Z., and Ebringerová, A., Degradation 
of hyaluronan by ultrasonication in comparison to microwave and conventional heating. 
Carbohydrate Polymers, 2005. 61 (4): p. 420-426. 
352. Bezáková, Z., Hermannová,  ., Dřímalová, E.,  a lovíková, A., Ebringerová, A., and Velebný, 
V., Effect of microwave irradiation on the molecular and structural properties of hyaluronan. 
Carbohydrate Polymers, 2008. 73 (4): p. 640-646. 
353. Choi, J.-i., Kim, J.-K., Kim, J.-H., Kweon, D.-K., and Lee, J.-W., Degradation of hyaluronic 
acid powder by electron beam irradiation, gamma ray irradiation, microwave irradiation and 
thermal treatment: A comparative study. Carbohydrate Polymers, 2010. 79 (4): p. 1080-1085. 
354. Microwave Chemistry: How it all works. CEM Corporation. Available from: 
http://cem.com/page130.html. [Accessed on:20 December 2011]. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
257 
 
355. Giguere, R.J., Bray, T.L., Duncan, S.M., and Majetich, G., Application of commercial 
microwave ovens to organic synthesis. Tetrahedron Letters, 1986. 27 (41): p. 4945-4948. 
356. Kunlan, L., Lixin, X., Jun, P., Guoying, C., and Zuwei, X., Salt assisted acid hydrolysis of 
starch to D-glucose under microwave irradiation. Carbohydrate Research, 2001. 331: p. 9-12. 
357. Chang, M., Meyers, H.V., Nakanishi, K., Ojika, M., Park, J.H., Park, M.H., Takeda, R., 
Vazquez, J.T., and Wiesler, W.T., Microscale structure determination of oligosaccharides by 
the exciton chirality method. Pure and Applied Chemistry, 1989. 61 (7): p. 1193-1200. 
358. Itonori, S., Takahashi, M., Kitamura, T., Aoki, K., Dulaney, J.T., and Sugita, M., Microwave-
mediated analysis for sugar, fatty acid, and sphingoid compositions of glycosphingolipids. 
Journal of Lipid Research, 2004. 45 (3): p. 574-581. 
359. Khan, M.U. and Williams, J.P., Microwave-mediated methanolysis of lipids and activation of 
thin-layer chromatographic plates. Lipids, 1993. 28: p. 953-955. 
360. Oigman, S.S., de Souza, R.O., Dos Santos Junior, H.M., Hovell, A.M., Hamerski, L., and 
Rezende, C.M., Microwave-assisted methanolysis of green coffee oil. Food Chemistry, 2012. 
134 (2): p. 999-1004. 
361. Larsson, K. and Petersson, G., Methanolysis of galacturonic acid. Dimethyl acetals. 
Carbohydrate Research, 1974. 34: p. 323-329. 
362. Petersson, G., Samuelson, O., Anjou, K., and von Sydow, E., Mass spectrometric 
identification of aldolactones as trimethylsilyl ethers. Acta Chemica Scandinavica, 1967. 21: p. 
1251-1256. 
363. Jones, C. and Mulloy, B., The application of nuclear magnetic resonance to structural studies 
of polysaccharides, in Methods in Molecular Biology, Jones, C. and Mulloy, B. 1993. Humana 
Press Inc. 
364. Watson, M.J. and Baddiley, J., The action of nitrous acid on C-teichoic acid (C-substance) 
from the walls of Diplococcus pneumoniae. Journal of Biochemistry (Great Britain), 1974. 137: 
p. 399-404. 
365. Kulakowska, M., Brisson, J.-R., Griffith, D.W., Young, N.M., and Jennings, H.J., High 
resolution NMR spectroscopic analysis of the C-polysaccharide of Streptococcus 
pneumoniae. Canadian Journal of Chemistry, 1993. 71 (5): p. 644-648. 
366. Karlsson, C., Jansson, P.E., and Sorenson, U., The pneumococcal common antigen C-
polysaccharide occurs in different forms. European Journal of Biochemistry, 1999. 265: p. 
1091-1097. 
367. Kniskern, P.J., Ip, C.C., Hagopian, A., Hennessey Jr, J.P., Miller, W.J., Kubek, D.J., Burke, 
P.D., Marburg, S., and Tolman, R.L. for Merck & Co Inc. Pneumococcal polysaccharide 
conjugate vaccine. 2010. Office, E.P. 92300655.5. EP 0497525B2.  
368. Enders, J.F. and Wu, C.-Y., An immunological study of the A substance or acetyl 
polysaccharide of pneumococcus type I. Journal of Experimental Medicine, 1934. 60 (2): p. 
127-147. 
369. Chow, B.F., Immunological studies on a new preparation of type specific polysaccharide from 
pneumococcus type I. Journal of Experimental Medicine, 1936. 64 (6): p. 843-854. 
370. Jansson, P.-E., Kenne, L., and Schweda, E., Nuclear magnetic resonance and conformational 
studies on monoacetylated methyl D-gluco- and D-galacto-pyranosides. Journal of the 
Chemical Society, Perkin Transactions 1, 1987. p. 377-383. 
371. Kapre, S. and Jana, S.K. for Serum Institute of India Ltd. Purification of capsular 
polysaccharides. 2011. Organization, W.I.P. PCT/IN2011/000332. WO 2011/145108 A2.  
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
258 
 
372. Goncalves, V.M., Takagi, M., Carmo, T.S., Lima, R.B., Ferreira, F., Albani, S.M., Pinto, F.R., 
Zangirolami, T.C., Giordano, R.C., Tanizaki, M.M., and Cabrera-Crespo, J., Simple and 
efficient method of bacterial polysaccharides purification for vaccines production using 
hydrolytic enzymes and tangential flow ultrafiltration, in Communicating Current Research and 
Educational Topics and Trends in Applied Microbiology, Mendez-Vilas, A. 2007. p. 450-457. 
373. Gonçalves, V.M., Zangirolami, T.C., Giordano, R.L.C., Raw, I., Tanizaki, M.M., and Giordano, 
R.C., Optimization of medium and cultivation conditions for capsular polysaccharide 
production by Streptococcus pneumoniae serotype 23F. Applied Microbiology & 
Biotechnology, 2002. 59 (6): p. 713-717. 
374. Yuan, Y., Ruppen, M.E., Sun, W., Chu, L., Simpson, J., Patch, J., Charbonneau, P., and 
Moran, J.K. for Wyeth. Shortened purification process for the production of capsular 
streptococcus pneumoniae polysaccharides. 2012. Office, E.P. 11194173.8. EP 2436700 A1.  
375. Ravenscroft, N. and Feavers, I.M., Conjugate Vaccines, in Meningococcal Disease. 
Pathogenicity and Prevention, Frosch, M. and Maiden, M. 2006. Wiley-VCH Verlag GmbH & 
Co KGaA: Weinheim. p. 343-369. 
376. Assessment report for Prevenar 13,  2009. European Medicines Agency Procedure No: 
EMEA/H/C/001104.   
377. Pawlowski, A. and Svenson, S.B., Electron beam fragmentation of bacterial polysaccharides 
as a method of producing oligosaccharides for the preparation of conjugate vaccines. FEMS 
Microbiology Letters, 1999. 174: p. 255-263. 
378. Svenson, S.B. and Lindberg, A.A., Oligosaccharide-protein conjugate: a novel approach for 
making Salmonella O-antigen immunogens. FEMS Microbiology Letters, 1977. 1: p. 145-148. 
379. Svenson, S.B. and Lindberg, A.A., Coupling of acid labile Salmonella specific 
oligosaccharides to macromolecular carriers. Journal of Immunological Methods, 1979. 25: p. 
232-335. 
380. Anderson, P.W., Pichichero, M.E., Stein, E.C., Porcelli, S., Betts, R.F., Connuck, D.M., 
Korones, D., Insel, R.A., Zahradnik, J.M., and Eby, R., Effect of oligosaccharide chain length, 
exposed terminal group, and hapten loading on the antibody response of human adults and 
infants to vaccines consisting on Haemophilus influenzae type b capsular antigen 
uniterminally coupled to the diphtheria protein CRM197. The Journal of Immunology, 1989. 
142 (7): p. 2464-2468. 
381. Paoletti, L.C., Kasper, D.L., Michon, F., DiFabio, J., Jennings, H.J., Tosteson, T.D., and 
Wessels, M.R., Effects of chain length on the immunogenicity in rabbits of group 
Streptococcus type III oligosaccharide-tetanus toxoid conjugates. Journal of Clinical 
Investigation, 1992. 89: p. 203-209. 
382. Kabat, E.A. and Bezer, A.E., The effect of variation in molecular weight on the antigenicity of 
dextran in man. Archives of Biochemistry and Biophysics, 1958. 78: p. 306-318. 
383. Brandt, B.L., Artenstein, M.S., and Smith, C.D., Antibody responses to meningococcal 
polysaccharide vaccines. Infection and Immunity, 1973. 8: p. 590-596. 
384. Martin, D.G., Jarvis, F.G., and Milner, K.C., Physicochemical and biological properties of 
sonically treated Vi antigen. Journal of Bacteriology, 1967. 94: p. 1411-1416. 
385. MacNair, J.E., Desai, T., Teyral, J., Abeygunawardana, C., and Hennessey, J.P., Jr., 
Alignment of absolute and relative molecular size specifications for a polyvalent 
pneumococcal polysaccharide vaccine (PNEUMOVAX 23). Biologicals, 2005. 33 (1): p. 49-
58. 
386. Biemans, R.L., Garcon, N.M.-J., Hermand, P., Poolman, J., and Van Mechellen, M.P. for 
GlaxoSmithKline Biologicals Vaccine comprising Streptococcus pneumoniae capsular 
polysaccharide conjugates. 2009. Office, U.S.P. 12/097631. US2009/0017059 A1.  
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
259 
 
387. Czechowska-Biskup, R., Rokita, B., Lotfy, S., Ulanski, P., and Rosiak, J.M., Degradation of 
chitosan and starch by 360-kHz ultrasound. Carbohydrate Polymers, 2005. 60 (2): p. 175-
184. 
388. Cook, E.J. and Lagace, A.P. for Biotechnology Development Corporation. Apparatus for 
forming emulsions. 1985. Office, U.S.P. 581568. 4533254.  
389. Zon, G., Szu, S., Egan, W., Robbins, J.D., and Robbins, J.B., Hydrolytic stability of 
pneumococcal group 6 (type 6A and 6B) capsular polysaccharides. Infection and Immunity, 
1982. 37 (1): p. 89-103. 
390. Lee, C.H. and Frasch, C.E. for The Government of the United States of America. 
Polysaccharide-protein conjugate vaccines. 2005. Organization, W.I.P. PCT/US2004/025477. 
WO 2005/014037 A2.  
391. Alouf, J.E. and Popoff, M.R. The comprehensive sourcebook of bacterial protein toxins.  
2006. Academic Press. 
392. Lavelle, E.C., Leavy, O., and Mills, K.H.G., Modified Bacterial Toxins, Hackett, C.J. and Harn, 
D.A. 2006. Humana Press. 
393. Robinson, J.P., Picklesimer, J.B., and Puett, D., Tetanus Toxin. The Journal of Biological 
Chemistry, 1975. 250 (18): p. 7435-7442. 
394. Bizzini, B., Blass, J., Turpin, A., and Raynaud, M., Chemical characterization of tetanus toxin 
and toxoid. European Journal of Biochemistry, 1970. 17: p. 100-105. 
395. Diphtheria toxin, diphtheria toxoid, CRM mutant, 1994. List Biological Laboratories Inc.   
396. Vliegenthart, J.F., Carbohydrate based vaccines. FEBS Letters, 2006. 580 (12): p. 2945-
2950. 
397. Pollabauer, E.M., Petermann, R., and Ehrlich, H.J., The influence of carrier protein on the 
immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine, 2009. 
27 (11): p. 1674-1679. 
398. Peptides for immunization,  2008. Thermo Fisher Scientific Application note: TI-PEP06-0908.   
399. Inman, J.K. and Dintzis, H.M., The derivatisation of cross-linked polyacrylamide beads. 
Controlled introduction of functional groups for the preparation of special purpose, 
biochemical adsorbants. Biochemistry, 1969. 8 (10): p. 4074-4082. 
400. Hermanson, G.T., Bioconjugate Techniques 2008. United Kingdon: Academic Press. 
401. NeisVac-C Product monograph: Suspension for injection in pre-filled syringe Meningococcal 
group C polysaccharide conjugate vaccine (adsorbed),  2009. Baxter International Inc.    
402. Verez Bencomo, V., Fernandez Santana, V., Hardy, E., Toledo, M.E., Rodriguez, M.C., 
Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo, M., Villar, A., Valdes, Y., 
Cosme, K., Deler, M.L., Montane, M., Garcia, E., Ramos, A., Aguilar, A., Medina, E., Torano, 
G., Sosa, I., Hernandez, I., Martinez, R., Muzachio, A., Carmenates, A., Costa, L., Cardoso, 
F., Campa, C., Diaz, M., and Roy, R., A synthetic conjugate polysaccharide vaccine against 
Haemophilus influenze type b. Science, 2004. 305: p. 522-525. 
403. Fernandez Santana, V., Peña Icart, L., Beurret, M., Costa, L., and Verez Bencomo, V., 
Glycoconjugate vaccines against Haemophilus influenzae type b. Methods in Enzymology, 
2006. 415: p. 153-163. 
404. Lee, C.H., Kuo, W.C., Beri, S., Kapre, S., Joshi, J.S., Bouveret, N., LaForce, F.M., and 
Frasch, C.E., Preparation and characterization of an immunogenic meningococcal group A 
conjugate vaccine for use in Africa. Vaccine, 2009. 27 (5): p. 726-732. 
405. Pace, D., Pollard, A.J., and Messonier, N.E., Quadrivalent meningococcal conjugate 
vaccines. Vaccine, 2009. 27 (Supplement 2): p. B30-B41. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
260 
 
406. WHO prequalified vaccines: Filterable search for prequalified vaccines with product detail. 
World Health Organization. Available from: 
http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/. 
[Accessed on:08 July 2012]. 
407. Knuf, M., Kowalzik, F., and Kieninger, D., Comparative effects of carrier proteins on vaccine-
induced immune response. Vaccine, 2011. 29 (31): p. 4881-4890. 
408. Ada, G. and Isaacs, D., Carbohydrate-protein conjugate vaccines. Clinical Microbiology and 
Infection, 2003. 9 (2): p. 79-85. 
409. Eskola, J., Use of conjugate vaccines to prevent meningitis caused by Haemophilus 
influenzae type b or Streptococcus pneumoniae. Journal of Hospital Infection, 1995. 30: p. 
313-321. 
410. Marburg, S., Jorn, D., Tolman, R.L., Arison, B., McCauley, J., Kniskern, P.J., Hagopian, A., 
and Vella, P.P., Bimolecular chemistry of macromolecules: Synthesis of bacterial 
polysaccharide conjugates with Neuisseria meningitidis membrane protein. Journal of the 
American Chemical Society, 1986. 108: p. 5282-5287. 
411. Eskola, J., Foresight in medicine: current challenges with Haemophilus influenzae type b 
conjugate vaccines. Journal of Internal Medicine, 2010. 267 (3): p. 241-250. 
412. Ladhani, S.N., Two decades of experience with the Haemophilus influenzae serotype b 
conjugate vaccine in the United Kingdom. Clinical Therapeutics, 2012. 34 (2): p. 385-399. 
413. Ward, J.I., Brenneman, G., Letson, G.W., and Heyward, W.L., Limited efficacy of a 
Haemophilus influenzae type b conjugate vaccine in Alaska native infants. New England 
Journal of Medicine, 1990. 323 (20): p. 1393-1401. 
414. Eskola, J., Kayhty, H., Takala, A.K., McVerry, P.H., and Makela, P.H., A randomised, 
prosprective field trial of a conjugate vaccine in the protection of infants and young children 
against invasive Haemophilus influenzae type b disease. New England Journal of Medicine, 
1990. 232 (20): p. 1381-1387. 
415. Schlesinger, Y. and Granoff, D.M., Avidity and bactericidal activity of antibody elicited by 
different Haemophilus influenzae type b conjugate vaccines. The Journal of the American 
Medical Association, 1992. 267: p. 1489-1494. 
416. Lucas, A.H. and Granoff, D.M., Functional differences in idiotypically defined IgG1 anti-
polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B 
polysaccharide-protein conjugates. The Journal of Immunology, 1995. 154 (8): p. 4195-4202. 
417. Decker, M.D., Edwards, K.M., Bradley, M., and Palmer, P., Comparitive trial in infants of four 
conjugate Haemophilus influenzae type b vaccines. Journal of Pediatrics, 1992. 120: p. 184-
189. 
418. Richmond, P., Borrow, R., Findlow, J., Martin, S., Thornton, C., Cartwright, K., and Miller, E., 
Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate 
vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal 
activity against O-acetylated and De-O-acetylated serogroup C strains. Infection and 
Immunity, 2001. 69 (4): p. 2378-2382. 
419. Fusco, P.C., Farley, E.K., Huang, C.H., Moore, S., and Michon, F., Protective meningococcal 
capsular polysaccharide epitopes and the role of O acetylation. Clinical and Vaccine 
Immunology, 2007. 14 (5): p. 577-584. 
420. Peltola, H., Safary, A., Kayhty, H., Karanko, V., and Andre, F.E., Evaluation of two tetravalent 
(ACYW135) meningococcal vaccines in infants and small children: A clinical study comparing 
immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. 
Pediatrics, 1985. 76: p. 91-96. 
421. Assessment report for Menveo,  2008. European Medicines Agency Procedure No: 
EMEA/H/C/001095.   
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
261 
 
422. Cooper, B., DeTora, L., and Stoddard, J., Menveo: a novel quadrivalent meningococcal 
CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Review of 
Vaccines, 2011. 10 (1): p. 21-33. 
423. Assessment report for Nimenrix,  2012. European Medicines Agency Procedure no: 
EMEA/H/C/002226.   
424. Dagan, R., Poolman, J., and Siegrist, C.A., Glycoconjugate vaccines and immune 
interference: A review. Vaccine, 2010. 28 (34): p. 5513-5523. 
425. Dagan, R., Eskola, J., Leclerc, C., and Leroy, O., Reduced response to multiple vaccines 
sharing common protein epitopes that are administered simultaneously to infants. Infection 
and Immunity, 1998. 66 (5): p. 2093-2098. 
426. Anderson, P., Treanor, J., Porcelli, S., and Pichichero, M., Non-interference between two 
protein carriers when used with the same polysaccharide for pneumococcal conjugate 
vaccines in 2-year-old children. Vaccine, 2003. 21 (13-14): p. 1554-1559. 
427. Murayama, K. and Tomida, M., Heat-induced secondary structure and conformation change 
of bovine serum albumin investigated by Fourier transform infrared spectroscopy. 
Biochemistry, 2004. 43 (36): p. 11526-11532. 
428. Weijers, R.N.M., Amino acid sequence in bovine serum albumin. Clinical Chemistry, 1977. 23 
(7): p. 1361-1362. 
429. Benjamin, D.C., Evidence for specific suppression in the maintenance of immunologic 
tolerance. Journal of Experimental Medicine, 1975. 141: p. 635-647. 
430. Ruoslahti, E. and Engvall, E., Immunological crossreaction between alpha-fetoprotein and 
albumin. Proceedings of the National Academy of Sciences, USA, 1976. 73 (12): p. 4641-
4644. 
431. Vicente-Serrano, J., Caballero, M.L., Rodríguez-Pérez, R., Carretero, P., Pérez, R., Blanco, 
J.G., Juste, S., and Moneo, I., Sensitization to serum albumins in children allergic to cow's 
milk and epithelia. Pediatric Allergy and Immunology, 2007. 18 (6): p. 503-507. 
432. Robbins, J.B. and Schneerson, R., Polysaccharide-protein conjugates: A new generation of 
vaccines. The Journal of Infectious Diseases, 1990. 161 (5): p. 821-832. 
433. Kossaczka, Z., Bystricky, S., Bryla, D., Shiloach, J., Robbins, J.B., and Szu, S., Synthesis and 
immunological properties of Vi and Di-O-acetyl pectin protein conjugates with adipic acid 
dihydrazide as the linker. Infection and Immunity, 1997. 65 (6): p. 2088-2093. 
434. Shafer, D.E., Toll, B., Schuman, R.F., Nelson, B.L., Mond, J.J., and Lees, A., Activation of 
soluble polysaccharides with 1-cyano-4-dimethylaminopyridium tetrafluoroborate (CDAP) for 
use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective 
crosslinking of proteins to CDAP-activated polysaccharides. Vaccine 2000. 18: p. 1273-1281. 
435. Beuvery, E.C., Miedema, F., van Delft, R., and Haverkamp, J., Preparation and 
immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid 
conjugates as a new generation of vaccines. Infection and Immunity, 1983. 40 (1): p. 39-45. 
436. Beuvery, E.C., Roy, R., Kanhai, V., and Jennings, H.J., Characteristics of two types of 
meningococcal group C polysaccharide conjugates using tetanus toxoid as carrier protein. 
Developments in Biological Standardization, 1986. 65: p. 197-204. 
437. Beuvery, E.C., Speijers, G.J.A., Lutz, B.I.G., Freudenthal, D., Kanhai, V., Haagmans, B., and 
Derks, H., Analytical, toxicological and immunological consequences of the use of N-ethyl-N'-
(3-dimethylaminopropyl) carbodiimide as coupling reagent for the preparation of 
meningococcal group C polysaccharide-tetanus toxoid conjugate as vaccine for human use. 
Developments in Biological Standardization, 1986. 63: p. 117-128. 
438. Pawlowski, A., Kallenius, G., and Svenson, S.B., Preparation of pneumococcal capsular 
polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation 
technologies. Vaccine, 2000. 18: p. 1873-1885. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
262 
 
439. Silveira, I.A., Bastos, R.C., Neto, M.S., Laranjeira, A.P., Assis, E.F., Fernandes, S.A., Leal, 
M.L., Silva, W.C., Lee, C.H., Frasch, C.E., Peralta, J.M., and Jessouroun, E., Characterization 
and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-
activated tetanus toxoid. Vaccine, 2007. 25 (41): p. 7261-7270. 
440. Wilson, S., R&D Process Development Report No: CBP005 - Development of a conjugate 
process for the manufacture of a Hib PRP:TT conjugate vaccine, Cape Biologicals. p. 1-59.    
441. Malito, E., Bursulaya, B., Chen, C., Lo Surdo, P., Picchianti, M., Balducci, E., Biancucci, M., 
Brock, A., Berti, F., Bottomley, M.J., Nissum, M., Costantino, P., Rappuoli, R., and Spraggon, 
G., Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proceedings of 
the National Academy of Sciences, USA, 2012. 109 (14): p. 5229-5234. 
442. Giannini, G., Rappuoli, R., and Ratti, G., The amino acid sequence of two non toxic mutants 
of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Research, 1984. 12 (10): p. 4063-
4069. 
443. Bröker, M., Dull, P.M., Rappuoli, R., and Costantino, P., Chemistry of a new investigational 
quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine, 
2009. 27 (41): p. 5574-5580. 
444. Micoli, F., Rondini, S., Pisoni, I., Proietti, D., Berti, F., Costantino, P., Rappuoli, R., Szu, S., 
Saul, A., and Martin, L.B., Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. 
Vaccine, 2011. 29 (4): p. 712-720. 
445. Michon, F., Fusco, P.C., Minetti, C.A., Laude-Sharp, M., Uitz, C., Huang, C.-H., D'Ambra, 
A.J., Moore, S., Remeta, D.P., Heron, I., and Blake, M.S., Multivalent pneumococcal capsular 
polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier 
protein. Vaccine, 1998. 16 (18): p. 1732-1741. 
446. Paton, J.C., Lock, R.A., Lee, C.-J., Li, J.P., Berry, A.M., Mitchell, T.J., Andrew, P.W., 
Hansman, D., and Boulnois, G.J., Purification and immunogenicity of genetically obtained 
pneumolysin toxoids and their conjugation to Streptococcus pneumonia type 19F 
polysaccharide Infection and Immunity, 1991. 59 (7): p. 2297-2304. 
447. Kuo, J.S.-C. and Ree, H.K. for American Cyanamid Company. Pneumococcal polysaccharide 
recombinant pneumolysin conjugate vaccines for immunisation against pneumococcal 
infections. 1996. Office, U.S.P. 295305. 5565204.  
448. Weintraub, A., Immunology of bacterial polysaccharide antigens. Carbohydrate Research, 
2003. 338 (23): p. 2539-2547. 
449. Makela, P.H. and Kayhty, H., Evolution of conjugate vaccines. Expert Review of Vaccines, 
2002. 1 (4): p. 399-410. 
450. Kohn, J. and Wilchek, M., A new approach (cyano-transfer) for cyanogen bromide activation 
of sepharose at neutral pH, which yields activated resins, free of interfering nitrogen 
derivatives. Biochemical and Biophysical Research Communications, 1982. 107 (3): p. 7. 
451. Peeters, C.C.A.M., Tenbergen-Meekes, A.-M.J., Poolman, J.T., Zegers, B.J.M., and Rijkers, 
G.T., Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein 
conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine, 
1992. 10 (12): p. 833-840. 
452. McMaster, R.P. for Connaught Laboratories. Purification of polysaccharide-protein conjugate 
vaccines by ultrafiltration with ammonium sulfate solutions. 2000. Organization, W.I.P. 
PCT/US99/30109. WO 00/38711.  
453. Gadzinowski, J., Albrecht, P., Hasiec, B., Konior, R., Dziduch, J., Witor, A., Mellelieu, T., 
Tansey, S.P., Jones, T., Sarkozy, D., Emini, E.A., Gruber, W.C., and Scott, D.A., Phase 3 trial 
evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent 
pneumococcal conjugate vaccine. Vaccine, 2011. 29 (16): p. 2947-2955. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
263 
 
454. Ghosh, S.S., Kao, P.M., McCue, A.W., and Chappelle, H.L., Use of maleimide-thiol coupling 
chemistry for efficientt synthesis of oligonucleotide-enzyme conjugate hybridization probes. 
Bioconjugate Chemistry, 1990. 1: p. 71-76. 
455. Hoare, D.G. and Koshland, D.E., A procedure for the selective modification of carboxyl 
groups in proteins. Journal of the American Chemical Society, 1967. 88 (9): p. 2057-2058. 
456. Ulrich, H., Chemistry and technology of carbodiimides 2007. United Kingdom: John Wiley and 
Sons Ltd. 
457. Sheehan, J.C., Cruickshank, P.A., and Boshart, G.L., A convenient synthesis of water soluble 
carbodiimides. Journal of Organic Chemistry, 1961. 26: p. 2525-2528. 
458. Sheehan, J.C., Preston, J., and Cruickshank, P.A., A rapid synthesis of oligonucleotide 
derivatives without isolation of intermediates. Journal of the American Chemical Society, 
1965. 87: p. 2492-2493. 
459. Williams, A. and Ibrahim, I.T., A new mechanism involving cyclic tautomers for the reaction 
with nucleophiles of the water soluble peptide coupling reagent 1-ethyl-3-(3-
(dimethylamino)propyl)carbodiimide (EDC). Journal of the American Chemical Society, 1981. 
103: p. 7090-7095. 
460. Gilles, M.A., Hudson, A.Q., and Borders, C.L., Stability of water soluble carbodiimides in 
queous solution. Analytical Biochemistry, 1990. 184: p. 244-248. 
461. Carbodiimides Pamphlet,  2011. Uptima: France.    
462. Nakajima, N. and Ikada, Y., Mechanism of amide formation by carbodiimides for 
bioconjugation in aqueous media. . Bioconjugate Chemistry, 1995. 6: p. 123-130. 
463. Hale, C., Bowe, F., Pickard, D., Clare, S., Haeuw, J.F., Powers, U., Menager, N., Mastroeni, 
P., and Dougan, G., Evaluation of a novel Vi conjugate vaccine in a murine model of 
salmonellosis. Vaccine, 2006. 24 (20): p. 4312-4320. 
464. Cabrera Blanco, O., Cuello Perez, M., Sierra Gonzalez, V.G., Soto Rodriguez, C.R., and 
Martinez Pozo, M.E. for Method of obtaining conjugate vaccines and vaccine compositions 
containing same. 2005. Office, E.P. 03773443.1. EP1582217 A1.  
465. Instructions - Gel filtration media,  2006. GE Healthcare Instruction code: 56-1190-98 AE.   
466. Carraway, K.L. and Triplett, R.B., Reaction of carbodiimides with protein sulfhydryl groups. 
Biochimica et Biophysica Acta, 1970. 200: p. 564-566. 
467. Carraway, K.L. and Koshland Jr, D.E., Reaction of tyrosine residues in proteins with 
carbodiimide reagents. Biochimica et Biophysica Acta, 1968. 160: p. 272-274. 
468. Chan, L.C. and Cox, B.G., Kinetics of amide formation through carbodiiimide/N-
hydroxybenzotriazole (HOBt) couplings. Journal of Organic Chemistry, 2007. 72: p. 8863-
8869. 
469. Li, P. and Xu, J.-C., HOBt and HOAt-derived immonium salts: new and highly efficient 
coupling reagents for peptide synthesis. Tetrahedron Letters, 2000. 41: p. 721-724. 
470. Singh, J., Fox, R., Wong, W., Kissick, T.P., and Moniot, J.L., The structures of 
alkoxycarbonyl, acyl and sulfonate derivatives of 1-hydroxybenzotriazole: N- vs O-
substitution. Journal of Organic Chemistry, 1988. 53 (1): p. 205-209. 
471. Bulpitt, P. and Aeschlimann, D., New strategy for chemical modification of hyaluronic acid 
preparation of functionalised derivatives and their use in the formation of novel biocompatible 
hydrogels Journal of Biomedical Materials Research, 1999. 47: p. 152-169. 
472. Brink, B.D., DeFrancisco, J.R., Hillner, J.A., and Linton, B.R., Curtin-Hammett and steric 
effects in HOBt acylation regiochemistry. Journal of Organic Chemistry, 2011. 76 (13): p. 
5258-5263. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
264 
 
473. Anders, E., Katritzky, A.R., Malhotra, N., and Stevens, J., A MO theoretical study on the 
rearrangement of 1-hydroxy- and 1-(acyloxy)-1,2,3,-triazoles and their benzotriazole 
analogues: Comparison of ab initio and semiempirical calculations. Journal of Organic 
Chemistry, 1992. 57: p. 3698-3705. 
474. Boyle, F.T. and Jones, R.A.Y., Azole N-oxides. Part I. The tautomerism of benzotriazole 1-
oxide and its 4- and 6-nitro-derivatives with the corresponding 1-hydroxybenzotriazole. 
Journal of the Chemical Society, Perkin Transactions 2, 1973. 0 (2): p. 160-164. 
475. Clayden, J., Greeves, N., Warren, S., and Wothers, P., Organic Chemistry 2001. New York: 
Oxford University Press. 
476. McCarthy, D.G., Hegarty, A.F., and Hathaway, B.J., N-hydroxy-compounds as acyl transfer 
agents. Part 1. Kinetics and mechanism of nucleophilic displacements on 1-
hydroxybenzotriazole esters and crystal and molecular structure of 1-
benzoyloxybenzotriazole. Journal of the Chemical Society, Perkin Transactions 2, 1977. (2): 
p. 224-231. 
477. Kaminski, Z.J., Paneth, P., and Rudinkski, J., A Study on the activation of carboxylic acids by 
means of 2-chloro-4,6-dimethoxy-1,3,5-triazine and 2-chloro-4,6-diphenoxy-1,3,5-triazine. 
Journal of Organic Chemistry, 1998. 63: p. 4245-4255. 
478. Bergman, K., Elvingson, C., Hilborn, J., Svensk, G., and Bowden, T., Hyaluronic Acid 
Derivatives Prepared in Aqueous Media by Triazine-Activated Amidation. Biomacromolecules, 
2007. 8 (7): p. 2190-2195. 
479. Garrett, C.E., Jiang, X., Prasad, K., and  e pič, O., New observations on peptide bond 
formation using CDMT. Tetrahedron Letters, 2002. 43: p. 4161-4165. 
480. Schanté, C., Zuber, G., Herlin, C., and Vandamme, T.F., Synthesis of N-alanyl-hyaluronamide 
with high degree of substitution for enhanced resist nce to hyaluronidase-mediated digestion. 
Carbohydrate Polymers, 2011. 86 (2): p. 747-752. 
481. Schanté, C.E., Zuber, G., Herlin, C., and Vandamme, T.F., Chemical modifications of 
hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. 
Carbohydrate Polymers, 2011. 85 (3): p. 469-489. 
482. Kunishima, M., Kawachi, C., Iwasaki, F., Terao, K., and Tani, S., Synthesis and 
characterization of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride. 
Tetrahedron Letters, 1999. 40: p. 5327-5330. 
483. Shieh, W.-C., Chen, Z., Xue, S., McKenna, J., Wang, R.- .,  Prasad, K., and  ep ič, O., 
Synthesis of sterically-hindered peptidomimetics using 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-
methyl-morpholinium chloride. Tetrahedron Letters, 2008. 49 (37): p. 5359-5362. 
484. Kaminski, Z.J., Triazine-based condensing reagents. Biopolymers, 2000. 55: p. 140-164. 
485. Schlottmann, S.A., Jain, N., Chirmule, N., and Esser, M.T., A novel chemistry for conjugating 
pneumococcal polysaccharides to Luminex microspheres. Journal of Immunological Methods, 
2006. 309 (1-2): p. 75-85. 
486. Kunishima, M., Kawachi, C., Morita, J., Terao, K., Iwasaki, F., and Tani, S., 4-(4,6-dimethoxy-
1,3,5-triazin-2-yl)-4-methylmorpholinium chloride: An efficient condensing agent leading to the 
formation of amides and esters. Tetrahedron, 1999. 55: p. 13159-13170. 
487. Moingeon, P., De Taisne, C., and Almond, A., Delivery technologies for human vaccines. 
British Medical Bulletin, 2002. 62: p. 29-44. 
488. Dekker, C.L., Gordon, L., and Klein, J., Dose optimization strategies for vaccines: the role of 
adjuvants and new technologies,  2008. National Vaccine Advisory Committee.    
489. Oxford Dictionaries. Oxford University Press. Available from: 
http://oxforddictionaries.com/definition/english/adjuvant?q=adjuvant. [Accessed on:24 
September 2012]. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
265 
 
490. Dey, A.K. and Srivastava, I.K., Novel adjuvants and delivery systems for enhancing immune 
responses induced by immunogens. Expert Review of Vaccines, 2011. 10 (2): p. 227-251. 
491. Committee for medicinal products for human use: Guideline on adjuvants in vaccines for 
human use.,  2005. EMEA: London, United Kingdom.    
492. Vogel, F.R., Improving vaccine performance with adjuvants. Clinical Infectious Diseases, 
2000. 30 (Supplement 3): p. S266-S270. 
493. Lindblad, E.B., Aluminium compounds for use in vaccines. Immunology and Cell Biology, 
2004. 82: p. 497-505. 
494. Romero Mendez, I.Z., Shi, Y., HogenEsch, H., and Hem, S.L., Potentiation of the immune 
response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine, 2007. 25 (5): 
p. 825-833. 
495. Jiang, D., Morefield, G.L., HogenEsch, H., and Hem, S.L., Relationship of adsorption 
mechanism of antigens by aluminum-containing adjuvants to in vitro elution in interstitial fluid. 
Vaccine, 2006. 24 (10): p. 1665-1669. 
496. Heimlich, J.M., Regnier, F.E., White, J.L., and Hem, S.L., The in vitro displacement of 
adsorbed modedl antigens from aluminium-containing adjuvants by interstitial proteins. 
Vaccine, 1999. 17: p. 2873-2881. 
497. Immunological adjuvants.,  1976. World Health Organization: Geneva World Health 
Organization Technical Report Series No. 595.   
498. Jendrek, S., Little, S.F., Hem, S., Mitra, G., and Giardina, S., Evaluation of the compatibility of 
a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. 
Vaccine, 2003. 21 (21-22): p. 3011-3018. 
499. Petrovsky, N. and Cooper, P.D., Carbohydrate-based immune adjuvants. Expert Review of 
Vaccines, 2011. 10 (4): p. 523-537. 
500. Singh, M. Vaccine adjuvants and delivery systems.  2007. Wiley Interscience: New Jersey. 
501. Seeber, S.J., White, J.L., and Hem, S.L., Predicting the adsorption of proteins by aluminium-
containing adjuvants. Vaccine, 1991. 9: p. 201-203. 
502. Derek, O.Ä. and Mahesh, C., Excipients Used in Vaccines, in Excipient Development for 
Pharmaceutical, Biotechnology, and Drug Delivery Systems 2006. Informa Healthcare. p. 
333-340. 
503. Al-Shakhshir, R.H., Lee, A.L., White, J.L., and Hem, S.L., Interactions in model vaccines 
composed of mixtures of aluminum-containing adjuvants. Journal of Colloid and Interface 
Science, 1995. 169 (1): p. 197-203. 
504. Kumar, S., Kumar, A., Gupta, P., Maheshwari, S.C., and Sokhey, J., Standardization for 
optimum adsorption of tetanus toxoid on adjuvant and its relationship with potency. Indian 
Journal of Microbiology, 2001. 41 (4): p. 293-296. 
505. Henckaerts, I., Durant, N., De Grave, D., Schuerman, L., and Poolman, J., Validation of a 
routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of 
conjugate vaccine in children. Vaccine, 2007. 25 (13): p. 2518-2527. 
506. Concepcion, N.F. and Frasch, C.E., Pneumococcal type 22F polysaccharide absorption 
improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent 
assay. Clinical and Diagnostic Laboratory Immunology, 2001. 8 (2): p. 266-272. 
507. Adrian, P., Immune response of different polysaccharide-protein conjugates against 
Streptococcus pneumoniae type 1,  2012. Research Report for The Biovac Institute.   
508. Fleck, R.A., Romero-Steiner, S., and Nahm, M.H., Use of HL-60 cell line to measure opsonic 
capacity of pneumococcal antibodies. Clinical and Diagnostic Laboratory Immunology, 2005. 
12 (1): p. 19-27. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
266 
 
509. Romero-Steiner, S., Frasch, C.E., Carlone, G., Fleck, R.A., Goldblatt, D., and Nahm, M.H., 
Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clinical and 
Vaccine Immunology, 2006. 13 (2): p. 165-169. 
510. Romero-Steiner, S., Libutti, D., Pais, L.B., Dykes, J., Anderson, P., Whitin, J.C., Keyserling, 
H.L., and Carlone, G., Standardization of an opsonophagocytic assay for the measurement of 
functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 
cells. Clinical and Diagnostic Laboratory Immunology, 1997. 4 (4): p. 415-422. 
511. Rehm, S., Sommer, R., and Deerberg, F., Spontaneous nonneopastic gastric lesions in 
female Han:NMRI mice and influence of food restriction throughout life. Veterinary Pathology 
Online, 1987. 21: p. 216-224. 
512. Deerberg, F. and Gleichmann, H., The occurrence of spontaneous immune-complex 
glomerulonephritis in Han: NMRI mice. Contributions to Nephrology, 1980. 19: p. 88-94. 
513. Löhrke, H., Hesse, B., and Goerttler, K., Spontaneous tumors and lifespan of female NMRI 
mice of the outbred stock sut: NMRT during a lifetime study. Journal of Cancer Research and 
Clinical Oncology, 1984. 108 (2): p. 192-196. 
514. Gruber, W., Kirschner, K., Tollefson, S., Thompson, J., Reed, G., Edwards, K.M., and Wright, 
P.F., Comparison of monovalent and trivalent live attenuated influenza vaccines in young 
children. The Journal of Infectious Diseases, 1993. 168 (1): p. 53-60. 
515. Garland, S.M., Steben, M., Hernandez-Avila, M., Koutsky, L.A., Wheeler, C.M., Perez, G., 
Harper, D.M., Leodolter, S., Tang, G.W., Ferris, D.G., Esser, M.T., Vuocolo, S.C., Nelson, M., 
Railkar, R., Sattler, C., and Barr, E., Noninferiority of antibody response to human 
papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like 
particle vaccines. Clin Vaccine Immunol, 2007. 14 (6): p. 792-795. 
516. de Kleijn, E.D., De Groot, R., Lafeber, A.B., Labadie, J., van Limpt, K.C.J.P., Visser, J., 
Berbers, G.A.M., van Alphen, L., and Rumke, H.C., Immunogenicity and safety of monovalent 
P1.7th,4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two 
vaccination schedules and two vaccine formulations. Vaccine, 2001. 19: p. 1141-1148. 
517. Fattom, A., Cho, Y.H., Chu, C., Fuller, S., Fries, L., and Naso, R., Epitopic overload at the site 
of injection may result in suppression of the immune response to combined capsular 
polysaccharide conjugate vaccines. Vaccine, 1999. 17: p. 126-133. 
 
 
